

WEST Search History

DATE: Wednesday, October 29, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L20	(beta-amyloid)	1767	L20
L19	L18 AND beta-amyloid	67	L19
L18	((514/2)!.CCLS.)	5449	L18
L17	L16 AND beta-amyloid	16	L17
L16	(424/130.1.CCLS.)	1159	L16
L15	L14 AND beta-amyloid	179	L15
L14	((530/300 530/350 530/387.1)!.CCLS.)	15553	L14
L13	Yednock-T.IN.	5	L13
L12	Yednock-Theodore.IN.	2	L12
L11	Yednock.IN.	33	L11
L10	Bard-Fred.IN.	0	L10
L9	Bard-F.IN.	5	L9
L8	Bard-Frederique.IN.	4	L8
L7	Bard.IN.	705	L7
L6	Schenk-D.IN.	6	L6
L5	Schenk-Dale.IN.	3	L5
L4	Schenk-D-B.IN.	16	L4
L3	Schenk-Dale-B.IN.	21	L3
L2	Schenk.IN.	2234	L2
L1	(Schenck.IN.)	468	L1


END OF SEARCH HISTORY

WEST Search History

DATE: Wednesday, October 29, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L6	L3 AND N-terminus	449	L6
L5	L4 AND N-terminus	425	L5
L4	L3 AND Alzheimer	1188	L4
L3	L2 AND antibody	1255	L3
L2	L1 AND beta-amyloid	1767	L2
L1	(amyloid)	6109	L1

END OF SEARCH HISTORY



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Book

Search PubMed

for **beta-amyloid AND human AND antibody**

Go Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

Display

Summary

Show: 500

Sort

Send to

Text

Items 1-342 of 342

One page.

1: [Miller DL, Currie JR, Mehta PD, Potempaska A, Hwang YW, Wegiel](#) Related Articles, Links
 Humoral immune response to fibrillar beta-amyloid peptide.
Biochemistry. 2003 Oct 14;42(40):11682-92.
 PMID: 14529278 [PubMed - in process]

2: [Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung TH, Illegi T, Nitsch RM, Hock C](#) Related Articles, Links
 Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
Arch Neurol. 2003 Sep;60(9):1202-6.
 PMID: 12975284 [PubMed - indexed for MEDLINE]

3: [LeVine II 3rd](#) Related Articles, Links
 Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide.
Arch Biochem Biophys. 2003 Sep 1;417(1):112-22.
 PMID: 12921787 [PubMed - indexed for MEDLINE]

4: [Torp R, Ottersen OP, Cotman CW, Head E](#) Related Articles, Links
 Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing.
Neuroscience. 2003;120(2):291-300.
 PMID: 12890502 [PubMed - indexed for MEDLINE]

5: [Tang K, Wang C, Shen C, Sheng S, Ravid R, Jing N](#) Related Articles, Links
 Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639.
Eur J Neurosci. 2003 Jul;18(1):102-8.
 PMID: 12859342 [PubMed - indexed for MEDLINE]

6: [Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB](#) Related Articles, Links
 Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.
J Immunol. 2003 Jul 15;171(2):812-20.
 PMID: 12847249 [PubMed - indexed for MEDLINE]

7: [Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M](#) Related Articles, Links
 Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.
Brain. 2003 Sep;126(Pt 9):1935-9. Epub 2003 Jun 23.
 PMID: 12821522 [PubMed - indexed for MEDLINE]

8: [Austin J, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D](#) Related Articles, Links

 Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice.
Behav Neurosci. 2003 Jun;117(3):478-84.
PMID: 12802876 [PubMed - indexed for MEDLINE]

 [9: Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE](#) [Related Articles](#), [Links](#)

 Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice.
Life Sci. 2003 Jun 20;73(5):555-62.
PMID: 12770611 [PubMed - indexed for MEDLINE]

 [10: Heck C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbrecht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM](#) [Related Articles](#), [Links](#)

 Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.
Neuron. 2003 May 22;38(4):547-54.
PMID: 12765607 [PubMed - indexed for MEDLINE]

 [11: Li G, Percontino L, Sun Q, Qazi AS, Frederikse PH](#) [Related Articles](#), [Links](#)

 Beta-amyloid secretases and beta-amyloid degrading enzyme expression in lens.
Mol Vis. 2003 May 1;9:179-83.
PMID: 12740567 [PubMed - indexed for MEDLINE]

 [12: Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D](#) [Related Articles](#), [Links](#)

 Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.
J Neurosci. 2003 May 1;23(9):3745-51.
PMID: 12736345 [PubMed - indexed for MEDLINE]

 [13: Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ](#) [Related Articles](#), [Links](#)

 Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane.
J Biol Chem. 2003 Jul 18;278(29):26687-94. Epub 2003 May 07.
PMID: 12736250 [PubMed - indexed for MEDLINE]

 [14: Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM](#) [Related Articles](#), [Links](#)

 Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
JAMA. 2003 Apr 23-30;289(16):2094-103.
PMID: 12709467 [PubMed - indexed for MEDLINE]

 [15: Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA](#) [Related Articles](#), [Links](#)

 Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
Vaccine. 2003 May 16;21(17-18):2206-15.
PMID: 12706711 [PubMed - in process]

 [16: Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S](#) [Related Articles](#), [Links](#)

 Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome.
Brain Dev. 2003 Apr;25(3):180-5.

PMID: 12689696 [PubMed - indexed for MEDLINE]

17: [Cantarcila G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M.](#) [Related Articles](#), [Links](#)

Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.
Cell Death Differ. 2003 Jan;10(1):134-41.
PMID: 12655302 [PubMed - in process]

18: [Cai J, Wang S, Zhong Y, Cheng J, Ji Z, Sheng S, Zhang C.](#) [Related Articles](#), [Links](#)

Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40.
Neuroreport. 2003 Feb 10;14(2):265-8.
PMID: 12598743 [PubMed - indexed for MEDLINE]

19: [Bard F, Barbour R, Cannon C, Carretero R, Fox M, Games D, Guido T, Hocknow K, Jhu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Trojanock T.](#) [Related Articles](#), [Links](#)

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 03.
PMID: 12566568 [PubMed - indexed for MEDLINE]

20: [Blasko I, Grabeck-Loebenstein B.](#) [Related Articles](#), [Links](#)

Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
Drugs Aging. 2003;20(2):101-13. Review.
PMID: 12534311 [PubMed - indexed for MEDLINE]

21: [Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olin V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K.](#) [Related Articles](#), [Links](#)

Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.
J Neurosci. 2003 Jan 1;23(1):29-33.
PMID: 12514198 [PubMed - indexed for MEDLINE]

22: [Friedland RP.](#) [Related Articles](#), [Links](#)

Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease.
Ann N Y Acad Sci. 2002 Nov;977:387-90. Review.
PMID: 12480777 [PubMed - indexed for MEDLINE]

23: [Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J.](#) [Related Articles](#), [Links](#)

A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker?
J Neural Transm Suppl. 2002;(62):87-95.
PMID: 12456054 [PubMed - indexed for MEDLINE]

24: [Leclercq PD, Stephenson MS, Murray LS, McIntosh TK, Graham DI, Gentleman SM.](#) [Related Articles](#), [Links](#)

Simple morphometry of axonal swellings cannot be used in isolation for dating lesions after traumatic brain injury.
J Neurotrauma. 2002 Oct;19(10):1183-92.
PMID: 12427327 [PubMed - indexed for MEDLINE]

25: [Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ.](#) [Related Articles](#), [Links](#)

Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.
Nat Neurosci. 2002 Dec;5(12):1288-93.

PMID: 12402041 [PubMed - indexed for MEDLINE]

□ 26: [Hoek C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J](#). Related Articles, Links von Rotz RC, Davey G, Moritz E, Nitsch RM.

□ Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

Nat Med. 2002 Nov;8(11):1270-5. Epub 2002 Oct 15.

PMID: 12379846 [PubMed - indexed for MEDLINE]

□ 27: [Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Baierger K, Hoft C, Hock C, Hock M, Moller HJ, Farlow M, Oertel WH, Sommer B, Du Y](#). Related Articles, Links

□ Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

Ann Neurol. 2002 Aug;52(2):253-6.

PMID: 12210803 [PubMed - indexed for MEDLINE]

□ 28: [Kovacs GG, Zerbi P, Voigtlander T, Strohschneider M, Trabattoni G, Hainfellner JA, Budka H](#). Related Articles, Links

□ The prion protein in human neurodegenerative disorders.

Neurosci Lett. 2002 Sep 6;329(3):269-72.

PMID: 12183028 [PubMed - indexed for MEDLINE]

□ 29: [Giri R, Selvaraj S, Miller CA, Hofman F, Yam SD, Stern D, Zlokovic BV, Kalra VK](#). Related Articles, Links

□ Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium.

Am J Physiol Cell Physiol. 2002 Sep;283(3):C895-904.

PMID: 12176746 [PubMed - indexed for MEDLINE]

□ 30: [Beher JD, Wrigley JD, Owens AP, Shearman MS](#). Related Articles, Links

□ Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

J Neurochem. 2002 Aug;82(3):563-75.

PMID: 12153480 [PubMed - indexed for MEDLINE]

□ 31: [Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA](#). Related Articles, Links

□ Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.

Brain Pathol. 2002 Jul;12(3):275-86.

PMID: 12146796 [PubMed - indexed for MEDLINE]

□ 32: [Clamagirand C, Joulie C, Panchal M, Sekhri R, Hanquez C, Cohen P, Rholam M](#). Related Articles, Links

□ Specific cleavage of beta-amyloid peptides by a metallopeptidase from *Xenopus laevis* skin secretions.

Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):751-9.

PMID: 12128061 [PubMed - in process]

□ 33: [Mohajeri MH, Wollmer MA, Nitsch RM](#). Related Articles, Links

□ Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.

J Biol Chem. 2002 Sep 20;277(38):35460-5. Epub 2002 Jul 08.

PMID: 12105192 [PubMed - indexed for MEDLINE]

□ 34: [Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z](#). Related Articles, Links

□ Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.

Neurosci Lett. 2002 Jun 28;326(2):117-20.
PMID: 12057842 [PubMed - indexed for MEDLINE]

□ 35: [Nagele RG, D'Andrea MR, Anderson WJ, Wang HY](#) [Related Articles](#), [Links](#)

□ **Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease.**
Neuroscience. 2002;110(2):199-211.
PMID: 11958863 [PubMed - indexed for MEDLINE]

□ 36: [Frenkel D, Solomon B](#) [Related Articles](#), [Links](#)

□ **Towards Alzheimer's beta-amyloid vaccination.**
Biologicals. 2001 Sep-Dec;29(3-4):243-7.
PMID: 11851323 [PubMed - indexed for MEDLINE]

□ 37: [Thal DR, Ghebremedhin E, Haass C, Schultz C](#) [Related Articles](#), [Links](#)

□ **UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain.**
Clin Neuropathol. 2002 Jan-Feb;21(1):35-40.
PMID: 11846043 [PubMed - indexed for MEDLINE]

□ 38: [Schenk D, Games D, Seubert P](#) [Related Articles](#), [Links](#)

□ **Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.**
J Mol Neurosci. 2001 Oct;17(2):259-67. Review.
PMID: 11816797 [PubMed - indexed for MEDLINE]

□ 39: [Cummings BJ, Mason AJ, Kim RC, Shen PC, Anderson AJ](#) [Related Articles](#), [Links](#)

□ **Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging.**
Neurobiol Aging. 2002 Mar-Apr;23(2):161-70.
PMID: 11804699 [PubMed - indexed for MEDLINE]

□ 40: [Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D](#) [Related Articles](#), [Links](#)

□ **Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels.**
DNA Cell Biol. 2001 Nov;20(11):731-6.
PMID: 11788051 [PubMed - indexed for MEDLINE]

□ 41: [Solomon B](#) [Related Articles](#), [Links](#)

□ **Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.**
DNA Cell Biol. 2001 Nov;20(11):697-703.
PMID: 11788047 [PubMed - indexed for MEDLINE]

□ 42: [Coraci JS, Husemann J, Berman JW, Hulette C, Dufour JH, Campenot GK, Luster AD, Silverstein SC, El-Khoury JB](#) [Related Articles](#), [Links](#)

□ **CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils.**
Am J Pathol. 2002 Jan;160(1):101-12.
PMID: 11786404 [PubMed - indexed for MEDLINE]

□ 43: [Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S](#) [Related Articles](#), [Links](#)

□ **Specificity and sensitivity of betaAPP in head injury.**
Clin Neuropathol. 2001 Nov-Dec;20(6):263-71.
PMID: 11758782 [PubMed - indexed for MEDLINE]

□ 44: [Lambert MP](#), [Viola KL](#), [Chromo BA](#), [Chang L](#), [Morgan TE](#), [Yu J](#), [Venton DL](#), [Krafft GA](#), [Finch CE](#), [Klein WL](#) Related Articles, Links
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
J Neurochem. 2001 Nov;79(3):595-605.
PMID: 11701763 [PubMed - indexed for MEDLINE]

□ 45: [Szpak GM](#), [Lewandowska E](#), [Lechowicz W](#), [Bertrand E](#), [Wierzbicka B](#), [Bobrowicz T](#), [Gwiazda E](#), [Pasenik E](#), [Kosno-Kruszewska E](#), [Lipczynska-Lojkowska W](#), [Bochynska A](#), [Fiszer U](#) Related Articles, Links
Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study.
Folia Neuropathol. 2001;39(2):63-71.
PMID: 11680637 [PubMed - indexed for MEDLINE]

□ 46: [Toupalik P](#), [Bouska I](#), [Chadova I](#) Related Articles, Links
[Differences in immunohistochemical findings in traumatic and hypoxic changes in the central nervous system]
Soud Lek. 2001 Jul;46(3):34-6. Czech.
PMID: 11669015 [PubMed - indexed for MEDLINE]

□ 47: [Nunan J](#), [Shearman MS](#), [Cheeler F](#), [Cappai R](#), [Evin G](#), [Beyreuther K](#), [Masters CL](#), [Small DH](#) Related Articles, Links
The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
Eur J Biochem. 2001 Oct;268(20):5329-36.
PMID: 11606195 [PubMed - indexed for MEDLINE]

□ 48: [Carter DB](#), [Dunn W](#), [McKinley DD](#), [Stratman NC](#), [Boyle TP](#), [Kuiper SL](#), [Oostveen JA](#), [Weaver RJ](#), [Boller JA](#), [Gurney ME](#) Related Articles, Links
Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.
Ann Neurol. 2001 Oct;50(4):468-75.
PMID: 11601499 [PubMed - indexed for MEDLINE]

□ 49: [von Bernhardi R](#), [Ramirez G](#), [Matile H](#), [Dobeli H](#) Related Articles, Links
Immobilized amyloid precursor protein constructs: a tool for the in vitro screening of glial cell reactivity.
Eur J Neurosci. 2001 Sep;14(6):946-56.
PMID: 11595033 [PubMed - indexed for MEDLINE]

□ 50: [Head E](#), [Garzon-Rodriguez W](#), [Johnson JK](#), [Lott IT](#), [Cotman CW](#), [Globe C](#) Related Articles, Links
Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome.
Neurobiol Dis. 2001 Oct;8(5):792-806.
PMID: 11592849 [PubMed - indexed for MEDLINE]

□ 51: [Thatté U](#) Related Articles, Links
AN-1792 (Elan).
Curr Opin Investig Drugs. 2001 May;2(5):663-7. Review.
PMID: 11569944 [PubMed - indexed for MEDLINE]

□ 52: [Gotz J](#), [Chen F](#), [van Dorpe J](#), [Nitsch RM](#) Related Articles, Links
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.
Science. 2001 Aug 24;293(5534):1491-5.
PMID: 11520988 [PubMed - indexed for MEDLINE]

 **53:** [Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL](#) [Related Articles](#) [Links](#)
 Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21.
PMID: 11517335 [PubMed - indexed for MEDLINE]

 **54:** [Brayden DJ, Templeton L, McClean S, Barbour R, Huang I, Nguyen M, Ahern D, Motter R, Johnson-Wood K, Vasquez N, Schenk D, Seubert P](#) [Related Articles](#) [Links](#)
 Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.
Vaccine. 2001 Jul 20;19(30):4185-93.
PMID: 11457544 [PubMed - indexed for MEDLINE]

 **55:** [Toupalik P, Bouska I, Jezkova J](#) [Related Articles](#) [Links](#)
 [Effect of autolysis on histochemical examinations of the central nervous system]
Soud Lek. 2001 Apr;46(2):18-20. Czech.
PMID: 11455721 [PubMed - indexed for MEDLINE]

 **56:** [Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S](#) [Related Articles](#) [Links](#)
 Possible reverse transport of beta-amyloid peptide across the blood-brain barrier.
Acta Neurochir Suppl. 2000;76:73-7.
PMID: 11450095 [PubMed - indexed for MEDLINE]

 **57:** [Town T, Tan J, Sansone N, Obregon D, Klejn T, Mullan M](#) [Related Articles](#) [Links](#)
 Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.
Neurosci Lett. 2001 Jul 13;307(2):101-4.
PMID: 11427310 [PubMed - indexed for MEDLINE]

 **58:** [Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Slezneva ND, Zharikov GA, Kolykhalov IV, Abramchenko TV, Serkova TP, Bachurin SQ](#) [Related Articles](#) [Links](#)
 Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.
Bull Exp Biol Med. 2001 Feb;131(2):127-9.
PMID: 11391392 [PubMed - indexed for MEDLINE]

 **59:** [Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T](#) [Related Articles](#) [Links](#)
 beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
Neuroscience. 2001;104(2):299-310.
PMID: 11377835 [PubMed - indexed for MEDLINE]

 **60:** [Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuyama S](#) [Related Articles](#) [Links](#)
 Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons.
Eur J Neurosci. 2001 May;13(9):1653-7.
PMID: 11359517 [PubMed - indexed for MEDLINE]

 **61:** [Chong YH, Sung JH, Shin SA, Chung JH, Sub YH](#) [Related Articles](#) [Links](#)
 Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's

amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. *J Biol Chem.* 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16. PMID: 11306564 [PubMed - indexed for MEDLINE]

62: Englund P, Jacobsson SO, Fowler CJ. [Related Articles](#) [Links](#)

Investigation into the effects of amyloid (1-42) beta-peptide upon basal and antigen-stimulated hexosaminidase and serotonin release from rat RBL-2H3 basophilic leukemia cells. *Methods Find Exp Clin Pharmacol.* 2000 Nov;22(9):657-61. PMID: 11294005 [PubMed - indexed for MEDLINE]

63: Cedazo-Minguez A, Wiegager B, Winblad B, Jellinger M, Cowburn RE. [Related Articles](#) [Links](#)

Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. *Neurochem Int.* 2001 Jun;38(7):615-25. PMID: 11290387 [PubMed - indexed for MEDLINE]

64: Frenkel D, Kariv N, Solomon B. [Related Articles](#) [Links](#)

Generation of auto-antibodies towards Alzheimer's disease vaccination. *Vaccine.* 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE]

65: Gerlai R. [Related Articles](#) [Links](#)

Alzheimer's disease: beta-amyloid hypothesis strengthened! *Trends Neurosci.* 2001 Apr;24(4):199. No abstract available. PMID: 11249992 [PubMed - indexed for MEDLINE]

66: Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T. [Related Articles](#) [Links](#)

Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids. *Neurosci Res.* 2001 Mar;39(3):313-7. PMID: 11248371 [PubMed - indexed for MEDLINE]

67: Husemann J, Silverstein SC. [Related Articles](#) [Links](#)

Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. *Am J Pathol.* 2001 Mar;158(3):825-32. PMID: 11238031 [PubMed - indexed for MEDLINE]

68: D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. [Related Articles](#) [Links](#)

Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. *Histopathology.* 2001 Feb;38(2):120-34. PMID: 11207825 [PubMed - indexed for MEDLINE]

69: Russo C, Salis S, Dolezini V, Venezia V, Song XH, Teller JK, Schettini G. [Related Articles](#) [Links](#)

Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. *Neurobiol Dis.* 2001 Feb;8(1):173-80. Erratum in: *Neurobiol Dis* 2001 Jun;8(3):540. PMID: 11162251 [PubMed - indexed for MEDLINE]

Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA.

 70: [Morley JE](#) Related Articles, Links
Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.
Peptides. 2000 Dec;21(12):1769-75.
PMID: 11150636 [PubMed - indexed for MEDLINE]

 71: [Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E](#) Related Articles, Links
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
Amyloid. 2000 Dec;7(4):245-58.
PMID: 11132093 [PubMed - indexed for MEDLINE]

 72: [Seiffert D, Mitchell T, Stern AM, Reach A, Zhan Y, Grzanna R](#) Related Articles, Links
Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing.
Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26.
PMID: 11113538 [PubMed - indexed for MEDLINE]

 73: [Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK](#) Related Articles, Links
beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.
Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81.
PMID: 11078691 [PubMed - indexed for MEDLINE]

 74: [Frenkel D, Katz O, Solomon B](#) Related Articles, Links
Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9.
PMID: 11027345 [PubMed - indexed for MEDLINE]

 75: [Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N](#) Related Articles, Links
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26.
PMID: 10997858 [PubMed - indexed for MEDLINE]

 76: [Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, Bogdanović](#) Related Articles, Links
nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease.
Exp Neurol. 2000 Sep;165(1):12-26.
PMID: 10964481 [PubMed - indexed for MEDLINE]

 77: [Taguchi J, Fujii A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Y, Wada I, Yamada T](#) Related Articles, Links
Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Aug;100(2):153-60.
PMID: 10963362 [PubMed - indexed for MEDLINE]

 78: [Tanabe Y, Ishizu H, Ishiguro K, Itoh N, Terada S, Haraguchi T, Kawa K, Kuwada S](#) Related Articles, Links

 **Tau pathology in diffuse neurofibrillary tangles with calcification (DNTC): biochemical and immunohistochemical investigation.**
Neuroreport. 2000 Aug 3;11(11):2473-7.
PMID: 10943706 [PubMed - indexed for MEDLINE]

 **79: Helmuth L.** [Related Articles](#), [Links](#)

 **Alzheimer's congress. Further progress on a beta-amyloid vaccine.**
Science. 2000 Jul 21;289(5478):375. No abstract available.
PMID: 10939941 [PubMed - indexed for MEDLINE]

 **80: Kaneko I, Kubo T, Morimoto K.** [Related Articles](#), [Links](#)

 **[Neurotoxicity of beta-amyloid]**
Nippon Yakurigaku Zasshi. 2000 Feb;115(2):67-77. Review. Japanese.
PMID: 10876793 [PubMed - indexed for MEDLINE]

 **81: Hershberger K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentileman SM, Graham DI, Nicoll JA.** [Related Articles](#), [Links](#)

 **beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.**
Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32.
PMID: 10840275 [PubMed - indexed for MEDLINE]

 **82: Rohn TT, Jvins KJ, Bahr BA, Cotman CW, Cribbs DH.** [Related Articles](#), [Links](#)

 **A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis.**
J Neurochem. 2000 Jun;74(6):2331-42.
PMID: 10820193 [PubMed - indexed for MEDLINE]

 **83: Sparks DL, Kuo YM, Roher AE, Martin T, Lukas RJ.** [Related Articles](#), [Links](#)

 **Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.**
Ann N Y Acad Sci. 2000 Apr;903:335-44.
PMID: 10818523 [PubMed - indexed for MEDLINE]

 **84: Brown WR, Moody DM, Thore CR, Challa VR.** [Related Articles](#), [Links](#)

 **Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis.**
Ann N Y Acad Sci. 2000 Apr;903:39-45.
PMID: 10818487 [PubMed - indexed for MEDLINE]

 **85: Frenkel D, Solomon B, Benhar I.** [Related Articles](#), [Links](#)

 **Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.**
J Neuroimmunol. 2000 Jul 1;106(1-2):23-31.
PMID: 10814779 [PubMed - indexed for MEDLINE]

 **86: Kane MJ, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC.** [Related Articles](#), [Links](#)

 **Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.**
J Neurosci. 2000 May 15;20(10):3606-11.
PMID: 10804202 [PubMed - indexed for MEDLINE]

 **87: Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW.** [Related Articles](#), [Links](#)

 **Region-specific age at onset of beta-amyloid in dogs.**
Neurobiol Aging. 2000 Jan-Feb;21(1):89-96.
PMID: 10794853 [PubMed - indexed for MEDLINE]

 **88: Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC.** [Related Articles](#), [Links](#)

Lott IT, Cotman CW.

 Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs.
Exp Neurol. 2000 May;163(1):111-22.
PMID: 10785449 [PubMed - indexed for MEDLINE]

 89: Capell A, Steiner H, Romig H, Keck S, Baader M, Grimm MG, Baumeister R, Haass C. Related Articles, Links
Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.
Nat Cell Biol. 2000 Apr;2(4):205-11.
PMID: 10783238 [PubMed - indexed for MEDLINE]

 90: Salinero O, Moreno-Flores MT, Wandosell F. Related Articles, Links
Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease.
J Neurosci Res. 2000 Apr 1;60(1):87-97.
PMID: 10723071 [PubMed - indexed for MEDLINE]

 91: Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Related Articles, Links
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60.
PMID: 10677483 [PubMed - indexed for MEDLINE]

 92: Cescato R, Durnerwirth E, Spiess M, Paganetti PA. Related Articles, Links
Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis.
J Neurochem. 2000 Mar;74(3):1131-9.
PMID: 10693945 [PubMed - indexed for MEDLINE]

 93: Matsumoto A. Related Articles, Links
The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate.
Neuroreport. 2000 Feb 7;11(2):373-7.
PMID: 10674489 [PubMed - indexed for MEDLINE]

 94: Yoshiyama Y, Asahina M, Hattori T. Related Articles, Links
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Feb;99(2):91-5.
PMID: 10672313 [PubMed - indexed for MEDLINE]

 95: Toro F, Lopera F, Ossa J, Madrigal L, Mira A, Diaz A, Parra S. Related Articles, Links
[Detection of antibodies to beta-amyloid in carriers of E280A mutation in the presenilin-1 gene]
Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish.
PMID: 10652730 [PubMed - indexed for MEDLINE]

 96: Campbell E, Pearson RC, Parkinson D. Related Articles, Links
Methods to uncover an antibody epitope in the KPI domain of Alzheimer's amyloid precursor protein for immunohistochemistry in human brain.
J Neurosci Methods. 1999 Nov 15;93(2):133-8.
PMID: 10634498 [PubMed - indexed for MEDLINE]

 97: Frederikse PH, Zigler SJ Jr, Farnsworth PN, Carper DA. Related Articles, Links

 Prion protein expression in mammalian lenses.
Curr Eye Res. 2000 Feb;20(2):137-43.
PMID: 10617916 [PubMed - indexed for MEDLINE]

 **98:** Webster SD, Tenner AJ, Poulos TL, Cribbs DH. [Related Articles](#), [Links](#)
The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
Neurobiol Aging. 1999 May-Jun;20(3):297-304.
PMID: 10588577 [PubMed - indexed for MEDLINE]

 **99:** Jung SS, Gauthier S, Cashman NR. [Related Articles](#), [Links](#)
Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease.
Neurobiol Aging. 1999 May-Jun;20(3):249-57.
PMID: 10588572 [PubMed - indexed for MEDLINE]

 **100:** Nakano S, Akiguchi I, Nakamura S, Sato H, Kawashima S, Kimura J. [Related Articles](#), [Links](#)
Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
Neurology. 1999 Nov 10;53(8):1671-6.
PMID: 10563611 [PubMed - indexed for MEDLINE]

 **101:** Fcres ER, Stephens DJ, Walters CE, Davies H, Austen BM. [Related Articles](#), [Links](#)
The role of cholesterol in the biosynthesis of beta-amyloid.
Neuroreport. 1999 Jun 3;10(8):1699-705.
PMID: 10501560 [PubMed - indexed for MEDLINE]

 **102:** Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H. [Related Articles](#), [Links](#)
Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.
Arch Neurol. 1999 Sep;56(9):1111-8.
PMID: 10488812 [PubMed - indexed for MEDLINE]

 **103:** Guenette SY, Chen J, Ferland A, Haass C, Capell A, Tanzi RE. [Related Articles](#), [Links](#)
hFE65L influences amyloid precursor protein maturation and secretion.
J Neurochem. 1999 Sep;73(3):985-93.
PMID: 10461887 [PubMed - indexed for MEDLINE]

 **104:** Kurt MA, Davies DC, Kidd M. [Related Articles](#), [Links](#)
beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: an electron microscope study.
Exp Neurol. 1999 Jul;158(1):221-8.
PMID: 10448435 [PubMed - indexed for MEDLINE]

 **105:** Markaryan A, Morozova I, Lee BS, Kaplan A. [Related Articles](#), [Links](#)
Atypical processing of amyloid precursor fusion protein by proteolytic activity in *Pichia pastoris*.
Biochem Biophys Res Commun. 1999 Aug 19;262(1):263-8. Erratum in: Biochem Biophys Res Commun 1999 Sep 24;263(2):596.
PMID: 10448103 [PubMed - indexed for MEDLINE]

 **106:** Schroder R, Linke RP. [Related Articles](#), [Links](#)
Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenous pattern.
Virchows Arch. 1999 Jun;434(6):551-60.
PMID: 10394892 [PubMed - indexed for MEDLINE]

□ 107: [Yuan H, Zhai P, Anderson LM, Fan J, Thimmapaya B, Koo EH, Marquez-Sterling NR](#) Related Articles, Links
Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons.
J Neurosci Methods. 1999 Apr 1;88(1):45-54.
PMID: 10379578 [PubMed - indexed for MEDLINE]

□ 108: [Fonseca MI, Head E, Velazquez P, Cotman CW, Teicher AJ](#) Related Articles, Links
The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.
Exp Neurol. 1999 Jun;157(2):277-88.
PMID: 10364440 [PubMed - indexed for MEDLINE]

□ 109: [Obsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S](#) Related Articles, Links
Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells.
Eur J Neurosci. 1999 Jun;11(6):1907-13.
PMID: 10336659 [PubMed - indexed for MEDLINE]

□ 110: [Oehmichen M, Theuerkauf I, Meissner C](#) Related Articles, Links
Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI.
Acta Neuropathol (Berl). 1999 May;97(5):491-4.
PMID: 10334486 [PubMed - indexed for MEDLINE]

□ 111: [Johnson G, Moore SW](#) Related Articles, Links
The adhesion function on acetylcholinesterase is located at the peripheral anionic site.
Biochem Biophys Res Commun. 1999 May 19;258(3):758-62.
PMID: 10329459 [PubMed - indexed for MEDLINE]

□ 112: [Abrahams CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, Hasteey R, Johnson R, Fine RL, Smith SJ, Simons ER, Davies TA](#) Related Articles, Links
Platelets and DAMI megakaryocytes possess beta-secretase-like activity.
J Lab Clin Med. 1999 May;133(5):507-15.
PMID: 10235134 [PubMed - indexed for MEDLINE]

□ 113: [Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, Spitzfaden C, Wadsworth H, Wood SJ, Markwell RE](#) Related Articles, Links
Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.
Biochem J. 1999 May 15;340 (Pt 1):283-9.
PMID: 10229684 [PubMed - indexed for MEDLINE]

□ 114: [Frenkel D, Balass M, Katchalski-Katzir E, Solomon B](#) Related Articles, Links
High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.
J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.
PMID: 10229123 [PubMed - indexed for MEDLINE]

□ 115: [Pike CJ](#) Related Articles, Links
Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease.
J Neurochem. 1999 Apr;72(4):1552-63.
PMID: 10098861 [PubMed - indexed for MEDLINE]

 **116:** Fabrizi C, Businaro R, Iauro GM, Starace G, Fumagalli L. [Related Articles](#), [Links](#)
Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Exp Neurol. 1999 Feb;155(2):252-9.
 PMID: 10072300 [PubMed - indexed for MEDLINE]

 **117:** Winkler K, Scharnagl H, Tisljar U, Horschitzky H, Friedrich L, Hofmann MM, Huttinger M, Wieland H, Matz W. [Related Articles](#), [Links](#)
Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
J Lipid Res. 1999 Mar;40(3):447-55.
 PMID: 10064733 [PubMed - indexed for MEDLINE]

 **118:** Huber G, Thompson A, Gruninger F, Mechler H, Hochstrasser R, Lauri HP, Malherbe P. [Related Articles](#), [Links](#)
cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?
J Neurochem. 1999 Mar;72(3):1215-23.
 PMID: 10037494 [PubMed - indexed for MEDLINE]

 **119:** Ohara S, Tsukada M, Ikeda S. [Related Articles](#), [Links](#)
On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.
Acta Neuropathol (Berl). 1999 Jan;97(1):85-90.
 PMID: 9930899 [PubMed - indexed for MEDLINE]

 **120:** Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. [Related Articles](#), [Links](#)
Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.
Acta Neuropathol (Berl). 1999 Feb;97(2):113-8.
 PMID: 9928821 [PubMed - indexed for MEDLINE]

 **121:** Toszynski MII, Smith DE, Roberts J, McKay H, Mufson E. [Related Articles](#), [Links](#)
Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition.
Exp Neurol. 1998 Dec;154(2):573-82.
 PMID: 9878192 [PubMed - indexed for MEDLINE]

 **122:** Jin L W, Jearn MG, Ogburn CE, Dang N, Nocklin D, Ladiges WC, Martin GM. [Related Articles](#), [Links](#)
Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Am J Pathol. 1998 Dec;153(6):1679-86.
 PMID: 9846957 [PubMed - indexed for MEDLINE]

 **123:** Daly J 4th, Lahiri DK, Justus DE, Kotwal GJ. [Related Articles](#), [Links](#)
Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain.
Life Sci. 1998;63(23):2121-31.
 PMID: 9839536 [PubMed - indexed for MEDLINE]

 **124:** Kraszpulski M, Soininen H, Rickkinen P Sr, Alafuzoff I. [Related Articles](#), [Links](#)
Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in

 **human brain tissue.**
Histochem Cell Biol. 1998 Oct;110(4):439-45.
PMID: 9792423 [PubMed - indexed for MEDLINE]

 **125: Mizuno T, Haass C, Michikawa M, Yanagisawa K.** [Related Articles](#), [Links](#)
Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells.
Biochim Biophys Acta. 1998 Aug 14;1373(1):119-30.
PMID: 9733943 [PubMed - indexed for MEDLINE]

 **126: Yilmazer-Hanke DM.** [Related Articles](#), [Links](#)
Pathogenesis of Alzheimer-related neuritic plaques: AT8 immunoreactive dystrophic neurites precede argyrophilic neurites in plaques of the entorhinal region, hippocampal formation, and amygdala.
Clin Neuropathol. 1998 Jul-Aug;17(4):194-8.
PMID: 9707333 [PubMed - indexed for MEDLINE]

 **127: Hock C, Golombowski S, Müller-Spahn F, Peschel O, Riederer A, Probst A, Mandelkow E, Unger J.** [Related Articles](#), [Links](#)
Histological markers in nasal mucosa of patients with Alzheimer's disease.
Eur Neurol. 1998 Jul;40(1):31-6.
PMID: 9693230 [PubMed - indexed for MEDLINE]

 **128: Munch G, Cunningham AM, Riederer P, Braak E.** [Related Articles](#), [Links](#)
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
Brain Res. 1998 Jun 15;796(1-2):307-10.
PMID: 9689484 [PubMed - indexed for MEDLINE]

 **129: Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW.** [Related Articles](#), [Links](#)
Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.
Brain Res. 1998 Jun 15;796(1-2):187-97.
PMID: 9689469 [PubMed - indexed for MEDLINE]

 **130: Terryberry JW, Thor G, Peter JB.** [Related Articles](#), [Links](#)
Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.
Neurobiol Aging. 1998 May-Jun;19(3):205-16.
PMID: 9661995 [PubMed - indexed for MEDLINE]

 **131: Nakamura Y, Yamamoto M, Kunimatsu E.** [Related Articles](#), [Links](#)
A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin.
Brain Res. 1998 May 18;793(1-2):47-53.
PMID: 9630508 [PubMed - indexed for MEDLINE]

 **132: Spuler S, Emslie-Smith A, Engel AG.** [Related Articles](#), [Links](#)
Amyloid myopathy: an underdiagnosed entity.
Ann Neurol. 1998 Jun;43(6):719-28.
PMID: 9629841 [PubMed - indexed for MEDLINE]

 **133: Alonso NC, Hyman BT, Rebeck GW, Greenberg SM.** [Related Articles](#), [Links](#)
Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels.
J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9.
PMID: 9600229 [PubMed - indexed for MEDLINE]

134: Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K. [Related Articles](#) [Links](#)

Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein. *J Clin Lab Anal.* 1998;12(3):172-8. PMID: 9591705 [PubMed - indexed for MEDLINE]

135: Rossner S. [Related Articles](#) [Links](#)

Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease. *Int J Dev Neurosci.* 1997 Nov;15(7):835-50. Review. PMID: 9568532 [PubMed - indexed for MEDLINE]

136: Minn A, Schubert M, Neiss WF, Muller-Hill B. [Related Articles](#) [Links](#)

Enhanced GFAP expression in astrocytes of transgenic mice expressing the human brain-specific trypsinogen IV. *Glia.* 1998 Apr;22(4):338-47. PMID: 9517566 [PubMed - indexed for MEDLINE]

137: Murai H, Piercey JE, Raghupathi R, Smith DH, Saatman KE, Trojanowski JQ, Lee VM, Loring JF, Dickman C, Younkin S, McIntosh TK. [Related Articles](#) [Links](#)

Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. *J Comp Neurol.* 1998 Mar 23;392(4):428-38. PMID: 9514508 [PubMed - indexed for MEDLINE]

138: Dwork AJ, Liu D, Kaufman MA, Prohovnik I. [Related Articles](#) [Links](#)

Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes. *Clin Neuropathol.* 1998 Jan-Feb;17(1):45-9. PMID: 9496540 [PubMed - indexed for MEDLINE]

139: Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazaki K, Fukutani Y, Mukai M, Koshino E. [Related Articles](#) [Links](#)

KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains. *Dement Geriatr Cogn Disord.* 1998 Jan-Feb;9(1):13-9. PMID: 9469259 [PubMed - indexed for MEDLINE]

140: Dickson TC, Saunders HL, Vickers JC. [Related Articles](#) [Links](#)

Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. *Neuropathol Appl Neurobiol.* 1997 Dec;23(6):483-91. PMID: 9460714 [PubMed - indexed for MEDLINE]

141: Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. [Related Articles](#) [Links](#)

Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. *Acta Neuropathol (Berl).* 1997 Dec;94(6):519-24. PMID: 9444352 [PubMed - indexed for MEDLINE]

142: Jen A, Wickenden C, Rohan de Silva HA, Patel AJ. [Related Articles](#) [Links](#)

Preparation and purification of antisera against different regions or isoforms of beta-amyloid precursor protein. *Brain Res Brain Res Protoc.* 1997 Dec 1;2(1):23-30.

PMID: 9438067 [PubMed - indexed for MEDLINE]

□ 143: [Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowska AW](#) Related Articles, Links

□ [Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia.](#)
Acta Neurochir Suppl (Wien). 1997;70:247-9.
PMID: 9416336 [PubMed - indexed for MEDLINE]

□ 144: [Gearing M, Levy AI, Mirra SS](#) Related Articles, Links

□ [Diffuse plaques in the striatum in Alzheimer disease \(AD\): relationship to the striatal mosaic and selected neuropeptide markers.](#)
J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70.
PMID: 9413285 [PubMed - indexed for MEDLINE]

□ 145: [An SF, Giometto B, Greves M, Miller RF, Beckett AA, Gray F, Tavolato B, Scaravilli F](#) Related Articles, Links

□ [Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS.](#)
J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8.
PMID: 9370237 [PubMed - indexed for MEDLINE]

□ 146: [Lahiri DK, Fariow MR, Sambamurti K, Nall C](#) Related Articles, Links

□ [The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells.](#)
Life Sci. 1997;61(20):1985-92.
PMID: 9366505 [PubMed - indexed for MEDLINE]

□ 147: [Matsumoto A, Minami M, Matsumoto R](#) Related Articles, Links

□ [The beta-amyloid epitope masking activity in human brain is identified as albumin.](#)
Neuroreport. 1997 Oct 20;8(15):3297-301.
PMID: 9351660 [PubMed - indexed for MEDLINE]

□ 148: [Lahiri DK, Fariow MR, Nurnberger JI Jr, Greig NH](#) Related Articles, Links

□ [Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.](#)
Ann N Y Acad Sci. 1997 Sep 26;826:416-21.
PMID: 9329715 [PubMed - indexed for MEDLINE]

□ 149: [Sasaki S, Iwata M](#) Related Articles, Links

□ [Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis.](#)
Acta Neuropathol (Berl). 1997 Oct;94(4):338-44.
PMID: 9341934 [PubMed - indexed for MEDLINE]

□ 150: [Shea TB, Prabhakar S, Ekinci FJ](#) Related Articles, Links

□ [Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system.](#)
J Neurosci Res. 1997 Sep 15;49(6):759-68.
PMID: 9335263 [PubMed - indexed for MEDLINE]

□ 151: [Miller JD, Cummings J, Maresh GA, Walker DG, Casullo GM, Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD](#) Related Articles, Links

□ [Localization of perlecan \(or a perlecan-related macromolecule\) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus.](#)

Glia. 1997 Oct;21(2):228-43.
PMID: 9336237 [PubMed - indexed for MEDLINE]

□ 152: [Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyriek T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM](#) Related Articles, Links

 **Zyme**, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.
J Biol Chem. 1997 Oct 3;272(40):25135-42.
PMID: 9312124 [PubMed - indexed for MEDLINE]

□ 153: [Yamada T, Tsuboi Y, Takahashi M](#) Related Articles, Links

 Interrelationship between beta-amyloid deposition and complement-activated oligodendroglia.
Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72.
PMID: 9298627 [PubMed - indexed for MEDLINE]

□ 154: [Dewji NN, Singer SJ](#) Related Articles, Links

 Cell surface expression of the Alzheimer disease-related presenilin proteins.
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31.
PMID: 9275228 [PubMed - indexed for MEDLINE]

□ 155: [Cataldo AM, Barnett JL, Pieroni C, Nixon RA](#) Related Articles, Links

 Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.
J Neurosci. 1997 Aug 15;17(16):6142-51.
PMID: 9236226 [PubMed - indexed for MEDLINE]

□ 156: [Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B](#) Related Articles, Links

 The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.
FEBS Lett. 1997 Jul 28;412(2):341-5.
PMID: 9256248 [PubMed - indexed for MEDLINE]

□ 157: [Ohsawa I, Takamura C, Kohsaka S](#) Related Articles, Links

 The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.
Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65.
PMID: 9223426 [PubMed - indexed for MEDLINE]

□ 158: [Giometto B, An SF, Groves M, Scaravilli T, Geddes JF, Miller R, Tavolato B, Beckett AA, Scaravilli F](#) Related Articles, Links

 Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.
Ann Neurol. 1997 Jul;42(1):34-40.
PMID: 9225683 [PubMed - indexed for MEDLINE]

□ 159: [Hagg C, Cazorla P, Miguel CD, Valdivieso F, Vazquez J](#) Related Articles, Links

 Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.
Biochem J. 1997 Jul 1;325 (Pt 1):169-75.
PMID: 9224643 [PubMed - indexed for MEDLINE]

□ 160: [Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T](#) Related Articles, Links

 Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.
Psychiatry Clin Neurosci. 1997 Jun;51(3):135-8.
PMID: 9225377 [PubMed - indexed for MEDLINE]

 **161:** [Arai Y, Suzuki A, Mizuguchi M, Takashima S](#) Related Articles, Links

 Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
Brain Dev. 1997 Jun;19(4):290-4.
PMID: 9187481 [PubMed - indexed for MEDLINE]

 **162:** [Sasaki A, Iijima M, Yokoo H, Sheji M, Nakazato Y](#) Related Articles, Links

 Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study.
Brain Res. 1997 May 2;755(2):193-201.
PMID: 9175887 [PubMed - indexed for MEDLINE]

 **163:** [Solomon B, Koppell R, Frankel D, Hanan-Alharon E](#) Related Articles, Links

 Disaggregation of Alzheimer beta-amyloid by site-directed mAb.
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.
PMID: 9108113 [PubMed - indexed for MEDLINE]

 **164:** [Xu S, Gaskin E](#) Related Articles, Links

 Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.
Mech Ageing Dev. 1997 Mar;94(1-3):213-22.
PMID: 9147373 [PubMed - indexed for MEDLINE]

 **165:** [Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM](#) Related Articles, Links

 Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice.
Am J Pathol. 1997 Feb;150(2):417-27.
PMID: 9033257 [PubMed - indexed for MEDLINE]

 **166:** [Marambaud P, Chevallier N, Barelli H, Wilk S, Checler F](#) Related Articles, Links

 Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells.
J Neurochem. 1997 Feb;68(2):698-703.
PMID: 9003058 [PubMed - indexed for MEDLINE]

 **167:** [Walter J, Capell A, Hung AY, Langen H, Schnolzer M, Thinakaran G, Sisodia SS, Selkoe DJ, Haass C](#) Related Articles, Links

 Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations.
J Biol Chem. 1997 Jan 17;272(3):1896-903.
PMID: 8999878 [PubMed - indexed for MEDLINE]

 **168:** [McDermott JR, Gibson AM](#) Related Articles, Links

 Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.
Neurochem Res. 1997 Jan;22(1):49-56.
PMID: 9021762 [PubMed - indexed for MEDLINE]

 **169:** [Drache B, Dichl GE, Beyreuther K, Perlmutter LS, Konig G](#) Related Articles, Links

Bcl-xL-specific antibody labels activated microglia associated with

 **Alzheimer's disease and other pathological states.**
J Neurosci Res. 1997 Jan 1;47(1):98-108.
PMID: 8981243 [PubMed - indexed for MEDLINE]

 **170: Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R.** [Related Articles](#), [Links](#)
Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain.
Neurosci Lett. 1996 Dec 20;220(3):159-62.
PMID: 8994217 [PubMed - indexed for MEDLINE]

 **171: Sihag RK, Cataldo AM.** [Related Articles](#), [Links](#)
Brain beta-spectrin is a component of senile plaques in Alzheimer's disease.
Brain Res. 1996 Dec 16;743(1-2):249-57.
PMID: 9017252 [PubMed - indexed for MEDLINE]

 **172: Nielson KA, Cummings BJ, Cotman CW.** [Related Articles](#), [Links](#)
Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex.
Brain Res. 1996 Nov 25;741(1-2):284-93.
PMID: 9001734 [PubMed - indexed for MEDLINE]

 **173: Citron M, Dickey TS, Gordon G, Bierer BE, Seubert P, Selkoe DJ.** [Related Articles](#), [Links](#)
Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5.
PMID: 8917563 [PubMed - indexed for MEDLINE]

 **174: Su JH, Cummings BJ, Cotman CW.** [Related Articles](#), [Links](#)
Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments.
Brain Res. 1996 Nov 11;739(1-2):79-87.
PMID: 8955927 [PubMed - indexed for MEDLINE]

 **175: Dewji NN, Singer SJ.** [Related Articles](#), [Links](#)
Specific transcellular binding between membrane proteins crucial to Alzheimer disease.
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12575-80.
PMID: 8901624 [PubMed - indexed for MEDLINE]

 **176: Stephens DJ, Austen BM.** [Related Articles](#), [Links](#)
Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells.
J Neurosci Res. 1996 Oct 15;46(2):211-25.
PMID: 8915898 [PubMed - indexed for MEDLINE]

 **177: De Bleecker JL, Ertl BB, Engel AG.** [Related Articles](#), [Links](#)
Patterns of abnormal protein expression in target formations and unstructured cores.
Neuromuscul Disord. 1996 Oct;6(5):339-49.
PMID: 8938698 [PubMed - indexed for MEDLINE]

 **178: Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Fujimori O, Ojika K.** [Related Articles](#), [Links](#)

 Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation.
Neuropathol Appl Neurobiol. 1996 Oct;22(5):440-5.
PMID: 8930956 [PubMed - indexed for MEDLINE]

 179: [Kuo H](#), [Ingram DK](#), [Walker LC](#), [Tian M](#), [Hengemihle JM](#), [Jucker M](#) [Related Articles](#), [Links](#)
 Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains.
Neuroscience. 1996 Oct;74(3):733-40.
PMID: 8884769 [PubMed - indexed for MEDLINE]

 180: [Vodovotz Y](#), [Lucia MS](#), [Flanders KC](#), [Chesler L](#), [Xie QW](#), [Smith TW](#), [Weidner J](#), [Mumford R](#), [Webber R](#), [Nathan C](#), [Roberts AB](#), [Lippa CF](#), [Sporn MB](#) [Related Articles](#), [Links](#)
 Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
J Exp Med. 1996 Oct 1;184(4):1425-33.
PMID: 8879214 [PubMed - indexed for MEDLINE]

 181: [De La Monte SM](#), [Carlson RL](#), [Brown NV](#), [Wands JR](#) [Related Articles](#), [Links](#)
 Profiles of neuronal thread protein expression in Alzheimer's disease.
J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50.
PMID: 8858001 [PubMed - indexed for MEDLINE]

 182: [Castille GM](#), [Cummings JA](#), [Ngo C](#), [Yang W](#), [Snow AD](#) [Related Articles](#), [Links](#)
 Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain.
J Biochem (Tokyo). 1996 Aug;120(2):433-44.
PMID: 8889831 [PubMed - indexed for MEDLINE]

 183: [Tamaoka A](#), [Endoh R](#), [Sheji S](#), [Takahashi H](#), [Hirokawa K](#), [Teplow DB](#), [Selkoe DJ](#), [Mori H](#) [Related Articles](#), [Links](#)
 Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Neurobiol Aging. 1996 May-Jun;17(3):405-14.
PMID: 8725902 [PubMed - indexed for MEDLINE]

 184: [Johnstone EM](#), [Babbey LE](#), [Stephenson D](#), [Paul DC](#), [Santerre RF](#), [Clemens JA](#), [Williams DC](#), [Little SP](#) [Related Articles](#), [Links](#)
 Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.
Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.
PMID: 8607830 [PubMed - indexed for MEDLINE]

 185: [Zhang M](#), [Olsson Y](#) [Related Articles](#), [Links](#)
 Beta-amyloid precursor protein accumulates in axons around hematogenous metastases of the human brain: immunohistochemical observations.
Clin Neuropathol. 1996 Mar-Apr;15(2):74-8.
PMID: 8925600 [PubMed - indexed for MEDLINE]

 186: [Tckirjan TL](#), [Cole GM](#), [Russell MJ](#), [Yang F](#), [Wekstein DR](#), [Patel E](#), [Snowdon DA](#), [Markesberry WR](#), [Geddes JW](#) [Related Articles](#), [Links](#)
 Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains.
Neurobiol Aging. 1996 Mar-Apr;17(2):249-57.

PMID: 8744406 [PubMed - indexed for MEDLINE]

 187: [Liberski PP, Yanagihara R, Brown P, Kordecki R, Kloszewska I, Bratosiewicz J, Gajdusek DC.](#) Related Articles, Links

 Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses. *Neurodegeneration*. 1996 Mar;5(1):95-9. PMID: 8731388 [PubMed - indexed for MEDLINE]

 188: [Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ.](#) Related Articles, Links

 Localization and cell association of C1q in Alzheimer's disease brain. *Exp Neurol*. 1996 Mar;138(1):22-32. PMID: 8593893 [PubMed - indexed for MEDLINE]

 189: [Yasuhara O, Schwab C, Matsuo A, Kim SU, Steele JC, Akiguchi I, Kimura J, McGeer EG, McGeer PL.](#) Related Articles, Links

 Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam. *Neurosci Lett*. 1996 Feb 23;205(2):107-10. PMID: 8907328 [PubMed - indexed for MEDLINE]

 190: [Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK.](#) Related Articles, Links

 Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. *Proc Natl Acad Sci U S A*. 1996 Feb 6;93(3):1314-9. PMID: 8577761 [PubMed - indexed for MEDLINE]

 191: [Konig G, Graham P, Bushnell A, Webster S, Wunderlich D, Perlmutter LS.](#) Related Articles, Links

 Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide. *Ann N Y Acad Sci*. 1996 Jan 17;777:344-55. PMID: 8624111 [PubMed - indexed for MEDLINE]

 192: [McGeer PL, McGeer EG.](#) Related Articles, Links

 Anti-inflammatory drugs in the fight against Alzheimer's disease. *Ann N Y Acad Sci*. 1996 Jan 17;777:213-20. Review. PMID: 8624086 [PubMed - indexed for MEDLINE]

 193: [Solomon B, Koppel R, Hanan E, Katzav T.](#) Related Articles, Links

 Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. *Proc Natl Acad Sci U S A*. 1996 Jan 9;93(1):452-5. PMID: 8552659 [PubMed - indexed for MEDLINE]

 194: [Lahiri DK, Farlow MR.](#) Related Articles, Links

 Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. *J Mol Neurosci*. 1996 Spring;7(1):41-9. PMID: 8835781 [PubMed - indexed for MEDLINE]

 195: [Mena R, Edwards PC, Harrington CR, Mukacova-Ladinska EB, Wischik CM.](#) Related Articles, Links

 Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. *Acta Neuropathol (Berl)*. 1996;91(6):633-41. PMID: 8781663 [PubMed - indexed for MEDLINE]

 196: [Akaaboune M, Verdiere-Sahuque M, Lachkar S, Festoff BW.](#) Related Articles, Links

Hantai D.

 **196:** Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro.
J Cell Physiol. 1995 Dec;165(3):503-11.
PMID: 7593229 [PubMed - indexed for MEDLINE]

 **197:** Saito Y, Buciak J, Yang J, Pardridge WM. Related Articles, Links
Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31.
PMID: 7479757 [PubMed - indexed for MEDLINE]

 **198:** Link CD. Related Articles, Links
Expression of human beta-amyloid peptide in transgenic *Caenorhabditis elegans*.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72.
PMID: 7568134 [PubMed - indexed for MEDLINE]

 **199:** Matsumoto A, Matsumoto R, Baba H, Fujiwara Y. Related Articles, Links
A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate.
Neurosci Lett. 1995 Aug 11;195(3):171-4.
PMID: 8584202 [PubMed - indexed for MEDLINE]

 **200:** Kounnas MZ, Moir RD, Rebeck GW, Bush Al, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. Related Articles, Links
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation.
Cell. 1995 Jul 28;82(2):331-40.
PMID: 7543026 [PubMed - indexed for MEDLINE]

 **201:** Kida E, Wisniewski KE, Wisniewski IJM. Related Articles, Links
Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain.
Neurosci Lett. 1995 Jun 30;193(2):105-8.
PMID: 7478152 [PubMed - indexed for MEDLINE]

 **202:** Saito F, Tani A, Miyatake T, Yanagisawa K. Related Articles, Links
N-linked oligosaccharide of beta-amyloid precursor protein (beta APP) of C6 glioma cells: putative regulatory role in beta APP processing.
Biochem Biophys Res Commun. 1995 May 25;210(3):703-10.
PMID: 7763244 [PubMed - indexed for MEDLINE]

 **203:** Yamada T, Kobayashi T. Related Articles, Links
The mutation in amyloid precursor protein inhibits both alpha- and beta-secretion.
Neurosci Lett. 1995 May 19;191(1-2):103-6.
PMID: 7659274 [PubMed - indexed for MEDLINE]

 **204:** Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin F. Related Articles, Links
VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.

Clin Immunol Immunopathol. 1995 May;75(2):159-67.
PMID: 7704974 [PubMed - indexed for MEDLINE]

□ 205: [Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horuchi S](#) Related Articles, Links

Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?
Neuroreport. 1995 Apr 19;6(6):866-8.
PMID: 7612872 [PubMed - indexed for MEDLINE]

□ 206: [Pike CJ, Cummings BJ, Cotman CW](#) Related Articles, Links

Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?
Neuroreport. 1995 Apr 19;6(6):866-8.
PMID: 7612872 [PubMed - indexed for MEDLINE]

□ 207: [Kim CS, Hian YF, Etcheberrigaray R, Nelson TJ, Olds JL, Yeshioka T, Alkon DL](#) Related Articles, Links

Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20.
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4.
PMID: 7708775 [PubMed - indexed for MEDLINE]

□ 208: [Walker DG, Kim SU, McGeer PL](#) Related Articles, Links

Complement and cytokine gene expression in cultured microglial derived from postmortem human brains.
J Neurosci Res. 1995 Mar 1;40(4):478-93.
PMID: 7616608 [PubMed - indexed for MEDLINE]

□ 209: [Van Gool D, De Strooper B, Van Leuven F, Dom R](#) Related Articles, Links

Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease.
Dementia. 1995 Mar-Apr;6(2):63-8.
PMID: 7606281 [PubMed - indexed for MEDLINE]

□ 210: [Armstrong RA, Winsper SJ, Blair JA](#) Related Articles, Links

Hypothesis: is Alzheimer's disease a metal-induced immune disorder?
Neurodegeneration. 1995 Mar;4(1):107-11.
PMID: 7600179 [PubMed - indexed for MEDLINE]

□ 211: [McRae A, Gilliland E, Bona E, Hagberg H](#) Related Articles, Links

Microglia activation after neonatal hypoxic-ischemia.
Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52.
PMID: 7743644 [PubMed - indexed for MEDLINE]

□ 212: [Saido TC, Iwatsubo T, Mana DM, Shimada H, Ihara Y, Kawashima S](#) Related Articles, Links

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.
Neuron. 1995 Feb;14(2):457-66.
PMID: 7857653 [PubMed - indexed for MEDLINE]

□ 213: [Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL](#) Related Articles, Links

Interaction of beta-amyloid peptides with integrins in a human nerve cell line.
Neurosci Lett. 1995 Jan 16;184(1):25-8.
PMID: 7739799 [PubMed - indexed for MEDLINE]

□ 214: [Cabal A, Alonso-Cortina V, Gonzalez-Vazquez L.O, Navares F.J, Del Valle M.E, Vega JA](#) Related Articles, Links

 beta-Amyloid precursor protein (beta APP) in human gut with special reference to the enteric nervous system.
Brain Res Bull. 1995;38(5):417-23.
PMID: 8665264 [PubMed - indexed for MEDLINE]

 **215:** Schwab C, Steele JC, Akhyama H, McGeer EG, McGeer PL. [Related Articles](#), [Links](#)
Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia.
Acta Neuropathol (Berl). 1995;90(3):287-98.
PMID: 8525803 [PubMed - indexed for MEDLINE]

 **216:** Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Sica RE. [Related Articles](#), [Links](#)
Early onset Alzheimer's disease in a South American pedigree from Argentina.
Acta Neurol Scand. 1995 Jan;91(1):6-13.
PMID: 7732777 [PubMed - indexed for MEDLINE]

 **217:** Mena R, Edwards P, Perez-Olvera O, Wischik CM. [Related Articles](#), [Links](#)
Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease.
Acta Neuropathol (Berl). 1995;89(1):50-6.
PMID: 7709731 [PubMed - indexed for MEDLINE]

 **218:** Jakes R, Harrington CR, Spillanini MG, Goedert M, Klug A. [Related Articles](#), [Links](#)
Characterisation of an antibody relevant to the neuropathology of Alzheimer disease.
Alzheimer Dis Assoc Disord. 1995 Spring;9(1):47-51.
PMID: 7605621 [PubMed - indexed for MEDLINE]

 **219:** Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamanoto T. [Related Articles](#), [Links](#)
Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells.
Acta Neuropathol (Berl). 1995;89(3):199-203.
PMID: 7538720 [PubMed - indexed for MEDLINE]

 **220:** Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. [Related Articles](#), [Links](#)
Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum.
Brain Res. 1994 Dec 19;667(1):138-42.
PMID: 7895077 [PubMed - indexed for MEDLINE]

 **221:** Oda T, Pasinetti GM, Osterburg HJ, Anderson C, Johnson SA, Finch CE. [Related Articles](#), [Links](#)
Purification and characterization of brain clusterin.
Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6.
PMID: 7980587 [PubMed - indexed for MEDLINE]

 **222:** O'Brien TJ, McKelvie PA, Vrados N. [Related Articles](#), [Links](#)
Bilateral trigeminal amyloidoma: an unusual case of trigeminal neuropathy with a review of the literature. Case report.
J Neurosurg. 1994 Nov;81(5):780-3. Review.
PMID: 7931626 [PubMed - indexed for MEDLINE]

 **223:** Katsetos CL, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J. [Related Articles](#), [Links](#)
Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies.

Clin Neuropathol. 1994 Nov-Dec;13(6):306-14.
PMID: 7851045 [PubMed - indexed for MEDLINE]

□ 224: [McGeer PI, Klegeris A, Walker DG, Yasuhara O, McGeer EG](#). [Related Articles](#), [Links](#)

Pathological proteins in senile plaques.
Tohoku J Exp Med. 1994 Nov;174(3):269-77.
PMID: 7761992 [PubMed - indexed for MEDLINE]

□ 225: [Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM](#). [Related Articles](#), [Links](#)

Monoclonal antibody to the C-terminus of beta-amyloid.
Neuroreport. 1994 Oct 27;5(16):2117-20.
PMID: 7865758 [PubMed - indexed for MEDLINE]

□ 226: [Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA](#). [Related Articles](#), [Links](#)

Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease.
Brain Res. 1994 Oct 24;661(1-2):35-42.
PMID: 7834382 [PubMed - indexed for MEDLINE]

□ 227: [Sherriff FE, Bridges LR, De Souza DS](#). [Related Articles](#), [Links](#)

Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity.
Neuroreport. 1994 Oct 3;5(15):1897-900.
PMID: 7531003 [PubMed - indexed for MEDLINE]

□ 228: [Dreyer RN, Bausch KM, Fracasso P, Hammond J, Wunderlich D, Wirak DO, Davis G, Brint CM, Buckholz TM, Konig G, et al](#). [Related Articles](#), [Links](#)

Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation.
Eur J Biochem. 1994 Sep 1;224(2):265-71.
PMID: 7523115 [PubMed - indexed for MEDLINE]

□ 229: [van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Swaab DF](#). [Related Articles](#), [Links](#)

The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas.
Brain Res. 1994 Aug 29;655(1-2):97-109.
PMID: 7812796 [PubMed - indexed for MEDLINE]

□ 230: [Durham HD, Minotti S, Dooley NP, Nalbantoglu J](#). [Related Articles](#), [Links](#)

Expression of the intermediate filament-associated protein related to beta-amyloid precursor protein is developmentally regulated in cultured cells.
J Neurosci Res. 1994 Aug 15;38(6):629-39.
PMID: 7807580 [PubMed - indexed for MEDLINE]

□ 231: [Heinonen O, Soininen H, Syrjanen S, Neitaanmaki H, Paljarvi L, Kosunen O, Syrjanen K, Riekkinen P, Si](#). [Related Articles](#), [Links](#)

beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study.
Arch Neurol. 1994 Aug;51(8):799-804.
PMID: 8042928 [PubMed - indexed for MEDLINE]

□ 232: [Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA](#). [Related Articles](#), [Links](#)

Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.
Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13.

PMID: 7888086 [PubMed - indexed for MEDLINE]

 233: Singh VK.[Related Articles](#), [Links](#) Studies of neuroimmune markers in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81.

PMID: 7534089 [PubMed - indexed for MEDLINE]

 234: Snyder SW, Wang GT, Barrett L, Ladrer US, Casuto D, Lee CM. [Related Articles](#), [Links](#)
Kraft GA, Holzman RB, Holzman TE. Complement C1q does not bind monomeric beta-amyloid.

Exp Neurol. 1994 Jul;128(1):136-42.

PMID: 8070518 [PubMed - indexed for MEDLINE]

 235: Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. [Related Articles](#), [Links](#) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Neuron. 1994 Jul;13(1):45-53.

PMID: 8043280 [PubMed - indexed for MEDLINE]

 236: Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S. [Related Articles](#), [Links](#) Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus.

J Biol Chem. 1994 May 27;269(21):15253-7.

PMID: 8195161 [PubMed - indexed for MEDLINE]

 237: Schmidt ML, DiDario AG, Lee VM, Trojanowski JQ. [Related Articles](#), [Links](#) An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease.

FEBS Lett. 1994 May 9;344(1):69-73.

PMID: 8181568 [PubMed - indexed for MEDLINE]

 238: Murphy GM Jr, Forno LS, Higgins J, Scardina JM, Eng LF, Cordell B. [Related Articles](#), [Links](#) Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Am J Pathol. 1994 May;144(5):1082-8.

PMID: 8178931 [PubMed - indexed for MEDLINE]

 239: Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. [Related Articles](#), [Links](#) Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease.

J Neuropathol Exp Neurol. 1994 May;53(3):231-8.

PMID: 8176406 [PubMed - indexed for MEDLINE]

 240: Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D. [Related Articles](#), [Links](#) Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy.

J Neurobiol. 1994 May;25(5):503-14.

PMID: 8071658 [PubMed - indexed for MEDLINE]

 241: Beeson JG, Shelton ER, Chan HW, Gage FH. [Related Articles](#), [Links](#) Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies.

J Comp Neurol. 1994 Apr 1;342(1):78-96.
PMID: 8207129 [PubMed - indexed for MEDLINE]

□ 242: [Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI](#) Related Articles, Links

□ Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.
J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25.
PMID: 8163989 [PubMed - indexed for MEDLINE]

□ 243: [Bilak M, Askanas V, Engel WK](#) Related Articles, Links

□ Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions.
Synapse. 1994 Apr;16(4):280-3.
PMID: 8059338 [PubMed - indexed for MEDLINE]

□ 244: [Bickel U, Lee VM, Trojanowski JQ, Pardridge WM](#) Related Articles, Links

□ Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease.
Bioconjug Chem. 1994 Mar-Apr;5(2):119-25.
PMID: 8031874 [PubMed - indexed for MEDLINE]

□ 245: [Löffler J, Langui D, Probst A, Huber G](#) Related Articles, Links

□ Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex.
Neurochem Int. 1994 Mar;24(3):281-8.
PMID: 8025536 [PubMed - indexed for MEDLINE]

□ 246: [Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K](#) Related Articles, Links

□ Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.
Am J Pathol. 1994 Feb;144(2):337-47.
PMID: 8311117 [PubMed - indexed for MEDLINE]

□ 247: [Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Brückner G](#) Related Articles, Links

□ Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid.
Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5 (8):following 1014.
PMID: 8025246 [PubMed - indexed for MEDLINE]

□ 248: [Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG](#) Related Articles, Links

□ An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain.
Neuron. 1994 Jan;12(1):219-34.
PMID: 8292358 [PubMed - indexed for MEDLINE]

□ 249: [Askanas V, Engel WK, Bilak M, Alvarez RR, Selkoe DJ](#) Related Articles, Links

□ Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.
Am J Pathol. 1994 Jan;144(1):177-87.
PMID: 8291607 [PubMed - indexed for MEDLINE]

□ 250: [Westarp ME, Foring B, Rasmussen H, Schraff S, Mertens T, Kornhuber HH](#) Related Articles, Links

 **Retroviral synthetic peptide serum antibodies in human sporadic amyotrophic lateral sclerosis.**
Peptides. 1994;15(2):207-14.
PMID: 8008625 [PubMed - indexed for MEDLINE]

251: Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA. [Related Articles](#), [Links](#)

 **Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology.**
Acta Neuropathol (Berl). 1994;88(4):371-8.
PMID: 7839831 [PubMed - indexed for MEDLINE]

252: Zemlan FP, Vogelsang GD, McLoughlin L, Dean GE. [Related Articles](#), [Links](#)

 **Alzheimer's paired helical filaments: amyloid precursor protein epitope mapping.**
Brain Res Bull. 1994;33(4):387-92.
PMID: 7510209 [PubMed - indexed for MEDLINE]

253: Cummings BJ, Su JI, Cotman CW. [Related Articles](#), [Links](#)

 **Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease.**
Exp Neurol. 1993 Dec;124(2):315-25.
PMID: 8287930 [PubMed - indexed for MEDLINE]

254: Sussman MA, Bilak M, Kedes L, Engel WK, Askanas V. [Related Articles](#), [Links](#)

 **Tropomodulin is highly concentrated at the postsynaptic domain of human and rat neuromuscular junctions.**
Exp Cell Res. 1993 Dec;209(2):388-91.
PMID: 8262158 [PubMed - indexed for MEDLINE]

255: Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. [Related Articles](#), [Links](#)

 **Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease.**
Neurobiol Aging. 1993 Nov-Dec;14(6):589-96.
PMID: 8295661 [PubMed - indexed for MEDLINE]

256: Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. [Related Articles](#), [Links](#)

 **Characterization of beta-amyloid peptide from human cerebrospinal fluid.**
J Neurochem. 1993 Nov;61(5):1965-8.
PMID: 8229004 [PubMed - indexed for MEDLINE]

257: Jucker M, Walker LC, Kibbey MC, Kleinman UK, Ingram DK. [Related Articles](#), [Links](#)

 **Localization of a laminin-binding protein in brain.**
Neuroscience. 1993 Oct;56(4):1009-22.
PMID: 8284032 [PubMed - indexed for MEDLINE]

258: Higgins LS, Catalano R, Quon D, Cordell B. [Related Articles](#), [Links](#)

 **Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology.**
Ann N Y Acad Sci. 1993 Sep 24;695:224-7.
PMID: 8239286 [PubMed - indexed for MEDLINE]

259: Askanas V, Bilak M, Engel WK, Leclerc A, Tome F. [Related Articles](#), [Links](#)

 **Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions.**
Neurosci Lett. 1993 Sep 3;159(1-2):111-4.
PMID: 8264949 [PubMed - indexed for MEDLINE]

260: Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM. [Related Articles](#) [Links](#)
 Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.
Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract available.
PMID: 8224394 [PubMed - indexed for MEDLINE]

261: Miklossy J. [Related Articles](#) [Links](#)
 Alzheimer's disease--a spirochetosis?
Neuroreport. 1993 Jul;4(7):841-8.
PMID: 8369471 [PubMed - indexed for MEDLINE]

262: Leclerc A, Tome FM, Fardeau M. [Related Articles](#) [Links](#)
 Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study.
Neuromuscul Disord. 1993 Jul;3(4):283-91.
PMID: 8268725 [PubMed - indexed for MEDLINE]

263: Singhrao SK, Neal JW, Newman GR. [Related Articles](#) [Links](#)
 Corpora amylacea could be an indicator of neurodegeneration.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76.
PMID: 8355813 [PubMed - indexed for MEDLINE]

264: Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor F Jr. [Related Articles](#) [Links](#)
 The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):261-8.
PMID: 8355812 [PubMed - indexed for MEDLINE]

265: DeWitt DA, Silver J, Canning DR, Perry G. [Related Articles](#) [Links](#)
 Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease.
Exp Neurol. 1993 Jun;121(2):149-52.
PMID: 8339766 [PubMed - indexed for MEDLINE]

266: Fukuchi K, Sopher B, Furlong CE, Smith AC, Dang N, Martin GM. [Related Articles](#) [Links](#)
 Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein.
Neurosci Lett. 1993 May 14;154(1-2):145-8.
PMID: 8361630 [PubMed - indexed for MEDLINE]

267: Scott SA, Johnson SA, Zarow C, Perlmutter LS. [Related Articles](#) [Links](#)
 Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia.
Exp Neurol. 1993 May;121(1):113-8.
PMID: 8495706 [PubMed - indexed for MEDLINE]

268: Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL. [Related Articles](#) [Links](#)
 Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease.
Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51.
PMID: 8476427 [PubMed - indexed for MEDLINE]

269: Lahiri DK. [Related Articles](#) [Links](#)
 The stability of beta-amyloid precursor protein in nine different cell types.
Biochem Mol Biol Int. 1993 Apr;29(5):849-58

PMID: 8508138 [PubMed - indexed for MEDLINE]

 270: [Gaskin F, Finley J, Fang Q, Xu S, Fu SM.](#) [Related Articles](#), [Links](#)
Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.
J Exp Med. 1993 Apr 1;177(4):1181-6.
PMID: 8459212 [PubMed - indexed for MEDLINE]

 271: [Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE.](#) [Related Articles](#), [Links](#)
Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.
Neuron. 1993 Feb;10(2):243-54.
PMID: 8094963 [PubMed - indexed for MEDLINE]

 272: [Bucci L, Ding W, Delacourte A, Fillit H.](#) [Related Articles](#), [Links](#)
Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.
Brain Res. 1993 Jan 22;601(1-2):154-63.
PMID: 8431762 [PubMed - indexed for MEDLINE]

 273: [Seubert P, Oltersdorf T, Lee MG, Barbour R, Blennquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Trojanowski J, et al.](#) [Related Articles](#), [Links](#)
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.
Nature. 1993 Jan 21;361(6409):260-3.
PMID: 7678698 [PubMed - indexed for MEDLINE]

 274: [Nelson PT, Marton L, Saper CB.](#) [Related Articles](#), [Links](#)
Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study.
Brain Res. 1993 Jan 15;600(2):285-97.
PMID: 8094642 [PubMed - indexed for MEDLINE]

 275: [Wisniewski HM, Weigel J.](#) [Related Articles](#), [Links](#)
Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation.
Acta Neuropathol (Berl). 1993;85(6):586-95.
PMID: 8337937 [PubMed - indexed for MEDLINE]

 276: [Su JH, Cummings BJ, Cotman CW](#) [Related Articles](#), [Links](#)
Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.
Neuroscience. 1992 Dec;51(4):801-13.
PMID: 1488123 [PubMed - indexed for MEDLINE]

 277: [Perlmutter LS, Scott SA, Barbour R, Chui HC.](#) [Related Articles](#), [Links](#)
MHC class II-positive microglia in human brain: association with Alzheimer lesions.
J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: *J Neurosci Res* 1993 Jun 15;35(3):346.
PMID: 1484388 [PubMed - indexed for MEDLINE]

 278: [Kammesheidt A, Boyce FM, Spanoianis AF, Cummings BJ, Ortega M, Cotman C, Vaught JL, Neve RL.](#) [Related Articles](#), [Links](#)
Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain.
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61

PMID: 1438289 [PubMed - indexed for MEDLINE]

□ 279: [Rogers J, Cooper NR, Webster S, Schultz J, McGaugh JL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al.](#) [Related Articles](#), [Links](#)

 Complement activation by beta-amyloid in Alzheimer disease.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20.
PMID: 1438191 [PubMed - indexed for MEDLINE]

□ 280: [Brewer GJ, Ashford JW.](#) [Related Articles](#), [Links](#)

 Human serum stimulates Alzheimer markers in cultured hippocampal neurons.
J Neurosci Res. 1992 Nov;33(3):355-69.
PMID: 1335088 [PubMed - indexed for MEDLINE]

□ 281: [Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al.](#) [Related Articles](#), [Links](#)

 Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.
Nature. 1992 Sep 24;359(6393):325-7.
PMID: 1406936 [PubMed - indexed for MEDLINE]

□ 282: [Haass C, Schlossmacher MG, Hock AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al.](#) [Related Articles](#), [Links](#)

 Amyloid beta-peptide is produced by cultured cells during normal metabolism.
Nature. 1992 Sep 24;359(6393):322-5.
PMID: 1383826 [PubMed - indexed for MEDLINE]

□ 283: [Dooley NT, Gauthier S, Durham IID.](#) [Related Articles](#), [Links](#)

 Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts.
J Neurosci Res. 1992 Sep;33(1):60-7.
PMID: 1453484 [PubMed - indexed for MEDLINE]

□ 284: [Askanas V, Engel WK, Alvarez RB.](#) [Related Articles](#), [Links](#)

 Strong immunoreactivity of beta-amyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions.
Neurosci Lett. 1992 Aug 31;143(1-2):96-100.
PMID: 1436686 [PubMed - indexed for MEDLINE]

□ 285: [Murphy GM Jr, Greenberg BD, Ellis WG, Forno LS, Salamat SM, Gonzalez-DeWhitt PA, Lowery DE, Tinklenberg JR, Eng LF.](#) [Related Articles](#), [Links](#)

 Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.
Am J Pathol. 1992 Aug;141(2):357-61.
PMID: 1386714 [PubMed - indexed for MEDLINE]

□ 286: [Lippa CF, Smith TW.](#) [Related Articles](#), [Links](#)

 The indusium griseum in Alzheimer's disease: an immunocytochemical study.
J Neurol Sci. 1992 Aug;111(1):39-45.
PMID: 1328542 [PubMed - indexed for MEDLINE]

□ 287: [Estoff BW, Rao JS, Chen M.](#) [Related Articles](#), [Links](#)

 Protease nexin I, thrombin- and urokinase-inhibiting serpin, concentrated in normal human cerebrospinal fluid.
Neurology. 1992 Jul;42(7):1361-6.

PMID: 1620346 [PubMed - indexed for MEDLINE]

□ 288: [Rogers J, Schultz J, Brachova L, Lue I.F., Webster S, Bradt B, Cooper NR, Moss DE.](#) [Related Articles](#), [Links](#)

□ Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.

Res Immunol. 1992 Jul-Aug;143(6):624-30. Review. No abstract available.
PMID: 1455054 [PubMed - indexed for MEDLINE]

□ 289: [Arai H, Schmitz ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ.](#) [Related Articles](#), [Links](#)

□ Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease.

Neurology. 1992 Jul;42(7):1315-22.
PMID: 1377804 [PubMed - indexed for MEDLINE]

□ 290: [Askanas V, Engel WK, Alvarez RB.](#) [Related Articles](#), [Links](#)

□ Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis.

Am J Pathol. 1992 Jul;141(1):31-6.
PMID: 1321564 [PubMed - indexed for MEDLINE]

□ 291: [Caputo CB, Sobel IR, Scott CW, Brunner WF, Barth PT, Blowers DP.](#) [Related Articles](#), [Links](#)

□ Association of the carboxy-terminus of beta-amyloid protein precursor with Alzheimer paired helical filaments.

Biochem Biophys Res Commun. 1992 Jun 30;185(3):1034-40.
PMID: 1627127 [PubMed - indexed for MEDLINE]

□ 292: [Haass C, Koo EH, Mellon A, Hung A.Y., Seikoc DJ.](#) [Related Articles](#), [Links](#)

□ Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.

Nature. 1992 Jun 11;357(6378):500-3.
PMID: 1608449 [PubMed - indexed for MEDLINE]

□ 293: [Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW.](#) [Related Articles](#), [Links](#)

□ Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease.

Neuroscience. 1992 Jun;48(4):763-77.
PMID: 1378573 [PubMed - indexed for MEDLINE]

□ 294: [McGeer PL, Akiyama H, Kawamata T, Yamada T, Walker DG, Ishii T.](#) [Related Articles](#), [Links](#)

□ Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy.

J Neurosci Res. 1992 Mar;31(3):428-42.
PMID: 1640495 [PubMed - indexed for MEDLINE]

□ 295: [Askanas V, Engel WK, Alvarez RB, Glenner GG.](#) [Related Articles](#), [Links](#)

□ beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis.

Lancet. 1992 Feb 29;339(8792):560-1. No abstract available.
PMID: 1346915 [PubMed - indexed for MEDLINE]

□ 296: [Ohgami T, Kitamoto T, Tatschishi J.](#) [Related Articles](#), [Links](#)

□ Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions.

Neurosci Lett. 1992 Feb 17;136(1):75-8.
PMID: 1635670 [PubMed - indexed for MEDLINE]

297: [Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV.](#) [Related Articles](#), [Links](#)

Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human beta amyloid precursor protein.
J Immunol Methods. 1992 Feb 14;147(1):1-11.
PMID: 1371794 [PubMed - indexed for MEDLINE]

298: [Delvaux A, Van der Elst L, Octave JN.](#) [Related Articles](#), [Links](#)

Inhibition of trypsin by the beta-amyloid protein precursor. A comparative study between transfected cells, human brain and cerebrospinal fluid.
FEBS Lett. 1992 Feb 3;297(1-2):124-6.
PMID: 1551418 [PubMed - indexed for MEDLINE]

299: [Chei-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M.](#) [Related Articles](#), [Links](#)

SP-40,40 is a constituent of Alzheimer's amyloid.
Acta Neuropathol (Berl). 1992;83(3):260-4.
PMID: 1373021 [PubMed - indexed for MEDLINE]

300: [Barcikowska M, Kujawa M, Wisniewski H.](#) [Related Articles](#), [Links](#)

beta-Amyloid deposits within the cerebellum of persons older than 80 years of age.
Neuropatol Pol. 1992;30(3-4):285-93.
PMID: 1340921 [PubMed - indexed for MEDLINE]

301: [Frautschy SA, Baird A, Cole GM.](#) [Related Articles](#), [Links](#)

Effects of injected Alzheimer beta-amyloid cores in rat brain.
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6.
PMID: 1924295 [PubMed - indexed for MEDLINE]

302: [Ito H, Hirano H, Yen SH, Kato S.](#) [Related Articles](#), [Links](#)

Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam.
Neuropathol Appl Neurobiol. 1991 Oct;17(5):365-73.
PMID: 1758569 [PubMed - indexed for MEDLINE]

303: [Cras P, Kawai M, Lowery D, Gonzalez DeWhitt P, Greenberg B, Perry G.](#) [Related Articles](#), [Links](#)

Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552-6.
PMID: 1652752 [PubMed - indexed for MEDLINE]

304: [Price JL, Davis PB, Morris JC, White DL.](#) [Related Articles](#), [Links](#)

The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.
Neurobiol Aging. 1991 Jul-Aug;12(4):295-312.
PMID: 1961359 [PubMed - indexed for MEDLINE]

305: [Knops J, Johnson-Wood K, Schenk D, Sinha S, Lieberburg I, McConlogue L.](#) [Related Articles](#), [Links](#)

Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.
J Biol Chem. 1991 Apr 15;266(11):7285-90.

PMID: 1901866 [PubMed - indexed for MEDLINE]

306: Fraser PE, Duffy J.K., O'Malley MB, Nguyen J, Inouye H, Kirschner DA. [Related Articles](#) [Links](#)

Morphology and antibody recognition of synthetic beta-amyloid peptides. *J Neurosci Res.* 1991 Apr;28(4):474-85.
PMID: 1908024 [PubMed - indexed for MEDLINE]

307: Matsunoto A, Fujiwara Y. [Related Articles](#) [Links](#)

Abnormal and deficient processing of beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells. *Biochem Biophys Res Commun.* 1991 Mar 15;175(2):361-5.
PMID: 1902089 [PubMed - indexed for MEDLINE]

308: Henriksson T, Barbour RM, Braa S, Ward P, Fritz J.C., Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Rickknen P, et al. [Related Articles](#) [Links](#)

Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. *J Neurochem.* 1991 Mar;56(3):1037-42.
PMID: 1899691 [PubMed - indexed for MEDLINE]

309: Pendleton WW, Iole ED, Tracy RP, Dill RA. [Related Articles](#) [Links](#)

Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment. *Ann Neurol.* 1991 Feb;29(2):210-3.
PMID: 1901466 [PubMed - indexed for MEDLINE]

310: Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D. [Related Articles](#) [Links](#)

Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. *Am J Pathol.* 1991 Feb;138(2):373-84.
PMID: 1704190 [PubMed - indexed for MEDLINE]

311: Takahashi H, Hirokawa K, Ando S, Obata K. [Related Articles](#) [Links](#)

Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5. *Acta Neuropathol (Berl).* 1991;81(6):626-31.
PMID: 1909079 [PubMed - indexed for MEDLINE]

312: Becker L, Mito T, Takashima S, Onodera K. [Related Articles](#) [Links](#)

Growth and development of the brain in Down syndrome. *Prog Clin Biol Res.* 1991;373:133-52. Review.
PMID: 1838182 [PubMed - indexed for MEDLINE]

313: Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN. [Related Articles](#) [Links](#)

Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. *Am J Pathol.* 1990 Nov;137(5):1253-70.
PMID: 2146882 [PubMed - indexed for MEDLINE]

314: Bodmer S, Podlisny MB, Selkoe DJ, Heid J, Fontana A. [Related Articles](#) [Links](#)

Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. *Biochem Biophys Res Commun.* 1990 Sep 14;171(2):890-7.
PMID: 2119582 [PubMed - indexed for MEDLINE]

315: Kanemaru K, Hasegawa M, Shimada H, Ihara Y. [Related Articles](#) [Links](#)
 The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section.
Am J Pathol. 1990 Sep;137(3):677-87.
PMID: 1698030 [PubMed - indexed for MEDLINE]

316: Tate-Ostroff B, Majocha RE, Walcott BC, Ventosa-Michelman M, Marotta CA. [Related Articles](#) [Links](#)
 Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein.
J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45.
PMID: 2126439 [PubMed - indexed for MEDLINE]

317: Shelton ER, Cohn R, Fish J, Oberholte R, Tahilramani R, Nestor JL, Chan JYW. [Related Articles](#) [Links](#)
 Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies.
J Neurochem. 1990 Jul;55(1):60-9.
PMID: 2113083 [PubMed - indexed for MEDLINE]

318: Wolf D, Quon D, Wang Y, Cordell B. [Related Articles](#) [Links](#)
 Identification and characterization of C-terminal fragments of the beta-amyloid precursor produced in cell culture.
EMBO J. 1990 Jul;9(7):2079-84.
PMID: 1694126 [PubMed - indexed for MEDLINE]

319: Stern RA, Trojanowski JQ, Lee VM. [Related Articles](#) [Links](#)
 Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood.
FEBS Lett. 1990 May 7;264(1):43-7.
PMID: 1692541 [PubMed - indexed for MEDLINE]

320: Spillantini MG, Goedert M, Jakes R, Klug A. [Related Articles](#) [Links](#)
 Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease.
Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51.
PMID: 2111023 [PubMed - indexed for MEDLINE]

321: Singhrao S, Cole G, Henderson WJ, Newman GR. [Related Articles](#) [Links](#)
 LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease.
Histochem J. 1990 May;22(5):257-68.
PMID: 1966829 [PubMed - indexed for MEDLINE]

322: Spillantini MG, Goedert M, Jakes R, Klug A. [Related Articles](#) [Links](#)
 Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease.
Proc Natl Acad Sci U S A. 1990 May;87(10):3952-6.
PMID: 1692627 [PubMed - indexed for MEDLINE]

323: Cataldo AM, Nixon RA. [Related Articles](#) [Links](#)
 Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.
Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5.
PMID: 1692625 [PubMed - indexed for MEDLINE]

324: Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE. [Related Articles](#) [Links](#)


Sharma SK, Schmidt ML, Trojanowski JQ.



Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.

Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53.

PMID: 1690426 [PubMed - indexed for MEDLINE]



325: Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H. [Related Articles](#) [Links](#)



Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9.

PMID: 2106318 [PubMed - indexed for MEDLINE]



326: Koo EJ, Sisodia SS, Archer DR, Martin JJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. [Related Articles](#) [Links](#)



Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.

Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5.

PMID: 1689489 [PubMed - indexed for MEDLINE]



327: Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Benes FM, Marotta CA. [Related Articles](#) [Links](#)



Alzheimer cortical neurons containing abundant amyloid mRNA.

Relationship to amyloid deposition and senile plaques.

J Psychiatr Res. 1990;24(1):37-50.

PMID: 2195164 [PubMed - indexed for MEDLINE]



328: Dewji NN, Shelton ER, Adier MJ, Chan JHW, Seegmiller JE, Coronel C. [Related Articles](#) [Links](#)



Processing of Alzheimer's disease-associated beta-amyloid precursor protein.

J Mol Neurosci. 1990;2(1):19-27.

PMID: 2124135 [PubMed - indexed for MEDLINE]



329: Murphy GM Jr, Eng LF, Cordell B, Wang Y, Ellis WG, Meissner L, Tinklenberg JR. [Related Articles](#) [Links](#)



Beta-amyloid precursor detected in human cerebral cortex.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17.

PMID: 2113696 [PubMed - indexed for MEDLINE]



330: Takahashi H, Kurashima C, Utsuyama M, Hirokawa K. [Related Articles](#) [Links](#)



Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.

Acta Neuropathol (Berl). 1990;80(3):260-5.

PMID: 1698004 [PubMed - indexed for MEDLINE]



331: Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski ML, Frangione B. [Related Articles](#) [Links](#)



Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.

J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8.

PMID: 1688925 [PubMed - indexed for MEDLINE]



332: Suenaga T, Hirano A, Lienna JF, Ksieczak-Reding H, Yen SH, Dickson DW. [Related Articles](#) [Links](#)



Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.

J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40.

PMID: 1688924 [PubMed - indexed for MEDLINE]

333: [Palmiter MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan IH, Usiak M, Selkoe DJ, Perry G, Younkin SG](#) Related Articles, Links

 Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein.
Biochem Biophys Res Commun. 1989 Nov 30;165(1):182-8.
PMID: 2480122 [PubMed - indexed for MEDLINE]

334: [Beltrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M](#) Related Articles, Links

 An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles.
J Gerontol. 1989 Nov;44(6):B156-9.
PMID: 2681356 [PubMed - indexed for MEDLINE]

335: [Palmiter MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG](#) Related Articles, Links

 The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42.
PMID: 2503832 [PubMed - indexed for MEDLINE]

336: [Anderson J, Wallace W, Snyder S, Haroutunian V, Roberts JL, Lieberburg J](#) Related Articles, Links

 Cellular forms of the rat and human beta-amyloid precursor protein (BAPP).
Brain Res. 1989 Jan 30;478(2):391-8.
PMID: 2647209 [PubMed - indexed for MEDLINE]

337: [Benes FM, Reisel JL, Majocha RE, Marotta CA](#) Related Articles, Links

 Evidence for a diffusional model of Alzheimer amyloid A4 (beta-amyloid) deposition during neuritic plaque formation.
Neuroscience. 1989;33(3):483-8.
PMID: 2700016 [PubMed - indexed for MEDLINE]

338: [Bird TD, Lampe TH, Nemens EJ, Sumi SM, Nochlin D, Schellenberg GD, Wijzman EM](#) Related Articles, Links

 Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry.
Prog Clin Biol Res. 1989;317:229-34.
PMID: 2602419 [PubMed - indexed for MEDLINE]

339: [Gentleman SM, Bruton C, Allsop D, Lewis SJ, Polak JM, Roberts GW](#) Related Articles, Links

 A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits.
Histochemistry. 1989;92(4):355-8.
PMID: 2478507 [PubMed - indexed for MEDLINE]

340: [Wisniewski HM, Wen GY, Kim KS](#) Related Articles, Links

 Comparison of four staining methods on the detection of neuritic plaques.
Acta Neuropathol (Berl). 1989;78(1):22-7.
PMID: 2472039 [PubMed - indexed for MEDLINE]

341: [Palmiter MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG](#) Related Articles, Links

 Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques.
Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7.
PMID: 3140814 [PubMed - indexed for MEDLINE]

 **342:** Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oitersdorf T. [Related Articles](#), [Links](#)

 Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneuronal tissues.

Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5.

PMID: 3140239 [PubMed - indexed for MEDLINE]

[Display](#) [Summary](#) Show: [500](#) [Sort](#) [Send to](#) [Text](#)

Items 1-342 of 342

One page.


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Oct 20 2003 06:54:00



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Book

Search PubMed

for beta-amyloid antibody

Go Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

Clinical Trials.gov

PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text One page.

Items 1-446 of 446

1: Miller DL, Currie JR, Mehta PD, Potempka A, Hwang YW, Wegiel J. Related Articles, Links
 Humoral immune response to fibrillar beta-amyloid peptide. *Biochemistry*. 2003 Oct 14;42(40):11682-92.
 PMID: 14529278 [PubMed - in process]

2: Wang DS, Iwata N, Hama I, Saido TC, Dickson DW. Related Articles, Links
 Oxidized neprilysin in aging and Alzheimer's disease brains. *Biochem Biophys Res Commun*. 2003 Oct 10;310(1):236-41.
 PMID: 14511676 [PubMed - in process]

3: Xu D, Yang C, Wang LN. Related Articles, Links
 [Prevalence and characteristics of cerebral amyloid angiopathy in the elderly] *Zhonghua Nei Ke Za Zhi*. 2003 Aug;42(8):541-4. Chinese.
 PMID: 14505543 [PubMed - in process]

4: Chauhan NB, Siegel GJ. Related Articles, Links
 Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. *J Neurosci Res*. 2003 Oct 1;74(1):142-7.
 PMID: 13130516 [PubMed - in process]

5: Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C. Related Articles, Links
 Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. *Arch Neurol*. 2003 Sep;60(9):1202-6.
 PMID: 12975284 [PubMed - indexed for MEDLINE]

6: LeVine H 3rd. Related Articles, Links
 Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide. *Arch Biochem Biophys*. 2003 Sep 1;417(1):112-22.
 PMID: 12921787 [PubMed - indexed for MEDLINE]

7: Torp R, Ottersen OP, Cotman CW, Head E. Related Articles, Links
 Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing. *Neuroscience*. 2003;120(2):291-300.
 PMID: 12890502 [PubMed - indexed for MEDLINE]

8: Schwyb C, Hosokawa M, Akiyama H, McGaugh JL. Related Articles, Links
 Familial British dementia: colocalization of furin and Abeta amyloid. *Acta Neuropathol (Berl)*. 2003 Sep;106(3):278-84. Epub 2003 Jul 16.
 PMID: 12883829 [PubMed - in process]

9: Tang K, Wang C, Shen C, Sheng S, Ravid R, Jing N. [Related Articles](#), [Links](#)
 Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639. *Eur J Neurosci*. 2003 Jul;18(1):102-8.
PMID: 12859342 [PubMed - indexed for MEDLINE]

10: Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB. [Related Articles](#), [Links](#)
 Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. *J Immunol*. 2003 Jul 15;171(2):812-20.
PMID: 12847249 [PubMed - indexed for MEDLINE]

11: Orgogozo JM, Gilman S, Dartigues JE, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Heck C. [Related Articles](#), [Links](#)
 Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. *Neurology*. 2003 Jul 8;61(1):46-54.
PMID: 12847155 [PubMed - as supplied by publisher]

12: Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M. [Related Articles](#), [Links](#)
 Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. *Brain*. 2003 Sep;126(Pt 9):1935-9. Epub 2003 Jun 23.
PMID: 12821522 [PubMed - indexed for MEDLINE]

13: Austin J, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. [Related Articles](#), [Links](#)
 Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. *Behav Neurosci*. 2003 Jun;117(3):478-84.
PMID: 12802876 [PubMed - indexed for MEDLINE]

14: Farr SA, Banks WA, Uezu K, Sano A, Gaskin I'S, Morley JE. [Related Articles](#), [Links](#)
 Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. *Life Sci*. 2003 Jun 20;73(5):555-62.
PMID: 12770611 [PubMed - indexed for MEDLINE]

15: Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. [Related Articles](#), [Links](#)
 Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron*. 2003 May 22;38(4):547-54.
PMID: 12765607 [PubMed - indexed for MEDLINE]

16: Li G, Percontino L, Sun Q, Qazi AS, Frederikse PH. [Related Articles](#), [Links](#)
 Beta-amyloid secretases and beta-amyloid degrading enzyme expression in lens. *Mol Vis*. 2003 May 1;9:179-83.
PMID: 12740567 [PubMed - indexed for MEDLINE]

17: Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE. [Related Articles](#), [Links](#)
 Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.

J Protein Chem. 2003 Jan;22(1):31-40.
PMID: 12739896 [PubMed - in process]

□ 18: [Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen](#) [Related Articles](#), [Links](#)
[KE, Gordon MN, Morgan D](#)

□ [Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.](#)
J Neurosci. 2003 May 1;23(9):3745-51.
PMID: 12736345 [PubMed - indexed for MEDLINE]

□ 19: [Pasternak SH, Babsbaw RD, Guiral M, Zhang S, Ackerley CA](#) [Related Articles](#), [Links](#)
[Pak BJ, Callahan JW, Mahuran DJ](#)

□ [Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane.](#)
J Biol Chem. 2003 Jul 18;278(29):26687-94. Epub 2003 May 07.
PMID: 12736250 [PubMed - indexed for MEDLINE]

□ 20: [Sunderland T, Linker G, Mirza N, Putnam K, Friedman DL](#) [Related Articles](#), [Links](#)
[Kimmel LH, Bergeson J, Manetti GL, Zimmermann M, Tang B, Bartko JJ, Cohen RM](#)

□ [Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.](#)
JAMA. 2003 Apr 23-30;289(16):2094-103.
PMID: 12709467 [PubMed - indexed for MEDLINE]

□ 21: [Leverone JR, Spooner ET, Lehman HK, Clements JD, Lemere CA](#) [Related Articles](#), [Links](#)

□ [Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".](#)
Vaccine. 2003 May 16;21(17-18):2206-15.
PMID: 12706711 [PubMed - in process]

□ 22: [Patel JR, Brewer GJ](#) [Related Articles](#), [Links](#)

□ [Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid.](#)
J Neurosci Res. 2003 May 15;72(4):527-36.
PMID: 12704814 [PubMed - indexed for MEDLINE]

□ 23: [Hirayama A, Horikoshi Y, Macda M, Ito M, Takashima S](#) [Related Articles](#), [Links](#)

□ [Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome.](#)
Brain Dev. 2003 Apr;25(3):180-5.
PMID: 12689696 [PubMed - indexed for MEDLINE]

□ 24: [Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I](#) [Related Articles](#), [Links](#)
[Sadzikava N, Batikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG](#)

□ [Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.](#)
Int Immunol. 2003 Apr;15(4):505-14.
PMID: 12663680 [PubMed - in process]

□ 25: [Dodart JC, Bales KR, Paul SM](#) [Related Articles](#), [Links](#)

□ [Immunotherapy for Alzheimer's disease: will vaccination work?](#)
Trends Mol Med. 2003 Mar;9(3):85-7.
PMID: 12657428 [PubMed - in process]

□ 26: [Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M](#) [Related Articles](#), [Links](#)

Neutralization of TRAIL death pathway protects human neuronal cell line

 from beta-amyloid toxicity.
Cell Death Differ. 2003 Jan;10(1):134-41.
PMID: 12655302 [PubMed - in process]

 27: [Li Y, Liu L, Barger SW, Griffin WS](#) Related Articles, Links
Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.
J Neurosci. 2003 Mar 1;23(5):1605-11.
PMID: 12629164 [PubMed - indexed for MEDLINE]

 28: [Cai J, Wang S, Zhong Y, Cheng J, Ji Z, Sheng S, Zhang C](#) Related Articles, Links
Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40.
Neuroreport. 2003 Feb 10;14(2):265-8.
PMID: 12598743 [PubMed - indexed for MEDLINE]

 29: [Luo X, Weber GA, Zheng J, Gendelman HE, Ikezu T](#) Related Articles, Links
C1q-calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease.
J Neuroimmunol. 2003 Feb;135(1-2):62-71.
PMID: 12576225 [PubMed - indexed for MEDLINE]

 30: [Bard F, Barbour R, Cannon C, Carretero R, Fox M, Games D, Guido T, Hock C, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Trojanowski J, Younkin S, Younkin P, Yednock T](#) Related Articles, Links
Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 03.
PMID: 12566568 [PubMed - indexed for MEDLINE]

 31: [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH](#) Related Articles, Links
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

 32: [Meske V, Albert F, Richter D, Schwarze J, Ohm TG](#) Related Articles, Links
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Eur J Neurosci. 2003 Jan;17(1):93-102.
PMID: 12534972 [PubMed - indexed for MEDLINE]

 33: [Blasko I, Grabeck-Loebenstein B](#) Related Articles, Links
Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
Drugs Aging. 2003;20(2):101-13. Review.
PMID: 12534311 [PubMed - indexed for MEDLINE]

 34: [Ehchalt R, Keller P, Haass C, Thiele C, Simons K](#) Related Articles, Links
Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts.
J Cell Biol. 2003 Jan 6;160(1):113-23. Epub 2003 Jan 06.
PMID: 12515826 [PubMed - indexed for MEDLINE]

 35: [Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V](#) Related Articles, Links

Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K.

 Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.
J Neurosci. 2003 Jan 1;23(1):29-33.
PMID: 12514198 [PubMed - indexed for MEDLINE]

 **36:** Friedland RP. Related Articles, Links

 Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease.
Ann N Y Acad Sci. 2002 Nov;977:387-90. Review.
PMID: 12480777 [PubMed - indexed for MEDLINE]

 **37:** Solomon B, Frenkel D. Related Articles, Links

 Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.
J Neural Transm Suppl. 2002;(62):321-5.
PMID: 12456075 [PubMed - indexed for MEDLINE]

 **38:** Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J. Related Articles, Links

 A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker?
J Neural Transm Suppl. 2002;(62):87-95.
PMID: 12456054 [PubMed - indexed for MEDLINE]

 **39:** Leclercq PJ, Stephenson MS, Murray LS, McIntosh TK, Graham DL, Gentleman SM. Related Articles, Links

 Simple morphometry of axonal swellings cannot be used in isolation for dating lesions after traumatic brain injury.
J Neurotrauma. 2002 Oct;19(10):1183-92.
PMID: 12427327 [PubMed - indexed for MEDLINE]

 **40:** Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M. Related Articles, Links

 Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

 **41:** Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Related Articles, Links

 Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.
Nat Neurosci. 2002 Dec;5(12):1288-93.
PMID: 12402041 [PubMed - indexed for MEDLINE]

 **42:** Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Related Articles, Links

 Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.
Nat Med. 2002 Nov;8(11):1270-5. Epub 2002 Oct 15.
PMID: 12379846 [PubMed - indexed for MEDLINE]

 **43:** Capsoni S, Giannotta S, Cattaneo A. Related Articles, Links

 Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.
Mol Cell Neurosci. 2002 Sep;21(1):15-28.
PMID: 12359148 [PubMed - indexed for MEDLINE]

 **44:** Dodel R, Hampe H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Jsof C, Jemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Related Articles, Links

 Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
Ann Neurol. 2002 Aug;52(2):253-6.
PMID: 12210803 [PubMed - indexed for MEDLINE]

 45: [Pan W](#), [Solomon B](#), [Maness LM](#), [Kastin AJ](#). [Related Articles](#), [Links](#)

 Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.
Exp Biol Med (Maywood). 2002 Sep;227(8):609-15.
PMID: 12192102 [PubMed - indexed for MEDLINE]

 46: [Kovacs GG](#), [Zerbi P](#), [Voigtlander T](#), [Strohschneider M](#), [Trabattoni G](#), [Hainfellner JA](#), [Budka H](#). [Related Articles](#), [Links](#)

 The prion protein in human neurodegenerative disorders.
Neurosci Lett. 2002 Sep 6;329(3):269-72.
PMID: 12183028 [PubMed - indexed for MEDLINE]

 47: [Giri R](#), [Selvaraj S](#), [Miller CA](#), [Hofman F](#), [Yan SD](#), [Stern D](#), [Zlokovic BV](#), [Kalra VK](#). [Related Articles](#), [Links](#)

 Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium.
Am J Physiol Cell Physiol. 2002 Sep;283(3):C895-904.
PMID: 12176746 [PubMed - indexed for MEDLINE]

 48: [Beher D](#), [Wrigley JD](#), [Owens AP](#), [Shearman MS](#). [Related Articles](#), [Links](#)

 Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.
J Neurochem. 2002 Aug;82(3):563-75.
PMID: 12153480 [PubMed - indexed for MEDLINE]

 49: [Wirths O](#), [Multhaup G](#), [Czech C](#), [Feldmann N](#), [Blanchard V](#), [Tremp G](#), [Beyreuther K](#), [Pradier L](#), [Bayer TA](#). [Related Articles](#), [Links](#)

 Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.
Brain Pathol. 2002 Jul;12(3):275-86.
PMID: 12146796 [PubMed - indexed for MEDLINE]

 50: [Clamagirand C](#), [Joulic C](#), [Panchal M](#), [Sekhri R](#), [Hanequez C](#), [Cohen P](#), [Rhoiam M](#). [Related Articles](#), [Links](#)

 Specific cleavage of beta-amyloid peptides by a metallopeptidase from *Xenopus laevis* skin secretions.
Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):751-9.
PMID: 12128061 [PubMed - in process]

 51: [Mohajeri MH](#), [Wollmer MA](#), [Nitsch RM](#). [Related Articles](#), [Links](#)

 Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.
J Biol Chem. 2002 Sep 20;277(38):35460-5. Epub 2002 Jul 08.
PMID: 12105192 [PubMed - indexed for MEDLINE]

 52: [Morley JE](#), [Farr SA](#), [Flood JF](#). [Related Articles](#), [Links](#)

 Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice.
Neurobiol Learn Mem. 2002 Jul;78(1):125-38.
PMID: 12071671 [PubMed - indexed for MEDLINE]

 53: [Sasaki N](#), [Takeuchi M](#), [Chowei H](#), [Kikuchi S](#), [Hayashi Y](#), [Nakano N](#), [Ikeda H](#), [Yamagishi S](#), [Kitamoto T](#), [Saito T](#), [Makita Z](#). [Related Articles](#), [Links](#)

 Advanced glycation end products (AGE) and their receptor (RAGE) in the

brain of patients with Creutzfeldt-Jakob disease with prion plaques.

Neurosci Lett. 2002 Jun 28;326(2):117-20.

PMID: 12057842 [PubMed - indexed for MEDLINE]

□ 54: [Stone JR, Okonkwo DO, Singleton RH, Muthu LK, Helm GA, Pavlisko JT](#) Related Articles, Links

□ Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury. J Neurotrauma. 2002 May;19(5):601-14. PMID: 12042095 [PubMed - indexed for MEDLINE]

□ 55: [DeGiorgio LA, Shimizu Y, Chun HS, Kim YS, Sugama S, Son JH, Juh TH, Volpe BT](#) Related Articles, Links

□ Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain Res. 2002 May 31;938(1-2):38-44. PMID: 12031533 [PubMed - indexed for MEDLINE]

□ 56: [Frenkel D, Solomon B](#) Related Articles, Links

□ Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5675-9. PMID: 11960022 [PubMed - indexed for MEDLINE]

□ 57: [Nagele RG, D'Andrea MR, Anderson WJ, Wang HY](#) Related Articles, Links

□ Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002;110(2):199-211. PMID: 11958863 [PubMed - indexed for MEDLINE]

□ 58: [Mbebi C, See V, Mercken L, Pradier L, Muller U, Loesli JP](#) Related Articles, Links

□ Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway. J Biol Chem. 2002 Jun 7;277(23):20979-90. Epub 2002 Mar 04. PMID: 11877414 [PubMed - indexed for MEDLINE]

□ 59: [Toro VC, Tehranian R, Zetterstrom M, Eriksson G, Langel U, Bartfai T, Iverfeldt K](#) Related Articles, Links

□ Increased gene expression of interleukin-1alpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment. J Mol Neurosci. 2001 Dec;17(3):341-50. PMID: 11859930 [PubMed - indexed for MEDLINE]

□ 60: [Frenkel D, Solomon B](#) Related Articles, Links

□ Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE]

□ 61: [Thal DR, Ghebremedhin E, Haass C, Schultz C](#) Related Articles, Links

□ UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain. Clin Neuropathol. 2002 Jan-Feb;21(1):35-40. PMID: 11846043 [PubMed - indexed for MEDLINE]

□ 62: [Nicolau C, Greerath R, Balaban TS, Lazarte JF, Hopkins RJ](#) Related Articles, Links

□ A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2332-7. Epub 2002 Feb 12. PMID: 11842183 [PubMed - indexed for MEDLINE]

63: Schenk D, Games D, Seubert P. [Related Articles](#) [Links](#)
 Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
J Mol Neurosci. 2001 Oct;17(2):259-67. Review.
PMID: 11816797 [PubMed - indexed for MEDLINE]

64: Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ. [Related Articles](#) [Links](#)
 Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging.
Neurobiol Aging. 2002 Mar-Apr;23(2):161-70.
PMID: 11804699 [PubMed - indexed for MEDLINE]

65: Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. [Related Articles](#) [Links](#)
 Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels.
DNA Cell Biol. 2001 Nov;20(11):731-6.
PMID: 11788051 [PubMed - indexed for MEDLINE]

66: Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. [Related Articles](#) [Links](#)
 Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

67: Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC. [Related Articles](#) [Links](#)
 beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology.
DNA Cell Biol. 2001 Nov;20(11):713-21.
PMID: 11788049 [PubMed - indexed for MEDLINE]

68: Lemere CA, Maron R, Selkoe DJ, Weiner HL. [Related Articles](#) [Links](#)
 Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease.
DNA Cell Biol. 2001 Nov;20(11):705-11.
PMID: 11788048 [PubMed - indexed for MEDLINE]

69: Solomon B. [Related Articles](#) [Links](#)
 Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
DNA Cell Biol. 2001 Nov;20(11):697-703.
PMID: 11788047 [PubMed - indexed for MEDLINE]

70: Coraci IS, Jlusemann J, Berman JW, Hulette C, Dufour JL, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. [Related Articles](#) [Links](#)
 CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils.
Am J Pathol. 2002 Jan;160(1):101-12.
PMID: 11786404 [PubMed - indexed for MEDLINE]

71: Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S. [Related Articles](#) [Links](#)
 Specificity and sensitivity of betaAPP in head injury.
Clin Neuropathol. 2001 Nov-Dec;20(6):263-71.
PMID: 11758782 [PubMed - indexed for MEDLINE]

72: [Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL](#) Related Articles, Links
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
J Neurochem. 2001 Nov;79(3):595-605.
PMID: 11701763 [PubMed - indexed for MEDLINE]

73: [Szpak GM, Lewandowska E, Lechowicz W, Bertrand E, Wierzbicka A, Bobrowicz T, Gwiazda E, Pasennik J, Kosno-Kruszewska E, Lipczynska-Lojkowska W, Bochniak A, Fiszer U](#) Related Articles, Links
Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study.
Folia Neuropathol. 2001;39(2):63-71.
PMID: 11680637 [PubMed - indexed for MEDLINE]

74: [Toupalik P, Bouska I, Chadova L](#) Related Articles, Links
[Differences in immunohistochemical findings in traumatic and hypoxic changes in the central nervous system]
Soud Lek. 2001 Jul;46(3):34-6. Czech.
PMID: 11669015 [PubMed - indexed for MEDLINE]

75: [Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH](#) Related Articles, Links
The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
Eur J Biochem. 2001 Oct;268(20):5329-36.
PMID: 11606195 [PubMed - indexed for MEDLINE]

76: [Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Kuiper SI, Oostveen JA, Weaver RJ, Boller JA, Gurney ME](#) Related Articles, Links
Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.
Ann Neurol. 2001 Oct;50(4):468-75.
PMID: 11601499 [PubMed - indexed for MEDLINE]

77: [von Bernhardi R, Ramirez G, Matile H, Dobeli H](#) Related Articles, Links
Immobilized amyloid precursor protein constructs: a tool for the in vitro screening of glial cell reactivity.
Eur J Neurosci. 2001 Sep;14(6):946-56.
PMID: 11595033 [PubMed - indexed for MEDLINE]

78: [Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C](#) Related Articles, Links
Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome.
Neurobiol Dis. 2001 Oct;8(5):792-806.
PMID: 11592849 [PubMed - indexed for MEDLINE]

79: [Thatte U](#) Related Articles, Links
AN-1792 (Elan).
Curr Opin Investig Drugs. 2001 May;2(5):663-7. Review.
PMID: 11569944 [PubMed - indexed for MEDLINE]

80: [Gotz J, Chen F, van Dorpe J, Nitsch RM](#) Related Articles, Links
Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils.
Science. 2001 Aug 24;293(5534):1491-5.
PMID: 11520988 [PubMed - indexed for MEDLINE]

81: [Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL](#) [Related Articles](#) [Links](#)

 **Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.**
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21.
PMID: 11517335 [PubMed - indexed for MEDLINE]

82: [Brayden DL, Templeton L, McClean S, Barbour R, Huang J, Nguyen M, Abeta D, Motter R, Johnson-Wood K, Vasquez N, Schenk D, Seubert P](#) [Related Articles](#) [Links](#)

 **Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.**
Vaccine. 2001 Jul 20;19(30):4185-93.
PMID: 11457544 [PubMed - indexed for MEDLINE]

83: [Toupalik P, Bouska I, Jezkova J](#) [Related Articles](#) [Links](#)

 **[Effect of autolysis on histochemical examinations of the central nervous system]**
Soud Lek. 2001 Apr;46(2):18-20. Czech.
PMID: 11455721 [PubMed - indexed for MEDLINE]

84: [Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S](#) [Related Articles](#) [Links](#)

 **Possible reverse transport of beta-amyloid peptide across the blood-brain barrier.**
Acta Neurochir Suppl. 2000;76:73-7.
PMID: 11450095 [PubMed - indexed for MEDLINE]

85: [Singleton RH, Stone JR, Okenwo DO, Pellicane AJ, Povlishock JT](#) [Related Articles](#) [Links](#)

 **The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury.**
J Neurotrauma. 2001 Jun;18(6):607-14.
PMID: 11437083 [PubMed - indexed for MEDLINE]

86: [Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M](#) [Related Articles](#) [Links](#)

 **Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.**
Neurosci Lett. 2001 Jul 13;307(2):101-4.
PMID: 11427310 [PubMed - indexed for MEDLINE]

87: [Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO](#) [Related Articles](#) [Links](#)

 **Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.**
Bull Exp Biol Med. 2001 Feb;131(2):127-9.
PMID: 11391392 [PubMed - indexed for MEDLINE]

88: [Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T](#) [Related Articles](#) [Links](#)

 **beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.**
Neuroscience. 2001;104(2):299-310.
PMID: 11377835 [PubMed - indexed for MEDLINE]

89: [Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuyama S](#) [Related Articles](#) [Links](#)

Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in

 **vitro, is expressed in the endoplasmic reticulum of neurons.**
Eur J Neurosci. 2001 May;13(9):1653-7.
PMID: 11359517 [PubMed - indexed for MEDLINE]

 **90: Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR.** [Related Articles](#), [Links](#)
Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice.
Neuroreport. 2001 May 8;12(6):1151-4.
PMID: 11338182 [PubMed - indexed for MEDLINE]

 **91: Chong YH, Song JH, Shin SA, Chung JH, Suh YH.** [Related Articles](#), [Links](#)
Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1.
J Biol Chem. 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16.
PMID: 11306564 [PubMed - indexed for MEDLINE]

 **92: Englund P, Jacobsson SG, Fowler CJ.** [Related Articles](#), [Links](#)
Investigation into the effects of amyloid (1-42) beta-peptide upon basal and antigen-stimulated hexosaminidase and serotonin release from rat RBL-2H3 basophilic leukemia cells.
Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61.
PMID: 11294005 [PubMed - indexed for MEDLINE]

 **93: Cedazo-Minguez A, Wiegager B, Winblad B, Huittinger M, Cowburn RF.** [Related Articles](#), [Links](#)
Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts.
Neurochem Int. 2001 Jun;38(7):615-25.
PMID: 11290387 [PubMed - indexed for MEDLINE]

 **94: Frenkel D, Kariy N, Solomon B.** [Related Articles](#), [Links](#)
Generation of auto-antibodies towards Alzheimer's disease vaccination.
Vaccine. 2001 Mar 21;19(17-19):2615-9.
PMID: 11257400 [PubMed - indexed for MEDLINE]

 **95: Duker NJ, Sperling L, Soprano KJ, Druin DP, Davis A, Ashworth R.** [Related Articles](#), [Links](#)
beta-Amyloid protein induces the formation of purine dimers in cellular DNA.
J Cell Biochem. 2001;81(3):393-400.
PMID: 11255222 [PubMed - indexed for MEDLINE]

 **96: Gerlai R.** [Related Articles](#), [Links](#)
Alzheimer's disease: beta-amyloid hypothesis strengthened!
Trends Neurosci. 2001 Apr;24(4):199. No abstract available.
PMID: 11249992 [PubMed - indexed for MEDLINE]

 **97: Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T.** [Related Articles](#), [Links](#)
Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids.
Neurosci Res. 2001 Mar;39(3):313-7.
PMID: 11248371 [PubMed - indexed for MEDLINE]

 **98: Husemann L, Silverstein SC.** [Related Articles](#), [Links](#)
Expression of scavenger receptor class B, type I, by astrocytes and vascular

 smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain.
Am J Pathol. 2001 Mar;158(3):825-32.
PMID: 11238031 [PubMed - indexed for MEDLINE]

 **99:** [D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH](#). [Related Articles](#), [Links](#)
Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.
Histopathology. 2001 Feb;38(2):120-34.
PMID: 11207825 [PubMed - indexed for MEDLINE]

 **100:** [Russell C, Salis S, Dolcini V, Venezia V, Song X, Teller JK, Schettini G](#). [Related Articles](#), [Links](#)
Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.
PMID: 11162251 [PubMed - indexed for MEDLINE]

 **101:** [Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, Morley JE](#). [Related Articles](#), [Links](#)
Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.
Peptides. 2000 Dec;21(12):1769-75.
PMID: 11150636 [PubMed - indexed for MEDLINE]

 **102:** [Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF](#). [Related Articles](#), [Links](#)
Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory.
Peptides. 2000 Dec;21(12):1761-7.
PMID: 11150635 [PubMed - indexed for MEDLINE]

 **103:** [Lin B, Ginsberg MD, Buste R](#). [Related Articles](#), [Links](#)
Hyperglycemic but not normoglycemic global ischemia induces marked early intraneuronal expression of beta-amyloid precursor protein.
Brain Res. 2001 Jan 5;888(1):107-116.
PMID: 11146057 [PubMed - indexed for MEDLINE]

 **104:** [Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E](#). [Related Articles](#), [Links](#)
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
Amyloid. 2000 Dec;7(4):245-58.
PMID: 11132093 [PubMed - indexed for MEDLINE]

 **105:** [Sudo H, Jiang H, Yasukawa T, Hashimoto Y, Niikura T, Kawasumi M, Matsuda S, Takeuchi Y, Aiso S, Matsuoka M, Murayama Y, Nishimoto I](#). [Related Articles](#), [Links](#)
Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein.
Mol Cell Neurosci. 2000 Dec;16(6):708-23.
PMID: 11124892 [PubMed - indexed for MEDLINE]

 **106:** [Seiffert D, Mitchell T, Stern AM, Roach A, Zhan Y, Grzanna R](#). [Related Articles](#), [Links](#)
Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing.

Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26.
PMID: 11113538 [PubMed - indexed for MEDLINE]

□ 107: [Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalta VK](#) Related Articles, Links

 beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.
Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81.
PMID: 11078691 [PubMed - indexed for MEDLINE]

□ 108: [Frenkel D, Katz O, Solomon B](#) Related Articles, Links

 Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9.
PMID: 11027345 [PubMed - indexed for MEDLINE]

□ 109: [Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford E, Mullan M](#) Related Articles, Links

 CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.
J Neurosci. 2000 Oct 15;20(20):7587-94.
PMID: 11027218 [PubMed - indexed for MEDLINE]

□ 110: [Rossner S, Beck M, Stahl T, Mendla K, Schliebs R, Bigl V](#) Related Articles, Links

 Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation.
Eur J Neurosci. 2000 Sep;12(9):3191-200.
PMID: 10998103 [PubMed - indexed for MEDLINE]

□ 111: [Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N](#) Related Articles, Links

 Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26.
PMID: 10997858 [PubMed - indexed for MEDLINE]

□ 112: [Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, Bogdanović B](#) Related Articles, Links

 nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease.
Exp Neurol. 2000 Sep;165(1):12-26.
PMID: 10964481 [PubMed - indexed for MEDLINE]

□ 113: [Taguchi J, Fujii A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Y, Wada I, Yamada T](#) Related Articles, Links

 Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Aug;100(2):153-60.
PMID: 10963362 [PubMed - indexed for MEDLINE]

□ 114: [DeGiorgio LA, DeGiorgio N, Milner TA, Conti B, Volpe BT](#) Related Articles, Links

 Neurotoxic APP C-terminal and beta-amyloid domains colocalize in the nuclei of substantia nigra pars reticulata neurons undergoing delayed degeneration.
Brain Res. 2000 Aug 25;874(2):137-46.
PMID: 10960598 [PubMed - indexed for MEDLINE]

Tanabe Y, Ishizuka H, Ishiguro K, Itoh N, Terada S, Haraguchi T

115: Kawai K, Kuroda S. [Related Articles](#) [Links](#)
 **Tau pathology in diffuse neurofibrillary tangles with calcification (DNTC): biochemical and immunohistochemical investigation.**
Neuroreport. 2000 Aug 3;11(11):2473-7.
PMID: 10943706 [PubMed - indexed for MEDLINE]

116: Helmuth L. [Related Articles](#) [Links](#)
 **Alzheimer's congress. Further progress on a beta-amyloid vaccine.**
Science. 2000 Jul 21;289(5478):375. No abstract available.
PMID: 10939941 [PubMed - indexed for MEDLINE]

117: Stone JR, Singleton RH, Povlishock JT. [Related Articles](#) [Links](#)
 **Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury.**
Brain Res. 2000 Jul 21;871(2):288-302.
PMID: 10899295 [PubMed - indexed for MEDLINE]

118: Kaneko I, Kubo T, Morimoto K. [Related Articles](#) [Links](#)
 **[Neurotoxicity of beta-amyloid]**
Nippon Yakurigaku Zasshi. 2000 Feb;115(2):67-77. Review. Japanese.
PMID: 10876793 [PubMed - indexed for MEDLINE]

119: Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA. [Related Articles](#) [Links](#)
 **beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.**
Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32.
PMID: 10840275 [PubMed - indexed for MEDLINE]

120: Robb TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH. [Related Articles](#) [Links](#)
 **A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis.**
J Neurochem. 2000 Jun;74(6):2331-42.
PMID: 10820193 [PubMed - indexed for MEDLINE]

121: Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ. [Related Articles](#) [Links](#)
 **Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.**
Ann N Y Acad Sci. 2000 Apr;903:335-44.
PMID: 10818523 [PubMed - indexed for MEDLINE]

122: Brown WR, Moody DM, Thore CR, Challa VR. [Related Articles](#) [Links](#)
 **Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis.**
Ann N Y Acad Sci. 2000 Apr;903:39-45.
PMID: 10818487 [PubMed - indexed for MEDLINE]

123: Frenkel D, Solomon B, Benhar I. [Related Articles](#) [Links](#)
 **Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.**
J Neuroimmunol. 2000 Jul 1;106(1-2):23-31.
PMID: 10814779 [PubMed - indexed for MEDLINE]

124: Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. [Related Articles](#) [Links](#)
 **Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.**
J Neurosci. 2000 May 15;20(10):3606-11.

PMID: 10804202 [PubMed - indexed for MEDLINE]

 **125:** [Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC.](#) [Related Articles](#), [Links](#)
Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. *J Neurosci Res.* 2000 May 1;60(3):401-11.
PMID: 10797543 [PubMed - indexed for MEDLINE]

 **126:** [Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW.](#) [Related Articles](#), [Links](#)
Region-specific age at onset of beta-amyloid in dogs. *Neurobiol Aging.* 2000 Jan-Feb;21(1):89-96.
PMID: 10794853 [PubMed - indexed for MEDLINE]

 **127:** [Aziach BY, Head E, Ibrahim MA, Torp R, Terner AJ, Kim RC, Lott IT, Cotman CW.](#) [Related Articles](#), [Links](#)
Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. *Exp Neurol.* 2000 May;163(1):111-22.
PMID: 10785449 [PubMed - indexed for MEDLINE]

 **128:** [Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C.](#) [Related Articles](#), [Links](#)
Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. *Nat Cell Biol.* 2000 Apr;2(4):205-11.
PMID: 10783238 [PubMed - indexed for MEDLINE]

 **129:** [Brazil MI, Chung II, Maxfield FR.](#) [Related Articles](#), [Links](#)
Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. *J Biol Chem.* 2000 Jun 2;275(22):16941-7.
PMID: 10747968 [PubMed - indexed for MEDLINE]

 **130:** [Salinero O, Moreno-Flores MT, Wandosell F.](#) [Related Articles](#), [Links](#)
Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease. *J Neurosci Res.* 2000 Apr 1;60(1):87-97.
PMID: 10723071 [PubMed - indexed for MEDLINE]

 **131:** [Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J.](#) [Related Articles](#), [Links](#)
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. *Proc Natl Acad Sci U S A.* 2000 Feb 15;97(4):1456-60.
PMID: 10677483 [PubMed - indexed for MEDLINE]

 **132:** [Cescato R, Dumermuth E, Spiess M, Paganetti PA.](#) [Related Articles](#), [Links](#)
Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis. *J Neurochem.* 2000 Mar;74(3):1131-9.
PMID: 10693945 [PubMed - indexed for MEDLINE]

 **133:** [Matsumoto A.](#) [Related Articles](#), [Links](#)
The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate. *Neuroreport.* 2000 Feb 7;11(2):373-7.
PMID: 10674489 [PubMed - indexed for MEDLINE]

134: Yoshiyama Y, Asahina M, Hattori T. [Related Articles](#) [Links](#)
 Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Feb;99(2):91-5.
PMID: 10672313 [PubMed - indexed for MEDLINE]

135: Toro F, Lopera F, Ossa J, Madrigal L, Mira A, Diaz A, Parra S. [Related Articles](#) [Links](#)
 [Detection of antibodies to beta-amyloid in carriers of E280A mutation in the presenilin-1 gene]
Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish.
PMID: 10652730 [PubMed - indexed for MEDLINE]

136: Al-Abed Y, Bucala R. [Related Articles](#) [Links](#)
 Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts.
Bioconjug Chem. 2000 Jan-Feb;11(1):39-45.
PMID: 10639083 [PubMed - indexed for MEDLINE]

137: Campbell E, Pearson RC, Parkinson D. [Related Articles](#) [Links](#)
 Methods to uncover an antibody epitope in the KPI domain of Alzheimer's amyloid precursor protein for immunohistochemistry in human brain.
J Neurosci Methods. 1999 Nov 15;93(2):133-8.
PMID: 10634498 [PubMed - indexed for MEDLINE]

138: Frederikse FH, Zigler SJ Jr, Farnsworth PN, Carper DA. [Related Articles](#) [Links](#)
 Prion protein expression in mammalian lenses.
Curr Eye Res. 2000 Feb;20(2):137-43.
PMID: 10617916 [PubMed - indexed for MEDLINE]

139: Webster SD, Tenner AJ, Poulos TL, Cribbs DH. [Related Articles](#) [Links](#)
 The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
Neurobiol Aging. 1999 May-Jun;20(3):297-304.
PMID: 10588577 [PubMed - indexed for MEDLINE]

140: Jung SS, Gauthier S, Cashman NR. [Related Articles](#) [Links](#)
 Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease.
Neurobiol Aging. 1999 May-Jun;20(3):249-57.
PMID: 10588572 [PubMed - indexed for MEDLINE]

141: Nakano S, Akiguchi I, Nakamura S, Sato H, Kawashima S, Kimura J. [Related Articles](#) [Links](#)
 Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
Neurology. 1999 Nov 10;53(8):1671-6.
PMID: 10563611 [PubMed - indexed for MEDLINE]

142: Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. [Related Articles](#) [Links](#)
 The role of cholesterol in the biosynthesis of beta-amyloid.
Neuroreport. 1999 Jun 3;10(8):1699-705.
PMID: 10501560 [PubMed - indexed for MEDLINE]

143: Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H. [Related Articles](#) [Links](#)
Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia

 with Lewy bodies from Alzheimer disease.
Arch Neurol. 1999 Sep;56(9):1111-8.
PMID: 10488812 [PubMed - indexed for MEDLINE]

 **144:** Guenette SY, Chen J, Ferland A, Haass C, Capell A, Tanzi RE. [Related Articles](#), [Links](#)
hFE65L influences amyloid precursor protein maturation and secretion.
J Neurochem. 1999 Sep;73(3):985-93.
PMID: 10461887 [PubMed - indexed for MEDLINE]

 **145:** Kurt MA, Davies DC, Kidd M. [Related Articles](#), [Links](#)
beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: an electron microscope study.
Exp Neurol. 1999 Jul;158(1):221-8.
PMID: 10448435 [PubMed - indexed for MEDLINE]

 **146:** Markaryan A, Morozova I, Lee BS, Kaplan A. [Related Articles](#), [Links](#)
Atypical processing of amyloid precursor fusion protein by proteolytic activity in *Pichia pastoris*.
Biochem Biophys Res Commun. 1999 Aug 19;262(1):263-8. Erratum in: Biochem Biophys Res Commun 1999 Sep 24;263(2):596.
PMID: 10448103 [PubMed - indexed for MEDLINE]

 **147:** Gonzalo-Ruiz A. [Related Articles](#), [Links](#)
[Changes in neurotransmission systems after the injection of beta-amyloid protein beta (12-28) in the hypothalamus and anterior thalamus of the rat]
Rev Neurol. 1999 May 16-31;28(10):931-41. Review. Spanish.
PMID: 10416226 [PubMed - indexed for MEDLINE]

 **148:** Schroder R, Linke RP. [Related Articles](#), [Links](#)
Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern.
Virchows Arch. 1999 Jun;434(6):551-60.
PMID: 10394892 [PubMed - indexed for MEDLINE]

 **149:** Yuan H, Zhai P, Anderson LM, Pan J, Thimmappaya B, Kee EH, Marquez-Sterling NR. [Related Articles](#), [Links](#)
Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons.
J Neurosci Methods. 1999 Apr 1;88(1):45-54.
PMID: 10379578 [PubMed - indexed for MEDLINE]

 **150:** Fonseca MI, Head E, Velazquez P, Coleman CW, Tenner AJ. [Related Articles](#), [Links](#)
The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.
Exp Neurol. 1999 Jun;157(2):277-88.
PMID: 10364440 [PubMed - indexed for MEDLINE]

 **151:** Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN. [Related Articles](#), [Links](#)
Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner.
Neuroscience. 1999;90(4):1217-26.
PMID: 10338292 [PubMed - indexed for MEDLINE]

 **152:** Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S. [Related Articles](#), [Links](#)
Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells.
Eur J Neurosci. 1999 Jun;11(6):1907-13.

PMID: 10336659 [PubMed - indexed for MEDLINE]

 **153:** [Oehmichen M, Theuerkauf I, Meissner C.](#) [Related Articles](#), [Links](#)
Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI.
Acta Neuropathol (Berl). 1999 May;97(5):491-4.
PMID: 10334486 [PubMed - indexed for MEDLINE]

 **154:** [Johnson G, Moore SW.](#) [Related Articles](#), [Links](#)
The adhesion function on acetylcholinesterase is located at the peripheral anionic site.
Biochem Biophys Res Commun. 1999 May 19;258(3):758-62.
PMID: 10329459 [PubMed - indexed for MEDLINE]

 **155:** [Abraham CR, Marshall DC, Tibbles JF, Otto K, Long HJ, Billingslea AM, Haste R, Johnson R, Fine RE, Smith SJ, Simons FR, Davies TA.](#) [Related Articles](#), [Links](#)
Platelets and DAMI megakaryocytes possess beta-secretase-like activity.
J Lab Clin Med. 1999 May;133(5):507-15.
PMID: 10235134 [PubMed - indexed for MEDLINE]

 **156:** [Howlett DR, Perry AE, Godfrey E, Swanton JE, Jennings KII, Spitzfaden C, Wadsworth H, Wood SJ, Markwell RE.](#) [Related Articles](#), [Links](#)
Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.
Biochem J. 1999 May 15;340 (Pt 1):283-9.
PMID: 10229684 [PubMed - indexed for MEDLINE]

 **157:** [Frenkel D, Balass M, Katchalski-Katzir E, Solomon B.](#) [Related Articles](#), [Links](#)
High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.
J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.
PMID: 10229123 [PubMed - indexed for MEDLINE]

 **158:** [Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD.](#) [Related Articles](#), [Links](#)
Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia.
Acta Neuropathol (Berl). 1999 Apr;97(4):359-68.
PMID: 10208275 [PubMed - indexed for MEDLINE]

 **159:** [Pike CJ.](#) [Related Articles](#), [Links](#)
Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease.
J Neurochem. 1999 Apr;72(4):1552-63.
PMID: 10098861 [PubMed - indexed for MEDLINE]

 **160:** [Fabrizi C, Businaro R, Lauro GM, Staraci G, Fumagalli L.](#) [Related Articles](#), [Links](#)
Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Exp Neurol. 1999 Feb;155(2):252-9.
PMID: 10072300 [PubMed - indexed for MEDLINE]

 **161:** [Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich L, Hoffmann MM, Huttinger M, Wieland H, Marz W.](#) [Related Articles](#), [Links](#)
Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
J Lipid Res. 1999 Mar;40(3):447-55.

PMID: 10064733 [PubMed - indexed for MEDLINE]

 162: [Huber G, Thompson A, Gruninger F, Mechler H, Hochstrasser R, Hauri HP, Malherbe P.](#) Related Articles, Links

 cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?
J Neurochem. 1999 Mar;72(3):1215-23.
PMID: 10037494 [PubMed - indexed for MEDLINE]

 163: [Broillet E, Trembleau A, Galanaud D, Volovitch M, Boillot C, Valenza C, Prochiantz A, Allinquant B.](#) Related Articles, Links

 The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction.
J Neurosci. 1999 Mar 1;19(5):1717-27.
PMID: 10024358 [PubMed - indexed for MEDLINE]

 164: [Ohara S, Tsukada M, Ikeda S.](#) Related Articles, Links

 On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.
Acta Neuropathol (Berl). 1999 Jan;97(1):85-90.
PMID: 9930899 [PubMed - indexed for MEDLINE]

 165: [Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA.](#) Related Articles, Links

 Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.
Acta Neuropathol (Berl). 1999 Feb;97(2):113-8.
PMID: 9928821 [PubMed - indexed for MEDLINE]

 166: [Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M.](#) Related Articles, Links

 Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage.
Brain Res. 1999 Feb 6;818(1):105-17.
PMID: 9914443 [PubMed - indexed for MEDLINE]

 167: [Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E.](#) Related Articles, Links

 Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition.
Exp Neurol. 1998 Dec;154(2):573-82.
PMID: 9878192 [PubMed - indexed for MEDLINE]

 168: [Leanza G.](#) Related Articles, Links

 Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions.
Neurosci Lett. 1998 Nov 20;257(1):53-6.
PMID: 9857964 [PubMed - indexed for MEDLINE]

 169: [Jin L W, Hearn MG, Ogburn CE, Dang N, Neechlin D, Ladiges WC, Martin GM.](#) Related Articles, Links

 Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Am J Pathol. 1998 Dec;153(6):1679-86.
PMID: 9846957 [PubMed - indexed for MEDLINE]

 170: [Daly J 4th, Lahiri DK, Justus DE, Kotwal GJ.](#) Related Articles, Links

Detection of the membrane-retained carboxy-terminal tail containing

 polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain.
Life Sci. 1998;63(23):2121-31.
PMID: 9839536 [PubMed - indexed for MEDLINE]

 171: [Ohshita T, Nakatani A, Hioi Y.](#) Related Articles, Links
Purification by column chromatographies of beta-amyloid precursor proteins and their association with other 95 kDa protein in rat brain.
J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1-2):107-18.
PMID: 9824223 [PubMed - indexed for MEDLINE]

 172: [Kraszpulski M, Soininen H, Rickkinen P Sr, Alafuzoff I.](#) Related Articles, Links
Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in human brain tissue.
Histochem Cell Biol. 1998 Oct;110(4):439-45.
PMID: 9792423 [PubMed - indexed for MEDLINE]

 173: [Mizuno T, Haass C, Michikawa M, Yanagisawa K.](#) Related Articles, Links
Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells.
Biochim Biophys Acta. 1998 Aug 14;1373(1):119-30.
PMID: 9733943 [PubMed - indexed for MEDLINE]

 174: [Yilmazer-Hanke DM.](#) Related Articles, Links
Pathogenesis of Alzheimer-related neuritic plaques: AT8 immunoreactive dystrophic neurites precede argyrophilic neurites in plaques of the entorhinal region, hippocampal formation, and amygdala.
Clin Neuropathol. 1998 Jul-Aug;17(4):194-8.
PMID: 9707333 [PubMed - indexed for MEDLINE]

 175: [Hock C, Goiombowski S, Muller-Spahn F, Peschel O, Riederer A, Probst A, Mandelkow E, Unger J.](#) Related Articles, Links
Histological markers in nasal mucosa of patients with Alzheimer's disease.
Eur Neurol. 1998 Jul;40(1):31-6.
PMID: 9693230 [PubMed - indexed for MEDLINE]

 176: [Munch G, Cunningham AM, Riederer P, Braak E.](#) Related Articles, Links
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
Brain Res. 1998 Jun 15;796(1-2):307-10.
PMID: 9689484 [PubMed - indexed for MEDLINE]

 177: [Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW.](#) Related Articles, Links
Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.
Brain Res. 1998 Jun 15;796(1-2):187-97.
PMID: 9689469 [PubMed - indexed for MEDLINE]

 178: [Frenkel D, Balass M, Solomon B.](#) Related Articles, Links
N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.
J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.
PMID: 9688328 [PubMed - indexed for MEDLINE]

 179: [Yang AJ, Chandrangshu D, Margol L, Glabe CG.](#) Related Articles, Links
Loss of endosomal/lysosomal membrane impermeability is an early event

in amyloid Abeta1-42 pathogenesis.
J Neurosci Res. 1998 Jun 15;32(6):691-8.
PMID: 9669318 [PubMed - indexed for MEDLINE]

□ 180: [Hoshino S, Tamaoka A, Takahashi M, Kobayashi S, Furukawa T](#). Related Articles, Links
Oaki Y, Mori O, Matsuno S, Shoji S, Inomata M, Teramoto A

□ Emergence of immunoreactivities for phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in rat brain.
Neuroreport. 1998 Jun 1;9(8):1879-83.
PMID: 9665619 [PubMed - indexed for MEDLINE]

□ 181: [Terryberry JW, Thor G, Peter JB](#). Related Articles, Links

□ Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.
Neurobiol Aging. 1998 May-Jun;19(3):205-16.
PMID: 9661995 [PubMed - indexed for MEDLINE]

□ 182: [McGillem GS, Guidry C, Dachencu RF](#). Related Articles, Links

□ Antigenic changes of rabbit retinal Muller cells in culture.
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1453-61.
PMID: 9660494 [PubMed - indexed for MEDLINE]

□ 183: [Miguel-Hidalgo JJ, Alvarez A, Cacabelos R](#). Related Articles, Links

□ Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system.
Cell Tissue Res. 1998 Jul;293(1):75-86.
PMID: 9634599 [PubMed - indexed for MEDLINE]

□ 184: [Salinero O, Garrido JJ, Wandosell F](#). Related Articles, Links

□ Amyloid precursor protein proteoglycan is increased after brain damage.
Biochim Biophys Acta. 1998 Apr 28;1406(3):237-50.
PMID: 9630651 [PubMed - indexed for MEDLINE]

□ 185: [Nakamura Y, Yamamoto M, Kumamaru E](#). Related Articles, Links

□ A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin.
Brain Res. 1998 May 18;793(1-2):47-53.
PMID: 9630508 [PubMed - indexed for MEDLINE]

□ 186: [Spuler S, Emslie-Smith A, Engel AG](#). Related Articles, Links

□ Amyloid myopathy: an underdiagnosed entity.
Ann Neurol. 1998 Jun;43(6):719-28.
PMID: 9629841 [PubMed - indexed for MEDLINE]

□ 187: [Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM](#). Related Articles, Links

□ Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels.
J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9.
PMID: 9600229 [PubMed - indexed for MEDLINE]

□ 188: [Honda S, Itoh F, Yoshimoto M, Jimoda Y, Imai K](#). Related Articles, Links

□ Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein.
J Clin Lab Anal. 1998;12(3):172-8.
PMID: 9591705 [PubMed - indexed for MEDLINE]

□ 189: [Rossner S](#). Related Articles, Links

 Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease.
Int J Dev Neurosci. 1997 Nov;15(7):835-50. Review.
PMID: 9568532 [PubMed - indexed for MEDLINE]

 **190:** Varner JA, Jensen KE, Horvath W, Isaacson RL. Related Articles, Links
Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity.
Brain Res. 1998 Feb 16;784(1-2):284-98.
PMID: 9518651 [PubMed - indexed for MEDLINE]

 **191:** Minn A, Schubert M, Neiss WF, Muller-Hill B. Related Articles, Links
Enhanced GFAP expression in astrocytes of transgenic mice expressing the human brain-specific trypsinogen IV.
Glia. 1998 Apr;22(4):338-47.
PMID: 9517566 [PubMed - indexed for MEDLINE]

 **192:** Murai H, Pierce JT, Raghupathi R, Smith DH, Saatman KE, Trojanowski JQ, Lee VM, Loring JF, Eickman C, Younkin S, McIntosh TK. Related Articles, Links
Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury.
J Comp Neurol. 1998 Mar 23;392(4):428-38.
PMID: 9514508 [PubMed - indexed for MEDLINE]

 **193:** Dwork AJ, Liu D, Kaufman MA, Prohovnik L. Related Articles, Links
Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes.
Clin Neuropathol. 1998 Jan-Feb;17(1):45-9.
PMID: 9496540 [PubMed - indexed for MEDLINE]

 **194:** Friedman LM, Matsuda Y, Lazarovici P. Related Articles, Links
The microbial alkaloid toxin staurosporine blocks the phorbol ester-induced increase in beta-amyloid precursor protein in PC12 cells.
Nat Toxins. 1997;5(5):173-9.
PMID: 9496375 [PubMed - indexed for MEDLINE]

 **195:** Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM. Related Articles, Links
Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice.
Neuroscience. 1998 Jan;82(1):171-80.
PMID: 9483513 [PubMed - indexed for MEDLINE]

 **196:** Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazu K, Fukutani Y, Mukai M, Koshino F. Related Articles, Links
KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains.
Dement Geriatr Cogn Disord. 1998 Jan-Feb;9(1):13-9.
PMID: 9469259 [PubMed - indexed for MEDLINE]

 **197:** Dickson TC, Saunders HL, Vickers JC. Related Articles, Links
Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease.
Neuropathol Appl Neurobiol. 1997 Dec;23(6):483-91.
PMID: 9460714 [PubMed - indexed for MEDLINE]

 **198:** Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K. Related Articles, Links

Multhaup G.

 Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease.

Acta Neuropathol (Berl). 1997 Dec;94(6):519-24.

PMID: 9444352 [PubMed - indexed for MEDLINE]

 199: Jen A, Wickenden C, Rohan de Silva H, Patel AJ. [Related Articles](#), [Links](#)

 Preparation and purification of antisera against different regions or isoforms of beta-amyloid precursor protein.

Brain Res Brain Res Protoc. 1997 Dec 1;2(1):23-30.

PMID: 9438067 [PubMed - indexed for MEDLINE]

 200: Shalit E, Sredni B, Rosenblatt-Bin H, Kazimirska G, Brodie C, Huberman M. [Related Articles](#), [Links](#)

 Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures.

Neuroreport. 1997 Nov 10;8(16):3577-80.

PMID: 9427329 [PubMed - indexed for MEDLINE]

 201: Zambrano N, De Renzis S, Minopoli G, Faraci R, Donini V, Scaloni A, Cimino F, Russo T. [Related Articles](#), [Links](#)

 DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter.

Biochem J. 1997 Nov 15;328 (Pt 1):293-300.

PMID: 9359867 [PubMed - indexed for MEDLINE]

 202: Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowski AW. [Related Articles](#), [Links](#)

 Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia.

Acta Neurochir Suppl (Wien). 1997;70:247-9.

PMID: 9416336 [PubMed - indexed for MEDLINE]

 203: Gearing M, Levey AI, Mirra SS. [Related Articles](#), [Links](#)

 Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers.

J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70.

PMID: 9413285 [PubMed - indexed for MEDLINE]

 204: An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F, Tavolato B, Scaravilli F. [Related Articles](#), [Links](#)

 Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS.

J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8.

PMID: 9370237 [PubMed - indexed for MEDLINE]

 205: Goodwin JL, Kehrli ME Jr, Uemura E. [Related Articles](#), [Links](#)

 Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide.

Brain Res. 1997 Sep 12;768(1-2):279-86.

PMID: 9369326 [PubMed - indexed for MEDLINE]

 206: Lahiri DK, Farlow MR, Sambamurti K, Nall C. [Related Articles](#), [Links](#)

 The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells.

Life Sci. 1997;61(20):1985-92.

PMID: 9366505 [PubMed - indexed for MEDLINE]

 207: Matsumoto A, Minami M, Matsumoto R. [Related Articles](#), [Links](#)

The beta-amyloid epitope masking activity in human brain is identified as

 **albumin.**
Neuroreport. 1997 Oct 20;8(15):3297-301.
PMID: 9351660 [PubMed - indexed for MEDLINE]

208: Lahiri DK, Fariow MR, Nurnberger JI Jr, Greig NH. Related Articles, Links
 Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Ann N Y Acad Sci. 1997 Sep 26;826:416-21.
PMID: 9329715 [PubMed - indexed for MEDLINE]

209: Sasaki S, Iwata M. Related Articles, Links
 Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis.
Acta Neuropathol (Berl). 1997 Oct;94(4):338-44.
PMID: 9341934 [PubMed - indexed for MEDLINE]

210: Garcia-Ladona EL, Huss Y, Frey P, Ghandour MS. Related Articles, Links
 Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: *in situ* hybridization and immunocytochemical detection.
J Neurosci Res. 1997 Oct 1;50(1):50-61.
PMID: 9379493 [PubMed - indexed for MEDLINE]

211: Shea TB, Prabhakar S, Ekinici EJ. Related Articles, Links
 Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system.
J Neurosci Res. 1997 Sep 15;49(6):759-68.
PMID: 9335263 [PubMed - indexed for MEDLINE]

212: Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD. Related Articles, Links
 Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia *in vitro* and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus.
Glia. 1997 Oct;21(2):228-43.
PMID: 9336237 [PubMed - indexed for MEDLINE]

213: Little SP, Dixon EP, Norris E, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM. Related Articles, Links
 Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.
J Biol Chem. 1997 Oct 3;272(40):25135-42.
PMID: 9312124 [PubMed - indexed for MEDLINE]

214: Brewer GJ. Related Articles, Links
 Effects of acidosis on the distribution of processing of the beta-amyloid precursor protein in cultured hippocampal neurons.
Mol Chem Neuropathol. 1997 Jun;31(2):171-86.
PMID: 9376023 [PubMed - indexed for MEDLINE]

215: Yainada T, Tsuboi Y, Takahashi M. Related Articles, Links
 Interrelationship between beta-amyloid deposition and complement-activated oligodendroglia.
Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72.
PMID: 9298627 [PubMed - indexed for MEDLINE]

 **216:** [Dewji NN, Singer SJ](#) [Related Articles](#) [Links](#)
 **Cell surface expression of the Alzheimer disease-related presenilin proteins.**
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31.
PMID: 9275228 [PubMed - indexed for MEDLINE]

 **217:** [Cataldo AM, Barnett JL, Pieroni C, Nixon RA](#) [Related Articles](#) [Links](#)
 **Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.**
J Neurosci. 1997 Aug 15;17(16):6142-51.
PMID: 9236226 [PubMed - indexed for MEDLINE]

 **218:** [Cutler P, Brown E, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B](#) [Related Articles](#) [Links](#)
 **The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.**
FEBS Lett. 1997 Jul 28;412(2):341-5.
PMID: 9256248 [PubMed - indexed for MEDLINE]

 **219:** [Ohsawa I, Takamura C, Kohsaka S](#) [Related Articles](#) [Links](#)
 **The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.**
Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65.
PMID: 9223426 [PubMed - indexed for MEDLINE]

 **220:** [Luth HJ, Arendt T](#) [Related Articles](#) [Links](#)
 **Co-expression of APP with cNOS but not iNOS after cortical injury in rat.**
Neuroreport. 1997 Jul 7;8(9-10):2321-4.
PMID: 9243633 [PubMed - indexed for MEDLINE]

 **221:** [Giometto B, An SF, Groves M, Scaravilli T, Geddes JE, Miller R, Tavolato B, Beckett AA, Scaravilli F](#) [Related Articles](#) [Links](#)
 **Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.**
Ann Neurol. 1997 Jul;42(1):34-40.
PMID: 9225683 [PubMed - indexed for MEDLINE]

 **222:** [Haas C, Cazorla P, Miguel CD, Valdivieso E, Vazquez J](#) [Related Articles](#) [Links](#)
 **Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.**
Biochem J. 1997 Jul 1;325 (Pt 1):169-75.
PMID: 9224643 [PubMed - indexed for MEDLINE]

 **223:** [Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, Patel A](#) [Related Articles](#) [Links](#)
 **Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes.**
Brain Res Mol Brain Res. 1997 Jul;47(1-2):147-56.
PMID: 9221912 [PubMed - indexed for MEDLINE]

 **224:** [Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H, Itoh Y](#) [Related Articles](#) [Links](#)
 **Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits.**
Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81.
PMID: 9210972 [PubMed - indexed for MEDLINE]

 225: [Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T](#) Related Articles, Links
Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.
Psychiatry Clin Neurosci. 1997 Jun;51(3):135-8.
PMID: 9225377 [PubMed - indexed for MEDLINE]

 226: [Arai Y, Suzuki A, Mizuguchi M, Takashina S](#) Related Articles, Links
Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
Brain Dev. 1997 Jun;19(4):290-4.
PMID: 9187481 [PubMed - indexed for MEDLINE]

 227: [Mielke JG, Murphy MP, Maritz J, Bengualid KM, Ivy GO](#) Related Articles, Links
Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.
Neurosci Lett. 1997 May 23;227(3):169-72.
PMID: 9185677 [PubMed - indexed for MEDLINE]

 228: [Sasaki A, Iijima M, Yokoo H, Sheji M, Nakazato Y](#) Related Articles, Links
Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study.
Brain Res. 1997 May 2;755(2):193-201.
PMID: 9175887 [PubMed - indexed for MEDLINE]

 229: [Solomon B, Koppel R, Frankel D, Hanan-Abaron E](#) Related Articles, Links
Disaggregation of Alzheimer beta-amyloid by site-directed mAb.
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.
PMID: 9108113 [PubMed - indexed for MEDLINE]

 230: [Xu S, Gaskin F](#) Related Articles, Links
Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.
Mech Ageing Dev. 1997 Mar;94(1-3):213-22.
PMID: 9147373 [PubMed - indexed for MEDLINE]

 231: [Koo EH](#) Related Articles, Links
Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production.
Mol Med. 1997 Mar;3(3):204-11.
PMID: 9100226 [PubMed - indexed for MEDLINE]

 232: [Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM](#) Related Articles, Links
Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice.
Am J Pathol. 1997 Feb;150(2):417-27.
PMID: 9033257 [PubMed - indexed for MEDLINE]

 233: [Marambaud P, Chevallier N, Barelli H, Wilk S, Checler F](#) Related Articles, Links
Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells.
J Neurochem. 1997 Feb;68(2):698-703.
PMID: 9003058 [PubMed - indexed for MEDLINE]

 **234:** [Walter J, Capell A, Hung AY, Langen H, Schnolzer M, Thinakaran G, Sisodia SS, Selkoe DJ, Haass C](#) [Related Articles](#) [Links](#)
 Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations.
J Biol Chem. 1997 Jan 17;272(3):1896-903.
PMID: 8999878 [PubMed - indexed for MEDLINE]

 **235:** [McDermott JR, Gibson AM](#) [Related Articles](#) [Links](#)
 Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.
Neurochem Res. 1997 Jan;22(1):49-56.
PMID: 9021762 [PubMed - indexed for MEDLINE]

 **236:** [Drache B, Diehl GE, Beyreuther K, Perlmuter LS, Konig G](#) [Related Articles](#) [Links](#)
 Bcl-xL-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states.
J Neurosci Res. 1997 Jan 1;47(1):98-108.
PMID: 8981243 [PubMed - indexed for MEDLINE]

 **237:** [Matsumoto A, Enomoto T, Fujiyara Y, Baba H, Matsumoto R](#) [Related Articles](#) [Links](#)
 Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain.
Neurosci Lett. 1996 Dec 20;220(3):159-62.
PMID: 8994217 [PubMed - indexed for MEDLINE]

 **238:** [Sihag RK, Cataldo AM](#) [Related Articles](#) [Links](#)
 Brain beta-spectrin is a component of senile plaques in Alzheimer's disease.
Brain Res. 1996 Dec 16;743(1-2):249-57.
PMID: 9017252 [PubMed - indexed for MEDLINE]

 **239:** [Hirai T, Kojima S, Shimada A, Umemura T, Sakai M, Itakura C](#) [Related Articles](#) [Links](#)
 Age-related changes in the olfactory system of dogs.
Neuropathol Appl Neurobiol. 1996 Dec;22(6):531-9.
PMID: 9004244 [PubMed - indexed for MEDLINE]

 **240:** [Nielson KA, Cummings BJ, Cotman CW](#) [Related Articles](#) [Links](#)
 Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex.
Brain Res. 1996 Nov 25;741(1-2):284-93.
PMID: 9001734 [PubMed - indexed for MEDLINE]

 **241:** [Citron M, Dichl TS, Gordon G, Biere AJ, Scubert P, Selkoe DJ](#) [Related Articles](#) [Links](#)
 Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5.
PMID: 8917563 [PubMed - indexed for MEDLINE]

 **242:** [Su JH, Cummings BJ, Cotman CW](#) [Related Articles](#) [Links](#)
 Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments.
Brain Res. 1996 Nov 11;739(1-2):79-87.
PMID: 8955927 [PubMed - indexed for MEDLINE]

243: Jung SS, Nalbantoglu L, Cashman NR. [Related Articles](#) [Links](#)
 Alzheimer's beta-amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study. *J Neurosci Res.* 1996 Nov 1;46(3):336-48.
PMID: 8933373 [PubMed - indexed for MEDLINE]

244: Yokota M, Saido TC, Tani E, Yamaura I, Minami N. [Related Articles](#) [Links](#)
 Cytotoxic fragment of amyloid precursor protein accumulates in hippocampus after global forebrain ischemia. *J Cereb Blood Flow Metab.* 1996 Nov;16(6):1219-23.
PMID: 8898694 [PubMed - indexed for MEDLINE]

245: Dewji NN, Singer SJ. [Related Articles](#) [Links](#)
 Specific transcellular binding between membrane proteins crucial to Alzheimer disease. *Proc Natl Acad Sci U S A.* 1996 Oct 29;93(22):12575-80.
PMID: 8901624 [PubMed - indexed for MEDLINE]

246: Stephens DJ, Austen BM. [Related Articles](#) [Links](#)
 Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells. *J Neurosci Res.* 1996 Oct 15;46(2):211-25.
PMID: 8915898 [PubMed - indexed for MEDLINE]

247: De Bleecker JL, Ertl BB, Engel AG. [Related Articles](#) [Links](#)
 Patterns of abnormal protein expression in target formations and unstructured cores. *Neuromuscul Disord.* 1996 Oct;6(5):339-49.
PMID: 8938698 [PubMed - indexed for MEDLINE]

248: Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Fujimori O, Ojika K. [Related Articles](#) [Links](#)
 Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation. *Neuropathol Appl Neurobiol.* 1996 Oct;22(5):440-5.
PMID: 8930956 [PubMed - indexed for MEDLINE]

249: Kuo H, Ingram DK, Walker LC, Tian M, Hengemihle JM, Jucker M. [Related Articles](#) [Links](#)
 Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains. *Neuroscience.* 1996 Oct;74(3):733-40.
PMID: 8884769 [PubMed - indexed for MEDLINE]

250: Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. [Related Articles](#) [Links](#)
 Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. *J Exp Med.* 1996 Oct 1;184(4):1425-33.
PMID: 8879214 [PubMed - indexed for MEDLINE]

251: De La Monte SM, Carlson RJ, Brown NV, Wands JR. [Related Articles](#) [Links](#)
 Profiles of neuronal thread protein expression in Alzheimer's disease. *J Neuropathol Exp Neurol.* 1996 Oct;55(10):1038-50.
PMID: 8858001 [PubMed - indexed for MEDLINE]

252: Castillo GM, Cummings JA, Ngo C, Yang W, Snow AD. [Related Articles](#) [Links](#)
Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain.
J Biochem (Tokyo). 1996 Aug;120(2):433-44.
PMID: 8889831 [PubMed - indexed for MEDLINE]

253: Brewer GJ. [Related Articles](#) [Links](#)
Thrombin causes cell spreading and redistribution of beta-amyloid immunoreactivity in cultured hippocampal neurons.
J Neurochem. 1996 Jul;67(1):119-30.
PMID: 8666982 [PubMed - indexed for MEDLINE]

254: Nomura Y, Yamanaka Y, Kitamura Y, Arinaga T, Ohnuki T, [Related Articles](#) [Links](#)
Oomura Y, Sasaki K, Nagashima K, Ihara Y
Senescence-accelerated mouse. Neurochemical studies on aging.
Ann N Y Acad Sci. 1996 Jun 15;786:410-8.
PMID: 8687038 [PubMed - indexed for MEDLINE]

255: Brown DM, Tumino DM, Spruyt MA, Jacobsen JS, [Related Articles](#) [Links](#)
Sonnenberg-Reines J
Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates.
J Neurochem. 1996 Jun;66(6):2436-45.
PMID: 8632167 [PubMed - indexed for MEDLINE]

256: Fukuchi K, Ohman T, Dang N, Smith AC, Furlong CE, Martin [Related Articles](#) [Links](#)
GM
Overexpressions of cDNAs for beta-amyloid precursor proteins 695, 751, and 770 enhance the secretion of beta-amyloid precursor protein derivatives and the survival of P19-derived neurons.
J Neurochem. 1996 May;66(5):2201-4.
PMID: 8780054 [PubMed - indexed for MEDLINE]

257: Fraser SP, Suh YH, Chong YH, Djangoz MB. [Related Articles](#) [Links](#)
Membrane currents induced in *Xenopus* oocytes by the C-terminal fragment of the beta-amyloid precursor protein.
J Neurochem. 1996 May;66(5):2034-40.
PMID: 8780033 [PubMed - indexed for MEDLINE]

258: Koo EH, Squazzo SL, Selkoe DJ, Koo CI. [Related Articles](#) [Links](#)
Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody.
J Cell Sci. 1996 May;109 (Pt 5):991-8.
PMID: 8743946 [PubMed - indexed for MEDLINE]

259: Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, [Related Articles](#) [Links](#)
Teplow DB, Selkoe DJ, Mori H
Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Neurobiol Aging. 1996 May-Jun;17(3):405-14.
PMID: 8725902 [PubMed - indexed for MEDLINE]

260: Nelson PT, Saper CB. [Related Articles](#) [Links](#)
Injections of okadaic acid, but not beta-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep.
Neurosci Lett. 1996 Apr 19;208(2):77-80.

PMID: 8859894 [PubMed - indexed for MEDLINE]

□ 261: [Johnstone EM](#), [Babbe L](#), [Stephenson D](#), [Paul DC](#), [Santerre RF](#) Related Articles, Links
[Clemens JA](#), [Williams DC](#), [Little SP](#)

 Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.

Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.
PMID: 8607830 [PubMed - indexed for MEDLINE]

□ 262: [Zhang M](#), [Olsson Y](#) Related Articles, Links

 Beta-amyloid precursor protein accumulates in axons around hematogenous metastases of the human brain: immunohistochemical observations.

Clin Neuropathol. 1996 Mar-Apr;15(2):74-8.
PMID: 8925600 [PubMed - indexed for MEDLINE]

□ 263: [Tekirian TL](#), [Cole GM](#), [Russell MJ](#), [Yang F](#), [Wekstein DR](#), [Patel E](#), [Snowdon DA](#), [Markesberry WR](#), [Geddes JW](#) Related Articles, Links

 Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains.

Neurobiol Aging. 1996 Mar-Apr;17(2):249-57.
PMID: 8744406 [PubMed - indexed for MEDLINE]

□ 264: [Liberksi PP](#), [Yanagihara R](#), [Brown P](#), [Kordok R](#), [Kloszewska I](#), [Bratosiewicz J](#), [Gajdusek DC](#) Related Articles, Links

 Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses.

Neurodegeneration. 1996 Mar;5(1):95-9.
PMID: 8731388 [PubMed - indexed for MEDLINE]

□ 265: [Asaghi A](#), [Cummings BJ](#), [Cribbs DH](#), [Cotman CW](#), [Tenner AJ](#) Related Articles, Links

 Localization and cell association of C1q in Alzheimer's disease brain.
Exp Neurol. 1996 Mar;138(1):22-32.
PMID: 8593893 [PubMed - indexed for MEDLINE]

□ 266: [Yasuhara O](#), [Schwab C](#), [Matsuo A](#), [Kim SU](#), [Steele JC](#), [Akiguchi I](#), [Kimura J](#), [McGeer EG](#), [McGeer PL](#) Related Articles, Links

 Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam.
Neurosci Lett. 1996 Feb 23;205(2):107-10.
PMID: 8907328 [PubMed - indexed for MEDLINE]

□ 267: [Askanas V](#), [McFerrin J](#), [Baque S](#), [Alvarez RR](#), [Sarkozi E](#), [Engel WK](#) Related Articles, Links

 Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle.
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1314-9.
PMID: 8577761 [PubMed - indexed for MEDLINE]

□ 268: [Konig G](#), [Graham F](#), [Bushnell A](#), [Webster S](#), [Wunderlich D](#), [Perlmann L](#), [S](#) Related Articles, Links

 Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide.
Ann N Y Acad Sci. 1996 Jan 17;777:344-55.
PMID: 8624111 [PubMed - indexed for MEDLINE]

□ 269: [McGeer PL](#), [McGeer EG](#) Related Articles, Links

 Anti-inflammatory drugs in the fight against Alzheimer's disease.
Ann N Y Acad Sci. 1996 Jan 17;777:213-20. Review.
PMID: 8624086 [PubMed - indexed for MEDLINE]

270: [Solomon B, Koppel R, Hanan E, Katzav T](#) Related Articles, Links
 Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5.
PMID: 8552659 [PubMed - indexed for MEDLINE]

271: [Lahiri DK, Farlow MR](#) Related Articles, Links
 Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines.
J Mol Neurosci. 1996 Spring;7(1):41-9.
PMID: 8835781 [PubMed - indexed for MEDLINE]

272: [Mena R, Edwards PC, Harrington CR, Mukacova-Ladinska EB, Wischik CM](#) Related Articles, Links
 Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.
Acta Neuropathol (Berl). 1996;91(6):633-41.
PMID: 8781663 [PubMed - indexed for MEDLINE]

273: [Akaaboune M, Verdier-Sahogue M, Lachkar S, Festoff BW, Hantai D](#) Related Articles, Links
 Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro.
J Cell Physiol. 1995 Dec;165(3):503-11.
PMID: 7593229 [PubMed - indexed for MEDLINE]

274: [Saito Y, Buciak J, Yang J, Pardridge WM](#) Related Articles, Links
 Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31.
PMID: 7479757 [PubMed - indexed for MEDLINE]

275: [Link CD](#) Related Articles, Links
 Expression of human beta-amyloid peptide in transgenic *Caenorhabditis elegans*.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72.
PMID: 7568134 [PubMed - indexed for MEDLINE]

276: [Matsumoto A, Matsumoto R, Baba H, Fujiwara Y](#) Related Articles, Links
 A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate.
Neurosci Lett. 1995 Aug 11;195(3):171-4.
PMID: 8584202 [PubMed - indexed for MEDLINE]

277: [Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK](#) Related Articles, Links
 LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation.
Cell. 1995 Jul 28;82(2):331-40.
PMID: 7543026 [PubMed - indexed for MEDLINE]

278: [Banati RB, Gehrmann J, Wiessner C, Hossmann KA, Kreutzberg GW](#) Related Articles, Links
 Glial expression of the beta-amyloid precursor protein (APP) in global ischemia.

J Cereb Blood Flow Metab. 1995 Jul;15(4):647-54.
PMID: 7790414 [PubMed - indexed for MEDLINE]

 **279:** Kida E, Wisniewski KE, Wisniewski HM. [Related Articles](#), [Links](#)

 Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain.
Neurosci Lett. 1995 Jun 30;193(2):105-8.
PMID: 7478152 [PubMed - indexed for MEDLINE]

 **280:** Griffith J S, Mathes M, Schmitz B. [Related Articles](#), [Links](#)

 Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine.
J Neurosci Res. 1995 Jun 1;41(2):270-8.
PMID: 7650762 [PubMed - indexed for MEDLINE]

 **281:** Saito F, Tani A, Miyatake T, Yanagisawa K. [Related Articles](#), [Links](#)

 N-linked oligosaccharide of beta-amyloid precursor protein (beta APP) of C6 glioma cells: putative regulatory role in beta APP processing.
Biochem Biophys Res Commun. 1995 May 25;210(3):703-10.
PMID: 7763244 [PubMed - indexed for MEDLINE]

 **282:** Yamada T, Kobayashi T. [Related Articles](#), [Links](#)

 The mutation in amyloid precursor protein inhibits both alpha- and beta-secretion.
Neurosci Lett. 1995 May 19;191(1-2):103-6.
PMID: 7659274 [PubMed - indexed for MEDLINE]

 **283:** Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin E. [Related Articles](#), [Links](#)

 VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.
Clin Immunol Immunopathol. 1995 May;75(2):159-67.
PMID: 7704974 [PubMed - indexed for MEDLINE]

 **284:** Greenberg SM, Kosik KS. [Related Articles](#), [Links](#)

 Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons.
Neurobiol Aging. 1995 May-Jun;16(3):403-7; discussion 407-8.
PMID: 7566349 [PubMed - indexed for MEDLINE]

 **285:** Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiochi S. [Related Articles](#), [Links](#)

 Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?
Neuroreport. 1995 Apr 19;6(6):866-8.
PMID: 7612872 [PubMed - indexed for MEDLINE]

 **286:** Oohira A, Kushima Y, Matsui F, Watanabe E. [Related Articles](#), [Links](#)

 Detection of Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate both in the juvenile rat brain and in the conditioned medium of primary cultured astrocytes.
Neurosci Lett. 1995 Apr 7;189(1):25-8.
PMID: 7603617 [PubMed - indexed for MEDLINE]

 **287:** Pike CJ, Cummings BJ, Cotman CW. [Related Articles](#), [Links](#)

 Early association of reactive astrocytes with senile plaques in Alzheimer's

disease.

Exp Neurol. 1995 Apr;132(2):172-9.

PMID: 7789457 [PubMed - indexed for MEDLINE]

□ 288: [Yamazaki T, Selkoe DJ, Koo EH](#)

[Related Articles](#), [Links](#)

 Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons.

J Cell Biol. 1995 Apr;129(2):431-42.

PMID: 7721945 [PubMed - indexed for MEDLINE]

□ 289: [Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL, Yoshioka T, Alkon DL](#)

[Related Articles](#), [Links](#)

 Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4.

PMID: 7708775 [PubMed - indexed for MEDLINE]

□ 290: [Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I](#)

[Related Articles](#), [Links](#)

 Ligand-dependent G protein coupling function of amyloid transmembrane precursor.

J Biol Chem. 1995 Mar 3;270(9):4205-8.

PMID: 7876177 [PubMed - indexed for MEDLINE]

□ 291: [Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ](#)

[Related Articles](#), [Links](#)

 Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner.

J Neurosci. 1995 Mar;15(3 Pt 2):2157-67.

PMID: 7891158 [PubMed - indexed for MEDLINE]

□ 292: [Palacios G, Mengod G, Tortosa A, Ferrer I, Palacios JM](#)

[Related Articles](#), [Links](#)

 Increased beta-amyloid precursor protein expression in astrocytes in the gerbil hippocampus following ischaemia: association with proliferation of astrocytes.

Eur J Neurosci. 1995 Mar 1;7(3):501-10.

PMID: 7773447 [PubMed - indexed for MEDLINE]

□ 293: [Walker DG, Kim SU, McGee PL](#)

[Related Articles](#), [Links](#)

 Complement and cytokine gene expression in cultured microglial derived from postmortem human brains.

J Neurosci Res. 1995 Mar 1;40(4):478-93.

PMID: 7616608 [PubMed - indexed for MEDLINE]

□ 294: [Van Gool D, De Strooper B, Van Leuven F, Dom R](#)

[Related Articles](#), [Links](#)

 Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease.

Dementia. 1995 Mar-Apr;6(2):63-8.

PMID: 7606281 [PubMed - indexed for MEDLINE]

□ 295: [Armstrong RA, Winsper SJ, Blair JA](#)

[Related Articles](#), [Links](#)

 Hypothesis: is Alzheimer's disease a metal-induced immune disorder?

Neurodegeneration. 1995 Mar;4(1):107-11.

PMID: 7600179 [PubMed - indexed for MEDLINE]

□ 296: [McRae A, Gilland E, Bona E, Hagberg H](#)

[Related Articles](#), [Links](#)

 Microglia activation after neonatal hypoxic-ischemia.

Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52.

PMID: 7743644 [PubMed - indexed for MEDLINE]

 **297:** Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. [Related Articles](#) [Links](#)
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. *Neuron*. 1995 Feb;14(2):457-66.
PMID: 7857653 [PubMed - indexed for MEDLINE]

 **298:** Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL. [Related Articles](#) [Links](#)
Interaction of beta-amyloid peptides with integrins in a human nerve cell line. *Neurosci Lett*. 1995 Jan 16;184(1):25-8.
PMID: 7739799 [PubMed - indexed for MEDLINE]

 **299:** Cañal A, Alonso-Cortina V, Gozalez-Vazquez LO, Naves EL, Del Valle MH, Vega JA. [Related Articles](#) [Links](#)
beta-Amyloid precursor protein (beta APP) in human gut with special reference to the enteric nervous system. *Brain Res Bull*. 1995;38(5):417-23.
PMID: 8665264 [PubMed - indexed for MEDLINE]

 **300:** Schwab C, Steele JC, Akiyama H, McGeer EG, McGeer PL. [Related Articles](#) [Links](#)
Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia. *Acta Neuropathol (Berl)*. 1995;90(3):287-98.
PMID: 8525803 [PubMed - indexed for MEDLINE]

 **301:** Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Siega RE. [Related Articles](#) [Links](#)
Early onset Alzheimer's disease in a South American pedigree from Argentina. *Acta Neurol Scand*. 1995 Jan;91(1):6-13.
PMID: 7732777 [PubMed - indexed for MEDLINE]

 **302:** Tiarhou LC, Sela C, Mengod G, Garcia-Ladona EL, Landwehrmeyer B, Ghetti B, Palacios JM. [Related Articles](#) [Links](#)
Ventral mesencephalic grafts in the neostriatum of the weaver mutant mouse: structural molecule and receptor studies. *Cell Transplant*. 1995 Jan-Feb;4(1):39-48.
PMID: 7728332 [PubMed - indexed for MEDLINE]

 **303:** Mena R, Edwards P, Perez-Olvera O, Wischik CM. [Related Articles](#) [Links](#)
Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. *Acta Neuropathol (Berl)*. 1995;89(1):50-6.
PMID: 7709731 [PubMed - indexed for MEDLINE]

 **304:** Jakes R, Harrington CR, Spillantini MG, Goedert M, Klug A. [Related Articles](#) [Links](#)
Characterisation of an antibody relevant to the neuropathology of Alzheimer disease. *Alzheimer Dis Assoc Disord*. 1995 Spring;9(1):47-51.
PMID: 7605621 [PubMed - indexed for MEDLINE]

 **305:** Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamamoto T. [Related Articles](#) [Links](#)
Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells. *Acta Neuropathol (Berl)*. 1995;89(3):199-203.
PMID: 7538720 [PubMed - indexed for MEDLINE]

306: Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. [Related Articles](#) [Links](#)
 **Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum.**
Brain Res. 1994 Dec 19;667(1):138-42.
PMID: 7895077 [PubMed - indexed for MEDLINE]

307: Oda T, Pasinetti GM, Osterburg H, Anderson C, Johnson SA, Finch CE. [Related Articles](#) [Links](#)
 **Purification and characterization of brain clusterin.**
Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6.
PMID: 7980587 [PubMed - indexed for MEDLINE]

308: O'Brien TJ, McKelvie PA, Vroodos N. [Related Articles](#) [Links](#)
 **Bilateral trigeminal amyloidoma: an unusual case of trigeminal neuropathy with a review of the literature. Case report.**
J Neurosurg. 1994 Nov;81(5):780-3. Review.
PMID: 7931626 [PubMed - indexed for MEDLINE]

309: Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J. [Related Articles](#) [Links](#)
 **Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies.**
Clin Neuropathol. 1994 Nov-Dec;13(6):306-14.
PMID: 7851045 [PubMed - indexed for MEDLINE]

310: McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG. [Related Articles](#) [Links](#)
 **Pathological proteins in senile plaques.**
Tohoku J Exp Med. 1994 Nov;174(3):269-77.
PMID: 7761992 [PubMed - indexed for MEDLINE]

311: Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM. [Related Articles](#) [Links](#)
 **Monoclonal antibody to the C-terminus of beta-amyloid.**
Neuroreport. 1994 Oct 27;5(16):2117-20.
PMID: 7865758 [PubMed - indexed for MEDLINE]

312: Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA. [Related Articles](#) [Links](#)
 **Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease.**
Brain Res. 1994 Oct 24;661(1-2):35-42.
PMID: 7834382 [PubMed - indexed for MEDLINE]

313: Sherriff FE, Bridges LR, De Souza DS. [Related Articles](#) [Links](#)
 **Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity.**
Neuroreport. 1994 Oct 3;5(15):1897-900.
PMID: 7531003 [PubMed - indexed for MEDLINE]

314: Dreyer RN, Bausch KM, Fracasso P, Hammond J, Wunderlich D, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al. [Related Articles](#) [Links](#)
 **Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation.**
Eur J Biochem. 1994 Sep 1;224(2):265-71.
PMID: 7523115 [PubMed - indexed for MEDLINE]

315: van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Swaab DF. [Related Articles](#) [Links](#)
 **The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of**

somatostatin neurons in the normal human hypothalamus and adjoining areas.

Brain Res. 1994 Aug 29;655(1-2):97-109.

PMID: 7812796 [PubMed - indexed for MEDLINE]

316: [Durham JJD, Minotti S, Dooley JP, Nalbantoglu L](#) [Related Articles](#) [Links](#)

 Expression of the intermediate filament-associated protein related to beta-amyloid precursor protein is developmentally regulated in cultured cells. *J Neurosci Res.* 1994 Aug 15;38(6):629-39.

PMID: 7807580 [PubMed - indexed for MEDLINE]

317: [Heinonen O, Soininen H, Syrjanen S, Neittaanmaki H, Paljarvi L, Kosunen O, Syrjanen K, Rickkinen P, Sr.](#) [Related Articles](#) [Links](#)

 beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study.

Arch Neurol. 1994 Aug;51(8):799-804.

PMID: 8042928 [PubMed - indexed for MEDLINE]

318: [Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA](#) [Related Articles](#) [Links](#)

 Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13.

PMID: 7888086 [PubMed - indexed for MEDLINE]

319: [Singh VK](#) [Related Articles](#) [Links](#)

 Studies of neuroimmune markers in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81.

PMID: 7534089 [PubMed - indexed for MEDLINE]

320: [Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Kraft GA, Holzman RB, Holzman TE](#) [Related Articles](#) [Links](#)

 Complement C1q does not bind monomeric beta-amyloid.

Exp Neurol. 1994 Jul;128(1):136-42.

PMID: 8070518 [PubMed - indexed for MEDLINE]

321: [Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y](#) [Related Articles](#) [Links](#)

 Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Neuron. 1994 Jul;13(1):45-53.

PMID: 8043280 [PubMed - indexed for MEDLINE]

322: [Walker LC, Price DL, Voytko ML, Schenk DB](#) [Related Articles](#) [Links](#)

 Labeling of cerebral amyloid in vivo with a monoclonal antibody.

J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.

PMID: 8021711 [PubMed - indexed for MEDLINE]

323: [Banati RB, Gehrmann J, Kreutzberg GW](#) [Related Articles](#) [Links](#)

 Glial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion.

Neuroreport. 1994 Jun 27;5(11):1359-61.

PMID: 7919199 [PubMed - indexed for MEDLINE]

324: [Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S](#) [Related Articles](#) [Links](#)

 Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus.

J Biol Chem. 1994 May 27;269(21):15253-7.

PMID: 8195161 [PubMed - indexed for MEDLINE]

325: [Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P.](#) Related Articles, Links

 Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603.
PMID: 8185615 [PubMed - indexed for MEDLINE]

326: [Schmidt ML, Dilavore AG, Lee VM, Trojanowski JQ.](#) Related Articles, Links

 An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease.

FEBS Lett. 1994 May 9;344(1):69-73.
PMID: 8181568 [PubMed - indexed for MEDLINE]

327: [Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B.](#) Related Articles, Links

 Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Am J Pathol. 1994 May;144(5):1082-8.
PMID: 8178931 [PubMed - indexed for MEDLINE]

328: [Stanley LC, Mrak RE, Woody RC, Perrot J, Zhang S, Marshak DR, Nelson SJ, Griffin WS.](#) Related Articles, Links

 Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease.

J Neuropathol Exp Neurol. 1994 May;53(3):231-8.
PMID: 8176406 [PubMed - indexed for MEDLINE]

329: [Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D.](#) Related Articles, Links

 Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy.

J Neurobiol. 1994 May;25(5):503-14.
PMID: 8071658 [PubMed - indexed for MEDLINE]

330: [Matsumoto A, Fujiwara Y.](#) Related Articles, Links

 Ca(2+)-dependent 68-kilodalton protease in familial Alzheimer's disease cells cleaves the N-terminus of beta-amyloid.

Biochemistry. 1994 Apr 5;33(13):3941-8.
PMID: 8142398 [PubMed - indexed for MEDLINE]

331: [Beeson JG, Shelton ER, Chan HW, Gage FH.](#) Related Articles, Links

 Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies.

J Comp Neurol. 1994 Apr 1;342(1):78-96.
PMID: 8207129 [PubMed - indexed for MEDLINE]

332: [Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DL.](#) Related Articles, Links

 Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.

J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25.
PMID: 8163989 [PubMed - indexed for MEDLINE]

333: [Bilak M, Askanas V, Engel WK.](#) Related Articles, Links

 Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions.

Synapse. 1994 Apr;16(4):280-3.
PMID: 8059338 [PubMed - indexed for MEDLINE]

 **334:** [Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Nolan CC, Anderton BH, Leigh PN.](#) [Related Articles](#), [Links](#)

 beta-Amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin.
Brain Res. 1994 Mar 21;640(1-2):25-32.
PMID: 8004453 [PubMed - indexed for MEDLINE]

 **335:** [Bickel U, Lee VM, Trojanowski JQ, Pardridge WM.](#) [Related Articles](#), [Links](#)

 Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease.
Bioconjug Chem. 1994 Mar-Apr;5(2):119-25.
PMID: 8031874 [PubMed - indexed for MEDLINE]

 **336:** [Loffler J, Langui D, Probst A, Huber G.](#) [Related Articles](#), [Links](#)

 Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex.
Neurochem Int. 1994 Mar;24(3):281-8.
PMID: 8025536 [PubMed - indexed for MEDLINE]

 **337:** [Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K.](#) [Related Articles](#), [Links](#)

 Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.
Am J Pathol. 1994 Feb;144(2):337-47.
PMID: 8311117 [PubMed - indexed for MEDLINE]

 **338:** [Hartig W, Hause D, Brauer K, Arendt T, Bigl V, Bruckner G.](#) [Related Articles](#), [Links](#)

 Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid.
Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5 (8):following 1014.
PMID: 8025246 [PubMed - indexed for MEDLINE]

 **339:** [Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG.](#) [Related Articles](#), [Links](#)

 An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain.
Neuron. 1994 Jan;12(1):219-34.
PMID: 8292358 [PubMed - indexed for MEDLINE]

 **340:** [Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ.](#) [Related Articles](#), [Links](#)

 Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.
Am J Pathol. 1994 Jan;144(1):177-87.
PMID: 8291607 [PubMed - indexed for MEDLINE]

 **341:** [Westarp ME, Foring B, Rasmussen H, Schraff S, Mertens T, Kornhuber JH.](#) [Related Articles](#), [Links](#)

 Retroviral synthetic peptide serum antibodies in human sporadic amyotrophic lateral sclerosis.
Peptides. 1994;15(2):207-14.
PMID: 8008625 [PubMed - indexed for MEDLINE]

 **342:** [Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos](#) [Related Articles](#), [Links](#)

RA

 **342:** Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology. *Acta Neuropathol (Berl)*. 1994;88(4):371-8. PMID: 7839831 [PubMed - indexed for MEDLINE]

 **343:** Zemlan FP, Vogelsang GD, McLaughlin L, Dean GE. [Related Articles](#), [Links](#)
Alzheimer's paired helical filaments: amyloid precursor protein epitope mapping. *Brain Res Bull*. 1994;33(4):387-92. PMID: 7510209 [PubMed - indexed for MEDLINE]

 **344:** Cummings BJ, Su JI, Cotman CW. [Related Articles](#), [Links](#)
Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. *Exp Neurol*. 1993 Dec;124(2):315-25. PMID: 8287930 [PubMed - indexed for MEDLINE]

 **345:** Sussman MA, Bilak M, Kedes L, Engel WK, Askanas V. [Related Articles](#), [Links](#)
Tropomodulin is highly concentrated at the postsynaptic domain of human and rat neuromuscular junctions. *Exp Cell Res*. 1993 Dec;209(2):388-91. PMID: 8262158 [PubMed - indexed for MEDLINE]

 **346:** Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. [Related Articles](#), [Links](#)
Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. *Neurobiol Aging*. 1993 Nov-Dec;14(6):589-96. PMID: 8295661 [PubMed - indexed for MEDLINE]

 **347:** Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. [Related Articles](#), [Links](#)
Characterization of beta-amyloid peptide from human cerebrospinal fluid. *J Neurochem*. 1993 Nov;61(5):1965-8. PMID: 8229004 [PubMed - indexed for MEDLINE]

 **348:** Jucker M, Walker LC, Kibbey MC, Kleinman HK, Ingram DK. [Related Articles](#), [Links](#)
Localization of a laminin-binding protein in brain. *Neuroscience*. 1993 Oct;56(4):1009-22. PMID: 8284032 [PubMed - indexed for MEDLINE]

 **349:** Higgins LS, Catalano R, Quon D, Cordell B. [Related Articles](#), [Links](#)
Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology. *Ann N Y Acad Sci*. 1993 Sep 24;695:224-7. PMID: 8239286 [PubMed - indexed for MEDLINE]

 **350:** Askanas V, Bilak M, Engel WK, Leclerc A, Tome F. [Related Articles](#), [Links](#)
Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions. *Neurosci Lett*. 1993 Sep 3;159(1-2):111-4. PMID: 8264949 [PubMed - indexed for MEDLINE]

 **351:** Ichida K, Okuda R, Yamaguchi R, Tateyama S, Nakayama H, Goto N. [Related Articles](#), [Links](#)
Double-labeling immunohistochemical studies on canine senile plaques and cerebral amyloid angiopathy. *J Vet Med Sci*. 1993 Aug;55(4):637-42.

PMID: 8399746 [PubMed - indexed for MEDLINE]

352: Holmes C, Webster MJ, Procter AW, Francis PT, Bowen DM. Related Articles, Links

Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.
Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract available.
PMID: 8224394 [PubMed - indexed for MEDLINE]

353: Miklossy J. Related Articles, Links

Alzheimer's disease--a spirochetosis?
Neuroreport. 1993 Jul;4(7):841-8.
PMID: 8369471 [PubMed - indexed for MEDLINE]

354: Leclerc A, Tome FM, Fardeau M. Related Articles, Links

Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study.
Neuromuscul Disord. 1993 Jul;3(4):283-91.
PMID: 8268725 [PubMed - indexed for MEDLINE]

355: Singhrao SK, Neal JW, Newman GR. Related Articles, Links

Corpora amylacea could be an indicator of neurodegeneration.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76.
PMID: 8355813 [PubMed - indexed for MEDLINE]

356: Coria F, Moreno A, Rubio J, Garcia MA, Morato E, Mayor F Jr. Related Articles, Links

The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):261-8.
PMID: 8355812 [PubMed - indexed for MEDLINE]

357: DeWitt DA, Silver J, Canning DR, Perry G. Related Articles, Links

Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease.
Exp Neurol. 1993 Jun;121(2):149-52.
PMID: 8339766 [PubMed - indexed for MEDLINE]

358: Fukuchi K, Sepher B, Furlong CE, Smith AC, Dang N, Martin GM. Related Articles, Links

Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein.
Neurosci Lett. 1993 May 14;154(1-2):145-8.
PMID: 8361630 [PubMed - indexed for MEDLINE]

359: Stoll J, Balbo A, Ault B, Rapoport SI, Fine A. Related Articles, Links

Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology.
Brain Res. 1993 May 7;610(2):295-304.
PMID: 8319091 [PubMed - indexed for MEDLINE]

360: Scott SA, Johnson SA, Zarow C, Perlmutter LS. Related Articles, Links

Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia.
Exp Neurol. 1993 May;121(1):113-8.
PMID: 8495706 [PubMed - indexed for MEDLINE]

361: Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H. Related Articles, Links

McGeer PL.

 **361:** Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease.

Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51.
PMID: 8476427 [PubMed - indexed for MEDLINE]

 **362:** Lahiri DK. Related Articles, Links

 **363:** The stability of beta-amyloid precursor protein in nine different cell types.

Biochem Mol Biol Int. 1993 Apr;29(5):849-58.
PMID: 8508138 [PubMed - indexed for MEDLINE]

 **364:** Gaskin F, Finley J, Fang Q, Xu S, Yu SM. Related Articles, Links

 **365:** Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.

J Exp Med. 1993 Apr 1;177(4):1181-6.
PMID: 8459212 [PubMed - indexed for MEDLINE]

 **366:** Mattson MP, Cheng B, Culwell AR, Eisch ES, Lieberburg I, Rydel RE. Related Articles, Links

 **367:** Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.

Neuron. 1993 Feb;10(2):243-54.
PMID: 8094963 [PubMed - indexed for MEDLINE]

 **368:** Buee L, Ding W, Delacourte A, Eillit H. Related Articles, Links

 **369:** Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.

Brain Res. 1993 Jan 22;601(1-2):154-63.
PMID: 8431762 [PubMed - indexed for MEDLINE]

 **370:** Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Tbat L, et al. Related Articles, Links

 **371:** Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.

Nature. 1993 Jan 21;361(6409):260-3.
PMID: 7678698 [PubMed - indexed for MEDLINE]

 **372:** Nelson PT, Marton L, Saper CB. Related Articles, Links

 **373:** Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study.

Brain Res. 1993 Jan 15;600(2):285-97.
PMID: 8094642 [PubMed - indexed for MEDLINE]

 **374:** Wismiewski HM, Weigel J. Related Articles, Links

 **375:** Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation.

Acta Neuropathol (Berl). 1993;85(6):586-95.
PMID: 8337937 [PubMed - indexed for MEDLINE]

 **376:** Su JH, Cummings BJ, Cotman CW. Related Articles, Links

 **377:** Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.

Neuroscience. 1992 Dec;51(4):801-13.
PMID: 1488123 [PubMed - indexed for MEDLINE]

 **378:** Perlmuter LS, Scott SA, Barron E, Chui HC. Related Articles, Links

 **379:** MHC class II-positive microglia in human brain: association with Alzheimer lesions.

J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci Res 1993 Jun 15;35(3):346.
PMID: 1484388 [PubMed - indexed for MEDLINE]

 371: [Lahiri DK, Nall C, Farlow MR.](#) [Related Articles](#), [Links](#)

 The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells.
Biochem Int. 1992 Dec;28(5):853-60.
PMID: 1288495 [PubMed - indexed for MEDLINE]

 372: [Kammesheidt A, Boyce FM, Spano yannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught JL, Neve RL.](#) [Related Articles](#), [Links](#)

 Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain.
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61.
PMID: 1438289 [PubMed - indexed for MEDLINE]

 373: [Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WI, Braehova L, Bradt B, Ward P, et al.](#) [Related Articles](#), [Links](#)

 Complement activation by beta-amyloid in Alzheimer disease.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20.
PMID: 1438191 [PubMed - indexed for MEDLINE]

 374: [Brewer GJ, Ashford JW.](#) [Related Articles](#), [Links](#)

 Human serum stimulates Alzheimer markers in cultured hippocampal neurons.
J Neurosci Res. 1992 Nov;33(3):355-69.
PMID: 1335088 [PubMed - indexed for MEDLINE]

 375: [Palacios G, Palacios JM, Mengod G, Frey P.](#) [Related Articles](#), [Links](#)

 Beta-amyloid precursor protein localization in the Golgi apparatus in neurons and oligodendrocytes. An immunocytochemical structural and ultrastructural study in normal and axotomized neurons.
Brain Res Mol Brain Res. 1992 Oct;15(3-4):195-206.
PMID: 1331676 [PubMed - indexed for MEDLINE]

 376: [Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al.](#) [Related Articles](#), [Links](#)

 Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.
Nature. 1992 Sep 24;359(6393):325-7.
PMID: 1406936 [PubMed - indexed for MEDLINE]

 377: [Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al.](#) [Related Articles](#), [Links](#)

 Amyloid beta-peptide is produced by cultured cells during normal metabolism.
Nature. 1992 Sep 24;359(6393):322-5.
PMID: 1383826 [PubMed - indexed for MEDLINE]

 378: [Dooley NP, Gauthier S, Durham HD.](#) [Related Articles](#), [Links](#)

 Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts.
J Neurosci Res. 1992 Sep;33(1):60-7.
PMID: 1453484 [PubMed - indexed for MEDLINE]

 379: [Askanas V, Jingel WK, Alvarez RB.](#) [Related Articles](#), [Links](#)

 Strong immunoreactivity of beta-amyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions.
Neurosci Lett. 1992 Aug 31;143(1-2):96-100.
PMID: 1436686 [PubMed - indexed for MEDLINE]

 380: Murphy GM Jr, Greenberg BD, Ellis WG, Forno LS, Salama SM, Gonzalez-DeWhitt PA, Lowery DF, Tinklenberg JR, Eng LF. [Related Articles](#), [Links](#)
Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.
Am J Pathol. 1992 Aug;141(2):357-61.
PMID: 1386714 [PubMed - indexed for MEDLINE]

 381: Lippa CF, Smith TW. [Related Articles](#), [Links](#)
The indusium griseum in Alzheimer's disease: an immunocytochemical study.
J Neurol Sci. 1992 Aug;111(1):39-45.
PMID: 1328542 [PubMed - indexed for MEDLINE]

 382: Shioi J, Anderson JP, Ripellino JA, Robakis NK. [Related Articles](#), [Links](#)
Chondroitin sulfate proteoglycan form of the Alzheimer's beta-amyloid precursor.
J Biol Chem. 1992 Jul 15;267(20):13819-22.
PMID: 1629183 [PubMed - indexed for MEDLINE]

 383: Mizuguchi M, Ikeda K, Kim SU. [Related Articles](#), [Links](#)
Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures.
Brain Res. 1992 Jul 3;584(1-2):219-25.
PMID: 1515940 [PubMed - indexed for MEDLINE]

 384: Festoff BW, Rao JS, Chen M. [Related Articles](#), [Links](#)
Protease nexin I, thrombin- and urokinase-inhibiting serpin, concentrated in normal human cerebrospinal fluid.
Neurology. 1992 Jul;42(7):1361-6.
PMID: 1620346 [PubMed - indexed for MEDLINE]

 385: Rogers J, Schultz J, Brachova L, Lue I, Webster S, Bradt B, Cooper NR, Moss DE. [Related Articles](#), [Links](#)
Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.
Res Immunol. 1992 Jul-Aug;143(6):624-30. Review. No abstract available.
PMID: 1455054 [PubMed - indexed for MEDLINE]

 386: Arai J, Schindt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ. [Related Articles](#), [Links](#)
Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease.
Neurology. 1992 Jul;42(7):1315-22.
PMID: 1377804 [PubMed - indexed for MEDLINE]

 387: Askanas V, Engel WK, Alvarez RB. [Related Articles](#), [Links](#)
Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis.
Am J Pathol. 1992 Jul;141(1):31-6.
PMID: 1321564 [PubMed - indexed for MEDLINE]

 388: Caputo CB, Sobel IR, Scott CW, Brunner WF, Barth PT, Blowers DP. [Related Articles](#), [Links](#)

 Association of the carboxy-terminus of beta-amyloid protein precursor with Alzheimer paired helical filaments.
Biochem Biophys Res Commun. 1992 Jun 30;185(3):1034-40.
PMID: 1627127 [PubMed - indexed for MEDLINE]

 **389:** [Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ.](#) [Related Articles](#), [Links](#)
Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.
Nature. 1992 Jun 11;357(6378):500-3.
PMID: 1608449 [PubMed - indexed for MEDLINE]

 **390:** [Cummings BJ, Su JI, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DJ, Cotman CW.](#) [Related Articles](#), [Links](#)
Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease.
Neuroscience. 1992 Jun;48(4):763-77.
PMID: 1378573 [PubMed - indexed for MEDLINE]

 **391:** [Mizuguchi M, Ikeda K, Kim SU.](#) [Related Articles](#), [Links](#)
beta-Amyloid precursor protein of Alzheimer's disease in cultured bovine oligodendrocytes.
J Neurosci Res. 1992 May;32(1):34-42.
PMID: 1629942 [PubMed - indexed for MEDLINE]

 **392:** [McGeer PL, Akiyama H, Kawamata T, Yamada T, Walker DG, Ishii T.](#) [Related Articles](#), [Links](#)
Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy.
J Neurosci Res. 1992 Mar;31(3):428-42.
PMID: 1640495 [PubMed - indexed for MEDLINE]

 **393:** [Askanas V, Engel WK, Alvarez RB, Glenner GG.](#) [Related Articles](#), [Links](#)
beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis.
Lancet. 1992 Feb 29;339(8792):560-1. No abstract available.
PMID: 1346915 [PubMed - indexed for MEDLINE]

 **394:** [Ohgami T, Kitamoto T, Tateishi J.](#) [Related Articles](#), [Links](#)
Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions.
Neurosci Lett. 1992 Feb 17;136(1):75-8.
PMID: 1635670 [PubMed - indexed for MEDLINE]

 **395:** [Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV.](#) [Related Articles](#), [Links](#)
Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human beta amyloid precursor protein.
J Immunol Methods. 1992 Feb 14;147(1):1-11.
PMID: 1371794 [PubMed - indexed for MEDLINE]

 **396:** [Delvaux A, Van der Elst L, Octave JN.](#) [Related Articles](#), [Links](#)
Inhibition of trypsin by the beta-amyloid protein precursor. A comparative study between transfected cells, human brain and cerebrospinal fluid.
FEBS Lett. 1992 Feb 3;297(1-2):124-6.
PMID: 1551418 [PubMed - indexed for MEDLINE]

397: Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M. [Related Articles](#), [Links](#)

 SP-40,40 is a constituent of Alzheimer's amyloid. *Acta Neuropathol (Berl)*. 1992;83(3):260-4.
PMID: 1373021 [PubMed - indexed for MEDLINE]

398: Barcikowska M, Kujawa M, Wisniewski H. [Related Articles](#), [Links](#)

 beta-Amyloid deposits within the cerebellum of persons older than 80 years of age. *Neuropatol Pol.* 1992;30(3-4):285-93.
PMID: 1340921 [PubMed - indexed for MEDLINE]

399: Frautschi SA, Baird A, Cole GM. [Related Articles](#), [Links](#)

 Effects of injected Alzheimer beta-amyloid cores in rat brain. *Proc Natl Acad Sci U S A.* 1991 Oct 1;88(19):8362-6.
PMID: 1924295 [PubMed - indexed for MEDLINE]

400: Ito H, Hirano H, Yen SH, Kato S. [Related Articles](#), [Links](#)

 Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam. *Neuropathol Appl Neurobiol.* 1991 Oct;17(5):365-73.
PMID: 1758569 [PubMed - indexed for MEDLINE]

401: Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. [Related Articles](#), [Links](#)

 Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. *Proc Natl Acad Sci U S A.* 1991 Sep 1;88(17):7552-6.
PMID: 1652752 [PubMed - indexed for MEDLINE]

402: Price JL, Davis PB, Morris JC, White DL. [Related Articles](#), [Links](#)

 The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol Aging.* 1991 Jul-Aug;12(4):295-312.
PMID: 1961359 [PubMed - indexed for MEDLINE]

403: Chen M, Yankner BA. [Related Articles](#), [Links](#)

 An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types. *Neurosci Lett.* 1991 Apr 29;125(2):223-6.
PMID: 1715534 [PubMed - indexed for MEDLINE]

404: Knops J, Johnson-Wood K, Schenk D, B, Sisodia SS, Lieberburg I, McCaughey E. [Related Articles](#), [Links](#)

 Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein. *J Biol Chem.* 1991 Apr 15;266(11):7285-90.
PMID: 1901866 [PubMed - indexed for MEDLINE]

405: Fraser PE, Duffy J, O'Malley MB, Nguyen J, Inouye H, Kirschner DA. [Related Articles](#), [Links](#)

 Morphology and antibody recognition of synthetic beta-amyloid peptides. *J Neurosci Res.* 1991 Apr;28(4):474-85.
PMID: 1908024 [PubMed - indexed for MEDLINE]

406: Matsumoto A, Fujiwara Y. [Related Articles](#), [Links](#)

 Abnormal and deficient processing of beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells. *Biochem Biophys Res Commun.* 1991 Mar 15;175(2):361-5

PMID: 1902089 [PubMed - indexed for MEDLINE]

□ 407: [Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et al](#) Related Articles, Links

□ [Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay.](#)
J Neurochem. 1991 Mar;56(3):1037-42.
PMID: 1899691 [PubMed - indexed for MEDLINE]

□ 408: [Pendlebury WW, Iole ED, Tracy RP, Dill BA.](#) Related Articles, Links

□ [Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment.](#)
Ann Neurol. 1991 Feb;29(2):210-3.
PMID: 1901466 [PubMed - indexed for MEDLINE]

□ 409: [Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D.](#) Related Articles, Links

□ [Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques.](#)
Am J Pathol. 1991 Feb;138(2):373-84.
PMID: 1704190 [PubMed - indexed for MEDLINE]

□ 410: [Takahashi H, Hirokawa K, Ando S, Obata K.](#) Related Articles, Links

□ [Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5.](#)
Acta Neuropathol (Berl). 1991;81(6):626-31.
PMID: 1909079 [PubMed - indexed for MEDLINE]

□ 411: [Becker L, Mito T, Takashima S, Onodera K.](#) Related Articles, Links

□ [Growth and development of the brain in Down syndrome.](#)
Prog Clin Biol Res. 1991;373:133-52. Review.
PMID: 1838182 [PubMed - indexed for MEDLINE]

□ 412: [Zhao XII, Schoenheit C, Duffy LK.](#) Related Articles, Links

□ [A heparin-binding protein from neuroblastoma cells: immunological comparison to beta-amyloid precursor protein.](#)
Comp Biochem Physiol A. 1991;100(3):715-8.
PMID: 1685979 [PubMed - indexed for MEDLINE]

□ 413: [Breen KC, Bruce M, Anderton BH.](#) Related Articles, Links

□ [Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion.](#)
J Neurosci Res. 1991 Jan;28(1):90-100.
PMID: 1645774 [PubMed - indexed for MEDLINE]

□ 414: [Yankner BA, Caceres A, Duffy LK.](#) Related Articles, Links

□ [Nerve growth factor potentiates the neurotoxicity of beta amyloid.](#)
Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3.
PMID: 2174172 [PubMed - indexed for MEDLINE]

□ 415: [Snow AJ, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN.](#) Related Articles, Links

□ [Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.](#)
Am J Pathol. 1990 Nov;137(5):1253-70.
PMID: 2146882 [PubMed - indexed for MEDLINE]

416: Bodmer S, Podlisny MB, Selkoe DJ, Heid J, Fontana A. [Related Articles](#) [Links](#)
 Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. *Biochem Biophys Res Commun*. 1990 Sep 14;171(2):890-7. PMID: 2119582 [PubMed - indexed for MEDLINE]

417: Kanemaru K, Hasegawa M, Shimada H, Ihara Y. [Related Articles](#) [Links](#)
 The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section. *Am J Pathol*. 1990 Sep;137(3):677-87. PMID: 1698030 [PubMed - indexed for MEDLINE]

418: Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman M, Marotta CA. [Related Articles](#) [Links](#)
 Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein. *J Geriatr Psychiatry Neurol*. 1990 Jul-Sep;3(3):139-45. PMID: 2126439 [PubMed - indexed for MEDLINE]

419: Sheltora ER, Cohn R, Fish L, Oberholzer R, Tahirovacihi R, Nestor J, Chan HW. [Related Articles](#) [Links](#)
 Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies. *J Neurochem*. 1990 Jul;55(1):60-9. PMID: 2113083 [PubMed - indexed for MEDLINE]

420: Wolf D, Quen D, Wang Y, Cordell R. [Related Articles](#) [Links](#)
 Identification and characterization of C-terminal fragments of the beta-amyloid precursor produced in cell culture. *EMBO J*. 1990 Jul;9(7):2079-84. PMID: 1694126 [PubMed - indexed for MEDLINE]

421: Stern RA, Trojanowski JQ, Lee VM. [Related Articles](#) [Links](#)
 Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. *FEBS Lett*. 1990 May 7;264(1):43-7. PMID: 1692541 [PubMed - indexed for MEDLINE]

422: Spillantini MG, Goedert M, Jakes R, Klug A. [Related Articles](#) [Links](#)
 Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1990 May;87(10):3947-51. PMID: 2111023 [PubMed - indexed for MEDLINE]

423: Singhrao S, Cole G, Henderson WJ, Newman GR. [Related Articles](#) [Links](#)
 LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease. *Histochem J*. 1990 May;22(5):257-68. PMID: 1966829 [PubMed - indexed for MEDLINE]

424: Spillantini MG, Goedert M, Jakes R, Klug A. [Related Articles](#) [Links](#)
 Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1990 May;87(10):3952-6. PMID: 1692627 [PubMed - indexed for MEDLINE]

425: Cataldo AM, Nixon RA. [Related Articles](#) [Links](#)


 Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.
Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5.
PMID: 1692625 [PubMed - indexed for MEDLINE]

 426: [Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ](#) Related Articles, Links
Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53.
PMID: 1690426 [PubMed - indexed for MEDLINE]

 427: [Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H](#) Related Articles, Links
Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.
Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9.
PMID: 2106318 [PubMed - indexed for MEDLINE]

 428: [Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL](#) Related Articles, Links
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5.
PMID: 1689489 [PubMed - indexed for MEDLINE]

 429: [Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RL, Benes FM, Marotta CA](#) Related Articles, Links
Alzheimer cortical neurons containing abundant amyloid mRNA. Relationship to amyloid deposition and senile plaques.
J Psychiatr Res. 1990;24(1):37-50.
PMID: 2195164 [PubMed - indexed for MEDLINE]

 430: [Dewji NN, Shelton ER, Adler MJ, Chan JH, Seegmiller JE, Coronel C](#) Related Articles, Links
Processing of Alzheimer's disease-associated beta-amyloid precursor protein.
J Mol Neurosci. 1990;2(1):19-27.
PMID: 2124135 [PubMed - indexed for MEDLINE]

 431: [Murphy GM Jr, Eng LF, Cordell B, Wang Y, Ellis WG, Weissner L, Tinklenberg JR](#) Related Articles, Links
Beta-amyloid precursor detected in human cerebral cortex.
Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17.
PMID: 2113696 [PubMed - indexed for MEDLINE]

 432: [Takahashi H, Kurashina C, Utsuyama M, Hirokawa K](#) Related Articles, Links
Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.
Acta Neuropathol (Berl). 1990;80(3):260-5.
PMID: 1698004 [PubMed - indexed for MEDLINE]

 433: [Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski ML, Frangione B](#) Related Articles, Links
Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.
J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8.
PMID: 1688925 [PubMed - indexed for MEDLINE]

434: Suenaga T, Hirano A, Llena JE, Ksieczak-Reding H, Yen SH, [Dickson DW](#) [Related Articles](#), [Links](#)

Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.
J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40.
PMID: 1688924 [PubMed - indexed for MEDLINE]

435: Palmer MR, Siedlak SL, Podlisny MB, Greenberg B, [Shelton ER](#), [Chan HW](#), [Usiak M](#), [Selkoe DJ](#), [Perry G](#), [Younkin SG](#) [Related Articles](#), [Links](#)

Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein.
Biochem Biophys Res Commun. 1989 Nov 30;165(1):182-8.
PMID: 2480122 [PubMed - indexed for MEDLINE]

436: Behroutz N, Defossez A, Delacourte A, [Hubba P](#), [Mazzacca M](#) [Related Articles](#), [Links](#)

An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles.
J Gerontol. 1989 Nov;44(6):B156-9.
PMID: 2681356 [PubMed - indexed for MEDLINE]

437: Siman R, [Card JP](#), [Nelson RB](#), [Davis LG](#) [Related Articles](#), [Links](#)

Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage.
Neuron. 1989 Sep;3(3):275-85.
PMID: 2518369 [PubMed - indexed for MEDLINE]

438: Palmer MR, Podlisny MB, [Witker DS](#), [Oltersdorf T](#), [Younkin LH](#), [Selkoe DJ](#), [Younkin SG](#) [Related Articles](#), [Links](#)

The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42.
PMID: 2503832 [PubMed - indexed for MEDLINE]

439: Takio K, [Hasegawa M](#), [Titani K](#), [Ihara Y](#) [Related Articles](#), [Links](#)

Identification of beta protein precursor in newborn rat brain.
Biochem Biophys Res Commun. 1989 May 15;160(3):1296-301.
PMID: 2499330 [PubMed - indexed for MEDLINE]

440: [Anderson J](#), [Wallace W](#), [Snyder S](#), [Haroutunian V](#), [Roberts JL](#), [Lieberburg I](#) [Related Articles](#), [Links](#)

Cellular forms of the rat and human beta-amyloid precursor protein (BAPP).
Brain Res. 1989 Jan 30;478(2):391-8.
PMID: 2647209 [PubMed - indexed for MEDLINE]

441: [Benes FM](#), [Reifel JL](#), [Majocchi RE](#), [Marotta CA](#) [Related Articles](#), [Links](#)

Evidence for a diffusional model of Alzheimer amyloid A4 (beta-amyloid) deposition during neuritic plaque formation.
Neuroscience. 1989;33(3):483-8.
PMID: 2700016 [PubMed - indexed for MEDLINE]

442: [Bird TD](#), [Lampe TH](#), [Nemens EJ](#), [Sumi SM](#), [Nochlin D](#), [Schellenberg GD](#), [Wijsman EM](#) [Related Articles](#), [Links](#)

Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry.
Prog Clin Biol Res. 1989;317:229-34.
PMID: 2602419 [PubMed - indexed for MEDLINE]

443: [Gentleman SM](#), [Bruton C](#), [Allsop D](#), [Lewis SJ](#), [Polak JM](#), [Roberts GW](#) [Related Articles](#), [Links](#)

 A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits.
Histochemistry. 1989;92(4):355-8.
PMID: 2478507 [PubMed - indexed for MEDLINE]

 444: Wisniewski HM, Wen GY, Kim KS. [Related Articles](#), [Links](#)
Comparison of four staining methods on the detection of neuritic plaques.
Acta Neuropathol (Berl). 1989;78(1):22-7.
PMID: 2472039 [PubMed - indexed for MEDLINE]

 445: Braimbridge MR, Podlisny MB, Wither DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG. [Related Articles](#), [Links](#)
Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques.
Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7.
PMID: 3140814 [PubMed - indexed for MEDLINE]

 446: Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oltersdorf T. [Related Articles](#), [Links](#)
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneuronal tissues.
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5.
PMID: 3140239 [PubMed - indexed for MEDLINE]

Display **Summary** **Show:** **500** **Sort** **Send to:** **Text** **One page.**

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:18:20 ON 29 OCT 2003

FILE 'FOMAD' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:18:20 ON 29 OCT 2003

FILE 'HEALSAFE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:18:20 ON 29 OCT 2003

FILE 'NIOSHTIC' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:18:20 ON 29 OCT 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 14:18:20 ON 29 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 14:18:20 ON 29 OCT 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 14:18:20 ON 29 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 14:18:20 ON 29 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:18:20 ON 29 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s beta-amyloid AND antibody
22 FILES SEARCHED...
48 FILES SEARCHED...
L1 7430 BETA-AMYLOID AND ANTIBODY

=> DUP REM L1
L2 3417 DUP REM L1 (4013 DUPLICATES REMOVED)

=> S L2 AND human
L3 2495 L2 AND HUMAN

=> S L3 AND N-terminus
L4 391 L3 AND N-TERMINUS

=> D L4 1-391

AN 2002:621745 BIOSIS
DN PREV200200621745
TI Simple morphometry of axonal swellings cannot be used in isolation for
dating lesions after traumatic brain injury.
AU Leclercq, Pascale D.; Stephenson, Matthew S.; Murray, Lillian S.;
McIntosh, Tracy K.; Graham, David I.; Gentleman, Stephen M. [Reprint
author]
CS Department of Neuroinflammation, Division of Neuroscience and
Psychological Medicine, Faculty of Medicine, Imperial College of Science,
Technology and Medicine, St. Dunstan's Road, Charing Cross Campus, London,
W6 8RP, UK
s.gentleman@ic.ac.uk
SO Journal of Neurotrauma, (October, 2002) vol. 19, No. 10, pp. 1183-1192.
print.
ISSN: 0897-7151.
DT Article
LA English
ED Entered STN: 4 Dec 2002
Last Updated on STN: 4 Dec 2002

L4 ANSWER 2 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:121222 BIOSIS
DN PREV200100121222
TI Intraneuronal Abeta42 immunoreactivity in Down syndrome brain.
AU Mori, C. [Reprint author]; Spooner, E. T.; Lu, M.; Wisniewski, K.;
Wisniewski, T.; Yamaguchi, H.; Saido, T. C.; Selkoe, D. J.; Lemere, C. A.
CS Brigham " Women's Hospital, Harvard Medical School, Boston, MA, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-764.7. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 7 Mar 2001
Last Updated on STN: 15 Feb 2002

L4 ANSWER 3 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:87711 BIOSIS
DN PREV200100087711
TI Ischemia and ***beta*** - ***amyloid*** peptide immunoreactivity in
rat brain.
AU Lin, B. [Reprint author]; Ginsberg, M. D.; Busto, R.; Li, L.
CS University of Miami School of Medicine, Miami, FL, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-276.13. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 4 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:122846 BIOSIS
DN PREV200000122846
TI The 68K protease has beta-secretase-like activity for lymphocyte precursor
protein but not for brain substrate.
AU Matsumoto, Akira [Reprint author]
CS Department of Radiation Biophysics and Genetics, Kobe University School of
Medicine, Kusunoki-cho 7, Kobe, 650-0017, Japan
SO Neuroreport, (Feb. 7, 2000) Vol. 11, No. 2, pp. 373-377. print.
CODEN: NERPEZ. ISSN: 0959-4965.
DT Article
LA English
ED Entered STN: 5 Apr 2000
Last Updated on STN: 3 Jan 2002

L4 ANSWER 5 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:271844 BIOSIS
DN PREV199900271844
TI Platelets and DAMI megakaryocytes possess beta-secretase-like activity.

Kimberly; Long, Heidi J.; Billingslea, Andrea M.; Hastey, Ryan; Johnson, Robin; Fine, Richard E.; Smith, Sally J.; Simons, Elizabeth R.; Davies, Theresa A. [Reprint author]
CS Boston University School of Medicine, 80 East Concord St, K6, Boston, MA, 02118, USA
SO Journal of Laboratory and Clinical Medicine, (May, 1999) Vol. 133, No. 5, pp. 507-515. print.
CODEN: JLCMAK. ISSN: 0022-2143.
DT Article
LA English
ED Entered STN: 15 Jul 1999
Last Updated on STN: 15 Jul 1999

L4 ANSWER 6 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:202760 BIOSIS
DN PREV199799501963
TI Cathepsin D displays in vitro beta-secretase-like specificity.
AU Chevallier, Nathalie; Vizzavona, Jean; Marambaud, Philippe; Baur, Claus Peter; Spillantini, Maria; Fulcrand, Pierre; Martinez, Jean; Goedert, Michel; Vincent, Jean-Pierre; Checler, Frederic [Reprint author]
CS Institut de Pharmacologie Moleculaire et Celulaire, CNRS, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France
SO Brain Research, (1997) Vol. 750, No. 1-2, pp. 11-19.
CODEN: BRREAP. ISSN: 0006-8993.
DT Article
LA English
ED Entered STN: 12 May 1997
Last Updated on STN: 12 May 1997

L4 ANSWER 7 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:69117 BIOSIS
DN PREV199799368320
TI Enhanced aggregation of ***beta*** - ***amyloid*** -containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from ***human*** brain.
AU Matsumoto, Akira; Enomoto, Taira; Fujiwara, Yoshisada; Baba, Hisamitsu; Matsumoto, Reiko
CS Dep. Radiation Biophysics and Genetics, Kobe Univ. Sch. Med., Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650, Japan
SO Neuroscience Letters, (1996) Vol. 220, No. 3, pp. 159-162.
CODEN: NELED5. ISSN: 0304-3940.
DT Article
LA English
ED Entered STN: 11 Feb 1997
Last Updated on STN: 11 Feb 1997

L4 ANSWER 8 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1996:562789 BIOSIS
DN PREV199799292145
TI Metabolites of the ***beta*** - ***amyloid*** precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells.
AU Stephens, David J.; Austen, Brian M. [Reprint author]
CS Dep. Surg., St. George's Hosp. Med. Sch., Cranmer Terrace, Tooting, London SW17 0RE, UK
SO Journal of Neuroscience Research, (1996) Vol. 46, No. 2, pp. 211-225.
CODEN: JNREDK. ISSN: 0360-4012.
DT Article
LA English
ED Entered STN: 23 Dec 1996
Last Updated on STN: 23 Dec 1996

L4 ANSWER 9 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:460388 BIOSIS
DN PREV199598474688
TI A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to ***beta*** - ***amyloid*** - ***N*** - ***terminus*** as natural substrate.
AU Matsumoto, Akira [Reprint author]; Matsumoto, Reiko; Baba, Hisamitsu; Fujiwara, Yoshisada
CS Dep. Radiation Biophysics Genetics, Kobe Univ. Sch. Med., Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650, Japan
SO Neuroscience Letters, (1995) Vol. 195, No. 3, pp. 171-174.
CODEN: NELED5. ISSN: 0304-3940.
DT Article

ED Entered STN: 27 Oct 1995
Last Updated on STN: 27 Oct 1995

L4 ANSWER 10 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:221264 BIOSIS
DN PREV199598235564
TI Characterisation of an ***antibody*** relevant to the neuropathology
of Alzheimer disease.
AU Jakes, R.; Harrington, C. R.; Spillantini, M. G.; Goedert, M.; Klug, A.
[Reprint author]
CS MRC Lab. Mol. Biol., Hills Road, Cambridge CB2 2QH, UK
SO Alzheimer Disease and Associated Disorders, (1995) Vol. 9, No. 1, pp.
47-51.
CODEN: ADADE2. ISSN: 0893-0341.

DT Article
LA English
ED Entered STN: 31 May 1995
Last Updated on STN: 31 May 1995

L4 ANSWER 11 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:499033 BIOSIS
DN PREV199497512033
TI Processing of the pre- ***beta*** - ***amyloid*** protein by
cathepsin D is enhanced by a familial Alzheimer's disease mutation.
AU Dreyer, Robert N.; Bausch, Kathryn M.; Fracasso, Paul; Hammond, Lisa J.;
Wunderlich, David; Wirak, Dana O.; Davis, Gary; Brini, Carla M.; Buckholz,
Thomas M.
CS P. P. Tamburini, Miles Inc., Pharmaceuticals Div., 400 Morgan Lane, West
Haven, CT 06516, USA
SO European Journal of Biochemistry, (1994) Vol. 224, No. 2, pp. 265-271.
CODEN: EJBCAI. ISSN: 0014-2956.

DT Article
LA English
ED Entered STN: 28 Nov 1994
Last Updated on STN: 29 Nov 1994

L4 ANSWER 12 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:229461 BIOSIS
DN PREV199497242461
TI Ca-2+-dependent 68-kilodalton protease in familial Alzheimer's disease
cells cleaves the ***N*** - ***terminus*** of ***beta*** -
amyloid.
AU Matsumoto, Akira [Reprint author]; Fujiwara, Yoshisada
CS Dep. Radiation Biophysics and Genetics, Kobe Univ. Sch. Med., Kusunoki-cho
7-5-1, Chuo-ku, Kobe 650, Japan
SO Biochemistry, (1994) Vol. 33, No. 13, pp. 3941-3948.
CODEN: BICHAW. ISSN: 0006-2960.

DT Article
LA English
ED Entered STN: 24 May 1994
Last Updated on STN: 14 Jul 1994

L4 ANSWER 13 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:181291 BIOSIS
DN PREV199497194291
TI Differential distribution of amyloid protein precursor immunoreactivity in
the rat brain studied by using five different ***antibodies***
AU Beeson, James G.; Shelton, Earl R.; Chan, Hardy W.; Gage, Fred H. [Reprint
author]
CS Univ. Calif., San Diego, 9500 Gilman Dr., La Jolla, CA 93093-0627, USA
SO Journal of Comparative Neurology, (1994) Vol. 342, No. 1, pp. 78-96.
CODEN: JCNEAM. ISSN: 0021-9967.

DT Article
LA English
ED Entered STN: 26 Apr 1994
Last Updated on STN: 27 Apr 1994

L4 ANSWER 14 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1993:591363 BIOSIS
DN PREV199497010733
TI Characterization of ***beta*** - ***amyloid*** peptide from
human cerebrospinal fluid.
AU Vigo-Pelfrey, Carmen [Reprint author]; Lee, Doris; Lieberburg, Pam VV
Keiman; Schenk, Dale B.
CS Athena Neurosciences, Inc., 800F Gateway Boulevard, South San Francisco,

SO Journal of Neurochemistry, (1993) vol. 61, No. 5, pp. 1965-1968.
CODEN: JONRA9. ISSN: 0022-3042.

DT Article
LA English
ED Entered STN: 28 Dec 1993
Last Updated on STN: 28 Dec 1993

L4 ANSWER 15 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:526911 BIOSIS
DN PREV199294134986; BA94:134986
TI STRONG IMMUNOREACTIVITY OF ***BETA*** ***AMYLOID*** PRECURSOR
PROTEIN INCLUDING THE ***BETA*** ***AMYLOID*** PROTEIN SEQUENCE AT
HUMAN NEUROMUSCULAR JUNCTIONS.

AU ASKANAS V [Reprint author]; ENGEL W K; ALVAREZ R B
CS USC NEUROMUSC CENT, 637 SOUTH LUCAS AVE, LOS ANGELES, CALIF 90017, USA
SO Neuroscience Letters, (1992) Vol. 143, No. 1-2, pp. 96-100.
CODEN: NELED5. ISSN: 0304-3940.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1992
Last Updated on STN: 24 Dec 1992

L4 ANSWER 16 OF 391 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI on STN
AN 2003-14872 BIOTECHDS
TI New Activity Dependent Neurotrophic Factor I complex polypeptide, useful
for reducing neuronal cell death, treating oxidative stress in a patient,
or improving learning and/or memory in a subject with e.g. Alzheimer's
disease;
protein and ***antibody*** useful for disease therapy and
diagnosis

AU BRENNEMAN D E; CASTELLON R; SPONG C Y; HAUSER J M; GOZES I
PA UNIV RAMOT AT TEL AVIV LTD; US DEPT HEALTH and HUMAN SERVICES
PI WO 2003022226 20 Mar 2003
AI WO 2002-US29146 12 Sep 2002
PRAI US 2002-371961 10 Apr 2002; US 2001-322760 12 Sep 2001
DT Patent
LA English
OS WPI: 2003-354501 [33]

L4 ANSWER 17 OF 391 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
AN 1996:26391320 BIOTECHNO
TI . ***beta*** .- ***amyloid*** protein precursor in Microcebus
murinus: Genotyping and brain localization
AU Silhol S.; Calenda A.; Jallageas V.; Mestre-Frances N.; Bellis M.; Bons
N.
CS Neuromorphologie Fonctionnelle, Ecole Pratique des Hautes Etudes, UMII,
Place Eugene Bataillon, 34095 Montpellier Cedex 5, France.
SO Neurobiology of Disease, (1996), 3/3 (169-182)
CODEN: NUDIEM ISSN: 0969-9961
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 18 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:691919 CAPLUS
TI Demonstration by FRET of BACE interaction with the amyloid precursor
protein at the cell surface and in early endosomes
AU Kinoshita, Aya; Fukumoto, Hiroaki; Shah, Tejal; Whelan, Christa M.;
Irizarry, Michael C.; Hyman, Bradley T.
CS Alzheimer Disease Research Laboratory, Harvard Medical School,
Massachusetts General Hospital, Charlestown, MA, 02129, USA
SO Journal of Cell Science (2003), 116(16), 3339-3346
CODEN: JNCSAI; ISSN: 0021-9533
PB Company of Biologists Ltd.
DT Journal
LA English

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:300608 CAPLUS
DN 138:319696
TI ***Antibodies*** specific to amyloid .beta. peptide for treating

IN Chain, Daniel G.
 PA Israel
 SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 402,820.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003073655	A1	20030417	US 2002-84380	20020228
	WO 9844955	A1	19981015	WO 1998-US6900	19980409
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 2003074081	A1	20030912	WO 2002-US31590	20021021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1997-41850P	P	19970409		
	WO 1998-US6900	W	19980409		
	US 1999-402820	A2	19991012		
	US 2002-84380	A	20020228		

L4 ANSWER 20 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:905741 CAPLUS
 DN 137:381934
 TI Detection of Alzheimer's amyloid by magnetic resonance imaging
 IN Wisniewski, Thomas; Turnbull, Daniel; Sigurdsson, Einar M.
 PA New York University, USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094191	A2	20021128	WO 2002-US16057	20020523
		W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003147811	A1	20030807	US 2002-151614	20020523
PRAI	US 2001-292625P	P	20010523		

L4 ANSWER 21 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:755708 CAPLUS
 DN 130:137213
 TI Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases
 AU Simons, Elizabeth R.; Marshall, Derek C. L.; Long, Heidi J.; Otto, Kim; Billingslea, Andrea; Tibbles, Heather; Wells, John; Eisenhauer, Patricia; Fine, Richard E.; Cribbs, David H.; Davies, Theresa A.; Abraham, Carmela R.
 CS Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
 SO Amyloid (1998), 5(3), 153-162

PB Parthenon Publishing Group

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:348622 CAPLUS

DN 127:31883

TI Alzheimer's soluble amyloid .beta. is a normal component of ***human*** urine

AU Ghiso, Jorge; Calero, Miguel; Matsubara, Etsuro; Governale, Samuel; Chuba, Joseph; Beavis, Ronald; Wisniewski, Thomas; Frangione, Blas
CS Dep. of Pathology, New York Univ. Medical Center, New York, NY, 10016, USA
SO FEBS Letters (1997), 408(1), 105-108
CODEN: FEBLAL; ISSN: 0014-5793

PB Elsevier

DT Journal

LA English

L4 ANSWER 23 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:227599 CAPLUS

DN 126:291920

TI GM1 ganglioside-bound amyloid .beta. -protein: A possible form of preamyloid

AU Yanagisawa, Katsuhiko; Ihara, Yasuo
CS Dep. Dementia Res., Natl. Inst. obu Sci., obu, 474, Japan
SO Shinkei Kenkyu no shinpo (1997), 41(1), 70-79
CODEN: SKNSAF; ISSN: 0001-8724

PB Igaku Shoin

DT Journal

LA Japanese

L4 ANSWER 24 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:489433 CAPLUS

DN 125:139682

TI Overexpression of a COOH-terminal fragment of . ***beta*** .- ***amyloid*** precursor protein in HeLa cells results in accumulation in a pre-Golgi compartment and generation of an A.beta.-like fragment

AU Kuentzel, Sandra L.; Gonzalez-DeWhitt, Patty A.; Lowery, David E.; Altman, Richard A.; Leone, Joseph W.; Heinrikson, Robert L.; Greenberg, Barry D.; Raub, Thomas J.

CS Drug Delivery Systems Research, Upjohn Company, Kalamazoo, MI, 49001, USA

SO Amyloid (1996), 3(2), 86-99

CODEN: AIJIET; ISSN: 1350-6129

PB Parthenon Publishing

DT Journal

LA English

L4 ANSWER 25 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:304682 CAPLUS

DN 125:7373

TI A novel brain cysteine protease forms an SDS stable complex with the . ***beta*** .- ***amyloid*** precursor protein

AU Chang, Tien; Abraham, Carmela R.

CS School of Medicine, Boston University, Boston, MA, 02118, USA

SO Annals of the New York Academy of Sciences (1996), 777(Neurobiology of Alzheimers Disease), 183-188

CODEN: ANYAA9; ISSN: 0077-8923

PB New York Academy of Sciences

DT Journal

LA English

L4 ANSWER 26 OF 391 DISSABS COPYRIGHT (C) 2003 Proquest Information and Learning Company; All Rights Reserved on STN

AN 96:22003 DISSABS Order Number: AAI9607953

TI PROCESSING OF BETA-APP IN ALZHEIMER'S DISEASE AND DOWN SYNDROME: CATHEPSIN S UPREGULATION AND A-BETA HETEROGENEITY (AMYLOID PRECURSOR PROTEIN)

AU LEMERE, CYNTHIA ANN [PH.D.]; BLUSZTAJN, JAN KRZYSZTOF [advisor]

CS BOSTON UNIVERSITY (0017)

SO Dissertation Abstracts International, (1996) Vol. 56, No. 11B, p. 5961.
Order No.: AAI9607953. 196 pages.

DT Dissertation

FS DAI

LA English

Last Updated on STN: 19960402

L4 ANSWER 27 OF 391 DISSABS COPYRIGHT (C) 2003 ProQuest Information and
AN Learning Company; All Rights Reserved on STN
TI 93:54275 DISSABS Order Number: AAR9330150
TI GENERATION OF POTENTIALLY AMYLOIDGENIC FRAGMENTS FROM THE ***BETA*** -
AMYLOID PRECURSOR PROTEIN BY BRAIN SERINE PROTEASES (ALZHEIMER'S
DISEASE)
AU MARTIN, BRONWYN L. [PH.D.]; ABRAHAM, CARMELA R. [advisor]
CS BOSTON UNIVERSITY (0017)
SO Dissertation Abstracts International, (1994) Vol. 54, No. 6B, p. 3048.
Order No.: AAR9330150. 342 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19931119
Last Updated on STN: 19931119

L4 ANSWER 28 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABU08509 peptide DGENE
TI Enabling measurement of full length ***beta*** - ***amyloid***
peptide level for tracking progression of Alzheimer's disease, comprises
capturing and binding terminus of ***beta*** - ***amyloid***
peptide with ***antibodies*** -
IN Fong K L
PA (FONG-I) FONG K L.
PI US 2002182660 A1 20021205 11p
AI US 2002-51496 20020118
PRAI US 2000-183407P 20000218
US 2001-784854 20010216
DT Patent
LA English
OS 2003-328616 [31]
DESC ***Human*** amyloid beta peptide (1-39).

L4 ANSWER 29 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABU08508 peptide DGENE
TI Enabling measurement of full length ***beta*** - ***amyloid***
peptide level for tracking progression of Alzheimer's disease, comprises
capturing and binding terminus of ***beta*** - ***amyloid***
peptide with ***antibodies*** -
IN Fong K L
PA (FONG-I) FONG K L.
PI US 2002182660 A1 20021205 11p
AI US 2002-51496 20020118
PRAI US 2000-183407P 20000218
US 2001-784854 20010216
DT Patent
LA English
OS 2003-328616 [31]
DESC ***Human*** amyloid beta peptide (1-40).

L4 ANSWER 30 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABU08507 peptide DGENE
TI Enabling measurement of full length ***beta*** - ***amyloid***
peptide level for tracking progression of Alzheimer's disease, comprises
capturing and binding terminus of ***beta*** - ***amyloid***
peptide with ***antibodies*** -
IN Fong K L
PA (FONG-I) FONG K L.
PI US 2002182660 A1 20021205 11p
AI US 2002-51496 20020118
PRAI US 2000-183407P 20000218
US 2001-784854 20010216
DT Patent
LA English
OS 2003-328616 [31]
DESC ***Human*** amyloid beta peptide (1-41).

L4 ANSWER 31 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABU08506 peptide DGENE
TI Enabling measurement of full length ***beta*** - ***amyloid***
peptide level for tracking progression of Alzheimer's disease, comprises
capturing and binding terminus of ***beta*** - ***amyloid***
peptide with ***antibodies*** -

PA (FONG-I) FONG K L.
PI US 2002182660 A1 20021205 11p
AI US 2002-51496 20020118
PRAI US 2000-183407P 20000218
US 2001-784854 20010216
DT Patent
LA English
OS 2003-328616 [31]
DESC ***Human*** amyloid beta peptide (1-42).

L4 ANSWER 32 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABU08505 peptide DGENE
TI Enabling measurement of full length ***beta*** - ***amyloid*** peptide level for tracking progression of Alzheimer's disease, comprises capturing and binding terminus of ***beta*** - ***amyloid*** peptide with ***antibodies*** -
IN Fong K L
PA (FONG-I) FONG K L.
PI US 2002182660 A1 20021205 11p
AI US 2002-51496 20020118
PRAI US 2000-183407P 20000218
US 2001-784854 20010216
DT Patent
LA English
OS 2003-328616 [31]
DESC ***Human*** amyloid beta peptide (1-43).

L4 ANSWER 33 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG76102 Protein DGENE
TI New purified recombinant catalytically active memapsin 2 (beta-secretase), useful for designing and screening of specific inhibitors for the diagnosis, prevention and/or treatment of Alzheimer's disease -
IN Lin X; Koelsch G; Tang J J N
PA (OKLA-N) OKLAHOMA MEDICAL RES FOUND.
PI US 2002164760 A1 20021107 44p
AI US 2001-795903 20010228
PRAI US 1999-141363P 19990628
US 1999-168060P 19991130
US 2000-177836P 20000125
US 2000-178368P 20000127
US 2000-210292P 20000608
US 2000-604608 20000627
DT Patent
LA English
OS 2003-246668 [25]
DESC ***Human*** memapsin 2/T7 fusion protein.

L4 ANSWER 34 OF 391 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 96343306 EMBASE
DN 1996343306
TI The 68 kDa .beta.-secretase with heparan sulfate is expressed in serum and lymphocyte cytosol of normal aged and Alzheimer's disease patients.
AU Matsumoto A.; Enamoto T.; Fujiwara Y.; Baba H.; Matsumoto R.
CS Dept. Radiation Biophysics Genetics, Kobe University School of Medicine, Kusunoki-cho 7-5-1,Chuo-Ku, Kobe 650, Japan
SO Alzheimer's Research, (1996) 2/4 (115-119).
ISSN: 1356-918X CODEN: ALREFB
CY United Kingdom
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 35 OF 391 FEDRIP COPYRIGHT 2003 NTIS on STN
AN 2003:166129 FEDRIP
NR CRISP 1Z01DK29029-06
TI New Solid State Nmr Methodology For Structural studies o
SF Principal Investigator: TYCKO, ROBERT
CSS Supported By: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
FYR 2002

L4 ANSWER 36 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10380918 IFIPAT;IFIUDB;IFICDB
TI COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING ***BETA*** -
AMYLOID PRODUCTION

IN Connop Bruce P (CA); Grant Amelia (CA); Nathwani Parimal S (CA)
PA Active Pass Pharmaceuticals Inc CA
PI US 2003125338 A1 20030703
AI US 2002-170224 20020612
PRAI US 2001-297845P 20010612 (Provisional)
US 2001-309257P 20010731 (Provisional)
FI US 2003125338 20030703
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION

CLMN 48
GI 8 Figure(s).

FIG. 1 is a bar graph showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on production and/or release of A beta-40 and A beta-42 from SM-4 cells. Cells were treated with 10-500 μ M pirinixic acid. After 16 hr, the culture media was harvested and assayed for extracellular levels of A beta-40 and A beta-42 by ELISA. Extracellular A beta was standardized to propidium iodide fluorescence as a measure of total cell number. Data are expressed as mean+SD with n=3-13 and statistical significance determined by ANOVA with Tukey's post hoc test at ***p less-than 0.001. Double hatched bars indicate A beta-40 levels and hatched bars indicate A beta-42 levels.

FIG. 2 is a bar graph showing the effect of Clofibrate on levels of extracellular levels of A beta-40 and A beta-42 from SM-4 cells. Cells were treated with 10-500 μ M Clofibrate. After 16 hrs, the culture media was harvested and assayed for extracellular A beta-40 and A beta-42 by ELISA. Secreted A beta was standardized to propidium iodide fluorescence as a measure of total cell number. Data are expressed as mean+SD with n=5 and statistical significance determined by ANOVA with Tukey's post hoc test at ***p less-than 0.001. Double hatched bars represent A beta-40 levels as a percent of vehicle, hatched bars represent A beta-42 levels as a percent of vehicle.

FIG. 3 is a bar graph showing the effect of ETYA on levels of extracellular levels of A beta-40 and A beta-42 from SM-4 cells. Cells were treated with 5-100 μ M ETYA. After 16 hrs, the culture media was harvested and assayed for extracellular A beta-40 and A beta-42 by ELISA. Secreted A beta was standardized to propidium iodide fluorescence as a measure of total cell number. Data are expressed as mean+SD with n=5 and statistical significance determined by ANOVA with Tukey's post hoc test at *p less-than 0.05 and **p less-than 0.01. Double hatched bars represent A beta-40 levels as a percent of vehicle, and hatched bars represent A beta-42 levels as a percent of vehicle.

FIG. 4 is a representative micrograph (upper panel) and a bar graph (lower panel) showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on cellular APP levels from SM-4 cells. Cells were treated with 50-500 μ M pirinixic acid for 16 hours and cellular APP was quantitated by Western blot analysis. Data are expressed as mean+SD with n=4 and statistical significance determined by ANOVA with Tukey's post hoc test at *p less-than 0.05 and **p less-than 0.01.

FIG. 5 is a representative micrograph (upper panel) and a bar graph (lower panel) showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on APPs alpha release from SM4 cells. Cells were treated with 50-500 μ M pirinixic acid for 16 hours and APPs alpha release was quantitated by Western blot analysis. Data are expressed as mean+SD with n=4 and statistical significance determined by ANOVA with Tukey's post hoc test at **p less-than 0.01.

FIG. 6 is a representative micrograph (upper panel) and a bar graph (lower panel) showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on C99 levels from SM-4 cells. Cells were treated with 50-500 μ M pirinixic acid for 16 hours and C99 was quantitated by Western blot analysis. Data are expressed as mean+SD with n=4 and statistical significance determined by ANOVA with Tukey's post hoc test at **p less-than 0.01.

FIG. 7 is a bar graph showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on secreted A beta-40 and A beta-42 from ***human*** neuroblastoma cells. Cells were treated with 100-200 μ M of pirinixic acid after transient transfection with Swedish mutant APP. After a 16-hour treatment, the culture media was harvested and assayed for A beta-40 and A beta-42 by ELISA as described in the Methods and

fluorescence as a measure of total cell number. Data are expressed as mean+SD with n=11 and statistical significance determined by ANOVA with Tukey's post hoc test at ***p less than 0.001.

FIG. 8 is a bar graph showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on A beta total and A beta42 from murine primary cortical neurons infected with APP 695. Cells were treated with 5-250 μM pirinixic acid for 16 hours and A beta total and A beta-42 levels were quantitated by immunoprecipitation and ELISA, respectively. Data are expressed as mean+SD with n=6 and statistical significance determined by ANOVA with Tukey's post hoc test at **p less than 0.01, ***p less than 0.001.

L4 ANSWER 37 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10347569 IFIPAT;IFIUDB;IFICDB
TI EPITOPE-TAGGED ***BETA*** - ***AMYLOID*** PRECURSOR PROTEIN AND
METHODS FOR MONITORING CELLULAR PROCESSING THEREOF
IN Mitchell Thomas J; Seiffert Dietmar A
PA Unassigned Or Assigned To Individual (68000)
PI US 2003091983 A1 20030515
AI US 2002-326049 20021220
RLI US 2000-481980 20000112 DIVISION 6518011
PRAI US 1999-115749P 19990113 (Provisional)
FI US 2003091983 20030515
US 6518011
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 18
GI 12 Figure(s).

FIG. 1 Shows a possible location of an epitope tag in the A-beta sequence of the beta-APP and predicted accumulation of epitope tagged cleavage fragments. The A-beta fragment (1-42), with the proposed proteolytic cleavage sites for secretases (alpha-, beta-, gamma 1 (40)-, and gamma 2 (42)), is indicated. The epitope tag in this example is centered on the alpha secretase site (amino acids 16 to 17 in A-beta). Cleavage by beta and gamma secretases is expected to lead to an accumulation of epitope tagged A-beta (1-40) and A-beta (1-42) in the conditioned medium, whereas cleavage by alpha secretase (within the epitope tag) is expected to destroy or reduce the accumulation of epitope tagged A-beta fragments in the conditioned medium.

FIG. 2 Shows an immunoblot analysis of HEK 293 (***human*** embryonic kidney cell line, ATTC #CRL-1573) cell lysates after transfection with epitope-tagged beta-APP. Cell lysates were prepared by lysis of HEK 293 cells into SDS and were fractionated by SDS-PAGE, followed by transfer to nitrocellulose membranes. The membranes were developed with mAB 22C11 (epitope in the ***N*** - ***terminus*** of full-length beta-APP; lanes 1 and 2), mAB anti HA 11 (influenza hemagglutinin epitope: YPYDVPDYA) (SEQ ID NO:6) (directed to the HA 11 epitope tag; lanes 3 and 4), and mAB 9E10 (directed to the myc epitope tag; lanes 5 and 6). Lane 1, HEK 293 cells transfected with HA 11 beta-APP 695; lane 2, HEK 293 cells transfected with vector alone ('Mock-transfection'); lane 3, HEK 293 cells transfected with HA 11 beta-APP 695; lane 4, HEK 293 cells transfected with vector alone; lane 5, HEK 293 cells transfected with myc betaAPP 695; lane 6, HEK 293 cells transfected with vector alone. The relative mobility of molecular weight standards is indicated to the left.

FIG. 3 Shows an accumulation of beta-APP fragments into HEK 293 conditioned medium. The 24 hour serum-free conditioned medium (lanes 1 and 2) or cell lysates (lanes 3 and 4) of HEK 293 cells transfected with vector alone (lanes 1 and 3) or HA 11 beta-APP 695 (lanes 2 and 4) were harvested. The resulting polypeptides were fractionated by SDS-PAGE (10% acrylamide in separating gel) and transferred to nitrocellulose membranes. Panel A was developed with mAB anti-HA 11, whereas panel B was developed with mAB 22C11. The relative mobility of molecular weight standards is indicated to the right.

FIG. 4 Shows the detection of epitope-tagged beta-APP fragments in HEK 293 conditioned medium after transfection with HA 11 beta-APP 695.

Panel A: Microtiter wells were coated with mAB anti-HA 11 and after blocking, incubated with a dose-response of a synthetic HA 11 A-beta (1-40) peptide containing the HA 11 epitope centered on the alpha secretase cleavage site. Bound A-beta HA 11 was detected with polyclonal ***antibodies*** specific for position 1 (Serotec) or position 40 (QCB), followed by HRPlabeled anti-rabbit IgG and TMB substrate. The change of absorbance at 650 nM was monitored and results are corrected for binding of secondary ***antibodies*** to wells not incubated with the A-beta HA 11 peptide. Results are expressed as change of absorbance

Panel B: Microtiter wells were coated as in panel A and incubated with the indicated dilutions of HEK 293/HA 11 betaAPP 695 conditioned medium (24 hours). Bound HA 11 beta-APP 695 fragments were detected with ***antibodies*** specific for position 1 and 40 as in panel A. Results are expressed and corrected as in panel A.

FIG. 5 Shows a time-course of the accumulation of HA 11 A-beta (1-40) and A-beta (1-42) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK 293/HA 11 beta-APP 695 was cultured in serum-free medium containing 0.2% bovine serum albumin in 96well microtiter plates for the indicated time intervals. The accumulation of HA 11 A-beta (1-40) and A-beta (1-42) was determined. For HA 11 A-beta polypeptides ending at position 40, microtiter wells were coated with mAB anti-HA 11 and bound polypeptides were detected with rabbit anti-A-beta 40 (QCB), followed by HRP-labeled anti-rabbit IgG. For the position 42specific ELISA, microtiter wells were coated with mAB anti-HA 11, and bound polypeptides were detected with biotin-labeled mAB 108 (position 42-specific), followed by streptavidin-HRP conjugate. Results are corrected for binding of secondary ***antibodies*** in the absence of conditioned medium and expressed as change of absorbance at 650 nM per minute (mOD/minute).

FIG. 6 Shows the effect of MDL 28170 and Brefeldin A on the accumulation of HA 11 A-beta (1-40) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK 293/HA 11 beta-APP 695 cells were plated at confluence in 96-well plates and the indicated doseresponse of either MDL 28170 (panel A), or Brefeldin A (panel B) was added for 16 hours. The accumulation of HA 11 A-beta (1-40) (position 40-specific ***antibody*** ; QCB) was determined as in FIG. 5. Results are expressed as percentage inhibition of HA 11 Abeta (1-40) accumulation in comparison to wells incubated with vehicle (dimethyl sulfoxide, DMSO) alone.

FIG. 7 Shows an isolation of HA 11 A-beta from HEK 293/HA 11 beta-APP 695 cells. Conditioned medium (serum-free containing 0. 2% BSA) was passed over an mAB anti-HA 11 affinity matrix. After washing, the column was eluted with 5% formic acid in water. The peak fractions were pooled, dried in a Speed-vac, resuspended in water and the pH was adjusted to 7.4 with Tris.

Panel A: The starting material, flow-through, and the pooled elution fractions (after dilution to account for the concentration of the HA 11 A-beta on the column) were analyzed by ELISA specific for position 40 in HA 11 A-beta as in FIGS. 4 and 5.

Panel B: The indicated dilutions of the pooled elution fractions were analyzed by ELISA specific for position 1, 40, and 42 in HA 11 A-beta. Note that approximately equal immunoreactivity is present for the position 1 and 40 ***antibodies***, whereas the 42specific reactivity is lost with 10-fold lesser dilution.

Panel C: The elution fractions were analyzed by SDS PAGE (16.5% polyacrylamide in separating gel), followed by immunoblotting with mAB anti-HA 11, followed by HRP-labeled anti-mouse Ig, and chemiluminescence detection (ECL tm, Amersham). Lane 1, elution fraction, stained with mAB anti-HA 11; lane 2, elution fraction spiked with HA 11 A-beta peptide (50 ng); lane 3, purified A-beta HA 11 1-40 peptide; and lane 4, elution fraction, stained under omission of anti-HA 11.

L4 ANSWER 38 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10143206 IFIPAT;IFIUDB;IFICDB
TI RECOMBINANT ***ANTIBODIES*** SPECIFIC FOR ***BETA*** -
AMYLOID ENDS, DNA ENCODING AND METHODS OF USE THEREOF; DNA
ENCODING A RECOMBINANT ***ANTIBODY*** MOLECULE END-SPECIFIC FOR AN
AMYLOID-BETA PEPTIDE FOR PREVENTING OR INHIBITING PROGRESSION OF
ALZHEIMER'S DISEASE
IN Chain Daniel G (IL)
PA Mindset Biopharmaceuticals USA
PI US 2002086847 A1 20020704
AI US 2001-975932 20011015
RLI US 1999-402820 19991012 DIVISION PENDING
WO 1998-US6900 19980409 Section 371 PCT Filing UNKNOWN
PRAI US 1997-41850P 19970409 (Provisional)
FI US 2002086847 20020704
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 30
GI 5 Figure(s).

FIG. 1 shows a schematic representation of the ***beta*** - ***amyloid*** precursor protein (beta APP) and the products of alpha, beta, and gamma-secretase cleavage. The general locations of various domains are indicated along with the cleavage sites (alpha, beta gamma)

expression and secretion of ectopic A beta-end-specific ***antibodies*** in the CNS inhibits (1) the accumulation of A beta peptides and (2) the neurotoxic consequences of amyloid deposition without affecting the biological functions of the soluble ***beta*** - ***amyloid*** precursor protein.

FIG. 2 shows the amino acid sequence (SEQ ID NO:1) of the region in beta APP from which ***beta*** - ***amyloid*** peptides (A beta) are derived. The arrows indicate the alpha-, beta- or gammasecretase cleavage sites, and the amino acid residues corresponding to the synthetic peptides to be used as immunogens are indicated underneath the sequence by line segments.

FIGS. 3A-3D schematically show the structure of a whole ***antibody*** (FIG. 3A) with the variable domain of heavy (VH) and light (VL) chains and the constant domain(s) of light (CL) and heavy (CH1, CH2, CH3) chains, a Fab fragment (FIG. 3B), a Fv fragment (FIG. 3C), and a single chain Fv fragment (scFv) (FIG. 3D). The Fab fragment shown in FIG. 3B consists of a variable domain of heavy VH and light VL chain and the first constant domain (CH1 and CL) joined by a disulfide bridge. The Fv fragment shown in FIG. 3C represents the antigen binding portion of an ***antibody*** formed by a non-covalently linked variable region complex (VHVL), whereas the single chain Fv shown in FIG. 3D joins the variable heavy VH with the variable light VL chain via a peptide linker.

FIG. 4 schematically shows the construction of a scFv ***antibody*** by cloning the variable region of an end-specific anti-A beta monoclonal ***antibody*** using the PCR amplification technique with primers A, B, C and D, and then joining together the variable heavy VL chain and the variable light VL chain with an interchain peptide linker (ICL). The shaded area represents hypervariable regions of the antigen binding site and LP designates the leader peptide of the heavy and light chains.

FIG. 5 shows a schematic representation of the AAV ScFv alpha A beta vector with the inverted terminal repeats (ITR), ***human*** beta APP promoter (Hu beta APPP), SV40 polyadenylation signal (SV40pA) indicated. The plasmid backbone is pSSV9.

L4 ANSWER 39 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10016325 IFIPAT;IFIUDB;IFICDB
TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO
NEURONS; PREVENTION COMPLEXING

IN GIULIAN DANA
PA Unassigned Or Assigned To Individual (68000)

PI US 2001016327 A1 20010823

AI US 1997-923055 19970903

RLI US 1996-717551 19960920 DIVISION

6071493

FI US 2001016327 20010823

US 6071493

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

CLMN 99

GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50= 10 mu M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from ***human*** brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorescamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of

number of clusters per mm² in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0. 0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Nissl stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 μl fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of ***human*** embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, DiI-ac-LDL Bar=40 μm, FIG. 7A; 25 μm FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding sphere implants. FIG. 8A reveals that at two weeks after implantation, there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with DiI-ac-LDL (0.5 nmoles injected. FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1. 0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar= 30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 μM) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 μM) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 μM of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal

acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MAP 2 ***antibodies*** found in control hippocampal cultures (1,200 cells per mm²) that were supplemented with microglia (500 per mm²). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic ***human*** A beta 1-42 (1 μ mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar= 20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to ***human*** A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the ***N*** - ***terminus*** of the peptide (A beta 1-11, A beta 1-16, and A beta 1-28) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 μ mole/l) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 μ moles/l). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BSA (which bind to scavenger receptors) or Spheres A beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of 0.01 units/ml for 60 min), or with chondroitinase ABC (chondroitin ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either Spheres A beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased Spheres A beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 μ g/ml) or A beta 1-16 (10 μ mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 μ g/ml) or acetylated LDL (ac-LDL, 200 μ g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mM), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 μ moles/l) in solution and or Spheres A beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 μ moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta. Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of ***beta*** - ***Amyloid*** peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 interactions with microglia. The peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 interactions with microglia.

microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA= not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIGS. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar= 25 μ m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/- standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 μ m moles/1) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 μ m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta.

FIGS. 20A-E displays soluble fractions of native plaques induce microglial reactivity. Bright field photomicrographs of rat microglia cultures exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta. As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar= 25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar= 5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 μ moles/1 on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 μ mole/1) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm² when incubated with 1 μ mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta. These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED₅₀ of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm²; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 μ mole/l A beta 1-42 (FIG. 22E); in contrast, 1 μ mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) cells.

conditioned media (10% vol/vol) from microglia incubated with 1 μ mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 μ mole/l A beta 1-42 (FIG. 22F). Bar= 25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm²). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar= 20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 μ moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm²) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuron-specific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodendroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIG. 24E and 24G, respectively). Bar= 10 μ m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+ A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays ***human*** microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 n mole/l), S4 (220 μ mole/l), and S5 (250 μ mole/l)) elicit ***human*** microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 μ mole/liter concentrations, synthetic A beta 1-40 and A beta 142 also stimulated release of neurotoxin from ***human*** microglia, while smaller AP fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by ***human*** cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by ***human*** or rat microglia exposed to 1 μ mole/liter of the ***human*** forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of ***human*** A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and ***human*** microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 μ mole/l A beta 1-42 (Rat/A beta 1-42) and ***human*** cells with fraction S5 (containing 250 μ mole/l of native A beta 1-42) from solubilized neuritic/core plaques (***Human*** /S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100 μ M; catalase, 25 units/ml; glutathione, 100 μ M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10 μ M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (A beta 7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 μ M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH₂O with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A

Sepharose bead coupled to ***human*** A beta 1-42 peptides. FIG. 27B shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker DiI-ac-LDL; Bar= 20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42.

Importantly, A beta 1-28 also promoted bead binding, while A beta 17-43 did not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/- standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm²) after 4 hour incubation at 37 degrees C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the ***N*** - ***terminus*** -containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/- standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between ***human*** and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 40 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN

AN 10016324 IFIPAT;IFIUDB;IFICDB

TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO NEURONS; PREVENTION COMPLEXING

IN GIULIAN DANA

PA Unassigned or Assigned To Individual (68000)

PI US 2001016326 A1 20010823

AI US 1997-922930 19970903

RLI US 1996-717551 19960920 DIVISION

6071493

FI US 2001016326 20010823

US 6071493

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

CLMN 99

GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50=10 μ M in the ultrafiltrate compared with 100 μ M for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from ***human*** brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorescamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for H&E-DR(+) microglial

number of clusters per mm² in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0. 0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Nissl stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 mu l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of ***human*** embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, Dil-ac-LDL Bar=40 mu m, FIG. 7A; 25 mu m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding sphere implants. FIG. 8A reveals that at two weeks after implantation, there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with Dil-ac-LDL (0.5 nmoles injected). FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1. 0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar=30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 mu M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 mu M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 mu M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal

acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MA beta 2

antibodies found in control hippocampal cultures (1,200 cells per mm²) that were supplemented with microglia (500 per mm²). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic ***human*** A beta 1-42 (1 mu mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar=20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to ***human*** A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the ***N***-***terminus*** of the peptide (A beta 1-11, A beta 1-16, and A beta 1-28) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 mu mole/l) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)-modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 mu moles/l). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BSA (which bind to scavenger receptors) or SpheresA beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of 0.01 units/ml for 60 min), or with chondroitinase ABC (chondroitin ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either SpheresA beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 mu g/ml) or A beta 1-16 (10 mu mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 mu g/ml) or acetylated LDL (ac-LDL, 200 mu g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mm), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 mu moles/l) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 mu moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta . Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of ***beta*** - ***Amyloid*** peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42

microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA=not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIG. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar=25 μ m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/- standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 μ moles/l) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 μ m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta.

FIGS. 20A-E displays soluble fractions of native plaques induce microglial reactivity. Bright field photomicrographs of rat microglia cultures exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta. As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar =25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar=5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 μ moles/l on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 μ mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm² when incubated with 1 μ mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta. These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED₅₀ of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm²; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 μ mole/l A beta 1-42 (FIG. 22E); in contrast, 1 μ mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) microglia.

conditioned media (10% vol/vol) from microglia incubated with 1 μ mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 μ mole/l A beta 1-42 (FIG. 22F). Bar =25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm²). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar=20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+) MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 μ moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm²) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuron-specific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodendroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIGS. 24E and 24G, respectively). Bar=10 μ m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays ***human*** microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/l), S4 (220 nmole/l), and S5 (250 nmole/l)) elicit ***human*** microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 μ mole/liter concentrations, synthetic A beta 1-40 and A beta 142 also stimulated release of neurotoxin from ***human*** microglia, while smaller A beta fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by ***human*** cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by ***human*** or rat microglia exposed to 1 μ mole/liter of the ***human*** forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of ***human*** A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and ***human*** microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 μ mole/l A beta 1-42 (Rat/A beta 1-42) and ***human*** cells with fraction S5 (containing 250 nmole/l of native A beta 1-42) from solubilized neuritic/core plaques (***Human*** /S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100 μ M; catalase, 25 units/ml; glutathione, 100 μ M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors

L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10 μ M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (AP7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 μ M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH₂O with 0.1% trifluoroacetic acid).

Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A shows a phase photomicrograph of rat microglial cell adhering to

shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker Dil-ac-LDL; Bar=20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta 1-28 also promoted bead binding, while A beta 17-43 did not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm²) after 4 hour incubation at 37 C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the ***N*** - ***terminus*** -containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between ***human*** and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 41 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
 AN 3902755 IFIPAT;IFIUDB;IFICDB
 TI TRANSGENIC RODENTS HARBORING APP ALLELE HAVING SWEDISH MUTATION
 IN McLonlogue Lisa; Sinha Sukanto; Zhao Jun
 PA Elan Pharmaceuticals Inc
 Lilly, Eli and Co
 (49246, 49800)

PI US 6586656 20030701
 AI US 2001-838556 20010418
 RLI US 1993-148211 19931101 CONTINUATION 5612486
 US 1997-785943 19970122 CONTINUATION 5850003
 US 1998-209647 19981210 CONTINUATION 6245964
 US 1993-143697 19931027 CONTINUATION-IN-PART 5604102
 FI US 6586656 20030701
 US 5612486
 US 5850003
 US 6245964
 US 5604102

DT Utility
 FS CHEMICAL
 GRANTED

CLMN 10

GI 5 Drawing Sheet(s), 6 Figure(s).

FIGS. 1(A-B), panels A and B are plasmid maps of pNSEAPPsw Delta 3' and pNSEAPPsw, respectively, which are used to produce transgenic mice as described herein.

FIG. 2 is a Western blot of soluble fractions of transgenic and control animal brains probed for the presence of secreted beta APP fragments reactive with the Swedish 192 ***antibody***. Lane 1: molecular weight markers; lane 2: non-transgenic line; lane 3: transgenic line.

FIGS. 3(A-B), panels A and B are Western blots of brain homogenates from transgenic (+) and non-transgenic (-) animals depleted of 6C6 ***antibody*** -reactive beta APP forms probed with ***antibody*** 8E5 (panel A) and Swedish 192 ***antibody*** (panel B).

FIG. 4 shows an immunoblot demonstrating specificity of the Swedish 192 ***antibody***. Lanes 1, 3, 5 contain material eluted from heparin agarose. Lanes 2, 4, 6 contain material eluted from the 6C6 resin. Lanes 1 and 2 were probed with ***antibody*** 8E5; Lanes 3 and 4 were probed with the Swedish 192 ***antibody***; Lanes 5 and 6 were probed with ***antibody*** 6C6.

L4 ANSWER 42 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
 AN 3827176 IFIPAT;IFIUDB;IFICDB

IN PRODUCTION MODULATORS
PA Mitchell Thomas J; Seiffert Dietmar A
Bristol-Myers Squibb Co (22921)
PI US 6518011 20030211
AI US 2000-481980 20000112
PRAI US 1999-115749P 19990113 (Provisional)
FI US 6518011 20030211
DT Utility
FS CHEMICAL
GRANTED
CLMN 7
GI

8 Drawing Sheet(s), 12 Figure(s).

FIG. 1 Shows a possible location of an epitope tag in the A-beta sequence of the beta-APP and predicted accumulation of epitope tagged cleavage fragments. The A-beta fragment (1-42), with the proposed proteolytic cleavage sites for secretases (alpha-, beta-, gamma 1 (40)-, and gamma 2 (42)), is indicated. The epitope tag in this example is centered on the alpha secretase site (amino acids 16 to 17 in A-beta). Cleavage by beta and gamma secretases is expected to lead to an accumulation of epitope tagged A-beta (1-40) and A-beta (1-42) in the conditioned medium, whereas cleavage by alpha secretase (within the epitope tag) is expected to destroy or reduce the accumulation of epitope tagged A-beta fragments in the conditioned medium.

FIG. 2 Shows an immunoblot analysis of HEK 293 (***human*** embryonic kidney cell line, ATTC #CRL-1573) cell lysates after transfection with epitope-tagged beta-APP. Cell lysates were prepared by lysis of HEK 293 cells into SDS and were fractionated by SDS-PAGE, followed by transfer to nitrocellulose membranes. The membranes were developed with mAB 22C11 (epitope in the ***N*** - ***terminus*** of full-length beta-APP; lanes 1 and 2), mAB anti-HA 11 (influenza hemagglutinin epitope: YPYDVPDYA) (SEQ ID NO: 6) (directed to the HA 11 epitope tag; lanes 3 and 4), and mAB 9E10 (directed to the myc epitope tag; lanes 5 and 6). Lane 1, HEK 293 cells transfected with HA 11 beta-APP 695; lane 2, HEK 293 cells transfected with vector alone ('Mock-transfection'); lane 3, HEK 293 cells transfected with HA 11 beta-APP 695; lane 4, HEK 293 cells transfected with vector alone; lane 5, HEK 293 cells transfected with myc betaAPP 695; lane 6, HEK 293 cells transfected with vector alone. The relative mobility of molecular weight standards is indicated to the left.

FIG. 3 Shows an accumulation of beta-APP fragments into HEK 293 conditioned medium. The 24 hour serum-free conditioned medium (lanes 1 and 2) or cell lysates (lanes 3 and 4) of HEK 293 cells transfected with vector alone (lanes 1 and 3) or HA 11 beta-APP 695 (lanes 2 and 4) were harvested. The resulting polypeptides were fractionated by SDS-PAGE (10% acrylamide in separating gel) and transferred to nitrocellulose membranes. Panel A was developed with mAB anti-HA 11, whereas panel B was developed with mAB 22C11. The relative mobility of molecular weight standards is indicated to the right.

FIG. 4 Shows the detection of epitope-tagged beta-APP fragments in HEK 293 conditioned medium after transfection with HA 11 beta-APP 695.

Panel A: Microtiter wells were coated with mAB anti-HA 11 and after blocking, incubated with a dose-response of a synthetic HA 11 A-beta (1-40) peptide containing the HA 11 epitope centered on the alpha secretase cleavage site. Bound A-beta HA 11 was detected with polyclonal ***antibodies*** specific for position 1 (Serotec) or position 40 (QCB), followed by HRP-labeled anti-rabbit IgG and TMB substrate. The change of absorbance at 650 nm was monitored and results are corrected for binding of secondary ***antibodies*** to wells not incubated with the A-beta HA 11 peptide. Results are expressed as change of absorbance per minute (MOD/minute).

Panel B: Microtiter wells were coated as in panel A and incubated with the indicated dilutions of HEK 293/HA 11 betaAPP 695 conditioned medium (24 hours). Bound HA 11 beta-APP 695 fragments were detected with ***antibodies*** specific for position 1 and 40 as in panel A. Results are expressed and corrected as in panel A.

FIG. 5 Shows a time-course of the accumulation of HA 11 A-beta (1-40) and A-beta (1-42) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK 293/HA 11 beta-APP 695 was cultured in serum-free medium containing 0.2% bovine serum albumin in 96well microtiter plates for the indicated time intervals. The accumulation of HA 11 A-beta (1-40) and A-beta (1-42) was determined. For HA 11 A-beta polypeptides ending at position 40, microtiter wells were coated with mAB anti-HA 11 and bound polypeptides were detected with rabbit anti-A-beta 40 (QCB), followed by HRP-labeled anti-rabbit IgG. For the position 42specific ELISA, microtiter wells were coated with mAB anti-HA 11, and bound polypeptides were detected with biotin-labeled mAB 108 (position 42-specific), followed by streptavidin-HRP.

secondary ***antibodies*** in the absence of conditioned medium and expressed as change of absorbance at 650 nm per minute (MOD/minute). FIG. 6 Shows the effect of MDL 28170 and Brefeldin A on the accumulation of HA 11 A-beta (1-40) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK 293/HA 11 beta-APP 695 cells were plated at confluence in 96-well plates and the indicated doseresponse of either MDL 28170 (panel A), or Brefeldin A (panel B) was added for 16 hours. The accumulation of HA 11 A-beta (1-40) (position 40-specific ***antibody*** ; QCB) was determined as in FIG. 5. Results are expressed as percentage inhibition of HA 11 Abeta (1-40) accumulation in comparison to wells incubated with vehicle (dimethyl sulfoxide, DMSO) alone.

FIG. 7 Shows an isolation of HA 11 A-beta from HEK 293/HA 11 beta-APP 695 cells. Conditioned medium (serum-free containing 0. 2% BSA) was passed over an mAB anti-HA 11 affinity matrix. After washing, the column was eluted with 5% formic acid in water. The peak fractions were pooled, dried in a Speed-Vac, resuspended in water and the pH was adjusted to 7.4 with Tris.

Panel A: The starting material, flow-through, and the pooled elution fractions (after dilution to account for the concentration of the HA 11 A-beta on the column) were analyzed by ELISA specific for position 40 in HA 11 A-beta as in FIGS. 4 and 5.

Panel B: The indicated dilutions of the pooled elution fractions were analyzed by ELISA specific for position 1, 40, and 42 in HA 11 A-beta. Note that approximately equal immunoreactivity is present for the position 1 and 40 ***antibodies***, whereas the 42specific reactivity is lost with 10-fold lesser dilution.

Panel C: The elution fractions were analyzed by SDS-PAGE (16.5% polyacrylamide in separating gel), followed by immunoblotting with mAB anti-HA 11, followed by HRP-labeled anti-mouse Ig, and chemiluminescence detection (ECL tm, Amersham). Lane 1, elution fraction, stained with mAB anti-HA 11; lane 2, elution fraction spiked with HA 11 A-beta peptide (50 ng); lane 3, purified A-beta HA 11 1-40 peptide; and lane 4, elution fraction, stained under omission of anti-HA 11.

L4 ANSWER 43 OF 391 JICST-EPlus COPYRIGHT 2003 JST on STN
AN 930792511 JICST-EPlus
TI Ca2+-Dependent 68 kDa Protease in Familial Alzheimer's Disease Cells
Cleaves the ***N*** - ***terminus*** of . ***BETA*** .-
Amyloid .

AU MATSUMOTO AKIRA; FUJIWARA YOSHISADA
CS Kobe Univ., School of Medicine
SO Kiso Roka Kenkyu (Biomedical Gerontology), (1993) vol. 17, no. 2, pp.
62-63. Journal Code: Y0748A (Ref. 4)
ISSN: 0912-8921

CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 44 OF 391 LIFESCI COPYRIGHT 2003 CSA on STN
AN 2000:62119 LIFESCI
TI Generation of the Amyloid- beta Peptide ***N*** ***Terminus*** in
Saccharomyces cerevisiae Expressing ***Human*** Alzheimer's Amyloid-
beta Precursor Protein
AU Greenfield, J.P.; Xu, H.; Greengard, P.; Gandy, S.; Seeger, M.
CS Laboratory of Molecular and Cellular Neuroscience, and Fisher Center for
Research on Alzheimer Disease, Rockefeller University, New York, New York
10021
SO Journal of Biological Chemistry [J. Biol. Chem.], (19991100) vol. 274, no.
48, pp. 33843-33846.
ISSN: 0021-9258.

DT Journal
FS N3; N
LA English
SL English

L4 ANSWER 45 OF 391 LIFESCI COPYRIGHT 2003 CSA on STN
AN 91:46552 LIFESCI
TI Alzheimer patients: Preamyloid deposits are immunoreactive with
antibodies to extracellular domains of the amyloid precursor
protein.
AU Tagliavini, F.; Giaccone, G.; Verga, L.; Ghiso, J.; Frangione, B.;
Bugiani, O.
CS Ist. Neurol. Carlo Besta, via Celoria 11, 20133 Milano, Italy
SO NEUROSCI. LETT., (1991) vol. 128, no. 1, pp. 117-120.

FS N3
LA English
SL English

L4 ANSWER 46 OF 391 MEDLINE on STN
AN 2001286060 MEDLINE
DN 21110573 PubMed ID: 11162251
TI Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
CM Erratum in: Neurobiol Dis 2001 Jun;8(3):540
AU Russo C; Salis S; Dolcini V; Venezia V; Song X H; Teller J K; Schettini G
CS Section of Pharmacology and Neuroscience, National Cancer Institute, Genova, Italy.
NC AG08012 (NIA)
AG08155 (NIA)
AG14359 (NIA)
NS37392 (NINDS)
SO NEUROBIOLOGY OF DISEASE, (2001 Feb) 8 (1) 173-80.
Journal code: 9500169. ISSN: 0969-9961.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010529
Last Updated on STN: 20010828
Entered Medline: 20010524

L4 ANSWER 47 OF 391 MEDLINE on STN
AN 91128587 MEDLINE
DN 91128587 PubMed ID: 2126439
TI Colocalization of amino terminal and A4 (***beta*** - ***amyloid***) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein.
AU Tate-Ostroff B; Majocha R E; Walcott E C; Ventosa-Michelman M; Marotta C A
CS Department of Psychiatry, Harvard Medical School, Boston, MA.
NC AG02126 (NIA)
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, (1990 Jul-Sep) 3 (3) 139-45.
Journal code: 8805645. ISSN: 0891-9887.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199103
ED Entered STN: 19910405
Last Updated on STN: 19980206
Entered Medline: 19910318

L4 ANSWER 48 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
on STN
AN 2002-0526261 PASCAL
CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
TIEN Divergent pathways account for two distinct effects of amyloid .beta. peptides on exocytosis and Ca.sup.2.sup.+ currents: involvement of ROS and NF-KB
AU GREEN Kim N.; PEERS Chris
CS Institute for Cardiovascular Research, University of Leeds, Leeds, United Kingdom
SO Journal of neurochemistry, (2002), 81(5), 1043-1051, refs. 1 p. 1/2
ISSN: 0022-3042 CODEN: JONRA9
DT Journal
BL Analytic
CY United States
LA English
AV INIST-4037, 354000108919100160

L4 ANSWER 49 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
on STN
AN 1998-0432550 PASCAL
CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.
TIEN GM1 ganglioside-bound amyloid .beta.-protein in Alzheimer's disease brain
The molecular biology of Alzheimer's disease and animal models: routes to the development of new therapies

CS MORI Hiroshi (ed.)
Department of Dementia Research, National Institute for Longevity Sciences, 36-3 Gengo, Morioka, Obu 474, Japan; Department of Neuropathology Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
Department of Molecular Biology, Tokyo Institute of Psychiatry, Japan
Tokyo Institute of Psychiatry, Japan (patr.)
SO Neurobiology of aging, (1998), 19(1, SUP), S65-S67, 14 refs.
Conference: 11 Annual Tokyo Institute of Psychiatry International Symposium, Tokyo (Japan), 4 Mar 1997
ISSN: 0197-4580 CODEN: NEAGDO

DT Journal; Conference
BL Analytic
CY United States
LA English
AV INIST-20387, 354000075429300130

L4 ANSWER 50 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
on STN
AN 1996-0219891 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN Monoclonal ***antibodies*** against the ***human***
metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's
disease brain
AU CONN K. J.; PIETROPAOLO M.; JU S.-T.; ABRAHAM C. R.
CS Arthritis Center, K-5, Boston University School of Medicine, 80 East
Concord Street, Boston, MA 02118, United States
SO Journal of neurochemistry, (1996), 66(5), 2011-2018, refs. 1 p.1/4
ISSN: 0022-3042 CODEN: JONRA9
DT Journal
BL Analytic
CY United States
LA English
AV INIST-4037, 354000044329370290

L4 ANSWER 51 OF 391 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 2001:73885 SCISEARCH
GA The Genuine Article (R) Number: 392HB
TI Immunomodulation of the ***human*** prion peptide 106-126 aggregation
AU Hanan E; Goren O; Eshkenazy M; Solomon B (Reprint)
CS Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel
Aviv, Israel (Reprint)
CYA Israel
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (12 JAN 2001) Vol.
280, No. 1, pp. 115-120.
Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA
92101-4495 USA.
ISSN: 0006-291X.
DT Article; Journal
LA English
REC Reference Count: 35
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 52 OF 391 USPATFULL on STN
AN 2003:282760 USPATFULL
TI Novel amino acid sequences for ***human*** epidermal growth
factor-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S.
corporation)
PI US 2003199103 A1 20031023
AI US 2001-977639 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 10459
INCL INCLM: 436/518.000

NCL NCLM: 436/518.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-485
ICS: C07H021-04; C12P021-02; C12N005-06; G01N033-543

L4 ANSWER 53 OF 391 USPATFULL on STN
AN 2003:282611 USPATFULL
TI ***Human*** cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003198954 A1 20031023
AI US 2001-1142 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-I81715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25681
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04

L4 ANSWER 54 OF 391 USPATFULL on STN
AN 2003:282304 USPATFULL
TI Stabilized HBC chimer particles as therapeutic vaccine for chronic hepatitis
IN Page, Mark, Allestree, UNITED KINGDOM
Friede, Martin, Cardiff, CA, UNITED STATES
PI US 2003198645 A1 20031023
AI US 2003-372076 A1 20030221 (10)
RLI Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb 2002,
PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb
2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 5638
INCL INCLM: 424/192.100
INCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
NCL NCLM: 424/192.100
NCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
IC [7]
ICM: C07H021-04
ICS: A61K039-29; A61K039-00; A61K039-002; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 55 OF 391 USPATFULL on STN
AN 2003:271511 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting ***beta*** -
amyloid peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PI US 2003191119 A1 20031009
AI US 2002-314221 A1 20021209 (10)
RLI Division of Ser. No. US 2001-984834, filed on 31 Oct 2001, PENDING
Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, GRANTED,
Pat. No. US 6333351 Continuation of Ser. No. US 1997-976179, filed on 21
Nov 1997, GRANTED, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
DT Utility

FS APPLICATION
LN.CNT 3753
INCL INCLM: 514/227.800
INCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
NCL NCLM: 514/227.800
NCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-44; A61K031-198; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 56 OF 391 USPATFULL on STN
AN 2003:271112 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Kekuda, Ramesh, Stamford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
PI US 2003190715 A1 20031009
AI US 2001-976782 A1 20011012 (9)
PRAI US 2000-240113P 20001012 (60)
US 2000-240662P 20001016 (60)
US 2000-240732P 20001016 (60)
US 2000-240625P 20001016 (60)
US 2000-240648P 20001016 (60)
US 2000-240703P 20001016 (60)
US 2000-241190P 20001016 (60)
US 2000-240637P 20001016 (60)
US 2000-240669P 20001016 (60)
US 2001-262455P 20010118 (60)

DT Utility
FS APPLICATION
LN.CNT 9839
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
IC [7]
ICM: C12N009-00
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 57 OF 391 USPATFULL on STN
AN 2003:265931 USPATFULL
TI O-linked N-acetylglucosamine pathway in the pathogenesis of
neurodegeneration and diabetes
IN Kudlow, Jeffrey, Birmingham, AL, UNITED STATES
Konrad, Robert, Carmel, IN, UNITED STATES
PI US 2003186948 A1 20031002
AI US 2003-392508 A1 20030320 (10)
RLI Continuation-in-part of Ser. No. US 2001-813534, filed on 21 Mar 2001,
GRANTED, Pat. No. US 6589995
PRAI US 2000-190785P 20000321 (60)
DT Utility
FS APPLICATION
LN.CNT 1426

INCL INCLM: 514/150.000
INCLS: 514/262.100; 514/062.000; 514/389.000
NCL NCLM: 514/150.000
NCLS: 514/262.100; 514/062.000; 514/389.000
IC [7]

ICS: A61K031-655; A61K031-519; A61K031-4162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 391 USPATFULL on STN
AN 2003:264865 USPATFULL
TI Therapy for ***human*** cancers using cisplatin and other drugs or genes encapsulated into liposomes
IN Boulikas, Teni, Palo Alto, CA, UNITED STATES
PI US 2003185879 A1 20031002
AI US 2003-350470 A1 20030123 (10)
RLI Continuation of Ser. No. US 1999-434345, filed on 5 Nov 1999, GRANTED, Pat. No. US 6511676
DT Utility
FS APPLICATION
LN.CNT 1652
INCL INCLM: 424/450.000
INCLS: 424/649.000
NCL NCLM: 424/450.000
NCLS: 424/649.000
IC [7]
ICM: A61K009-127
ICS: A61K033-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 391 USPATFULL on STN
AN 2003:264844 USPATFULL
TI Immunogenic HBC chimer particles stabilized with an N-terminal cysteine
IN Birkett, Ashley J., Escondido, CA, UNITED STATES
PI US 2003185858 A1 20031002
AI US 2002-82014 A1 20020221 (10)
RLI Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 5511
INCL INCLM: 424/227.100
INCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
NCL NCLM: 424/227.100
NCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
IC [7]
ICM: C07H021-04
ICS: A61K039-002; A61K045-00; C12N015-00; C12N015-63; C12N015-74; C07K014-00; A61K039-00; A61K047-00; C12N015-70; C07K017-00; A61K039-29; C12N015-09; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 391 USPATFULL on STN
AN 2003:260805 USPATFULL
TI .beta.-secretase enzyme compositions and methods
IN Anderson, John P., San Francisco, CA, United States
Basi, Gurqbal, Palo Alto, CA, United States
Doan, Minh Tam, Hayward, CA, United States
Frigon, Normand, Milbrae, CA, United States
John, Varghese, San Francisco, CA, United States
Power, Michael, Fremont, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Tatsuno, Gwen, Oakland, CA, United States
Tung, Jay, Belmont, CA, United States
Wang, Shuwen, Hersey, PA, United States
McConlogue, Lisa, Burlingame, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6627739 B1 20030930
AI US 2000-724566 20001128 (9)
RLI Continuation of Ser. No. US 2000-501708, filed on 10 Feb 2000
PRAI US 1999-119571P 19990210 (60)
US 1999-139172P 19990615 (60)
DT Utility
FS GRANTED
LN.CNT 4793
INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
NCL NCLM: 530/387.900
NCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
IC [7]

EXF 530/387.9; 530/388.1; 530/388.26; 530/389.1; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 391 USPATFULL on STN
AN 2003:257841 USPATFULL
TI Interleukin-20
IN Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Murphy, Marianne, London, UNITED KINGDOM
Ruben, Steven M., Brookeville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2003180892 A1 20030925
AI US 2002-277726 A1 20021023 (10)
RLI Division of Ser. No. US 1999-231788, filed on 15 Jan 1999, GRANTED, Pat. No. US 6486301 Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING
PRAI US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
US 1997-52870P 19970716 (60)
US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
US 1997-52870P 19970716 (60)
DT Utility
FS APPLICATION
LN.CNT 5982
INCL INCLM: 435/069.520
INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
NCL NCLM: 435/069.520
NCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
IC [7]
ICM: C07K014-54
ICS: C07H021-04; C12P021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 62 OF 391 USPATFULL on STN
AN 2003:257831 USPATFULL
TI Expression of proteolytically-sensitive peptides
IN Courchesne, William E., Soda Springs, CA, UNITED STATES
Schooley, David A., Reno, NV, UNITED STATES
Copley, Kathrin, San Diego, CA, UNITED STATES
PI US 2003180882 A1 20030925
AI US 2002-278242 A1 20021023 (10)
RLI Continuation of Ser. No. US 2000-661452, filed on 13 Sep 2000, ABANDONED
Continuation of Ser. No. US 1999-237936, filed on 27 Jan 1999, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1347
INCL INCLM: 435/069.100
INCLS: 435/219.000; 435/254.200; 435/320.100; 536/023.200; 435/483.000;
530/350.000
NCL NCLM: 435/069.100
NCLS: 435/219.000; 435/254.200; 435/320.100; 536/023.200; 435/483.000;
530/350.000
IC [7]
ICM: C12P021-02
ICS: C07H021-04; C12N001-18; C12N009-50; C12N015-74; C07K014-39
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 63 OF 391 USPATFULL on STN
AN 2003:257737 USPATFULL
TI Avian and reptile derived polynucleotide encoding a polypeptide having heparanase activity
IN Goldshmidt, Orit, Jerusalem, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Michal, Israel, Ashkelon, ISRAEL
Zcharia, Eyal, Jerusalem, ISRAEL
PA Insight Strategy & Marketing Ltd. (non-U.S. corporation)
Hadassit Medical Research Services and Development Ltd. (non-U.S. corporation)

AI US 2003-431438 A1 20030508 (10)
RLI Division of Ser. No. US 2001-930218, filed on 16 Aug 2001, PENDING
Continuation-in-part of Ser. No. US 2000-666390, filed on 20 Sep 2000,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2265
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/200.000; 435/325.000; 435/349.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/200.000; 435/325.000; 435/349.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-24; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 391 USPATFULL on STN
AN 2003:257671 USPATFULL
TI Methods and materials relating to alpha-2-macroglobulin-like
polypeptides and polynucleotides
IN Godbole, Shubhada D., Santa Clara, CA, UNITED STATES
Boyle, Bryan J., San Francisco, CA, UNITED STATES
Mize, Nancy K., Mountain View, CA, UNITED STATES
Deng, Cenhuia, Cupertino, CA, UNITED STATES
Goodrich, Ryle W., San Jose, CA, UNITED STATES
Arterburn, Matthew C., Los Gatos, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Yeung, George, Mountain View, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2003180722 A1 20030925
AI US 2001-756247 A1 20010108 (9)
RLI Continuation-in-part of Ser. No. US 2000-649167, filed on 23 Aug 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-540217, filed on 31
Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-684711,
filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US
2000-560875, filed on 27 Apr 2000, PENDING Continuation-in-part of Ser.
No. US 2000-496914, filed on 3 Feb 2000, ABANDONED

DT Utility
FS APPLICATION
LN.CNT 7553
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/386.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/386.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 391 USPATFULL on STN
AN 2003:251133 USPATFULL
TI ITI-D1 Kunitz domain mutants as hNE inhibitors
IN Ley, Arthur Charles, Newton, MA, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
PI US 2003175919 A1 20030918
AI US 2002-38722 A1 20020108 (10)
RLI Continuation of Ser. No. US 1999-849406, filed on 21 Jul 1999, PENDING A
371 of International Ser. No. WO 1995-US16349, filed on 15 Dec 1995,
UNKNOWN Continuation-in-part of Ser. No. US 1994-358160, filed on 16 Dec
1994, GRANTED, Pat. No. US 5663143 Continuation-in-part of Ser. No. US
1993-133031, filed on 13 Oct 1993, ABANDONED A 371 of International Ser.
No. WO 1992-US1501, filed on 28 Feb 1992, UNKNOWN Division of Ser. No.
US 1991-664989, filed on 1 Mar 1991, PATENTED Continuation-in-part of
Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED
Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,
ABANDONED

DT Utility
FS APPLICATION
LN.CNT 3925

NCL INCLS: 435/069.200; 435/320.100; 435/325.000; 536/023.200
NCLM: 435/184.000
NCLS: 435/069.200; 435/320.100; 435/325.000; 536/023.200
[7]
ICM: C12N009-99
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 391 USPATFULL on STN
AN 2003:250925 USPATFULL
TI Molecular antigen array
IN Renner, Wolfgang A., Zurich, SWITZERLAND
Bachmann, Martin, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Maurer, Patrick, Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Sebbel, Peter, Zurich, SWITZERLAND
Piossek, Christine, Winterthur, SWITZERLAND
Ortmann, Rainer, Saint Louis, SWITZERLAND
Luond, Rainer, Therwil, SWITZERLAND
Staufenbiel, Matthias, Lorrach, GERMANY, FEDERAL REPUBLIC OF
Frey, Peter, Bern, SWITZERLAND
PA Cytos Biotechnology AG (non-U.S. corporation)
PI US 2003175711 A1 20030918
AI US 2002-50898 A1 20020118 (10)
PRAI US 2001-331045P 20011107 (60)
US 2001-326998P 20011005 (60)
US 2001-288549P 20010504 (60)
US 2001-262379P 20010119 (60)
DT Utility
FS APPLICATION
LN.CNT 14673
INCL INCLM: 435/006.000
INCLS: 424/201.100; 435/005.000; 435/007.320
NCL NCLM: 435/006.000
NCLS: 424/201.100; 435/005.000; 435/007.320
[7]
ICM: C12Q001-70
ICS: G01N033-554; G01N033-569; A61K039-295; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 391 USPATFULL on STN
AN 2003:250504 USPATFULL
TI Molecular antigen array
IN Renner, Wolfgang A., Zurich, SWITZERLAND
Bachmann, Martin, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Maurer, Patrick, Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Sebbel, Peter, Zurich, SWITZERLAND
Piossek, Christine, Winterthur, SWITZERLAND
PA Cytos Biotechnology AG (non-U.S. corporation)
PI US 2003175290 A1 20030918
AI US 2002-50902 A1 20020118 (10)
PRAI US 2001-331045P 20011107 (60)
US 2001-326998P 20011005 (60)
US 2001-288549P 20010504 (60)
US 2001-262379P 20010119 (60)
DT Utility
FS APPLICATION
LN.CNT 15306
INCL INCLM: 424/186.100
INCLS: 435/005.000; 435/007.900; 435/287.200; 435/006.000
NCL NCLM: 424/186.100
NCLS: 435/005.000; 435/007.900; 435/287.200; 435/006.000
[7]
ICM: A61K039-12
ICS: C12Q001-70; G01N033-53; G01N033-542; C12M001-34; C12Q001-68;
C12M003-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 68 OF 391 USPATFULL on STN
AN 2003:250493 USPATFULL
TI Ubiquilin, a presenilin interactor and methods of using same
IN Monteiro, Mervyn J., Columbia, MD, UNITED STATES

Perry, George, University Heights, OH, UNITED STATES
Smith, Mark A., Cleveland, OH, UNITED STATES
PI US 2003175278 A1 20030918
AI US 2002-293000 A1 20021113 (10)
PRAI US 2001-338549P 20011113 (60)
DT Utility
FS APPLICATION
LN.CNT 2516
INCL INCLM: 424/146.100
INCLS: 435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000;
536/023.200; 530/388.260
NCL NCLM: 424/146.100
NCLS: 435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000;
536/023.200; 530/388.260
IC [7]
ICM: A61K039-395
ICS: G01N033-53; G01N033-567; C07H021-04; C12N009-64; C12P021-02;
C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 69 OF 391 USPATFULL on STN
AN 2003:244990 USPATFULL
TI Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives
thereof as aggrecanase inhibitors
IN Barta, Thomas E., Evanston, IL, UNITED STATES
Arner, Elizabeth C., Wadsworth, IL, UNITED STATES
Becker, Daniel, Glenview, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
McDonald, Joseph, Wildwood, MO, UNITED STATES
PI US 2003171404 A1 20030911
AI US 2002-194897 A1 20020712 (10)
PRAI US 2001-306629P 20010719 (60)
DT Utility
FS APPLICATION
LN.CNT 5693
INCL INCLM: 514/335.000
INCLS: 514/422.000; 514/602.000; 514/255.050
NCL NCLM: 514/335.000
NCLS: 514/422.000; 514/602.000; 514/255.050
IC [7]
ICM: A61K031-4965
ICS: A61K031-4439; A61K031-4025; A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 70 OF 391 USPATFULL on STN
AN 2003:244942 USPATFULL
TI Methods for alzheimer's disease treatment and cognitive enhancement
IN Etcheberrigaray, Rene, Bethesda, MD, UNITED STATES
Alkon, Daniel L., Bethesda, MD, UNITED STATES
PA Neurologic, Inc. (U.S. corporation)
PI US 2003171356 A1 20030911
AI US 2002-167491 A1 20020613 (10)
PRAI US 2002-362080P 20020307 (60)
DT Utility
FS APPLICATION
LN.CNT 1098
INCL INCLM: 514/212.030
INCLS: 514/424.000; 514/450.000
NCL NCLM: 514/212.030
NCLS: 514/424.000; 514/450.000
IC [7]
ICM: A61K031-55
ICS: A61K031-4015; A61K031-353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 71 OF 391 USPATFULL on STN
AN 2003:244343 USPATFULL
TI Alpha-fetoprotein peptides and uses thereof
IN Andersen, Thomas T., Albany, NY, UNITED STATES
Bennett, James A., Delmar, NY, UNITED STATES
Jacobson, Herbert I., Albany, NY, UNITED STATES
Mesfin, Fassil B., Albany, NY, UNITED STATES
PI US 2003170752 A1 20030911
AI US 2001-872623 A1 20010602 (9)
PRAI US 2002-326114 20020302 (6)

DT Utility
FS APPLICATION
LN.CNT 1173
INCL INCLM: 435/007.230
INCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000
NCL NCLM: 435/007.230
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000
IC [7]
ICM: G01N033-574
ICS: C07K007-08; C07K007-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 72 OF 391 USPATFULL on STN
AN 2003:244336 USPATFULL
TI Early detection marker for chronic inflammatory associated diseases
IN Pereira, Heloise Anne, Edmond, OK, UNITED STATES
PI US 2003170745 A1 20030911
AI US 2003-384474 A1 20030307 (10)
PRAI US 2002-363114P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 1079
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 73 OF 391 USPATFULL on STN
AN 2003:244219 USPATFULL
TI ***Human*** cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003170628 A1 20030911
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25549
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 391 USPATFULL on STN
AN 2003:243794 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003170203 A1 20030911
AI US 2002-189189 A1 20020705 (10)
RLI Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000,
PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar
1997, GRANTED, Pat. No. US 6153402
PRAI US 2001-314314P 20010824 (60)
US 2001-303155P 20010706 (60)
US 1999-136741P 19990528 (60)
US 1999-130488P 19990422 (60)
US 1997-37341P 19970206 (60)

US 1996-13285P 19960312 (60)
DT Utility
FS APPLICATION
LN.CNT 9858
INCL INCLM: 424/085.100
INCLS: 424/145.100; 514/210.090; 514/011.000
NCL NCLM: 424/085.100
NCLS: 424/145.100; 514/210.090; 514/011.000
IC [7]
ICM: A61K039-395
ICS: A61K031-407; A61K038-19; A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 391 USPATFULL on STN
AN 2003:243518 USPATFULL
TI Data relationship model
IN Sonmez, Kemal, Menlo Park, CA, UNITED STATES
Toll, Lawrence R., Redwood City, CA, UNITED STATES
Lincoln, Patrick Denis, Woodside, CA, UNITED STATES
Karp, Peter D., San Mateo, CA, UNITED STATES
PI US 2003169926 A1 20030911
AI US 2001-4580 A1 20011203 (10)
PRAI US 2000-250743P 20001201 (60)
DT Utility
FS APPLICATION
LN.CNT 1575
INCL INCLM: 382/219.000
INCLS: 382/228.000
NCL NCLM: 382/219.000
NCLS: 382/228.000
IC [7]
ICM: G06K009-68

L4 ANSWER 76 OF 391 USPATFULL on STN
AN 2003:240440 USPATFULL
TI Cysteinyl protease inhibitors
IN Munoz, Benito, 10741 Frank Daniels Rd., San Diego, CA, United States 92131
Srinivasan, Kuman, 7693 Palmilla Dr., Apt. #2116, San Diego, CA, United States 92122
Wang, Bowei, 7825 Roan Rd., San Diego, CA, United States 92129
PI US 6617426 B1 20030909
AI US 1999-338409 19990622 (9)
DT Utility
FS GRANTED
LN.CNT 2060
INCL INCLM: 530/331.000
INCLS: 514/018.000; 514/019.000
NCL NCLM: 530/331.000
NCLS: 514/018.000; 514/019.000
IC [7]
ICM: C07K005-08
EXF 530/331; 514/18; 514/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 391 USPATFULL on STN
AN 2003:239326 USPATFULL
TI Double transgenic mice overexpressing ***human*** beta secretase and ***human*** APP-London
IN Jacobsen, Helmut, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
Mosbach-Ozmen, Laurence, Saint-Louis, FRANCE
Nelboeck-Hochstetter, Peter, Basel, SWITZERLAND
PI US 2003167486 A1 20030904
AI US 2003-372730 A1 20030224 (10)
PRAI EP 2002-4331 20020301
DT Utility
FS APPLICATION
LN.CNT 2177
INCL INCLM: 800/012.000
INCLS: 800/014.000
NCL NCLM: 800/012.000
NCLS: 800/014.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 78 OF 391 USPATFULL on STN
AN 2003:238559 USPATFULL
TI Hydroxy alkyl amines
IN Freskos, John, Clayton, MO, UNITED STATES
Brown, David L., Chesterfield, MO, UNITED STATES
Fobian, Yvette M., Wildwood, MO, UNITED STATES
Fang, Larry, Foster City, CA, UNITED STATES
Romero, Arthur Glenn, Kalamazoo, MI, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
PI US 2003166717 A1 20030904
AI US 2002-160777 A1 20020531 (10)
PRAI US 2001-343772P 20011228 (60)
US 2001-332639P 20011119 (60)
US 2001-295332P 20010601 (60)
DT Utility
FS APPLICATION
LN.CNT 10078
INCL INCLM: 514/526.000
INCLS: 514/629.000; 514/600.000; 514/601.000; 558/482.000; 564/095.000;
564/163.000; 564/503.000
NCL NCLM: 514/526.000
NCLS: 514/629.000; 514/600.000; 514/601.000; 558/482.000; 564/095.000;
564/163.000; 564/503.000
IC [7]
ICM: A61K031-275
ICS: A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 391 USPATFULL on STN
AN 2003:238482 USPATFULL
TI Reverse-turn mimetics and methods relating thereto
IN Urban, Jan, Kirkland, WA, UNITED STATES
Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES
Lee, Min S., Sammamish, WA, UNITED STATES
PA Molecumetics, Ltd., Bellevue, WA (U.S. corporation)
PI US 2003166640 A1 20030904
AI US 2002-150481 A1 20020516 (10)
PRAI US 2001-291663P 20010516 (60)
DT Utility
FS APPLICATION
LN.CNT 1913
INCL INCLM: 514/224.200
INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
544/095.000; 544/014.000; 544/350.000; 544/345.000
NCL NCLM: 514/224.200
NCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
544/095.000; 544/014.000; 544/350.000; 544/345.000
IC [7]
ICM: G01N033-53
ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 391 USPATFULL on STN
AN 2003:238478 USPATFULL
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of
A-beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
Thompson, Lorin A., Wilmington, DE, UNITED STATES
PI US 2003166636 A1 20030904
AI US 2002-287117 A1 20021104 (10)
RLI Division of Ser. No. US 2001-805645, filed on 14 Mar 2001, GRANTED, Pat.
No. US 6503902 Continuation-in-part of Ser. No. US 2000-661008, filed on
13 Sep 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 6969
INCL INCLM: 514/212.080
INCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500;
514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;
546/207.000
NCL NCLM: 514/212.080
NCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500;
514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;
546/207.000
IC [7]

ICM: A61K031-55
ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4545; A61K031-454;
C07D417-02; C07D413-02; C07D043-02; C07D041-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 391 USPATFULL on STN
AN 2003:238422 USPATFULL
TI Substituted amino carboxamides for the treatment of alzheimer's disease
IN Warpehoski, Martha A., Portage, MI, UNITED STATES
Jagodzinska, Barbara, Redwood City, CA, UNITED STATES
PI US 2003166580 A1 20030904
AI US 2003-337075 A1 20030106 (10)
PRAI US 2002-345316P 20020104 (60)
US 2002-350419P 20020118 (60)
DT Utility
FS APPLICATION
LN.CNT 4157
INCL INCLM: 514/019.000
INCLS: 560/041.000; 546/335.000
NCL NCLM: 514/019.000
NCLS: 560/041.000; 546/335.000
IC [7]
ICM: A61K038-04
ICS: C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 391 USPATFULL on STN
AN 2003:238400 USPATFULL
TI Synthetic immunogenic but non-deposit-forming polypeptides and peptides
homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or
polyglutamine repeats for induction of an immune response thereto
IN Frangione, Blas, New York, NY, UNITED STATES
Wisniewski, Thomas, Statent Island, NY, UNITED STATES
Sigurdsson, Einar M., New York, NY, UNITED STATES
PA NEW YORK UNIVERSITY (U.S. corporation)
PI US 2003166558 A1 20030904
AI US 2002-301488 A1 20021121 (10)
PRAI US 2001-331801P 20011121 (60)
DT Utility
FS APPLICATION
LN.CNT 4966
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;
530/327.000; 530/328.000; 530/326.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;
530/327.000; 530/328.000; 530/326.000
IC [7]
ICM: A61K038-16
ICS: A61K038-10; A61K038-08; C07K014-00; C07K007-08; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 391 USPATFULL on STN
AN 2003:237862 USPATFULL
TI Monoclonal ***antibody***
IN Wiltfang, Jens, Eddigehausen, GERMANY, FEDERAL REPUBLIC OF
Dyrks, Thomas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Monning, Ursula, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2003166019 A1 20030904
AI US 2002-170272 A1 20020611 (10)
PRAI EP 2001-114192 20010612
DT Utility
FS APPLICATION
LN.CNT 3683
INCL INCLM: 435/007.210
INCLS: 530/388.260
NCL NCLM: 435/007.210
NCLS: 530/388.260
IC [7]
ICM: G01N033-567
ICS: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 391 USPATFULL on STN
AN 2003:237706 USPATFULL

thereof
IN Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003165863 A1 20030904
AI US 2002-47855 A1 20020115 (10)
PRAI US 2001-262306P 20010116 (60)
DT Utility
FS APPLICATION
LN.CNT 4471
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 391 USPATFULL on STN
AN 2003:237324 USPATFULL
TI Amyloid peptide inactivating enzyme to treat Alzheimer's disease
IN Hersh, Louis B., Lexington, KY, UNITED STATES
PI US 2003165481 A1 20030904
AI US 2002-159279 A1 20020603 (10)
RLI Division of Ser. No. US 2001-792079, filed on 26 Feb 2001, PENDING
PRAI US 2000-184826P 20000224 (60)
DT Utility
FS APPLICATION
LN.CNT 1712
INCL INCLM: 424/093.210
INCLS: 435/455.000; 435/368.000
NCL NCLM: 424/093.210
NCLS: 435/455.000; 435/368.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 391 USPATFULL on STN
AN 2003:232056 USPATFULL
TI PTH1R and PTH3R receptors, methods and uses thereof
IN Juppner, Harald, Cambridge, MA, UNITED STATES
Rubin, David A., Needham, MA, UNITED STATES
PA The Massachusetts General Hospital (U.S. corporation)
PI US 2003162256 A1 20030828
AI US 2003-372095 A1 20030225 (10)
RLI Division of Ser. No. US 1999-449632, filed on 30 Nov 1999, GRANTED, Pat.
No. US 6541220
PRAI US 1998-110467P 19981130 (60)
DT Utility
FS APPLICATION
LN.CNT 2869
INCL INCLM: 435/069.100
INCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K038-17
ICS: C07K014-72; C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 87 OF 391 USPATFULL on STN
AN 2003:231986 USPATFULL
TI ***Human*** CDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003162186 A1 20030828
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 25533

INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 391 USPATFULL on STN
AN 2003:231625 USPATFULL
TI Therapeutic and cosmetic uses of heparanases
IN Ilan, Neta, Rehovot, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Yacoby-Zeevi, Oron, Moshav Bizaron, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PI US 2003161823 A1 20030828
AI US 2003-341582 A1 20030114 (10)
RLI Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001,
PENDING Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001,
PENDING Continuation of Ser. No. US 1999-258892, filed on 1 Mar 1999,
ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31
Aug 1998, PENDING Continuation-in-part of Ser. No. WO 2001-IL830, filed
on 5 Sep 2001, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 7437
INCL INCLM: 424/094.610
INCLS: 435/006.000; 435/200.000
NCL NCLM: 424/094.610
NCLS: 435/006.000; 435/200.000
IC [7]
ICM: A61K038-47
ICS: C12Q001-68; C12N009-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 391 USPATFULL on STN
AN 2003:226348 USPATFULL
TI Substituted saponogenins and their use
IN Barraclough, Paul, Maidstone, UNITED KINGDOM
Hanson, Jim, Steyning, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
Rees, Daryl, Sandy, UNITED KINGDOM
Xia, Zongqin, Shanghai, CHINA
Hu, Yaer, Shanghai, CHINA
PA PHYTOPHARM PLC. (non-U.S. corporation)
PI US 2003158161 A1 20030821
AI US 2002-189024 A1 20020703 (10)
RLI Continuation-in-part of Ser. No. WO 2001-GB48, filed on 8 Jan 2001,
UNKNOWN
PRAI GB 2000-228 20000106
DT Utility
FS APPLICATION
LN.CNT 2249
INCL INCLM: 514/173.000
INCLS: 514/172.000
NCL NCLM: 514/173.000
NCLS: 514/172.000
IC [7]
ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 391 USPATFULL on STN
AN 2003:225892 USPATFULL
TI Reagents and methods for identifying and modulating expression of genes
regulated by CDK inhibitors
IN Roninson, Igor B., Wilmette, IL, UNITED STATES
Poole, Jason C., Chicago, IL, UNITED STATES
PI US 2003157704 A1 20030821
AI US 2002-233032 A1 20020829 (10)
PRAI US 2001-315791P 20010829 (60)
DT Utility
FS APPLICATION
LN.CNT 3944

NCL INCLS: 435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
NCLM: 435/320.100
NCLS: 435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
[7]
ICM: C12Q001-70
ICS: C12Q001-68; C12N007-00; C12N007-01; C12N007-02; C12N015-00;
C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 391 USPATFULL on STN
AN 2003:225673 USPATFULL
TI ***Human*** cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003157485 A1 20030821
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;
C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 92 OF 391 USPATFULL on STN
AN 2003:220443 USPATFULL
TI Methods for producing pure perlecan and other heparan sulfate
proteoglycans
IN Castillo, Gerardo, Seattle, WA, UNITED STATES
Snow, Alan D., Lynnwood, WA, UNITED STATES
PI US 2003153734 A1 20030814
AI US 2002-323323 A1 20021218 (10)
RLI Continuation of Ser. No. US 2000-698518, filed on 26 Oct 2000, PENDING
Continuation of Ser. No. US 1998-36492, filed on 6 Mar 1998, ABANDONED
PRAI US 1997-38613P 19970306 (60)
DT Utility
FS APPLICATION
LN.CNT 2512
INCL INCLM: 530/370.000
INCLS: 530/395.000
NCL NCLM: 530/370.000
NCLS: 530/395.000
IC [7]
ICM: C07K014-47
ICS: C07K014-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 93 OF 391 USPATFULL on STN
AN 2003:220436 USPATFULL
TI Controlling protein levels in eucaryotic organisms
IN Kenten, John H., Boyds, MD, UNITED STATES
Roberts, Steven F., Bethesda, MD, UNITED STATES
PA Proteinix, Inc. (U.S. corporation)
PI US 2003153727 A1 20030814
AI US 2003-345281 A1 20030116 (10)
RLI Division of Ser. No. US 2001-880132, filed on 14 Jun 2001, GRANTED, Pat.
No. US 6559280 Division of Ser. No. US 1999-406781, filed on 28 Sep
1999, GRANTED, Pat. No. US 6306663
PRAI US 1999-119851P 19990212 (60)
DT Utility
FS APPLICATION

INCL INCLM: 530/323.000
INCLS: 435/106.000; 424/070.140; 530/330.000
NCL NCLM: 530/323.000
NCLS: 435/106.000; 424/070.140; 530/330.000
IC [7]
ICM: A61K007-06
ICS: A61K007-11; C12P013-04; C07K005-00; C07K007-00; C07K016-00;
C07K017-00; A61K038-00; A61K038-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 94 OF 391 USPATFULL on STN
AN 2003:219631 USPATFULL
TI Full-length ***human*** cDNAs encoding potentially secreted proteins
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2003152921 A1 20030814
AI US 2001-876997 A1 20010608 (9)
RLI Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000,
PENDING
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 27600
INCL INCLM: 435/006.000
INCLS: 435/183.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/183.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C12N009-00; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 391 USPATFULL on STN
AN 2003:214611 USPATFULL
TI Methods and compositions comprising Renilla GFP
IN Anderson, David, San Bruno, CA, UNITED STATES
Peelle, Beau, Sommerville, MA, UNITED STATES
PA Rigel Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003149254 A1 20030807
AI US 2002-133973 A1 20020424 (10)
RLI Continuation of Ser. No. US 2000-710058, filed on 10 Nov 2000, PENDING
PRAI US 2001-290287P 20010510 (60)
US 1999-164592P 19991110 (60)
DT Utility
FS APPLICATION
LN.CNT 5908
INCL INCLM: 536/023.100
INCLS: 435/006.000; 435/320.100; 435/325.000; 435/069.700; 530/350.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 435/320.100; 435/325.000; 435/069.700; 530/350.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-04; C07K014-435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 96 OF 391 USPATFULL on STN
AN 2003:213718 USPATFULL
TI Novel APP mutation associated with an unusual Alzheimer's disease
pathology
IN Cruts, Mare, Antwerpen, BELGIUM
Jonghe, Chris De, Edegem, BELGIUM
Singh, Samir Kumar, Edegem, BELGIUM
Broeckhoven, Christine van, Edegem, BELGIUM
PI US 2003148356 A1 20030807
AI US 2003-337970 A1 20030106 (10)
RLI Continuation of Ser. No. WO 2001-EP7830, filed on 6 Jul 2001, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 1415
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
IC [7]

ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12N001-21; C12P021-02; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 97 OF 391 USPATFULL on STN
AN 2003:213627 USPATFULL
TI Phage displayed PDZ domain ligands
IN Held, Heike A., Oakland, CA, UNITED STATES
Lasky, Laurence A., Sausalito, CA, UNITED STATES
Laura, Richard P., San Bruno, CA, UNITED STATES
Sidhu, Sachdev S., San Francisco, CA, UNITED STATES
Wong, Wai Lee Tan, Los Altos, CA, UNITED STATES
Wu, Yan, Foster City, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 2003148264 A1 20030807
AI US 2002-190082 A1 20020703 (10)
PRAI US 2001-303634P 20010706 (60)
DT Utility
FS APPLICATION
LN.CNT 8976
INCL INCLM: 435/005.000
INCLS: 435/007.100; 435/235.100; 536/023.720; 530/350.000
NCL NCLM: 435/005.000
NCLS: 435/007.100; 435/235.100; 536/023.720; 530/350.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; C07H021-04; C12N007-00; C07K014-005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 391 USPATFULL on STN
AN 2003:207362 USPATFULL
TI High throughput functional genomics
IN Hickman, James J., Falls Church, VA, UNITED STATES
PI US 2003143720 A1 20030731
AI US 2002-286760 A1 20021104 (10)
RLI Continuation of Ser. No. US 2000-575377, filed on 22 May 2000, PENDING
PRAI US 1999-135275P 19990521 (60)
DT Utility
FS APPLICATION
LN.CNT 2781
INCL INCLM: 435/287.100
INCLS: 702/019.000; 205/777.500
NCL NCLM: 435/287.100
NCLS: 702/019.000; 205/777.500
IC [7]
ICM: G06F019-00
ICS: G01N033-48; G01N033-50; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 99 OF 391 USPATFULL on STN
AN 2003:206852 USPATFULL
TI Targeted adenovirus vectors for delivery of heterologous genes
IN Vigne, Emmanuelle, L'Hay-Les-Roses, FRANCE
Dedieu, Jean-Francois, Paris, FRANCE
Latta, Martine, Charenton Le pont, FRANCE
Yeh, Patrice, Gif Sur Yvette, FRANCE
Perricaudet, Michel, Ecrosnes, FRANCE
PI US 2003143209 A1 20030731
AI US 2001-791524 A1 20010222 (9)
RLI Continuation of Ser. No. WO 1999-IB1524, filed on 27 Aug 1999, UNKNOWN
PRAI US 1998-98028P 19980827 (60)
DT Utility
FS APPLICATION
LN.CNT 3374
INCL INCLM: 424/093.210
INCLS: 435/235.100
NCL NCLM: 424/093.210
NCLS: 435/235.100
IC [7]
ICM: A61K048-00
ICS: C12N007-00; C12N007-01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 391 USPATFULL on STN
AN 2003:200784 USPATFULL

IN Birkett, Ashley J., Escondido, CA, UNITED STATES
PI US 2003138769 A1 20030724
AI US 2001-930915 A1 20010815 (9)
RLI Continuation-in-part of Ser. No. US 2000-226867, filed on 22 Aug 2000,
PENDING Continuation-in-part of Ser. No. US 2000-225843, filed on 16 Aug
2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 6993
INCL INCLM: 435/005.000
INCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100
NCL NCLM: 435/005.000
NCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100
IC [7]
ICM: C12Q001-70
ICS: C12P021-02; C12N005-06; C07K014-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 391 USPATFULL on STN
AN 2003:195233 USPATFULL
TI Novel gamma secretase inhibitors
IN Asberom, Theodros, West Orange, NJ, UNITED STATES
Guzik, Henry S., Brooklyn, NY, UNITED STATES
Josien, Hubert B., Hoboken, NJ, UNITED STATES
Pissarnitski, Dmitri A., Scotch Plains, NJ, UNITED STATES
PA SCHERING CORPORATION (U.S. corporation)
PI US 2003135044 A1 20030717
AI US 2002-210829 A1 20020801 (10)
PRAI US 2002-355510P 20020206 (60)
US 2001-310013P 20010803 (60)
DT Utility
FS APPLICATION
LN.CNT 1170
INCL INCLM: 540/593.000
INCLS: 546/153.000; 548/494.000; 514/217.010; 514/312.000
NCL NCLM: 540/593.000
NCLS: 546/153.000; 548/494.000; 514/217.010; 514/312.000
IC [7]
ICM: A61K031-55
ICS: C07D215-16; A61K031-47; C07D209-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 391 USPATFULL on STN
AN 2003:195030 USPATFULL
TI Succinoylamino lactams as inhibitors of A-beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Maduskuie, Thomas P., Wilmington, DE, UNITED STATES
Thompson, Lorin Andrew, Wilmington, DE, UNITED STATES
PI US 2003134841 A1 20030717
AI US 2002-285776 A1 20021101 (10)
RLI Division of Ser. No. US 2000-506360, filed on 17 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 1999-370089, filed on 6 Aug 1999,
ABANDONED
PRAI US 1999-120227P 19990215 (60)
US 1998-113558P 19981223 (60)
US 1998-95698P 19980807 (60)
DT Utility
FS APPLICATION
LN.CNT 11008
INCL INCLM: 514/212.080
INCLS: 514/316.000; 514/326.000; 514/327.000; 514/422.000; 514/212.030;
514/424.000; 540/524.000; 540/527.000; 546/188.000; 546/207.000;
546/216.000; 548/518.000; 548/550.000
NCL NCLM: 514/212.080
NCLS: 514/316.000; 514/326.000; 514/327.000; 514/422.000; 514/212.030;
514/424.000; 540/524.000; 540/527.000; 546/188.000; 546/207.000;
546/216.000; 548/518.000; 548/550.000
IC [7]
ICM: A61K031-55
ICS: A61K031-4545; A61K031-454; A61K031-4025; A61K031-4015; C07D043-02;
C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 391 USPATFULL on STN
AN 2003:194619 USPATFULL
TI

IN elegans-like protein polypeptides
Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT (U.S. corporation)
PI US 2003134430 A1 20030717
AI US 2001-977751 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 10285
INCL INCLM: 436/518.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 436/518.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-435; G01N033-543; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 391 USPATFULL on STN
AN 2003:188691 USPATFULL
TI Inhibitors and disassemblers of fibrillogenesis
IN Gordon, David J., Chicago, IL, UNITED STATES
Meredith, Stephen C., Chicago, IL, UNITED STATES
PI US 2003130484 A1 20030710
AI US 2002-103658 A1 20020320 (10)
PRAI US 2001-277477P 20010320 (60)
DT Utility
FS APPLICATION
LN.CNT 4503
INCL INCLM: 530/350.000
INCLS: 514/012.000; 435/007.100
NCL NCLM: 530/350.000
NCLS: 514/012.000; 435/007.100
IC [7]
ICM: A61K038-17
ICS: C07K014-435; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 391 USPATFULL on STN
AN 2003:188458 USPATFULL
TI Amino lactam sulfonamides as inhibitors of A-beta protein production
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES
Han, Amy Qi, Hockessin, DE, UNITED STATES
PI US 2003130251 A1 20030710
AI US 2002-287367 A1 20021104 (10)
RLI Division of Ser. No. US 2000-684718, filed on 7 Oct 2000, GRANTED, Pat. No. US 6503901
PRAI US 1999-158565P 19991008 (60)
DT Utility
FS APPLICATION
LN.CNT 4917
INCL INCLM: 514/183.000
INCLS: 514/212.080; 514/227.800; 514/231.500; 514/253.130; 514/254.010;
514/326.000; 514/327.000; 514/422.000; 514/424.000; 540/524.000;
544/060.000; 544/130.000; 544/141.000; 544/360.000; 544/372.000;
546/207.000; 546/243.000; 548/517.000; 548/543.000
NCL NCLM: 514/183.000
NCLS: 514/212.080; 514/227.800; 514/231.500; 514/253.130; 514/254.010;
514/326.000; 514/327.000; 514/422.000; 514/424.000; 540/524.000;
544/060.000; 544/130.000; 544/141.000; 544/360.000; 544/372.000;
546/207.000; 546/243.000; 548/517.000; 548/543.000
IC [7]
ICM: A61K031-55
ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4439; A61K031-454;
C07D417-02; C07D413-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:188395 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and
methods for inhibiting ***beta*** - ***amyloid*** peptide release
and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Droste, James, Indianapolis, IN, UNITED STATES
PI US 2003130188 A1 20030710
AI US 2002-246558 A1 20020919 (10)
RLI Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 11320
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
514/018.000; 514/019.000; 514/400.000; 514/419.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
514/018.000; 514/019.000; 514/400.000; 514/419.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 391 USPATFULL on STN
AN 2003:181532 USPATFULL
TI Hydroxypropylamines
IN Fisher, Jed F., Kalamazoo, MI, UNITED STATES
Jacobs, Jon S., Kalamazoo, MI, UNITED STATES
Sherer, Brian, Ballston Spa, NY, UNITED STATES
PI US 2003125365 A1 20030703
AI US 2002-264707 A1 20021004 (10)
PRAI US 2001-327149P 20011004 (60)
US 2001-334058P 20011128 (60)
DT Utility
FS APPLICATION
LN.CNT 4089
INCL INCLM: 514/374.000
INCLS: 514/602.000; 514/617.000; 548/215.000; 564/176.000; 564/084.000;
564/503.000
NCL NCLM: 514/374.000
NCLS: 514/602.000; 514/617.000; 548/215.000; 564/176.000; 564/084.000;
564/503.000
IC [7]
ICM: A61K031-421
ICS: A61K031-165; C07D263-02; C07C311-15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 391 USPATFULL on STN
AN 2003:181424 USPATFULL
TI Assay for identifying beta secretase inhibitors
IN Brockhaus, Manfred, Bettingen, SWITZERLAND
Doebeli, Heinz, Ziefen, SWITZERLAND
Grueninger, Fiona, Arlesheim, SWITZERLAND
Huguenin, Philipp, Liestal, SWITZERLAND
Kitas, Eric Argirios, Aesch, SWITZERLAND
Nelboeck-Hochstetter, Peter, Basel, SWITZERLAND
PI US 2003125257 A1 20030703
AI US 2002-322684 A1 20021218 (10)
PRAI EP 2001-130282 20011220
DT Utility
FS APPLICATION
LN.CNT 1045
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 435/023.000; 435/184.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 435/023.000; 435/184.000
IC [7]
ICM: A61K038-55
ICS: C12Q001-37; C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:174039 USPATFULL
TI Lactacystin analogs
IN Schreiber, Stuart L., Boston, MA, UNITED STATES
Standaert, Robert F., Bryan, TX, UNITED STATES
Fenteany, Gabriel, Cambridge, MA, UNITED STATES
Jamison, Timothy F., Cambridge, MA, UNITED STATES
PI US 2003119887 A1 20030626
AI US 2001-924993 A1 20010808 (9)
RLI Continuation of Ser. No. US 1998-945092, filed on 26 Jan 1998, PENDING A
371 of International Ser. No. WO 1996-US5072, filed on 12 Apr 1996,
PENDING Continuation-in-part of Ser. No. US 1995-421583, filed on 12 Apr
1995, GRANTED, Pat. No. US 6335358
DT Utility
FS APPLICATION
LN.CNT 3836
INCL INCLM: 514/369.000
INCLS: 514/376.000; 514/386.000; 514/409.000; 514/424.000; 514/438.000;
514/471.000; 514/473.000; 548/182.000; 548/190.000; 548/229.000;
548/233.000; 548/316.400; 548/321.500; 548/543.000; 548/558.000;
549/062.000; 549/321.000
NCL NCLM: 514/369.000
NCLS: 514/376.000; 514/386.000; 514/409.000; 514/424.000; 514/438.000;
514/471.000; 514/473.000; 548/182.000; 548/190.000; 548/229.000;
548/233.000; 548/316.400; 548/321.500; 548/543.000; 548/558.000;
549/062.000; 549/321.000
IC [7]
ICM: C07D333-32
ICS: C07D333-34; C07D277-12; C07D277-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 391 USPATFULL on STN
AN 2003:173967 USPATFULL
TI Lactams substituted by cyclic succinates as inhibitors of A-beta protein
production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
PI US 2003119815 A1 20030626
AI US 2002-287099 A1 20021104 (10)
RLI Division of Ser. No. US 2001-871840, filed on 1 Jun 2001, GRANTED, Pat.
No. US 6509333
PRAI US 2000-208536P 20000601 (60)
DT Utility
FS APPLICATION
LN.CNT 6497
INCL INCLM: 514/212.030
INCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;
540/524.000; 540/527.000; 546/207.000; 546/216.000
NCL NCLM: 514/212.030
NCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;
540/524.000; 540/527.000; 546/207.000; 546/216.000
IC [7]
ICM: A61K031-55
ICS: A61K031-454; C07D043-02; C07D041-02; C07D223-12; C07D211-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 391 USPATFULL on STN
AN 2003:173922 USPATFULL
TI Intercellular delivery of a herpes simplex virus VP22 fusion protein
from cells infected with lentiviral vectors
IN Lai, Zhennan, N. Potomac, MD, UNITED STATES
Reiser, Jakob, New Orleans, LA, UNITED STATES
Brady, Roscoe O., Rockville, MD, UNITED STATES
PI US 2003119770 A1 20030626
AI US 2002-212634 A1 20020802 (10)
PRAI US 2001-310012P 20010802 (60)
DT Utility
FS APPLICATION
LN.CNT 2103
INCL INCLM: 514/044.000
INCLS: 424/093.200; 435/456.000; 435/320.100; 435/235.100
NCL NCLM: 514/044.000
NCLS: 424/093.200; 435/456.000; 435/320.100; 435/235.100
IC [7]
ICM: A61K048-00
ICS: C12N007-00; C12N015-867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 391 USPATFULL on STN
AN 2003:165862 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003113717 A1 20030619
AI US 2001-893878 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15933
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/455.000; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/455.000; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 391 USPATFULL on STN
AN 2003:159944 USPATFULL
TI N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
IN Gailunas, Andrea, Burlingame, CA, UNITED STATES
Tucker, John A., San Mateo, CA, UNITED STATES
TenBrink, Ruth, Kalamazoo, MI, UNITED STATES
Mickelson, John, Mattawan, MI, UNITED STATES
PI US 2003109559 A1 20030612
AI US 2002-193044 A1 20020711 (10)
PRAI US 2001-341341P 20011217 (60)
US 2002-380574P 20020514 (60)
US 2001-308756P 20010730 (60)
US 2001-341416P 20011217 (60)
US 2001-344872P 20011221 (60)
US 2001-304525P 20010711 (60)
DT Utility
FS APPLICATION
LN.CNT 5746
INCL INCLM: 514/357.000
INCLS: 514/408.000; 514/617.000; 514/114.000; 514/517.000; 514/521.000;
514/563.000; 514/603.000; 548/567.000; 548/413.000; 546/330.000;
546/336.000; 558/166.000; 558/167.000; 558/414.000; 564/152.000
NCL NCLM: 514/357.000
NCLS: 514/408.000; 514/617.000; 514/114.000; 514/517.000; 514/521.000;
514/563.000; 514/603.000; 548/567.000; 548/413.000; 546/330.000;
546/336.000; 558/166.000; 558/167.000; 558/414.000; 564/152.000
IC [7]
ICM: A61K031-66
ICS: A61K031-44; A61K031-40; A61K031-277; A61K031-198; A61K031-165;
A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 391 USPATFULL on STN
AN 2003:159842 USPATFULL
TI Multi-component antioxidant compounds, pharmaceutical compositions
containing same and their use for reducing or preventing oxidative
stress
IN Atlas, Daphne, Jerusalem, ISRAEL
PA Yissum Research Development Company of the Hebrew University of
Jerusalem (non-U.S. corporation)
PI US 2003109457 A1 20030612
AI US 2002-234319 A1 20020905 (10)
PRAI WO 2001-IL984 20011025
DT Utility
FS

LN.CNT 1867
INCL INCLM: 514/018.000
INCLS: 514/017.000; 530/330.000; 530/331.000
NCL NCLM: 514/018.000
NCLS: 514/017.000; 530/330.000; 530/331.000
IC [7]
ICM: A61K038-06
ICS: A61K038-05; C07K005-06; C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 391 USPATFULL on STN
AN 2003:159365 USPATFULL
TI Whole cell assay systems for cell surface proteases
IN Ciambrone, Gary J., Redwood City, CA, UNITED STATES
Gibbons, Ian, Portola Valley, CA, UNITED STATES
PI US 2003108978 A1 20030612
AI US 2002-281458 A1 20021025 (10)
PRAI US 2001-337641P 20011025 (60)
DT Utility
FS APPLICATION
LN.CNT 2061
INCL INCLM: 435/024.000
INCLS: 435/810.000
NCL NCLM: 435/024.000
NCLS: 435/810.000
IC [7]
ICM: C12Q001-37
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 391 USPATFULL on STN
AN 2003:159291 USPATFULL
TI Novel scavenger receptors
IN Wakamiya, Nobutaka, Hokkaido, JAPAN
PI US 2003108904 A1 20030612
AI US 2002-203860 A1 20020930 (10)
WO 2001-JP874 20010208
PRAI JP 2000-35155 20000214
JP 2000-309068 20001010
DT Utility
FS APPLICATION
LN.CNT 3200
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 391 USPATFULL on STN
AN 2003:158903 USPATFULL
TI Death domain containing receptor 4
IN Ni, Jian, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Pan, James G., Belmont, CA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003108516 A1 20030612
AI US 2002-175902 A1 20020621 (10)
RLI Division of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Division of Ser. No. US 1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
PRAI US 1999-132922P 19990506 (60)
US 1997-37829P 19970205 (60)
US 1997-35722P 19970128 (60)
DT Utility
FS APPLICATION
LN.CNT 9230

INCL INCLM: 424/085.100
INCLS: 424/155.100; 514/012.000
NCL NCLM: 424/085.100
NCLS: 424/155.100; 514/012.000
IC [7]

ICS: A61K038-19; A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 391 USPATFULL on STN
AN 2003:152699 USPATFULL
TI Method of reducing cellular production of amyloid beta
IN Gurney, Mark E., Grand Rapids, MI, UNITED STATES
Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
PI US 2003104365 A1 20030605
AI US 2000-548366 A1 20000412 (9)
RLI Division of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999,
ABANDONED Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23
Sep 1999, UNKNOWN
PRAI US 1998-101594P 19980924 (60)
US 1999-155493P 19990923 (60)
DT Utility
FS APPLICATION
LN.CNT 5578
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/368.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/368.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12N005-08; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 391 USPATFULL on STN
AN 2003:146795 USPATFULL
TI 5-hydroxysapogenin derivatives with anti-dementia activity
IN Barracough, Paul, Maidstone, UNITED KINGDOM
Hanson, Jim, Steyning, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
Rees, Daryl, Sandy, UNITED KINGDOM
Xia, Zongqin, Shanghai, CHINA
Hu, Yaer, Shanghai, CHINA
PI US 2003100542 A1 20030529
AI US 2002-108737 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. WO 2000-GB3750, filed on 29 Sep 2000,
UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 887
INCL INCLM: 514/172.000
NCL NCLM: 514/172.000
IC [7]
ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 391 USPATFULL on STN
AN 2003:146345 USPATFULL
TI Metalloprotease-disintegrin ADAM23 (SVPH3-17)
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES
PA Immunex Corporation (U.S. corporation)
PI US 2003100091 A1 20030529
AI US 2002-202675 A1 20020723 (10)
RLI Division of Ser. No. US 634252, PENDING Continuation of Ser. No. WO
1999-US3016, filed on 11 Feb 1999, PENDING
PRAI US 1998-74310P 19980211 (60)
DT Utility
FS APPLICATION
LN.CNT 3070
INCL INCLM: 435/196.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/196.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-16
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:146281 USPATFULL
TI Methods and compositions using coiled binding partners
IN Colyer, John, West Yorkshire, UNITED KINGDOM
Lightowler, Joanne, York, UNITED KINGDOM
PI US 2003100027 A1 20030529
AI US 2000-491614 A1 20000126 (9)
RLI Continuation-in-part of Ser. No. US 1999-259474, filed on 26 Feb 1999,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2588
INCL INCLM: 435/007.400
NCL NCLM: 435/007.400
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 391 USPATFULL on STN
AN 2003:145900 USPATFULL
TI CD40 ligand and CD40 agonist compositions and methods of use
IN Ahuja, Seema A., San Antonio, TX, UNITED STATES
Bonenwald, Lynda F., San Antonio, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003099644 A1 20030529
AI US 2002-242212 A1 20020912 (10)
RLI Division of Ser. No. US 2000-645926, filed on 24 Aug 2000, GRANTED, Pat.
No. US 6482411
PRAI US 1999-151250P 19990827 (60)
DT Utility
FS APPLICATION
LN.CNT 5263
INCL INCLM: 424/144.100
INCLS: 514/012.000
NCL NCLM: 424/144.100
NCLS: 514/012.000
IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 391 USPATFULL on STN
AN 2003:140906 USPATFULL
TI Methods and compositions for the treatment of diseases associated with
signal transduction aberrations
IN Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES
Ling, Song, Ann Arbor, MI, UNITED STATES
PA The Regents of The University of Michigan (U.S. corporation)
PI US 2003096748 A1 20030522
AI US 2002-161959 A1 20020603 (10)
PRAI US 2001-295691P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 2986
INCL INCLM: 514/012.000
INCLS: 530/359.000
NCL NCLM: 514/012.000
NCLS: 530/359.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 391 USPATFULL on STN
AN 2003:140551 USPATFULL
TI 21163, a novel ***human*** prolyl oligopeptidase and uses therefor
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003096392 A1 20030522
AI US 2001-25950 A1 20011219 (10)
PRAI US 2000-257736P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 4648
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/006.000; 435/320.100; 435/325.000; 536/023.200

IC NCLS: 435/069.100; 435/006.000; 435/320.100; 435/325.000; 536/023.200
[7]
ICM: C12N009-64
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 391 USPATFULL on STN
AN 2003:140515 USPATFULL
TI Novel G-protein-coupled receptor like proteins and polynucleotides
encoded by them, and methods of using same
IN Ozenberger, Bradley A., Newtown, PA, UNITED STATES
Kajkowski, Eileen M., Ringoes, NJ, UNITED STATES
Lo, Ching-Hsiung Frederick, Pennington, NJ, UNITED STATES
Sofia, Heidi, Walla Walla, WA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2003096356 A1 20030522
AI US 2002-199881 A1 20020718 (10)
RLI Continuation of Ser. No. US 2001-833503, filed on 12 Apr 2001, PENDING
PRAI WO 1999-US21621 19991013
US 1998-104104P 19981013 (60)
DT Utility
FS APPLICATION
LN.CNT 1744
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 391 USPATFULL on STN
AN 2003:140406 USPATFULL
TI ***Human*** CDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25656
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 391 USPATFULL on STN
AN 2003:135733 USPATFULL
TI Transgenic animal model of neurodegenerative disorders
IN St. George-Hyslop, Peter H., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
Westaway, David, Etobicoke, CANADA
PI US 2003093822 A1 20030515
AI US 2001-884629 A1 20010619 (9)
PRAI US 2000-212534P 20000620 (60)
DT Utility
FS APPLICATION
LN.CNT 1380
INCL INCLM: 800/018.000
INCLS: 800/012.000
NCL NCLM: 800/018.000

IC [7]
ICM: A01K067-027

L4 ANSWER 128 OF 391 USPATFULL on STN
AN 2003:134658 USPATFULL
TI Aminediols for the treatment of Alzheimer's disease
IN Schostarez, Heinrich Josef, Portage, MI, UNITED STATES
Chrusciel, Robert Alan, Portage, MI, UNITED STATES
PI US 2003092747 A1 20030515
AI US 2002-171343 A1 20020613 (10)
PRAI US 2001-297827P 20010613 (60)
US 2001-333084P 20011119 (60)
DT Utility
FS APPLICATION
LN.CNT 4779
INCL INCLM: 514/357.000
INCLS: 514/428.000; 514/651.000; 514/620.000; 514/603.000; 514/522.000;
514/534.000; 546/329.000; 546/330.000; 548/561.000; 558/415.000;
560/037.000; 564/355.000; 564/086.000; 564/164.000
NCL NCLM: 514/357.000
NCLS: 514/428.000; 514/651.000; 514/620.000; 514/603.000; 514/522.000;
514/534.000; 546/329.000; 546/330.000; 548/561.000; 558/415.000;
560/037.000; 564/355.000; 564/086.000; 564/164.000

IC [7]
ICM: A61K031-44
ICS: A61K031-40; A61K031-277; A61K031-165; A61K031-137; A61K031-24;
A61K031-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 391 USPATFULL on STN
AN 2003:134570 USPATFULL
TI Antisense compounds which prevent cell death and uses thereof
IN Troy, Carol M., Hastings-on-Hudson, NY, UNITED STATES
Shelanski, Michael L., Brooklyn, NY, UNITED STATES
PI US 2003092659 A1 20030515
AI US 2002-185084 A1 20020628 (10)
RLI Continuation of ser. No. US 1999-397711, filed on 3 Sep 1999, PENDING
Continuation of ser. No. WO 1998-US4128, filed on 3 Mar 1998, PENDING
Continuation-in-part of Ser. No. US 1997-810540, filed on 3 Mar 1997,
GRANTED, Pat. No. US 5929042

DT Utility
FS APPLICATION
LN.CNT 1113
INCL INCLM: 514/044.000
INCLS: 514/014.000; 536/023.100; 530/326.000
NCL NCLM: 514/044.000
NCLS: 514/014.000; 536/023.100; 530/326.000
IC [7]
ICM: A61K048-00
ICS: A61K038-10; C07H021-04; C07K007-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 391 USPATFULL on STN
AN 2003:134541 USPATFULL
TI Inhibitors of memapsin 2 and use thereof
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Ghosh, Arun K., River Forest, IL, UNITED STATES
PA Oklahoma Medical Research Foundation, Oklahoma City, OK (U.S.
corporation)
PI US 2003092629 A1 20030515
AI US 2001-32818 A1 20011228 (10)
PRAI US 2001-275756P 20010314 (60)
US 2000-258705P 20001228 (60)

DT Utility
FS APPLICATION
LN.CNT 2203
INCL INCLM: 514/013.000
INCLS: 530/326.000
NCL NCLM: 514/013.000
NCLS: 530/326.000
IC [7]
ICM: A61K038-10
ICS: C07K007-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 131 OF 391 USPATFULL on STN
AN 2003:134526 USPATFULL
TI ADPI-41, a novel protein isolated from brain tissue homogenate and uses
therefor
IN Herath, Herath Mudiyanselage Athula Chandrasiri, Abingdon, UNITED
KINGDOM
Parekh, Rajesh Bhikhu, Near Wendlebury, UNITED KINGDOM
Rohlf, Christian, Oxford, UNITED KINGDOM
Terrett, Jonathan Alexander, Abingdon, UNITED KINGDOM
Tyson, Kerry Louise, Caversham, UNITED KINGDOM
PI US 2003092614 A1 20030515
AI US 2001-14338 A1 20011210 (10)
PRAI US 2000-254431P 20001208 (60)
DT Utility
FS APPLICATION
LN.CNT 4183
INCL INCLM: 514/012.000
INCLS: 530/350.000; 435/069.700; 435/325.000; 435/320.100; 536/023.500
NCL NCLM: 514/012.000
NCLS: 530/350.000; 435/069.700; 435/325.000; 435/320.100; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; A61K038-17; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 391 USPATFULL on STN
AN 2003:133985 USPATFULL
TI Genetic construct intracellular monitoring system
IN Zhao, Sharon, Union City, CA, UNITED STATES
Vainshtein, Inna, Palo Alto, CA, UNITED STATES
Eglen, Richard, Los Altos, CA, UNITED STATES
PI US 2003092070 A1 20030515
AI US 2002-229747 A1 20020827 (10)
PRAI US 2001-316428P 20010830 (60)
US 2001-343156P 20011021 (60)
US 2002-353086P 20020130 (60)
DT Utility
FS APPLICATION
LN.CNT 1578
INCL INCLM: 435/007.200
INCLS: 435/200.000; 435/207.000
NCL NCLM: 435/007.200
NCLS: 435/200.000; 435/207.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N009-24; C12N009-38
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 391 USPATFULL on STN
AN 2003:133926 USPATFULL
TI ***Human*** cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25607
INCL INCLM: 435/006.000
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;
435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;
435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02;
C12N005-06

L4 ANSWER 134 OF 391 USPATFULL on STN
AN 2003:127194 USPATFULL
TI Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
IN Soto-Jara, Claudio, New York, NY, UNITED STATES
Baumann, Marc H., Helsinki, FINLAND
Frangione, Blas, New York, NY, UNITED STATES
PA New York University, New York, NY (U.S. corporation)
PI US 2003087407 A1 20030508
AI US 2002-235483 A1 20020906 (10)
RLI Continuation of Ser. No. US 1996-766596, filed on 12 Dec 1996, GRANTED, Pat. No. US 6462171 Continuation-in-part of Ser. No. US 1996-630645, filed on 10 Apr 1996, GRANTED, Pat. No. US 5948763 Continuation-in-part of Ser. No. US 1995-478326, filed on 7 Jun 1995, ABANDONED

DT Utility
FS APPLICATION

LN.CNT 1973

INCL INCLM: 435/184.000

INCL INCLS: 435/069.200; 435/320.100; 435/325.000

NCL NCLM: 435/184.000

NCL NCLS: 435/069.200; 435/320.100; 435/325.000

IC [7]

ICM: C12N009-99

ICS: C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 391 USPATFULL on STN
AN 2003:121034 USPATFULL
TI Substituted alcohols useful in treatment of Alzheimer's disease

IN John, Varghese, San Francisco, CA, UNITED STATES

Hom, Roy, San Francisco, CA, UNITED STATES

Tucker, John, San Mateo, CA, UNITED STATES

PI US 2003083518 A1 20030501

AI US 2002-183126 A1 20020627 (10)

PRAI US 2001-301210P 20010627 (60)

US 2001-323396P 20010918 (60)

US 2001-332736P 20011119 (60)

DT Utility

FS APPLICATION

LN.CNT 3285

INCL INCLM: 558/390.000

INCL INCLS: 560/037.000; 564/355.000

NCL NCLM: 558/390.000

NCL NCLS: 560/037.000; 564/355.000

IC [7]

ICM: C07C255-58

ICS: C07C317-26; C07C229-52; C07C215-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 391 USPATFULL on STN

AN 2003:120872 USPATFULL

TI Statine derivatives for the treatment of Alzheimer's disease

IN Schostarez, Heinrich Josef, Portage, MI, UNITED STATES

Chrusciel, Robert Alan, Portage, MI, UNITED STATES

PI US 2003083356 A1 20030501

AI US 2002-192424 A1 20020710 (10)

PRAI US 2001-304128P 20010710 (60)

US 2001-327424P 20011005 (60)

DT Utility

FS APPLICATION

LN.CNT 4084

INCL INCLM: 514/357.000

INCL INCLS: 514/428.000; 514/620.000; 514/626.000; 546/336.000; 548/567.000;
564/164.000; 564/193.000

NCL NCLM: 514/357.000

NCL NCLS: 514/428.000; 514/620.000; 514/626.000; 546/336.000; 548/567.000;
564/164.000; 564/193.000

IC [7]

ICM: A61K031-44

ICS: A61K031-40; A61K031-165; A61K031-16; C07D207-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 391 USPATFULL on STN

AN 2003:120860 USPATFULL

TI Diaminediols for the treatment of Alzheimer's disease
IN Schostarez, Heinrich Josef, Portage, MI, UNITED STATES
Chrusciel, Robert A., Portage, MI, UNITED STATES
PI US 2003083353 A1 20030501
AI US 2002-192625 A1 20020710 (10)
PRAI US 2001-304305P 20010710 (60)
US 2001-334480P 20011130 (60)
DT Utility
FS APPLICATION
LN.CNT 4041
INCL INCLM: 514/349.000
INCLS: 514/426.000; 514/485.000; 514/519.000; 514/567.000; 514/669.000;
514/646.000; 548/557.000; 546/304.000; 558/453.000; 560/024.000;
560/157.000; 564/506.000
NCL NCLM: 514/349.000
NCLS: 514/426.000; 514/485.000; 514/519.000; 514/567.000; 514/669.000;
514/646.000; 548/557.000; 546/304.000; 558/453.000; 560/024.000;
560/157.000; 564/506.000
IC [7]
ICM: C07D213-72
ICS: A61K031-44; A61K031-275; A61K031-325; A61K031-13; A61K031-135;
A61K031-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 391 USPATFULL on STN
AN 2003:120793 USPATFULL
TI Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's
disease in patients
IN Hersh, Louis B., Lexington, KY, UNITED STATES
PI US 2003083277 A1 20030501
AI US 2001-792079 A1 20010226 (9)
PRAI US 2000-184826P 20000224 (60)
DT Utility
FS APPLICATION
LN.CNT 1117
INCL INCLM: 514/044.000
INCLS: 424/094.630; 424/093.210
NCL NCLM: 514/044.000
NCLS: 424/094.630; 424/093.210
IC [7]
ICM: A61K048-00
ICS: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 391 USPATFULL on STN
AN 2003:120290 USPATFULL
TI Nucleic acids encoding ***human*** adamalysin SVPH1-8
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES
PA Immunex Corporation (U.S. corporation)
PI US 2003082771 A1 20030501
AI US 2002-265125 A1 20021003 (10)
RLI Division of Ser. No. US 2000-617145, filed on 14 Jul 2000, GRANTED, Pat.
No. US 6485956 Continuation of Ser. No. WO 1999-US603, filed on 12 Jan
1999, PENDING
PRAI US 1998-71505P 19980114 (60)
DT Utility
FS APPLICATION
LN.CNT 2031
INCL INCLM: 435/189.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/189.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-02; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 140 OF 391 USPATFULL on STN
AN 2003:120089 USPATFULL
TI High-throughput transcriptome and functional validation analysis
IN Melcher, Thorsten, San Francisco, CA, UNITED STATES
McFarland, K. C., Davis, CA, UNITED STATES
Gan, Li, San Francisco, CA, UNITED STATES
Ye, Shiming, Albany, CA, UNITED STATES
Gonzalez-Zulueta, Mirella, Pacifica, CA, UNITED STATES
PT US 2003082570 A1 20030501

AI US 2002-116437 A1 20020403 (10)
RLI Continuation-in-part of Ser. No. US 2001-27807, filed on 19 Oct 2001,
PENDING Continuation-in-part of Ser. No. US 2000-627362, filed on 28 Jul
2000, ABANDONED
PRAI US 1999-146640P 19990730 (60)
DT Utility
FS APPLICATION
LN.CNT 3093
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 391 USPATFULL on STN
AN 2003:120071 USPATFULL
TI Novel nucleic acid sequences encoding ***human*** cell adhesion
molecule protein-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, 06511
PI US 2003082554 A1 20030501
AI US 2001-977033 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)

DT Utility
FS APPLICATION
LN.CNT 7063
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-435
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 391 USPATFULL on STN
AN 2003:113499 USPATFULL
TI Phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs
as beta-secretase inhibitors
IN Etcheberrigaray, Rene, Columbia, MD, UNITED STATES
Qiao, Lixin, Arlington, VA, UNITED STATES
PA Neurologic, Inc. (U.S. corporation)
PI US 2003078240 A1 20030424
AI US 2002-274523 A1 20021021 (10)
RLI Division of Ser. No. US 2001-866764, filed on 30 May 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 776
INCL INCLM: 514/114.000
INCLS: 514/120.000; 562/011.000; 562/015.000; 562/024.000
NCL NCLM: 514/114.000
NCLS: 514/120.000; 562/011.000; 562/015.000; 562/024.000
IC [7]
ICM: A61K031-66
ICS: A61K031-663; C07F009-22; C07F009-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 391 USPATFULL on STN
AN 2003:113462 USPATFULL
TI Covalently reactive transition state analogs and methods of use thereof
IN Paul, Sudhir, Missouri City, TX, UNITED STATES
Nishiyama, Yasuhiro, Houston, TX, UNITED STATES
PI US 2003078203 A1 20030424
AI US 2002-114716 A1 20020401 (10)
RLI Continuation-in-part of Ser. No. US 2001-27807, filed on 19 Oct 2001, PENDING

PRAI PENDING Division of Ser. No. US 1998-46373, filed on 23 Mar 1998,
GRANTED, Pat. No. US 6235714
US 2001-280624P 20010331 (60)
DT Utility
FS APPLICATION
LN.CNT 2260
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/351.000; 424/085.100; 424/085.200; 424/189.100;
424/190.100
NCL NCLM: 514/012.000
NCLS: 530/350.000; 530/351.000; 424/085.100; 424/085.200; 424/189.100;
424/190.100
IC [7]
ICM: A61K039-29
ICS: A61K039-02; A61K038-20; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 391 USPATFULL on STN
AN 2003:112961 USPATFULL
TI DEATH DOMAIN CONTAINING RECEPTORS
IN YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
NI, JIAN, ROCKVILLE, MD, UNITED STATES
DIXIT, VISHVA, ANN ARBOR, MI, UNITED STATES
GENTZ, REINER L., SILVER SPRING, MD, UNITED STATES
DILLON, PATRICK J., GAITHERSBURG, MD, UNITED STATES
PI US 2003077694 A1 20030424
AI US 1999-314889 A1 19990519 (9)
RLI Continuation of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED,
Pat. No. US 6153402
PRAI US 1996-13285P 19960312 (60)
US 1996-28711P 19961017 (60)
US 1997-37341P 19970206 (60)
DT Utility
FS APPLICATION
LN.CNT 3011
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/320.100; 530/324.000; 530/387.900; 514/002.000
NCL NCLM: 435/069.100
NCLS: 536/023.500; 435/320.100; 530/324.000; 530/387.900; 514/002.000
IC [7]
ICM: A01N037-18
ICS: A61K038-00; C07H021-04; C12P021-06; C12N015-00; C12N015-09;
C12N015-63; C12N015-70; C12N015-74; C07K005-00; C07K007-00; C07K016-00;
C07K017-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 391 USPATFULL on STN
AN 2003:112496 USPATFULL
TI Alzheimer's disease, secretase, app substrates therefor, and uses
therefor
IN Gurney, Mark E, Gran Rapids, MI, UNITED STATES
Bienkowski, Michael J, Kalamazoo, MI, UNITED STATES
Heinrikson, Robert L, Plainwell, MI, UNITED STATES
Parodi, Luis A, Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
PI US 2003077226 A1 20030424
AI US 2001-869414 A1 20010627 (9)
WO 2001-IB797 20010509
DT Utility
FS APPLICATION
LN.CNT 5976
INCL INCLM: 424/009.600
INCLS: 530/350.000; 435/366.000; 435/069.100; 435/320.100
NCL NCLM: 424/009.600
NCLS: 530/350.000; 435/366.000; 435/069.100; 435/320.100
IC [7]
ICM: A61K049-00
ICS: C12N005-08; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 391 USPATFULL on STN
AN 2003:106932 USPATFULL
TI Sulfonyl aryl hydroxamates and their use as matrix metalloprotease
inhibitors
IN Barta, Thomas E., Evanston, IL, UNITED STATES

Bedell, Louis J., Prospect Heights, IL, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
Freskos, John N., Clayton, MO, UNITED STATES
Getman, Daniel P., Chesterfield, MO, UNITED STATES
McDonald, Joseph J., Wildwood, MO, UNITED STATES
Mischke, Brent V., Defiance, MO, UNITED STATES
Rao, Shashidhar N., Saint Louis, MO, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
PI US 2003073845 A1 20030417
AI US 2001-909227 A1 20010719 (9)
RLI Continuation-in-part of Ser. No. US 2000-569034, filed on 11 May 2000,
PENDING Continuation-in-part of Ser. No. US 1999-310813, filed on 12 May
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-230209, filed
on 24 Jun 1999, GRANTED, Pat. No. US 6380258 A 371 of International Ser.
No. WO 1998-US4300, filed on 4 Mar 1998, UNKNOWN Continuation-in-part of
Ser. No. US 2000-728408, filed on 1 Dec 2000, PENDING Continuation of
Ser. No. US 1999-310813, filed on 12 May 1999, ABANDONED

PRAI US 1997-35182P 19970304 (60)

DT Utility

FS APPLICATION

LN.CNT 5507

INCL INCLM: 546/216.000

INCLS: 546/223.000; 534/751.000

NCL NCLM: 546/216.000

NCLS: 546/223.000; 534/751.000

IC [7]

ICM: C07D211-54

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 391 USPATFULL on STN

AN 2003:106806 USPATFULL

TI Aromatic sulfone hydroxamic acids and their use as protease inhibitors

IN Barta, Thomas E., Evanston, IL, UNITED STATES

Becker, Daniel P., Glenview, IL, UNITED STATES

Bedell, Louis J., Mt.Prospect, IL, UNITED STATES

Boehm, Terri L., Ballwin, MO, UNITED STATES

Carroll, Jeffery N., Columbia, IL, UNITED STATES

DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES

Fobian, Yvette M., Wildwood, MO, UNITED STATES

Freskos, John N., Clayton, MO, UNITED STATES

Getman, Daniel P., Chesterfield, MO, UNITED STATES

McDonald, Joseph J., Wildwood, MO, UNITED STATES

Li, Madeleine H., Vernon Hills, MO, UNITED STATES

Hockerman, Susan L., Chicago, IL, UNITED STATES

Howard, Carol Pearcy, Fenton, MO, UNITED STATES

Kolodziej, Steve A., Ballwin, MO, UNITED STATES

Mischke, Deborah A., Defiance, MO, UNITED STATES

Rico, Joseph G., Ballwin, MO, UNITED STATES

Stehle, Nathan W., Grafton, WI, UNITED STATES

Tollefson, Michael B., Hainesville, IL, UNITED STATES

Vernier, William F., St.Louis, MO, UNITED STATES

Villamil, Clara I., Glenview, IL, UNITED STATES

Kassab, Darren J., Wildwood, MO, UNITED STATES

PI US 2003073718 A1 20030417

AI US 2001-989943 A1 20011121 (9)

RLI Continuation-in-part of Ser. No. US 2000-570731, filed on 12 May 2000,

PENDING

DT Utility

FS APPLICATION

LN.CNT 4996

INCL INCLM: 514/316.000

INCLS: 514/317.000; 514/326.000; 546/189.000; 546/207.000

NCL NCLM: 514/316.000

NCLS: 514/317.000; 514/326.000; 546/189.000; 546/207.000

IC [7]

ICM: A61K031-4545

ICS: C07D047-02; C07D041-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 391 USPATFULL on STN

AN 2003:106789 USPATFULL

TI Succinoylamino heterocycles as inhibitors of a beta protein production

IN Thompson, Lorin A., Wilmington, DE, UNITED STATES

Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES

PI US 2003073701 A1 20030417

DT Utility
FS APPLICATION
LN.CNT 3957
INCL INCLM: 514/255.010
INCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;
514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000;
544/333.000; 546/208.000
NCL NCLM: 514/255.010
NCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;
514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000;
544/333.000; 546/208.000
IC [7]
ICM: A61K031-496
ICS: A61K031-506; A61K031-4545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 391 USPATFULL on STN
AN 2003:106698 USPATFULL
TI Yeast screens for treatment of ***human*** disease
IN Lindquist, Susan, Chestnut Hill, MA, UNITED STATES
Krobitsch, Sylvia, Berlin, GERMANY, FEDERAL REPUBLIC OF
Outeiro, Tiago Fleming, Cambridge, MA, UNITED STATES
PA The University of Chicago (U.S. corporation)
PI US 2003073610 A1 20030417
AI US 2002-77584 A1 20020215 (10)
PRAI US 2001-269157P 20010215 (60)
DT Utility
FS APPLICATION
LN.CNT 3198
INCL INCLM: 514/001.000
INCLS: 435/007.310; 435/254.200; 435/483.000
NCL NCLM: 514/001.000
NCLS: 435/007.310; 435/254.200; 435/483.000
IC [7]
ICM: A61K031-00
ICS: G01N033-53; G01N033-569; C12N001-18; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 391 USPATFULL on STN
AN 2003:106163 USPATFULL
TI DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF AB ABNORMALITIES
IN TANZI, RUDOLPH E., CANTON, MA, UNITED STATES
BUSH, ASHLEY I., SOMERVILLE, MA, UNITED STATES
MOIR, ROBERT D., BOSTON, MA, UNITED STATES
PI US 2003073074 A1 20030417
AI US 1999-425956 A1 19991025 (9)
RLI Continuation of Ser. No. US 1997-817423, filed on 4 Aug 1997, GRANTED,
Pat. No. US 5972634 A 371 of International Ser. No. WO 1994-US11895,
filed on 19 Oct 1994, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 2343
INCL INCLM: 435/006.000
INCLS: 435/287.200; 435/007.900
NCL NCLM: 435/006.000
NCLS: 435/287.200; 435/007.900
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 391 USPATFULL on STN
AN 2003:105883 USPATFULL
TI Encapsulation of plasmid DNA (lipogenes.TM.) and therapeutic agents with
nuclear localization signal/fusogenic peptide conjugates into targeted
liposome complexes
IN Boulikas, Teni, Mountain View, CA, UNITED STATES
PI US 2003072794 A1 20030417
AI US 2001-876904 A1 20010608 (9)
PRAI US 2000-210925P 20000609 (60)
DT Utility
FS APPLICATION
LN.CNT 4201
INCL INCLM: 424/450.000
INCLS: 435/458.000; 435/320.100; 514/044.000; 264/004.000
NCL NCLM: 424/450.000

IC NCLS: 435/458.000; 435/320.100; 514/044.000; 264/004.000
[7]
ICM: A61K048-00
ICS: A61K009-127; C12N015-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 152 OF 391 USPATFULL on STN
AN 2003:102440 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Zhang, Shuguang, Cambridge, MA, United States
Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States
Holmes, Todd, Cambridge, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6548630 B1 20030415
AI US 1997-898300 19970722 (8)
RLI Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994, now patented, Pat. No. US 5670483 Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 2187
INCL INCLM: 530/300.000
INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000;
514/012.000; 514/013.000; 514/014.000
NCL NCLM: 530/300.000
NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
IC [7]
ICM: C07K007-00
ICS: C07K016-00; A61K038-00
EXF 514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 391 USPATFULL on STN
AN 2003:102126 USPATFULL
TI Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
IN Cuthbertson, Alan, Oslo, NORWAY
Solbakken, Magne, Oslo, NORWAY
Wolfe, Henry Raphael, Glenmoore, PA, United States
PA Amersham Health AS, Oslo, NORWAY (non-U.S. corporation)
PI US 6548048 B1 20030415
AI US 2000-695273 20001025 (9)
RLI Continuation of Ser. No. WO 1999-GB1247, filed on 22 Apr 1999
PRAI GB 1998-9084 19980428
US 1998-84833P 19980508 (60)
DT Utility
FS GRANTED
LN.CNT 1281
INCL INCLM: 424/009.520
INCLS: 424/009.510; 424/450.000; 424/489.000; 424/499.000
NCL NCLM: 424/009.520
NCLS: 424/009.510; 424/450.000; 424/489.000; 424/499.000
IC [7]
ICM: A61B008-00
ICS: A61K009-127; A61K009-14
EXF 424/9.51; 424/9.52; 424/9.5; 424/450; 424/489; 424/499; 600/441; 600/458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 391 USPATFULL on STN
AN 2003:100334 USPATFULL
TI Biological reagents and methods for determining the mechanism in the generation of ***beta*** - ***amyloid*** peptide
IN Audia, James E., Indianapolis, IN, UNITED STATES
Hyslop, Paul A., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Tanner, Laura I., San Francisco, CA, UNITED STATES
PI US 2003069445 A1 20030410
AI US 2002-217459 A1 20020814 (10)
RLI Division of Ser. No. US 1999-408283, filed on 29 Sep 1999, GRANTED, Pat. No. US 6486350

DT Utility
FS APPLICATION
LN.CNT 2200
INCL INCLM: 564/059.000
INCLS: 530/333.000; 560/157.000; 564/152.000
NCL NCLM: 564/059.000
NCLS: 530/333.000; 560/157.000; 564/152.000
IC [7]
ICM: C07K007-00
ICS: C07C275-14; C07C271-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 155 OF 391 USPATFULL on STN
AN 2003:100060 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IN Soltoro, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Li Li, Bovet, Chapel Hill, NC, UNITED STATES
PI US 2003069170 A1 20030410
AI US 2002-235284 A1 20020905 (10)
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LN.CNT 3615
INCL INCLM: 514/002.000
INCLS: 514/012.000; 514/171.000; 514/560.000
NCL NCLM: 514/002.000
NCLS: 514/012.000; 514/171.000; 514/560.000
IC [7]
ICM: A61K038-23
ICS: A61K031-56; A61K031-202; A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 156 OF 391 USPATFULL on STN
AN 2003:99221 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of Alzheimers Disease
IN Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
PI US 2003068325 A1 20030410
AI US 2001-865294 A1 20010525 (9)
DT Utility
FS APPLICATION
LN.CNT 2076
INCL INCLM: 424/185.100
INCLS: 435/226.000
NCL NCLM: 424/185.100
NCLS: 435/226.000
IC [7]
ICM: A61K039-00
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 157 OF 391 USPATFULL on STN
AN 2003:99212 USPATFULL
TI Anti-ADDL ***antibodies*** and uses thereof
IN Klein, William L., Winnetka, IL, UNITED STATES
Krafft, Grant A., Glenview, IL, UNITED STATES
Lambert, Mary P., Glenview, IL, UNITED STATES
Viola, Kirsten L., Chicago, IL, UNITED STATES
Chromy, Brett A., Pleasanton, CA, UNITED STATES
Gong, Yue Song, Evanston, IL, UNITED STATES
Chang, Lei, Evanston, IL, UNITED STATES
Morgan, Todd E., Los Angeles, CA, UNITED STATES
Rozofsky, Irina, Pasadena, CA, UNITED STATES
Finch, Caleb E., Altadena, CA, UNITED STATES
PI US 2003068316 A1 20030410
AI US 2002-166856 A1 20020611 (10)
RLI Continuation-in-part of Ser. No. US 1999-369236, filed on 4 Aug 1999,
PENDING Continuation-in-part of Ser. No. US 1997-796089, filed on 5 Feb
1997, GRANTED, Pat. No. US 6218506

DT Utility
FS APPLICATION
LN.CNT 2982
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 158 OF 391 USPATFULL on STN
AN 2003:96167 USPATFULL
TI Catalytically active recombinant memapsin and methods of use thereof
IN Tang, Jordan J. N., Edmond, OK, United States
Lin, Xinli, Edmond, OK, United States
Koelsch, Gerald, Oklahoma City, OK, United States
Hong, Lin, Oklahoma City, OK, United States
PA Oklahoma Medical Research Foundation, Oklahoma City, OK, United States
(U.S. corporation)
PI US 6545127 B1 20030408
AI US 2000-604608 20000627 (9)
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)

DT Utility
FS GRANTED
LN.CNT 2563
INCL INCLM: 530/350.000
INCLS: 702/019.000; 530/300.000; 536/023.100
NCL NCLM: 530/350.000
NCLS: 530/300.000; 536/023.100; 702/019.000
IC [7]
ICM: G01N033-48
ICS: G01N031-00; G06F019-00; A16K038-00; C07K001-00; C07K014-00;
C07K017-00; C07M021-02; C07M021-04
EXF 435/212; 435/183; 435/7.1; 435/226; 435/15; 530/300; 536/350; 536/23.1;
702/19; 702/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 159 OF 391 USPATFULL on STN
AN 2003:94733 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the
treatment or prevention of Alzheimer's Disease
IN Monte, Suzanne De La, East Greenwich, RI, UNITED STATES
Wands, Jack R., Waban, MA, UNITED STATES
PI US 2003066097 A1 20030403
AI US 2001-964678 A1 20010928 (9)
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371
of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2091
INCL INCLM: 800/012.000
INCLS: 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 800/012.000
NCLS: 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: A01K067-027
ICS: C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 391 USPATFULL on STN
AN 2003:94089 USPATFULL
TI High throughput functional genomics
IN Hickman, James J., Falls Church, VA, UNITED STATES
PI US 2003065452 A1 20030403
AI US 2002-286761 A1 20021104 (10)
RLI Division of Ser. No. US 2000-575377, filed on 22 May 2000, PENDING
PRAI US 1999-135275P 19990521 (60)
DT Utility
FS APPLICATION
LN.CNT 2780
INCL INCLM: 702/019.000
INCLS: 435/325.000; 435/320.100; 536/023.200

NCL NCLM: 702/019.000
NCLS: 435/007.210
IC [7]
ICM: G01N033-567
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 391 USPATFULL on STN
AN 2003:93790 USPATFULL
TI Secreted protein HCEJQ69
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Young, Paul, Gaithersburg, MD, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Mucenski, Michael, Cincinnati, OH, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2003065151 A1 20030403
AI US 2002-115123 A1 20020404 (10)
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING
Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999,
UNKNOWN

PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)

DT Utility
FS APPLICATION
LN.CNT 18779
INCL INCLM: 530/388.260
NCL NCLM: 530/388.260
IC [7]
ICM: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 162 OF 391 USPATFULL on STN
AN 2003:93780 USPATFULL
TI Mutant presenilin 1 and presenilin 2 polypeptides
IN Carter, Donald Bainbridge, Kalamazoo, MI, UNITED STATES
Tomasselli, Alfredo Giuseppe, Kalamazoo, MI, UNITED STATES
PI US 2003065141 A1 20030403
AI US 2001-896621 A1 20010629 (9)
PRAI US 2000-215345P 20000630 (60)

DT Utility
FS APPLICATION
LN.CNT 2497
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/007.200
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/007.200
IC [7]
ICM: C07K014-435
ICS: G01N033-53; G01N033-567; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 391 USPATFULL on STN
AN 2003:93067 USPATFULL
TI Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
IN Poole, Jason, Chicago, IL, UNITED STATES
Chang, Bey-Dih, Lombard, IL, UNITED STATES

PI US 2003064426 A1 20030403
AI US 2001-861925 A1 20010521 (9)
PRAI US 2001-265840P 20010201 (60)
DT Utility
FS APPLICATION
LN.CNT 3443
INCL INCLM: 435/008.000
INCLS: 435/184.000; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 435/008.000
NCLS: 435/184.000; 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C12Q001-66
ICS: C12N009-99; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 391 USPATFULL on STN
AN 2003:93057 USPATFULL
TI Process for differential diagnosis of Alzheimer's dementia in patients exhibiting mild cognitive impairment
IN Jackowski, George, Kettleby, CANADA
Takahashi, Miyoko, North York, CANADA
PI US 2003064416 A1 20030403
AI US 2002-246383 A1 20020917 (10)
RLI Continuation-in-part of Ser. No. US 2001-971740, filed on 4 Oct 2001, PENDING Continuation of Ser. No. US 2001-842079, filed on 25 Apr 2001, GRANTED, Pat. No. US 6451547
DT Utility
FS APPLICATION
LN.CNT 888
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]
ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 391 USPATFULL on STN
AN 2003:89258 USPATFULL
TI Nucleic acid encoding PTH1R receptor
IN Juppner, Harald, Cambridge, MA, United States
Rubin, David A., Needham, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6541220 B1 20030401
AI US 1999-449632 19991130 (9)
PRAI US 1998-110467P 19981130 (60)
DT Utility
FS GRANTED
LN.CNT 2932
INCL INCLM: 435/069.100
INCLS: 536/023.500; 536/024.300; 536/024.310; 530/350.000; 435/071.100; 435/071.200; 435/471.000; 435/325.000; 435/320.100; 435/252.300; 435/254.110
NCL NCLM: 435/069.100
NCLS: 435/071.100; 435/071.200; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/471.000; 530/350.000; 536/023.500; 536/024.300; 536/024.310
IC [7]
ICM: C12N015-12
ICS: C12N015-63; C12N005-10; C07K014-705
EXF 536/23.1; 536/23.5; 536/24.3; 536/24.31; 530/350; 435/69.1; 435/71.1; 435/71.2; 435/471; 435/325; 435/252.3; 435/254.11; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 391 USPATFULL on STN
AN 2003:89115 USPATFULL
TI Methods for using elk-L to enhance neuronal survival
IN Lyman, Stewart, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
Carpenter, Melissa K., Issaquah, WA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6540992 B1 20030401
AI US 1998-39642 19980316 (9)
RLI Division of Ser. No. US 1996-747240, filed on 12 Nov 1996, now patented,

1995, now patented, Pat. No. US 5670625 Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented, Pat. No. US 5512457 Continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992, now abandoned

DT Utility
FS GRANTED
LN.CNT 1752
INCL INCLM: 424/085.100
INCLS: 424/130.100; 424/134.100; 424/184.100; 424/185.100; 424/192.100;
530/350.000; 530/351.000; 530/387.100; 530/387.300
NCL NCLM: 424/085.100
NCLS: 424/130.100; 424/134.100; 424/184.100; 424/185.100; 424/192.100;
530/350.000; 530/351.000; 530/387.100; 530/387.300
IC [7]
ICM: A61K038-19
ICS: C07K014-52
EXF 530/387.3; 530/351; 530/350; 530/387.1; 424/85.1; 424/192.1; 424/134.1;
424/130.1; 424/184.1; 424/185.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 391 USPATFULL on STN
AN 2003:86317 USPATFULL
TI Polynucleotide encoding a novel ***human*** potassium channel
alpha-subunit, K+alphaM1, and variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003059923 A1 20030327
AI US 2001-999220 A1 20011101 (9)
PRAI US 2000-245383P 20001102 (60)
US 2000-257780P 20001221 (60)
US 2001-269854P 20010220 (60)
DT Utility
FS APPLICATION
LN.CNT 16037
INCL INCLM: 435/252.300
INCLS: 536/023.100
NCL NCLM: 435/252.300
NCLS: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04; C12N001-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 391 USPATFULL on STN
AN 2003:78523 USPATFULL
TI 90 ***human*** secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PI US 2003054443 A1 20030320
AI US 2001-969730 A1 20011004 (9)
RLI Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001,
PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999,
ABANDONED Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4
Aug 1998, UNKNOWN
PRAI US 2000-238291P 20001006 (60)
US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)

US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54809P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)
US 1997-56557P 19970819 (60)
US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 26693
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;
536/023.100; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;
536/023.100; 530/350.000
IC [7]
ICM: C12P021-02
ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435;
C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 391 USPATFULL on STN
AN 2003:72975 USPATFULL
TI Animal models for neurodegenerative disease
IN Greenfield, Susan Adele, Oxford, UNITED KINGDOM
Rawlins, John Nicholas Pepys, Oxford, UNITED KINGDOM
Deacon, Robert Michael John, Oxford, UNITED KINGDOM
PI US 2003051262 A1 20030313
AI US 2002-169343 A1 20020911 (10)
WO 2000-GB4991 20001222
PRAI GB 1999-30825 19991230
DT Utility
FS APPLICATION
LN.CNT 1016
INCL INCLM: 800/009.000
INCLS: 800/012.000; 800/018.000
NCL NCLM: 800/009.000
NCLS: 800/012.000; 800/018.000
IC [7]
ICM: A01K067-027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 391 USPATFULL on STN
AN 2003:72015 USPATFULL
TI Treatment of conditions associated with amyloid processing using PKC
activators
IN Etcheberrigaray, Rene, Columbia, MD, UNITED STATES
Qiao, Lixin, Arlington, VA, UNITED STATES
Kozikowski, Alan P., Princeton, NJ, UNITED STATES
PA Neurologic, Inc. (U.S. corporation)
PI US 2003050302 A1 20030313
AI US 2002-254916 A1 20020926 (10)
RLI Division of Ser. No. US 2000-652656, filed on 31 Aug 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 933
INCL INCLM: 514/212.070
NCL NCLM: 514/212.070
IC [7]
ICM: A61K031-55

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:71403 USPATFULL
TI Protein fragment complementation assays for the detection of biological
or drug interactions
IN Michnick, Stephen William Watson, Westmount, CANADA
Pelletier, Joelle Nina, Westmount, CANADA
Remy, Ingrid, Montreal, CANADA
PA Odyssey Pharmaceuticals, Inc., San Ramon, CA (non-U.S. corporation)
PI US 2003049688 A1 20030313
AI US 2002-154758 A1 20020524 (10)
RLI Continuation of Ser. No. US 2000-499464, filed on 7 Feb 2000, GRANTED,
Pat. No. US 6428951 Continuation of Ser. No. US 1998-17412, filed on 2
Feb 1998, GRANTED, Pat. No. US 6270964
PRAI CA 1997-2196496 19970131
DT Utility
FS APPLICATION
LN.CNT 2757
INCL INCLM: 435/007.100
INCLS: 435/007.900; 702/019.000
NCL NCLM: 435/007.100
NCLS: 435/007.900; 702/019.000
IC [7]
ICM: G01N033-53
ICS: G01N033-542; G06F019-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 391 USPATFULL on STN
AN 2003:70968 USPATFULL
TI Polymeric conjugates for delivery of MHC-recognized epitopes via peptide
vaccines
IN Li, Frank Q., Montgomery Village, MD, UNITED STATES
Chu, Yong-Liang, Rockville, MD, UNITED STATES
Qiu, Jian-Tai, Rockville, MD, UNITED STATES
PI US 2003049253 A1 20030313
AI US 2002-62710 A1 20020205 (10)
PRAI US 2001-310498P 20010808 (60)
DT Utility
FS APPLICATION
LN.CNT 1790
INCL INCLM: 424/144.100
INCLS: 424/178.100
NCL NCLM: 424/144.100
NCLS: 424/178.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 173 OF 391 USPATFULL on STN
AN 2003:67840 USPATFULL
TI Genetic sequences related to Alzheimer's Disease
IN St. George-Hyslop, Peter H., Toronto, CANADA
Rommens, Johanna M., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA The Hospital for Sick Children, Toronto, CANADA (non-U.S. corporation)
HSC Research and Development Limited Partnership, Toronto, CANADA
(non-U.S. corporation)
The Governing Council of the University of Toronto, Toronto, CANADA
(non-U.S. corporation)
PI US 6531586 B1 20030311
AI US 1995-431048 19950428 (8)
DT Utility
FS GRANTED
LN.CNT 3650
INCL INCLM: 536/023.500
INCLS: 536/023.100; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 536/023.500
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: C12N015-11
ICS: C12N015-63; C12N015-85; C07H021-04
EXF 435/6; 435/69.1; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/375;
435/252.3; 435/254.11; 800/2; 800/DIG.1; 800/DIG.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 391 USPATFULL on STN
AN 2003:64775 USPATFULL

IN Courchesne, William E., Soda Springs, CA, UNITED STATES
Schooley, David A., Reno, NV, UNITED STATES
Copley, Kathrin, San Diego, CA, UNITED STATES
PI US 2003044896 A1 20030306
AI US 2001-7447 A1 20011105 (10)
RLI Continuation of Ser. No. US 2000-661452, filed on 13 Sep 2000, PENDING
Continuation of Ser. No. US 1999-237936, filed on 27 Jan 1999, ABANDONED
PRAI US 1998-72691P 19980127 (60)
DT Utility
FS APPLICATION
LN.CNT 1389
INCL INCLM: 435/069.100
INCLS: 435/226.000; 435/254.200
NCL NCLM: 435/069.100
NCLS: 435/226.000; 435/254.200
IC [7]
ICM: C12P021-02
ICS: C12N009-64; C12N001-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 391 USPATFULL on STN
AN 2003:64730 USPATFULL
TI Secreted protein HCEJQ69
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Mucenski, Michael, Cincinnati, OH, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Komatsoulis, George A., Silver Spring, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 2003044851 A1 20030306
US 6627741 B2 20030930
AI US 2001-12542 A1 20011212 (10)
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING
Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999, UNKNOWN

PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 18831
INCL INCLM: 435/007.200
INCLS: 530/387.100; 435/326.000
NCL NCLM: 530/389.200
NCLS: 530/387.100; 530/387.300; 530/387.700; 530/388.100; 530/388.150;
530/387.900; 530/389.200; 530/389.100
IC [7]
ICM: G01N033-53
ICS: C07K016-00; C12N005-16; C12N005-06; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 391 USPATFULL on STN
AN 2003:46308 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
Wands, Jack R., Waban, MA, UNITED STATES
PI US 2003033621 A1 20030213
AI US 2001-964667 A1 20010928 (9)
DT Utility
FS APPLICATION
LN.CNT 18831
INCL INCLM: 435/007.200
INCLS: 530/387.100; 435/326.000
NCL NCLM: 530/389.200
NCLS: 530/387.100; 530/387.300; 530/387.700; 530/388.100; 530/388.150;
530/387.900; 530/389.200; 530/389.100
IC [7]
ICM: G01N033-53
ICS: C07K016-00; C12N005-16; C12N005-06; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PRAI of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2088
INCL INCLM: 800/012.000
INCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
NCL NCLM: 800/012.000
NCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
IC [7]
ICM: A01K067-027
ICS: C07H021-04; C12N005-06; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 391 USPATFULL on STN
AN 2003:45292 USPATFULL
TI Smilagenin and its use
IN Xia, Zongqin, Shanghai, CHINA
Rubin, Ian, Leicester, UNITED KINGDOM
Whittle, Brian, East Yorkshire, UNITED KINGDOM
Gunning, Philip, Essex, UNITED KINGDOM
Hu, Yaer, Shanghai, CHINA
Brostoff, Jonathan, London, UNITED KINGDOM
Wang, Weijun, Cambridgeshire, UNITED KINGDOM
PI US 2003032604 A1 20030213
AI US 2002-228153 A1 20020826 (10)
RLI Continuation of Ser. No. US 2001-866234, filed on 25 May 2001, ABANDONED
Division of Ser. No. US 1999-362328, filed on 28 Jul 1999, GRANTED, Pat.
No. US 6258386
PRAI GB 1999-5275 19990308
DT Utility
FS APPLICATION
LN.CNT 682
INCL INCLM: 514/026.000
NCL NCLM: 514/026.000
IC [7]
ICM: A61K031-704
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 391 USPATFULL on STN
AN 2003:38351 USPATFULL
TI Novel genes encoding proteins having prognostic, diagnostic, preventive,
therapeutic, and other uses
IN Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
Barnes, Thomas M., Brookline, MA, UNITED STATES
PI US 2003027998 A1 20030206
AI US 2001-796753 A1 20010301 (9)
RLI Continuation-in-part of Ser. No. US 1998-183175, filed on 30 Oct 1998,
ABANDONED Continuation-in-part of Ser. No. US 2000-599596, filed on 22
Jun 2000, ABANDONED Division of Ser. No. US 1998-223546, filed on 30 Dec
1998, ABANDONED Division of Ser. No. US 1999-471179, filed on 23 Dec
1999, PENDING Continuation-in-part of Ser. No. US 1998-223546, filed on
30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474072,
filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US
1998-224246, filed on 30 Dec 1998, ABANDONED Continuation-in-part of
Ser. No. US 1999-474071, filed on 29 Dec 1999, ABANDONED
Continuation-in-part of Ser. No. US 1998-223094, filed on 30 Dec 1998,
ABANDONED Continuation-in-part of Ser. No. US 2000-514010, filed on 25
Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-259388,
filed on 26 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US
2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser.
No. US 2000-597993, filed on 19 Jun 2000, PENDING Continuation-in-part
of Ser. No. US 1999-336536, filed on 18 Jun 1999, PENDING
Continuation-in-part of Ser. No. US 2000-630334, filed on 31 Jul 2000,
PENDING Continuation-in-part of Ser. No. US 1999-365164, filed on 30 Jul
1999, ABANDONED Continuation-in-part of Ser. No. US 2000-665666, filed
on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-399723,
filed on 20 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US
2000-667751, filed on 21 Sep 2000, PENDING Continuation-in-part of Ser.
No. US 1999-409634, filed on 30 Sep 1999, ABANDONED Continuation-in-part
of Ser. No. US 2000-572002, filed on 15 May 2000, PENDING
Continuation-in-part of Ser. No. US 1999-312359, filed on 14 May 1999,
ABANDONED Continuation-in-part of Ser. No. US 2000-606565, filed on 29
Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-342687, filed
on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US
2000-606217, filed on 29 Jun 1999, PENDING

PRAI No. US 1999-345464, filed on 30 Jun 1999, ABANDONED
US 1999-122458P 19990301 (60)
DT Utility
FS APPLICATION
LN.CNT 22222
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 391 USPATFULL on STN
AN 2003:37643 USPATFULL
TI Methods of screening for agents that inhibit aggregation of polypeptides
IN Housman, David E., Newton, MA, UNITED STATES
Preisinger, Elizabeth A., Roslindale, MA, UNITED STATES
Kazantsev, Aleksey G., Boston, MA, UNITED STATES
PA Massachusetts Institute of Technology, a Massachusetts corporation (U.S. corporation)
PI US 2003027288 A1 20030206
AI US 2002-194584 A1 20020712 (10)
RLI Division of Ser. No. US 1999-405048, filed on 27 Sep 1999, GRANTED, Pat. No. US 6420122
DT Utility
FS APPLICATION
LN.CNT 1058
INCL INCLM: 435/091.100
INCLS: 435/091.330; 424/186.100; 424/208.100
NCL NCLM: 435/091.100
NCLS: 435/091.330; 424/186.100; 424/208.100
IC [7]
ICM: C12P019-34
ICS: A61K039-12; A61K039-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 391 USPATFULL on STN
AN 2003:37614 USPATFULL
TI Novel ABCG4 transporter and uses thereof
IN Chen, Hongyun, Vancouver, CANADA
Le Bihan, Stephane, Vancouver, CANADA
PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S. corporation)
PI US 2003027259 A1 20030206
AI US 2002-90455 A1 20020301 (10)
PRAI US 2001-272886P 20010302 (60)
US 2001-309262P 20010731 (60)
US 2001-316339P 20010829 (60)
DT Utility
FS APPLICATION
LN.CNT 4484
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/006.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/006.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 391 USPATFULL on STN
AN 2003:37603 USPATFULL
TI ***Human*** cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25650

INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
435/006.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
435/006.000
IC [7]
ICM: C12P021-02
ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 182 OF 391 USPATFULL on STN
AN 2003:37523 USPATFULL
TI High-throughput transcriptome and functional validation analysis
IN Gan, Li, San Francisco, CA, UNITED STATES
Gonzalez-Zulueta, Mirella, Pacifica, CA, UNITED STATES
Anton, Kristin, San Ramon, CA, UNITED STATES
Wilson, Richa, San Francisco, CA, UNITED STATES
Melcher, Thorsten, San Francisco, CA, UNITED STATES
Chin, Daniel, Foster City, CA, UNITED STATES
PA AGY Therapeutics, Inc., South San Francisco, CA, UNITED STATES, 94080
(U.S. corporation)
PI US 2003027168 A1 20030206
AI US 2001-27807 A1 20011019 (10)
RLI Continuation-in-part of Ser. No. US 2000-627362, filed on 28 Jul 2000,
PENDING
PRAI US 1999-146640P 19990730 (60)
DT Utility
FS APPLICATION
LN.CNT 2696
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 391 USPATFULL on STN
AN 2003:37516 USPATFULL
TI ***Human*** CDNAS and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
IN Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25529
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 391 USPATFULL on STN
AN 2003:37513 USPATFULL
TI Novel nucleic acid sequences encoding ***human*** breast
tumor-associated protein 47-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S.)

PI US 2003027158 A1 20030206
AI US 2001-977418 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 7101
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 391 USPATFULL on STN
AN 2003:32043 USPATFULL
TI TRANSGENIC C. ELEGANS AS A MODEL ORGANISM FOR INVESTIGATIONS ON
ALZHEIMER'S DISEASE
IN PERAUS, GISELA, MUNCHEN, GERMANY, FEDERAL REPUBLIC OF
HOPPE, EDMUND, KRAILING, GERMANY, FEDERAL REPUBLIC OF
BAUMEISTER, RALF, GROBENZELL, GERMANY, FEDERAL REPUBLIC OF
PI US 2003023997 A1 20030130
AI US 1999-422569 A1 19991021 (9)
PRAI DE 1998-19849073 19981024
DT Utility
FS APPLICATION
LN.CNT 841
INCL INCLM: 800/013.000
INCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100; 435/069.700;
435/455.000
NCL NCLM: 800/013.000
NCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100; 435/069.700;
435/455.000
IC [7]
ICM: A01K067-00
ICS: C07H021-04; C12P021-04; C12N015-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 186 OF 391 USPATFULL on STN
AN 2003:30408 USPATFULL
TI Vectors and methods for gene transfer
IN Wickham, Thomas J., Germantown, MD, UNITED STATES
Kovesdi, Imre, Rockville, MD, UNITED STATES
Brough, Douglas E., Gaithersburg, MD, UNITED STATES
PA GenVec, Inc., Gaithersburg, MD (U.S. corporation)
PI US 2003022355 A1 20030130
AI US 2001-999724 A1 20011024 (9)
RLI Continuation of Ser. No. US 1999-101751, filed on 29 Jan 1999, PENDING A
371 of International Ser. No. WO 1996-US19150, filed on 27 Nov 1996,
UNKNOWN Continuation-in-part of Ser. No. US 1995-563368, filed on 28 Nov
1995, PATENTED Continuation-in-part of Ser. No. US 1996-701124, filed on
21 Aug 1996, PATENTED Continuation-in-part of Ser. No. US 1996-700846,
filed on 21 Aug 1996, PATENTED Continuation-in-part of Ser. No. US
1996-634060, filed on 17 Apr 1996, PATENTED Continuation-in-part of Ser.
No. US 1994-303162, filed on 8 Sep 1994, PATENTED
DT Utility
FS APPLICATION
LN.CNT 3106
INCL INCLM: 435/235.100
INCLS: 435/456.000
NCL NCLM: 435/235.100
NCLS: 435/456.000
IC [7]
ICM: C12N015-861
ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 187 OF 391 USPATFULL on STN
AN 2003:30205 USPATFULL
TI

IN Thinakaran, Gopal, Chicago, IL, UNITED STATES
PI US 2003022151 A1 20030130
AI US 2002-51767 A1 20020117 (10)
PRAI US 2001-262353P 20010117 (60)
DT Utility
FS APPLICATION
LN.CNT 3900
INCL INCLM: 435/004.000
INCLS: 435/006.000; 435/007.200
NCL NCLM: 435/004.000
NCLS: 435/006.000; 435/007.200
IC [7]
ICM: C12Q001-00
ICS: C12Q001-68; G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 391 USPATFULL on STN
AN 2003:26157 USPATFULL
TI Therapy for ***human*** cancers using cisplatin and other drugs or genes encapsulated into liposomes
IN Boulikas, Teni, 249 Matadero Ave., Palo Alto, CA, United States 94306
PI US 6511676 B1 20030128
AI US 1999-434345 19991105 (9)
DT Utility
FS GRANTED
LN.CNT 1642
INCL INCLM: 424/450.000
INCLS: 264/004.100; 264/004.300
NCL NCLM: 424/450.000
NCLS: 264/004.100; 264/004.300
IC [7]
ICM: A61K009-127
EXF 424/450; 264/4.1; 264/4.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 391 USPATFULL on STN
AN 2003:18018 USPATFULL
TI Composition, synthesis and therapeutic applications of polyamines
IN Murphy, Michael A., La Jolla, CA, UNITED STATES
MaLachowski, Mitchell R., San Diego, CA, UNITED STATES
PI US 2003013772 A1 20030116
AI US 2001-17235 A1 20011218 (10)
RLI Continuation-in-part of Ser. No. US 2000-486310, filed on 23 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US17301, filed on 21 Aug 1998, UNKNOWN A 371 of International Ser. No. US 1997-915660, filed on 21 Aug 1997, GRANTED, Pat. No. US 5906996
DT Utility
FS APPLICATION
LN.CNT 3034
INCL INCLM: 514/674.000
INCLS: 564/512.000
NCL NCLM: 514/674.000
NCLS: 564/512.000
IC [7]
ICM: A61K031-13
ICS: C07C211-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 391 USPATFULL on STN
AN 2003:17384 USPATFULL
TI ***Human*** KCR1 regulation of HERG potassium channel block
IN Balser, Jeffrey R., Brentwood, TN, UNITED STATES
George, Alfred L., JR., Brentwood, TN, UNITED STATES
Roden, Dan M., Nashville, TN, UNITED STATES
PI US 2003013136 A1 20030116
AI US 2001-151 A1 20011030 (10)
PRAI US 2000-244340P 20001030 (60)
DT Utility
FS APPLICATION
LN.CNT 5075
INCL INCLM: 435/007.210
INCLS: 435/006.000; 435/455.000; 435/325.000
NCL NCLM: 435/007.210
NCLS: 435/006.000; 435/455.000; 435/325.000
IC [7]

ICS: C12Q001-68; C12P021-02; C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 191 OF 391 USPATFULL on STN
AN 2003:13325 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Audia, James E., Indianapolis, IN, United States
Droste, James, Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6506782 B1 20030114
AI US 1998-32019 19980227 (9)
DT Utility
FS GRANTED
LN.CNT 9870
INCL INCLM: 514/364.000
NCL NCLM: 514/364.000
IC [7]
ICM: A61K031-4245
EXF 514/364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 391 USPATFULL on STN
AN 2003:11397 USPATFULL
TI In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
IN Hyman, Bradley T., Charlestown, MA, UNITED STATES
Christie, Richard, New York, NY, UNITED STATES
Bacska, Brian, Charlestown, MA, UNITED STATES
Webb, Watt W., Ithaca, NY, UNITED STATES
Zipfel, Warren R., Ithaca, NY, UNITED STATES
PI US 2003009104 A1 20030109
AI US 2001-1643 A1 20011031 (10)
PRAI US 2000-245306P 20001102 (60)
DT Utility
FS APPLICATION
LN.CNT 1919
INCL INCLM: 600/476.000
NCL NCLM: 600/476.000
IC [7]
ICM: A61B006-00

L4 ANSWER 193 OF 391 USPATFULL on STN
AN 2003:6903 USPATFULL
TI Amino Lactam sulfonamides as inhibitors of A.beta. protein production
IN Thompson, Lorin Andrew, Wilmington, DE, United States
Han, Amy Qi, Hockessin, DE, United States
PA Bristol Myers Squibb Pharma Company, United States (U.S. corporation)
PI US 6503901 B1 20030107
AI US 2000-684718 20001007 (9)
PRAI US 1999-158565P 19991008 (60)
DT Utility
FS GRANTED
LN.CNT 5315
INCL INCLM: 514/221.000
INCLS: 540/509.000
NCL NCLM: 514/221.000
NCLS: 540/509.000
IC [7]
ICM: C07D413-12
ICS: C07D409-12; C07D401-12; A61K031-55; A61P025-28
EXF 540/509; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 391 USPATFULL on STN
AN 2003:4108 USPATFULL
TI 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Hanson, Jim, West Sussex, UNITED KINGDOM
Gunning, Phil, Cambs, UNITED KINGDOM
Rees, Daryl, Sandy, UNITED KINGDOM
Xia, Zongqin, Shanghai, CHINA
Hu, Yaer, Shanghai, CHINA
PI US 2003004147 A1 20030102
AI US 2002-109095 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. WO 2000-GB37367, filed on 29 Sep 2000,
UNKNOWN
PRAI GB 1999-23076 19990929
DT Utility
FS APPLICATION
LN.CNT 1261
INCL INCLM: 514/172.000
INCLS: 514/173.000
NCL NCLM: 514/172.000
NCLS: 514/173.000
IC [7]
ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 391 USPATFULL on STN
AN 2003:4068 USPATFULL
TI Method of preventing cell death using segments of neural thread proteins
IN Averback, Paul A., Beaconsfield, CANADA
PI US 2003004107 A1 20030102
AI US 2002-146130 A1 20020516 (10)
PRAI US 2001-290971P 20010516 (60)
DT Utility
FS APPLICATION
LN.CNT 1698
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000
IC [7]
ICM: A61K038-17
ICS: A61K038-10; A61K038-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 391 USPATFULL on STN
AN 2003:3520 USPATFULL
TI 90 ***human*** secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
PI US 2003003555 A1 20030102
AI US 2001-774639 A1 20010201 (9)
RLI Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED
Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998,
UNKNOWN

PRAI US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)
US 1997-54798P 19970805 (60)
US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54809P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)

US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 15472
INCL INCLM: 435/183.000
INCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;
536/023.200
NCL NCLM: 435/183.000
NCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;
536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12N005-06; C07K016-40; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 197 OF 391 USPATFULL on STN
AN 2003:3410 USPATFULL
TI Method of preventing cell death using ***antibodies*** to neural
thread proteins
IN Averback, Paul A., Quebec, CANADA
PI US 2003003445 A1 20030102
AI US 2002-138516 A1 20020506 (10)
PRAI US 2001-288463P 20010504 (60)
DT Utility
FS APPLICATION
LN.CNT 1705
INCL INCLM: 435/005.000
INCLS: 435/069.100; 435/345.000; 435/007.100
NCL NCLM: 435/005.000
NCLS: 435/069.100; 435/345.000; 435/007.100
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; C12P021-06; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 391 USPATFULL on STN
AN 2002:346816 USPATFULL
TI Aspartyl protease 2 (Asp2) antisense oligonucleotides
IN Gurney, Mark E., Grand Rapids, MI, United States
Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S.
corporation)
PI US 6500667 B1 20021231
AI US 2000-551853 20000418 (9)
RLI Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
PRAI US 1998-101594P 19980924 (60)
US 1999-155493P 19990923 (60)
DT Utility
FS GRANTED
LN.CNT 5638
INCL INCLM: 435/375.000
INCLS: 536/023.100; 536/024.100; 536/024.500; 514/044.000
NCL NCLM: 435/375.000
NCLS: 514/044.000; 536/023.100; 536/024.100; 536/024.500
IC [7]
ICM: C12N005-00
EXF 536/23.1; 536/24.1; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 391 USPATFULL on STN
AN 2002:343880 USPATFULL
TI Compositions and methods for monitoring the modification of modification
dependent binding partner polypeptides

PI US 2002197606 A1 20021226
AI US 2001-770102 A1 20010125 (9)
PRAI US 2000-179283P 20000131 (60)
DT Utility
FS APPLICATION
LN.CNT 3550
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 200 OF 391 USPATFULL on STN
AN 2002:339256 USPATFULL
TI Transgenic knockouts of BACE-1
IN McConlogue, Lisa, Burlingame, CA, UNITED STATES
Gurney, Mark E., Reykjavik, ICELAND
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES,
94080 (u.s. corporation)
PI US 2002194632 A1 20021219
AI US 2002-82804 A1 20020222 (10)
PRAI US 2001-271092P 20010223 (60)
US 2001-271514P 20010226 (60)
US 2001-293762P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 1051
INCL INCLM: 800/012.000
INCLS: 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/018.000
IC [7]
ICM: A01K067-027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 201 OF 391 USPATFULL on STN
AN 2002:337952 USPATFULL
TI Steroidal saponins and their derivatives for treating alzheimer's
disease
IN Xia, Zongqin, Shanghai, CHINA
Hu, Yaer, Shanghai, CHINA
Rubin, Ian, Nottingham, UNITED KINGDOM
Brostoff, Jonathan, London, UNITED KINGDOM
Whittle, Brian, East Yorkshire, UNITED KINGDOM
Wang, Weijun, Huntingdon, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
PI US 2002193317 A1 20021219
AI US 2002-77493 A1 20020215 (10)
RLI Continuation of Ser. No. US 2001-647110, filed on 11 Jan 2001, ABANDONED
PRAI GB 1998-6513 19980326
GB 1999-5275 19990308
DT Utility
FS APPLICATION
LN.CNT 885
INCL INCLM: 514/026.000
INCLS: 514/033.000
NCL NCLM: 514/026.000
NCLS: 514/033.000
IC [7]
ICM: A61K031-704

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 391 USPATFULL on STN
AN 2002:337363 USPATFULL
TI Modular molecular clasps and uses thereof
IN Rizzuto, Carlo Dante, Cambridge, MA, UNITED STATES
Afeyan, Noubar Boghos, Lexington, MA, UNITED STATES
Lee, Frank Don, Chestnut Hill, MA, UNITED STATES
Church, George McDonald, Brookline, MA, UNITED STATES
Gupta, Ruchira Das, Jamaica Plain, MA, UNITED STATES
Schwartz, John Jacob, Newtonville, MA, UNITED STATES
Zhang, Bin, Belmont, CA, UNITED STATES
Lugovskoy, Alexey Alexandrovich, Brighton, MA, UNITED STATES
PA engeneOS, Inc., Waltham, MA (u.s. corporation)
PI US 2002192721 A1 20021219

PRAI US 2001-279524P 20010328 (60)

DT Utility

FS APPLICATION

LN.CNT 2440

INCL INCLM: 435/007.900

INCLS: 435/287.200

NCL NCLM: 435/007.900

NCLS: 435/287.200

IC [7]

ICM: G01N033-53

ICS: G01N033-542; C12M001-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 391 USPATFULL on STN

AN 2002:330416 USPATFULL

TI CHIMERIC DNA-BINDING/DNA METHYLTRANSFERASE NUCLEIC ACID AND POLYPEPTIDE AND USES THEREOF

IN BESTOR, TIMOTHY H., NEW YORK, NY, UNITED STATES

PI US 2002188103 A1 20021212

AI US 1998-51013 A1 19981009 (9)

WO 1996-US15576 19960927

DT Utility

FS APPLICATION

LN.CNT 2050

INCL INCLM: 530/350.000

INCLS: 435/320.100; 435/325.000; 435/455.000; 435/456.000; 435/458.000; 435/459.000; 435/461.000; 424/093.200; 514/044.000; 536/023.100; 536/023.200; 536/023.500; 800/013.000

NCL NCLM: 530/350.000

NCLS: 435/320.100; 435/325.000; 435/455.000; 435/456.000; 435/458.000; 435/459.000; 435/461.000; 424/093.200; 514/044.000; 536/023.100; 536/023.200; 536/023.500; 800/013.000

IC [7]

ICM: C07K001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 204 OF 391 USPATFULL on STN

AN 2002:330327 USPATFULL

TI Method for treating Alzheimer's disease

IN Bisgaier, Charles Larry, Ann Arbor, MI, UNITED STATES

Emmerling, Mark Richard, Chelsea, MI, UNITED STATES

PI US 2002188012 A1 20021212

AI US 2002-71663 A1 20020208 (10)

RLI Continuation of Ser. No. US 2000-554994, filed on 23 May 2000, ABANDONED A 371 of International Ser. No. WO 1998-US25495, filed on 2 Dec 1998, UNKNOWN

PRAI US 1998-72912P 19980128 (60)

DT Utility

FS APPLICATION

LN.CNT 822

INCL INCLM: 514/356.000

INCLS: 514/369.000; 514/381.000; 514/560.000; 514/572.000; 514/574.000

NCL NCLM: 514/356.000

NCLS: 514/369.000; 514/381.000; 514/560.000; 514/572.000; 514/574.000

IC [7]

ICM: A61K031-455

ICS: A61K031-426; A61K031-41; A61K031-202; A61K031-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 391 USPATFULL on STN

AN 2002:330245 USPATFULL

TI Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as B-secretase inhibitors

IN Qiao, Lixin, Arlington, VA, UNITED STATES

Etchebeheregaray, Rene, Columbia, MD, UNITED STATES

PI US 2002187928 A1 20021212

US 6562783 B2 20030513

AI US 2001-866764 A1 20010530 (9)

DT Utility

FS APPLICATION

LN.CNT 824

INCL INCLM: 514/007.000

INCLS: 514/080.000; 514/081.000; 514/120.000; 530/331.000; 544/243.000; 544/244.000; 546/021.000; 562/011.000; 562/024.000; 562/012.000

NCL NCLM: 514/007.000

IC [7]
ICM: A61K038-06
ICS: C07F009-28; A61K031-675; C07F009-6512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 391 USPATFULL on STN
AN 2002:323128 USPATFULL
TI Sapogenin derivatives and their use in the treatment of cognitive dysfunction
IN Barracough, Paul, Maidstone, UNITED KINGDOM
Hanson, Jim, Steyning, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
Rees, Daryl, Sandy, UNITED KINGDOM
Xia, Zongqin, Shanghai, CHINA
Hu, Yaer, Shanghai, CHINA
PI US 2002183294 A1 20021205
AI US 2002-109204 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. WO 2000-GB3745, filed on 29 Sep 2000,
UNKNOWN
PRAI GB 1999-23077 19990929
DT Utility
FS APPLICATION
LN.CNT 1039
INCL INCLM: 514/172.000
INCLS: 514/178.000
NCL NCLM: 514/172.000
NCLS: 514/178.000
IC [7]
ICM: A61K031-58
ICS: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 391 USPATFULL on STN
AN 2002:314710 USPATFULL
TI ***HUMAN*** SEL-10 POLYPEPTIDES AND POLYNUCLEOTIDES THAT ENCODE THEM
IN GURNEY, MARK E., GRAND RAPIDS, MI, UNITED STATES
PAULEY, ADELE M., PLAINWELL, MI, UNITED STATES
LI, JINHE, KALAMAZOO, MI, UNITED STATES
PI US 2002177187 A1 20021128
AI US 1999-328877 A1 19990609 (9)
PRAI US 1997-68243P 19971219 (60)
DT Utility
FS APPLICATION
LN.CNT 2859
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 424/130.100; 435/007.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 424/130.100; 435/007.100
IC [7]
ICM: C07K017-00
ICS: C07K014-00; C07K001-00; C12N005-02; C12N005-00; C12N015-74;
C12N015-70; C12N015-63; C12N015-09; C12N015-00; A61K039-395; C12P021-06;
G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 391 USPATFULL on STN
AN 2002:314672 USPATFULL
TI Systems and methods for automated analysis of cells and tissues
IN Rimm, David L., Branford, CT, UNITED STATES
Camp, Robert L., Stamford, CT, UNITED STATES
PI US 2002177149 A1 20021128
AI US 2002-62308 A1 20020201 (10)
PRAI US 2001-334723P 20011031 (60)
US 2001-285155P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 1254
INCL INCLM: 435/006.000
INCLS: 435/007.200; 702/019.000; 702/020.000; 382/128.000
NCL NCLM: 435/006.000
NCLS: 435/007.200; 702/019.000; 702/020.000; 382/128.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; G06F019-00; G01N033-48; G01N033-50;
G06K009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 391 USPATFULL on STN
AN 2002:311059 USPATFULL
TI Biological reagents and methods for determining the mechanism in the generation of . ***beta*** .- ***amyloid*** peptide
IN Audia, James E., Indianapolis, IN, United States
Hyslop, Paul A., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Tung, Jay S., Belmont, CA, United States
Tanner, Laura I., San Francisco, CA, United States
PA Elan Pharmaceuticals Inc., So. San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6486350 B1 20021126
AI US 1999-408283 19990929 (9)
PRAI US 1998-160082P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 2017
INCL INCLM: 564/153.000
INCLS: 560/025.000; 560/027.000; 560/029.000; 540/522.000
NCL NCLM: 564/153.000
NCLS: 540/522.000; 560/025.000; 560/027.000; 560/029.000
IC [7]
ICM: C07C233-05
EXF 564/153; 560/25; 560/27; 560/29; 540/522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 391 USPATFULL on STN
AN 2002:311025 USPATFULL
TI Interleukin-20
IN Ebner, Reinhard, Gaithersburg, MD, United States
Murphy, Marianne, Richmond, UNITED KINGDOM
Ruben, Steven M., Olney, MD, United States
Hu, Jing-Shan, Sunnyvale, CA, United States
Duan, D. Roxanne, Bethesda, MD, United States
Florence, Kimberly A., Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6486301 B1 20021126
AI US 1999-231788 19990115 (9)
RLI Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998
PRAI US 1997-52870P 19970716 (60)
US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
DT Utility
FS GRANTED
LN.CNT 5643
INCL INCLM: 530/351.000
INCLS: 424/085.100
NCL NCLM: 530/351.000
NCLS: 424/085.100
IC [7]
ICM: C07K014-475
ICS: A61K038-19
EXF 530/351; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 391 USPATFULL on STN
AN 2002:310800 USPATFULL
TI Testis-specific ***human*** SVPH1-8 proteinase
IN Cerretti, Douglas P., Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6485956 B1 20021126
AI US 2000-617145 20000714 (9)
DT Utility
FS GRANTED
LN.CNT 2072
INCL INCLM: 435/219.000
INCLS: 435/069.100; 435/183.000; 435/218.000
NCL NCLM: 435/219.000
NCLS: 435/069.100; 435/183.000; 435/218.000
IC [7]
ICM: C12R021-06

ICS: C12N009-00; C12N009-66; C12N009-50
EXF 435/69.1; 435/183; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 391 USPATFULL on STN
AN 2002:310766 USPATFULL
TI Methods for determining risk of developing alzheimer's disease by
detecting mutations in the presenilin 2 (PS-2) gene
IN St. George-Hyslop, Peter H., Toronto, CANADA
Rommens, Johanna M., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA HSC Research and Development Limited Partnership, CANADA (non-U.S.
corporation)
The Governing Council of the University of Toronto, CANADA (non-U.S.
corporation)
PI US 6485911 B1 20021126
AI US 2000-636796 20000811 (9)
RLI Division of Ser. No. US 1998-127480, filed on 31 Jul 1998, now patented,
Pat. No. US 6194153 Division of Ser. No. US 1996-592541, filed on 26 Jan
1996, now patented, Pat. No. US 5986054 Continuation-in-part of Ser. No.
US 1995-509359, filed on 31 Jul 1995, now abandoned Continuation-in-part
of Ser. No. US 1995-496841, filed on 28 Jun 1995, now patented, Pat. No.
US 6210919 Continuation-in-part of Ser. No. US 1995-431048, filed on 28
Apr 1995
DT Utility
FS GRANTED
LN.CNT 6790
INCL INCLM: 435/006.000
INCLS: 435/091.200; 435/091.210; 435/091.510; 536/023.500; 536/024.310;
536/024.330
NCL NCLM: 435/006.000
NCLS: 435/091.200; 435/091.210; 435/091.510; 536/023.500; 536/024.310;
536/024.330
IC [7]
ICM: C12Q001-68
EXF 435/6; 435/91.2; 435/91.21; 435/91.51; 536/24.31; 536/24.33; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 213 OF 391 USPATFULL on STN
AN 2002:309311 USPATFULL
TI Identification of genes involved in alzheimer's disease using drosophila
melanogaster
IN Cohen, Dalia, Livingston, NJ, UNITED STATES
Dengler, Uwe Jochen, Loerrach, GERMANY, FEDERAL REPUBLIC OF
Finelli, Alyce Lynn, Parsippany, NJ, UNITED STATES
Freuler, Felix, Riehen, SWITZERLAND
Konsolaki, Mary, Westfield, NJ, UNITED STATES
Reinhardt, Mischa Werner Henri Marie, Bantzenheim, FRANCE
Zusman, Susan, Sudbury, MA, UNITED STATES
PI US 2002174446 A1 20021121
AI US 2001-964899 A1 20010927 (9)
PRAI US 2000-236893P 20000929 (60)
US 2001-298309P 20010614 (60)
DT Utility
FS APPLICATION
LN.CNT 5722
INCL INCLM: 800/008.000
INCLS: 514/001.000
NCL NCLM: 800/008.000
NCLS: 514/001.000
IC [7]
ICM: A01K067-033
ICS: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 214 OF 391 USPATFULL on STN
AN 2002:307925 USPATFULL
TI Controlling protein levels in eucaryotic organisms
IN Kenten, John H., Boyds, MD, UNITED STATES
Roberts, Steven F., Bethesda, MD, UNITED STATES
PA Proteinix, Inc. (U.S. corporation)
PI US 2002173049 A1 20021121
US 6559280 B2 20030506
AI US 2001-880132 A1 20010614 (9)
RLI Division of Ser. No. US 1999-406781, filed on 28 Sep 1999, PATENTED

DT Utility
FS APPLICATION
LN.CNT 3227
INCL INCLM: 436/501.000
INCLS: 435/041.000; 435/106.000; 435/004.000; 435/007.720; 514/002.000;
530/300.000; 530/350.000; 930/020.000; 424/094.100
NCL NCLM: 530/323.000
NCLS: 424/070.140; 435/004.000; 435/106.000; 435/108.000; 435/109.000;
435/115.000; 435/116.000; 436/501.000; 530/329.000; 530/330.000;
530/331.000; 530/332.000
IC [7]
ICM: A01N037-18
ICS: C12Q001-00; C12P001-04; C07K004-00; C07K007-00;
C07K016-00; C07K001-00; A61K038-00; G01N033-53; A61K038-43; C07K002-00;
C07K005-00; C07K014-00; C07K017-00; G01N033-566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 215 OF 391 USPATFULL on STN
AN 2002:307880 USPATFULL
TI Novel ABCA6 transporter and uses thereof
IN Chen, Hongyun, Vancouver, CANADA
Le Bihan, Stephane, Vancouver, CANADA
Kulhanek, Barbara, Surrey, CANADA
PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S.
corporation)
PI US 2002173004 A1 20021121
AI US 2002-90453 A1 20020304 (10)
PRAI US 2001-273650P 20010305 (60)

DT Utility
FS APPLICATION
LN.CNT 3798
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.200; 536/024.300
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.200; 536/024.300
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 216 OF 391 USPATFULL on STN
AN 2002:307870 USPATFULL
TI 28 ***human*** secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Li, Haodong, Gaithersburg, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
PI US 2002172994 A1 20021121
AI US 2001-852797 A1 20010511 (9)
RLI Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998,
PENDING Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar
1998, UNKNOWN

PRAI US 2001-265583P 20010202 (60)
US 1997-40762P 19970314 (60)
US 1997-40710P 19970314 (60)
US 1997-50934P 19970530 (60)
US 1997-48100P 19970530 (60)
US 1997-48357P 19970530 (60)
US 1997-48189P 19970530 (60)
US 1997-57765P 19970905 (60)
US 1997-48970P 19970606 (60)
US 1997-68368P 19971219 (60)

DT Utility
FS APPLICATION
LN.CNT 17794

NCL INCLS: 435/226.000; 435/325.000; 435/320.100; 536/023.200
NCLM: 435/069.100
NCLS: 435/226.000; 435/325.000; 435/320.100; 536/023.200
[7]
ICM: C12P021-02
ICS: C12N005-06; C07H021-04; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 217 OF 391 USPATFULL on STN
AN 2002:303718 USPATFULL
TI Methods of reducing bone loss with CD40 ligand
IN Ahuja, Seema A., San Antonio, TX, United States
Bonewald, Lynda F., San Antonio, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6482411 B1 20021119
AI US 2000-645926 20000824 (9)
PRAI US 1999-151250P 19990827 (60)
DT Utility
FS GRANTED
LN.CNT 5120
INCL INCLM: 424/185.100
INCLS: 424/085.100; 424/184.100; 424/192.100; 424/178.100; 514/002.000;
514/008.000; 514/012.000; 514/885.000; 530/350.000; 530/351.000
NCL NCLM: 424/185.100
NCLS: 424/085.100; 424/178.100; 424/184.100; 424/192.100; 514/002.000;
514/008.000; 514/012.000; 514/885.000; 530/350.000; 530/351.000
IC [7]
ICM: A61K038-17
ICS: A61K038-19; C07K014-435; C07K014-52
EXF 424/85.1; 424/185.1; 424/278.1; 514/2; 514/8; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 218 OF 391 USPATFULL on STN
AN 2002:301592 USPATFULL
TI Regulation of amyloid precursor protein expression by modification of
ABC transporter expression or activity
IN Reiner, Peter B., Vancouver, CANADA
Connop, Bruce P., Vancouver, CANADA
Pollard, Michelle, Vancouver, CANADA
PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S.
corporation)
PI US 2002169137 A1 20021114
AI US 2002-72621 A1 20020208 (10)
PRAI US 2001-267975P 20010209 (60)
US 2001-309256P 20010731 (60)
DT Utility
FS APPLICATION
LN.CNT 3827
INCL INCLM: 514/044.000
INCLS: 514/002.000
NCL NCLM: 514/044.000
NCLS: 514/002.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 219 OF 391 USPATFULL on STN
AN 2002:301144 USPATFULL
TI Inhibition of tau-tau-association
IN Wischik, Claude Michel, Cambridge, UNITED KINGDOM
Edwards, Patricia Carol, Cambridge, UNITED KINGDOM
Harrington, Charles Robert, Cambridge, UNITED KINGDOM
Roth, Martin, Cambridge, UNITED KINGDOM
Klug, Aaron, Cambridge, UNITED KINGDOM
PA University Court of the University of Aberdeen, Aberdeen, UNITED KINGDOM
(3)
PI US 2002168687 A1 20021114
AI US 2002-107181 A1 20020328 (10)
RLI Division of Ser. No. US 1997-913915, filed on 12 Dec 1997, GRANTED, Pat.
No. US 6376205 A 371 of International Ser. No. WO 1996-EP1307, filed on
25 Mar 1996, UNKNOWN
PRAI GB 1995-6197 19950327
DT Utility

LN.CNT 2030
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 391 USPATFULL on STN
AN 2002:300827 USPATFULL
TI Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
IN McDonald, John R., Calgary, AB, UNITED STATES
Coggins, Philip J., Calgary, AB, UNITED STATES
PI US 2002168370 A1 20021114
AI US 2001-792793 A1 20010222 (9)
RLI Division of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING
Division of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING
Continuation of Ser. No. US 1998-120523, filed on 22 Jul 1998, ABANDONED
PRAI WO 1999-CA659 19990721
US 1998-155186P 19980722 (60)
DT Utility
FS APPLICATION
LN.CNT 7972
INCL INCLM: 424/178.100
INCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
435/325.000
NCL NCLM: 424/178.100
NCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
435/325.000
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 391 USPATFULL on STN
AN 2002:295299 USPATFULL
TI Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative disease
IN Kirsch, Wolff M., Redlands, CA, UNITED STATES
Lennart, Anto, Loma Linda, CA, UNITED STATES
Kelln, Wayne J., Loma Linda, CA, UNITED STATES
Kang, Dae-Kyung, Rockville, MD, UNITED STATES
Levine, Rodney L., Rockville, MD, UNITED STATES
Rouault, Tracey A., North Bethesda, MD, UNITED STATES
PI US 2002165349 A1 20021107
AI US 2001-924396 A1 20010806 (9)
PRAI US 2000-222863P 20000804 (60)
DT Utility
FS APPLICATION
LN.CNT 3514
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/006.000; 435/007.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/006.000; 435/007.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 391 USPATFULL on STN
AN 2002:294717 USPATFULL
TI Catalytically active recombinant memapsin and methods of use thereof
IN Lin, Xinli, Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Tang, Jordan J.N., Edmond, OK, UNITED STATES
PA Oklahoma Medical Research Foundation
PI US 2002164760 A1 20021107
AI US 2001-795903 A1 20010228 (9)
RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)
DT Utility

LN.CNT 2440
INCL INCLM: 435/220.000
INCL INCLS: 435/069.100; 435/252.300; 435/320.100
NCL NCLM: 435/220.000
NCL NCLS: 435/069.100; 435/252.300; 435/320.100
IC [7]
ICM: C12N009-52
ICS: C12P021-02; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 391 USPATFULL on STN
AN 2002:294625 USPATFULL
TI Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
IN Durham, L. Kathryn, New London, CT, UNITED STATES
Friedman, David L., Madison, CT, UNITED STATES
Chandrasiri Herath, Herath Mudiyanselage Athula, Abingdom, UNITED KINGDOM
Kimmel, Lida H., Chester, CT, UNITED STATES
Parekh, Rajesh Bhikhu, New Wembley, UNITED KINGDOM
Potter, David M., Ledyard, CT, UNITED STATES
Rohlf, Christian, Oxford, UNITED KINGDOM
Silber, B. Michael, Madison, CT, UNITED STATES
Stiger, Thomas R., Pawcatuck, CT, UNITED STATES
Sunderland, P. Trey, Chevy Chase, MD, UNITED STATES
Townsend, Robert Reid, Oxford, UNITED KINGDOM
White, W. Frost, Ledyard, CT, UNITED STATES
Williams, Stephen A., Groton, CT, UNITED STATES
PI US 2002164668 A1 20021107
AI US 2001-826290 A1 20010403 (9)
PRAI US 2000-194504P 20000403 (60)
US 2000-253647P 20001128 (60)
DT Utility
FS APPLICATION
LN.CNT 5696
INCL INCLM: 435/007.920
INCL INCLS: 435/069.100; 435/325.000; 435/226.000; 536/023.200
NCL NCLM: 435/007.920
NCL NCLS: 435/069.100; 435/325.000; 435/226.000; 536/023.200
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543; C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 391 USPATFULL on STN
AN 2002:291111 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6476263 B1 20021105
AI US 2001-826412 20010403 (9)
RLI Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility

LN.CNT 12409
INCL INCLM: 564/152.000
INCLS: 564/153.000; 564/159.000; 564/160.000; 564/161.000; 564/041.000;
560/041.000; 562/450.000
NCL NCLM: 564/152.000
NCLS: 560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000;
564/160.000; 564/161.000
IC [7]
ICM: C07C233-00
EXF 564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 225 OF 391 USPATFULL on STN
AN 2002:290742 USPATFULL
TI 94 ***Human*** Secreted Proteins
IN Ruben, Steven M., Olney, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Wei, Ying-Fei, Berkeley, CA, United States
Young, Paul, Gaithersburg, MD, United States
Florence, Kimberly, Rockville, MD, United States
Soppet, Daniel R., Centreville, VA, United States
Brewer, Laurie A., St. Paul, MN, United States
Endress, Gregory A., Potomac, MD, United States
Carter, Kenneth C., Potomac, MD, United States
Mucenski, Michael, Cincinnati, OH, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Lafleur, David W., Washington, DC, United States
Olsen, Henrik, Gaithersburg, MD, United States
Shi, Yanggu, Gaithersburg, MD, United States
Moore, Paul A., Germantown, MD, United States
Komatsoulis, George, Silver Spring, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6475753 B1 20021105
AI US 1999-461325 19991214 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999
PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)

DT Utility
FS GRANTED
LN.CNT 18031
INCL INCLM: 435/069.100
INCLS: 435/069.400; 435/071.100; 435/252.300; 435/032.500; 435/320.100;
435/471.000; 536/023.500; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/069.400; 435/071.100; 435/252.300; 435/320.100; 435/325.000;
435/471.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N015-12; C12N005-10; C07K014-47
EXF 435/69.1; 435/69.4; 435/71.1; 435/91.1; 435/252.3; 435/325; 435/320.1;
435/471; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 226 OF 391 USPATFULL on STN
AN 2002:290736 USPATFULL
TI Identification of agents that protect against inflammatory injury to
neurons
IN Julian, Dana, Houston, TX, United States
PA Baylor College of Medicine, Houston, TX, United States (U.S.
corporation)
PI US 6475745 B1 20021105
AI US 1997-922889 19970903 (8)

RLI Division of Ser. No. US 1996-717551, filed on 20 Sep 1996
DT Utility
FS GRANTED
LN.CNT 2755
INCL INCLM: 435/007.200
INCLS: 530/300.000; 530/350.000; 530/402.000
NCL NCLM: 435/007.200

IC [7]
ICM: G01N033-53
ICS: C07K007-00; C07K004-12
EXF 435/7.2; 435/7.1; 530/300; 530/350; 530/402; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 391 USPATFULL on STN
AN 2002:287562 USPATFULL
TI Process for differential diagnosis of Alzheimer's dementia and device
therefor
IN Jackowski, George, Kettleby, CANADA
Takahashi, Miyoko, North York, CANADA
PI US 2002160425 A1 20021031
AI US 2001-971740 A1 20011004 (9)
RLI Continuation of Ser. No. US 2001-842079, filed on 25 Apr 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 940
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 391 USPATFULL on STN
AN 2002:273382 USPATFULL
TI Methods and compositions for the treatment of ***human***
immunodeficiency virus infection
IN Ikezu, Tsuneya, Omaha, NE, UNITED STATES
Leisman, Gary, Omaha, NE, UNITED STATES
Carlson, Kimberly A., Omaha, NE, UNITED STATES
Gendelman, Howard E., Omaha, NE, UNITED STATES
PI US 2002151510 A1 20021017
AI US 2001-828648 A1 20010406 (9)
PRAI US 2000-246331P 20001106 (60)
DT Utility
FS APPLICATION
LN.CNT 1948
INCL INCLM: 514/044.000
INCLS: 514/012.000; 536/023.720; 435/069.100; 435/325.000; 435/320.100;
435/219.000; 530/388.260; 424/207.100; 424/208.100
NCL NCLM: 514/044.000
NCLS: 514/012.000; 536/023.720; 435/069.100; 435/325.000; 435/320.100;
435/219.000; 530/388.260; 424/207.100; 424/208.100
IC [7]
ICM: A61K038-17
ICS: C12N009-50; C07H021-02; C12N005-06; C12P021-02; C12N015-867;
A61K038-00; C07H021-04; A61K031-70; A01N043-04; C12P021-06; A61K039-21;
C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00;
C12N005-02; C07K016-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 391 USPATFULL on STN
AN 2002:273336 USPATFULL
TI Methods for preventing neural tissue damage and for the treatment of
alpha-synuclein diseases
IN Wolozin, Benjamin, Hinsdale, IL, UNITED STATES
Ostretsova-Golts, Natalie, Forrest Park, IL, UNITED STATES
Lebowitz, Michael S., Baltimore, MD, UNITED STATES
PI US 2002151464 A1 20021017
AI US 2001-901187 A1 20010709 (9)
PRAI US 2000-217319P 20000707 (60)
US 2001-279199P 20010328 (60)
DT Utility
FS APPLICATION
LN.CNT 1374
INCL INCLM: 514/002.000
INCLS: 435/007.200; 435/025.000
NCL NCLM: 514/002.000
NCLS: 435/007.200; 435/025.000
IC [7]
ICM: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 391 USPATFULL on STN
AN 2002:272761 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2002150881 A1 20021017
AI US 2001-781988 A1 20010214 (9)
RLI Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15696
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 435/235.100
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/235.100
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 391 USPATFULL on STN
AN 2002:268610 USPATFULL
TI Vectors and methods for gene transfer to cells
IN Wickham, Thomas J., Falls Church, VA, United States
Kovesdi, Imre, Rockville, MD, United States
Brough, Douglas E., Olney, MD, United States
PA GenVec, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 6465253 B1 20021015
WO 9720051 19970605
AI US 1999-101751 19990129 (9)
WO 1996-US19150 19961127
19990129 PCT 371 date
RLI Continuation-in-part of Ser. No. US 1996-700846, filed on 21 Aug 1996,
now patented, Pat. No. US 5962311 Continuation-in-part of Ser. No. US
1996-634060, filed on 17 Apr 1996, now patented, Pat. No. US 5712136
Continuation-in-part of Ser. No. US 1996-701124, filed on 21 Aug 1996,
now patented, Pat. No. US 5846782 Continuation-in-part of Ser. No. US
1995-563368, filed on 28 Nov 1995, now patented, Pat. No. US 5965541
Continuation-in-part of Ser. No. US 634060 Continuation-in-part of Ser.
No. US 1994-303162, filed on 8 Sep 1994, now patented, Pat. No. US
5559099
DT Utility
FS GRANTED
LN.CNT 3207
INCL INCLM: 435/456.000
INCLS: 435/320.100; 435/325.000; 435/455.000; 530/330.000; 530/329.000;
530/328.000; 530/327.000; 530/326.000; 530/324.000; 530/350.000
NCL NCLM: 435/456.000
NCLS: 435/320.100; 435/325.000; 435/455.000; 530/324.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/350.000
IC [7]
ICM: C12N015-861
ICS: C12N015-63; C12N005-10; C07K007-04; C07K014-075
EXF 435/69.1; 435/235.1; 435/320.1; 435/325; 435/366; 435/455; 435/456;
530/350; 530/330; 530/329; 530/328; 530/327; 530/326; 530/324; 424/93.1;
424/93.2; 424/93.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 391 USPATFULL on STN
AN 2002:265967 USPATFULL
TI Controlling protein levels in eucaryotic organisms
IN Kenten, John H., Boyds, MD, UNITED STATES

PA Proteinix, Inc. (U.S. corporation)
PI US 2002146843 A1 20021010
AI US 2001-880149 A1 20010614 (9)
RLI Continuation of Ser. No. US 1999-406781, filed on 28 Sep 1999, GRANTED,
Pat. No. US 6306663
PRAI US 1999-119851P 19990212 (60)
DT Utility
FS APPLICATION
LN.CNT 3226
INCL INCLM: 436/501.000
INCLS: 424/094.100; 435/106.000; 435/004.000; 435/041.000; 435/007.720;
514/002.000; 530/300.000; 530/350.000; 930/020.000
NCL NCLM: 436/501.000
NCLS: 424/094.100; 435/106.000; 435/004.000; 435/041.000; 435/007.720;
514/002.000; 530/300.000; 530/350.000; 930/020.000
IC [7]
ICM: A01N037-18
ICS: C12Q001-00; C12P001-00; C12P013-04; C07K004-00; C07K007-00;
C07K016-00; C07K001-00; A61K038-00; A61K038-43; C07K005-00; C07K017-00;
G01N033-53; C07K014-00; C07K002-00; G01N033-566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 391 USPATFULL on STN
AN 2002:265884 USPATFULL
TI Novel G-protein-coupled receptor-like proteins and polynucleotides
encoded by them, and methods of using same
IN Ozenberger, Bradley A., Newtown, PA, UNITED STATES
Kajkowski, Eileen M., Ringoes, NJ, UNITED STATES
Lo, Ching-Hsiung Frederick, Pennington, NJ, UNITED STATES
Walker, Stephen G., East Windsor, NJ, UNITED STATES
Sofia, Heidi, Walla Walla, WA, UNITED STATES
PA American Home Products Corporation, Madison, NJ, 07940-0874 (U.S.
corporation)
PI US 2002146760 A1 20021010
AI US 2001-833503 A1 20010412 (9)
PRAI WO 1999-US21621 19991013
US 1998-104104P 19981013 (60)
DT Utility
FS APPLICATION
LN.CNT 1524
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-705; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 391 USPATFULL on STN
AN 2002:265848 USPATFULL
TI Biopolymer sequence comparison
IN Toll, Lawrence R., Redwood City, CA, UNITED STATES
Lincoln, Patrick Denis, Woodside, CA, UNITED STATES
Karp, Peter, San Mateo, CA, UNITED STATES
Sonmez, Kemal, Menlo Park, CA, UNITED STATES
PI US 2002146724 A1 20021010
AI US 2001-6492 A1 20011203 (10)
PRAI US 2000-250743P 20001201 (60)
DT Utility
FS APPLICATION
LN.CNT 1796
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50

L4 ANSWER 235 OF 391 USPATFULL on STN
AN 2002:262446 USPATFULL
TI Peptides and pharmaceutical compositions thereof for treatment of
disorders or diseases associated with abnormal protein folding into
amyloid or amyloid-like deposits

Baumann, Marc H., Helsinki, FINLAND
Frangione, Blas, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 6462171 B1 20021008
AI US 1996-766596 19961212 (8)
RLI Continuation-in-part of Ser. No. US 1996-630645, filed on 10 Apr 1996,
now patented, Pat. No. US 5948763 Continuation-in-part of Ser. No. US
1995-478326, filed on 7 Jun 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 1979
INCL INCLM: 530/326.000
INCLS: 530/327.000; 530/238.000; 530/329.000; 530/330.000; 514/014.000;
514/015.000; 514/016.000; 514/017.000; 514/018.000
NCL NCLM: 530/326.000
NCLS: 530/327.000; 530/328.000; 530/329.000; 530/330.000
IC [7]
ICM: A61K038-00
ICS: C07K016-00
EXF 514/2; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 530/300;
530/324; 530/325; 530/326; 530/327; 530/328; 530/330; 530/331; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 391 USPATFULL on STN
AN 2002:254378 USPATFULL
TI Lactacystin analogs
IN Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)
PI US 6458825 B1 20021001
AI US 2000-639242 20000815 (9)
RLI Continuation of Ser. No. US 1995-421583, filed on 12 Apr 1995, now
patented, Pat. No. US 6335358
DT Utility
FS GRANTED
LN.CNT 2298
INCL INCLM: 514/421.000
INCLS: 514/444.000; 514/470.000
NCL NCLM: 514/421.000
NCLS: 514/444.000; 514/470.000
IC [7]
ICM: A61K031-40
ICS: A61K031-38; A61K031-34
EXF 514/421; 514/444; 514/470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 391 USPATFULL on STN
AN 2002:251790 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting ***beta*** -
amyloid peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PI US 2002137743 A1 20020926
AI US 2001-984834 A1 20011031 (9)
RLI Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, PATENTED
Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, PATENTED
DT Utility
FS APPLICATION
LN.CNT 3784
INCL INCLM: 514/227.500
INCLS: 514/237.800; 514/252.120; 514/357.000; 514/534.000; 514/561.000;
544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000;
560/155.000
NCL NCLM: 514/227.500
NCLS: 514/237.800; 514/252.120; 514/357.000; 514/534.000; 514/561.000;

544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000;
560/155.000

IC [7]

ICM: A61K031-54

ICS: A61K031-535; A61K031-495; A61K031-44; A61K031-198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 391 USPATFULL on STN

AN 2002:251784 USPATFULL

TI Lactams substituted by cyclic succinates as inhibitors of a beta protein production

IN Olson, Richard E., Wilmington, DE, UNITED STATES

PI US 2002137737 A1 20020926

US 6509333 B2 20030121

AI US 2001-871840 A1 20010601 (9)

PRAI US 2000-208536P 20000601 (60)

DT Utility

FS APPLICATION

LN.CNT 6581

INCL INCLM: 514/212.030

INCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000

NCL NCLM: 514/221.000

NCLS: 540/509.000

IC [7]

ICM: A61K031-55

ICS: A61K031-445; A61K031-4015; C07D211-54; C07D223-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 391 USPATFULL on STN

AN 2002:243784 USPATFULL

TI VEGF-modulated genes and methods employing them

IN Gerber, Hans-Peter, San Francisco, CA, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

PI US 2002132978 A1 20020919

AI US 2001-815153 A1 20010321 (9)

PRAI US 2000-191201P 20000322 (60)

DT Utility

FS APPLICATION

LN.CNT 5514

INCL INCLM: 530/350.000

INCLS: 536/023.500; 530/388.100; 435/325.000; 435/320.100; 435/069.100

NCL NCLM: 530/350.000

NCLS: 536/023.500; 530/388.100; 435/325.000; 435/320.100; 435/069.100

IC [7]

ICM: C07K014-705

ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 391 USPATFULL on STN

AN 2002:243133 USPATFULL

TI Peptide mutant of ***human*** ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof

IN Abreo, Melwyn A., Jamul, CA, UNITED STATES

Agree, Charles S., San Diego, CA, UNITED STATES

Aust, Robert M., Alpine, CA, UNITED STATES

Kissinger, Charles R., San Diego, CA, UNITED STATES

Margosiak, Stephen, Escondido, CA, UNITED STATES

Meng, Jerry J., San Diego, CA, UNITED STATES

Pelletier, Laura A., Escondido, CA, UNITED STATES

Rejto, Paul Abraham, Carlsbad, CA, UNITED STATES

Showalter, Richard Edward, Santee, CA, UNITED STATES

Thomson, James Arthur, San Diego, CA, UNITED STATES

Tempczyk-Russell, Anna, Ramona, CA, UNITED STATES

Vanderpool, Darin, San Diego, CA, UNITED STATES

Villafranca, Jesus Ernesto, San Diego, CA, UNITED STATES

PI US 2002132319 A1 20020919

AI US 2001-931186 A1 20010817 (9)

PRAI US 2000-226123P 20000818 (60)

DT Utility

FS APPLICATION

LN.CNT 12914

INCL INCLM: 435/189.000

INCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000

NCL NCLM: 435/189.000

NCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000

IC [7]

ICM: C12N009-02

ICS: C12N009-64; G06F019-00; G01N033-48; G01N033-50; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 241 OF 391 USPATFULL on STN

AN 2002:238832 USPATFULL

TI Process for differential diagnosis of Alzheimer's dementia and device
therefor

IN Jackowski, George, Kettleby, CANADA

Takahashi, Miyoko, North York, CANADA

PA Syn X Pharma, CANADA (non-U.S. corporation)

PI US 6451547 B1 20020917

AI US 2001-842079 20010425 (9)

DT Utility

FS GRANTED

LN.CNT 817

INCL INCLM: 435/007.400

INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.930; 435/007.940;
435/007.950; 530/387.200; 530/388.100; 530/388.250; 530/388.260;
530/389.100; 530/389.300; 530/391.100

NCL NCLM: 435/007.400

NCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.930; 435/007.940;
435/007.950; 530/387.200; 530/388.100; 530/388.250; 530/388.260;
530/389.100; 530/389.300; 530/391.100

IC [7]

ICM: C07K016-18

ICS: C07K016-40; G01N033-48; G01N033-49; G01N033-53

EXF 530/387.2; 530/388.1; 530/388.25; 530/388.26; 530/389.1; 530/389.3;
530/391.1; 435/7.1; 435/7.4; 435/7.9; 435/7.92; 435/7.93; 435/7.94;
435/7.95

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 391 USPATFULL on STN

AN 2002:237182 USPATFULL

TI Transgenic animals and cell lines for screening drugs effective for the
treatment or prevention of alzheimer's disease

IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES

Wands, Jack R., Waban, MA, UNITED STATES

PI US 2002129391 A1 20020912

AI US 2001-964412 A1 20010928 (9)

RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371
of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN

PRAI US 1997-38908P 19970226 (60)

DT Utility

FS APPLICATION

LN.CNT 2087

INCL INCLM: 800/012.000

INCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200

NCL NCLM: 800/012.000

NCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200

IC [7]

ICM: A01K067-027

ICS: C07H021-04; C12N015-74

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 243 OF 391 USPATFULL on STN

AN 2002:236057 USPATFULL

TI Compounds to treat alzheimer's disease

IN Beck, James P., Kalamazoo, MI, UNITED STATES

Fang, Lawrence Y., Foster City, CA, UNITED STATES

Freskos, John N., Clayton, MO, UNITED STATES

Gailunas, Andrea, San Francisco, CA, UNITED STATES

Hom, Roy, San Francisco, CA, UNITED STATES

Jagodzinska, Barbara, Redwood City, CA, UNITED STATES

John, Varghese, San Francisco, CA, UNITED STATES

Maillard, Michel, Redwood Shores, CA, UNITED STATES

Pulley, Shon R., Hickory Corners, MI, UNITED STATES

TenBrink, Ruth E., Kalamazoo, MI, UNITED STATES

PI US 2002128255 A1 20020912

AI US 2001-896139 A1 20010629 (9)

PRAI US 2000-215323P 20000630 (60)

US 2000-252736P 20001122 (60)

US 2000-255956P 20001215 (60)

US 2001-268497P 20010213 (60)

US 2001-270770 20010222 (60)

US 2001-295589P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 21437
INCL INCLM: 514/211.150
INCLS: 514/396.000; 514/423.000; 514/357.000; 514/438.000; 514/616.000
NCL NCLM: 514/211.150
NCLS: 514/396.000; 514/423.000; 514/357.000; 514/438.000; 514/616.000
IC [7]
ICM: A61K031-553
ICS: A61K031-554; A01N043-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 244 OF 391 USPATFULL on STN
AN 2002:235353 USPATFULL
TI Alzheimer's related proteins and methods of use
IN St. George-Hyslop, Peter H., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA The Governing Council of the University of Toronto (non-U.S.
corporation)
PI US 2002127541 A1 20020912
AI US 2002-71900 A1 20020208 (10)
RLI Division of Ser. No. US 1999-227725, filed on 8 Jan 1999, GRANTED, Pat.
No. US 6383758
PRAI US 1998-70948P 19980109 (60)
DT Utility
FS APPLICATION
LN.CNT 1479
INCL INCLM: 435/004.000
INCLS: 435/023.000; 435/007.200
NCL NCLM: 435/004.000
NCLS: 435/023.000; 435/007.200
IC [7]
ICM: C12Q001-00
ICS: C12Q001-37; G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 245 OF 391 USPATFULL on STN
AN 2002:235107 USPATFULL
TI Methods of reducing ***beta*** - ***amyloid*** polypeptides
IN Eckman, Christopher B., Ponte Vedra Beach, FL, UNITED STATES
Yager, Debra, Jacksonville, FL, UNITED STATES
Haugabook, Sharie, Jacksonville, FL, UNITED STATES
Fauq, Abdul, Jacksonville, FL, UNITED STATES
PI US 2002127290 A1 20020912
AI US 2001-804420 A1 20010312 (9)
DT Utility
FS APPLICATION
LN.CNT 934
INCL INCLM: 424/773.000
INCLS: 424/764.000
NCL NCLM: 424/773.000
NCLS: 424/764.000
IC [7]
ICM: A61K035-78

L4 ANSWER 246 OF 391 USPATFULL on STN
AN 2002:230959 USPATFULL
TI Testis expressed polypeptide
IN Ruben, Steven M., Olney, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Zeng, Zhizhen, Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6448230 B1 20020910
AI US 1998-152060 19980911 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar 1998
PRAI US 1997-40762P 19970314 (60)
US 1997-40710P 19970314 (60)
US 1997-50934P 19970530 (60)
US 1997-48100P 19970530 (60)
US 1997-48357P 19970530 (60)
US 1997-48189P 19970530 (60)
US 1997-57765P 19970905 (60)
US 1997-48970P 19970606 (60)

DT Utility
FS GRANTED
LN.CNT 7777
INCL INCLM: 514/021.000
INCLS: 514/012.000; 514/002.000; 514/044.000; 530/300.000; 530/350.000;
530/305.000; 530/324.000; 424/185.100; 424/193.100; 424/194.100;
424/234.100
NCL NCLM: 514/021.000
NCLS: 424/185.100; 424/193.100; 424/194.100; 424/234.100; 514/002.000;
514/012.000; 514/044.000; 530/300.000; 530/305.000; 530/324.000;
530/350.000

IC [7]
ICM: A61K038-00
ICS: C07K001-00; C07K005-00; C07K007-00
EXF 435/6; 435/69.1; 435/252.3; 435/320.1; 435/325; 514/12; 514/2; 514/44;
514/21; 530/300; 530/350; 530/305; 530/324; 530/333; 530/344; 530/345;
530/356; 530/358; 530/362; 530/391.5; 424/234.1; 424/184.1; 424/185.1;
424/193.1; 424/194.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 247 OF 391 USPATFULL on STN
AN 2002:227919 USPATFULL
TI Assay for disease related conformation of a protein and isolating same
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Safar, Jiri G., Walnut Creek, CA, UNITED STATES
PI US 2002123072 A1 20020905
AI US 2002-47431 A1 20020114 (10)
RLI Continuation of Ser. No. US 2001-754443, filed on 3 Jan 2001, PENDING
Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
Pat. No. US 6214565 Continuation of Ser. No. US 1998-26967, filed on 20
Feb 1998, GRANTED, Pat. No. US 5977324

DT Utility
FS APPLICATION
LN.CNT 1643
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 248 OF 391 USPATFULL on STN
AN 2002:227617 USPATFULL
TI Stable radiopharmaceutical compositions and methods for preparation
thereof
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
Barrett, John A., Groton, MA, UNITED STATES
Carpenter, Alan P., JR., Carlisle, MA, UNITED STATES
PI US 2002122768 A1 20020905
AI US 2001-899629 A1 20010705 (9)
PRAI US 2000-216396P 20000706 (60)
DT Utility
FS APPLICATION
LN.CNT 4115

INCL INCLM: 424/001.110
NCL NCLM: 424/001.110
IC [7]
ICM: A61K051-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 249 OF 391 USPATFULL on STN
AN 2002:224705 USPATFULL
TI Hydrophobically-modified hedgehog protein compositions and methods
IN Pepinsky, R. Blake, Arlington, MA, United States
Baker, Darren P., Hingham, MA, United States
Wen, Dingyi, Waltham, MA, United States
Williams, Kevin P., Natick, MA, United States
Garber, Ellen A., Cambridge, MA, United States
Taylor, Frederick R., Milton, MA, United States
Galdes, Alphonse, Lexington, MA, United States
Porter, Jeffrey, Cambridge, MA, United States
PA Curis, Inc., Cambridge, MA, United States (U.S. corporation)
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

AI US 1999-325256 19990603 (9)
RLI Continuation of Ser. No. WO 1998-US25676, filed on 3 Dec 1998
PRAI US 1998-99800P 19980910 (60)
US 1998-89685P 19980617 (60)
US 1998-78935P 19980320 (60)
US 1997-67423P 19971203 (60)
DT Utility
FS GRANTED
LN.CNT 5426
INCL INCLM: 530/402.000
INCLS: 530/350.000; 530/399.000; 530/359.000; 436/071.000; 514/012.000;
514/506.000; 514/762.000
NCL NCLM: 530/402.000
NCLS: 436/071.000; 530/350.000; 530/359.000; 530/399.000
IC [7]
ICM: C07K014-435
ICS: C07K001-107
EXF 436/71; 530/350; 530/399; 530/402; 530/359; 514/12; 514/506; 514/762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 250 OF 391 USPATFULL on STN
AN 2002:221784 USPATFULL
TI Inhibitors of IAPP fibril formation and uses thereof
IN Fraser, Paul, Toronto, CANADA
PI US 2002119926 A1 20020829
AI US 2001-956625 A1 20010919 (9)
PRAI US 2000-233482P 20000919 (60)
DT Utility
FS APPLICATION
LN.CNT 1753
INCL INCLM: 514/012.000
INCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
IC [7]
ICM: A61K038-17
ICS: A61K038-10; A61K038-08; C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 251 OF 391 USPATFULL on STN
AN 2002:217052 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., 910 Rosewood Ave. SE., Grand Rapids, MI, United States
49506
Bienkowski, Michael J., 3431 Hollow Wood, Portage, MI, United States
49024
Heinrikson, Robert L., 81 S. Lake Doster Dr., Plainwell, MI, United
States 49080
Parodi, Luis A., Grevgafar 24, S-11543 Stockholm, SWEDEN
Yan, Riqiang, 5026 Queen Victoria St., Kalamazoo, MI, United States
49009
PI US 6440698 B1 20020827
AI US 2000-548367 20000412 (9)
RLI Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS GRANTED
LN.CNT 5651
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/325.000; 435/320.100; 536/023.100
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: C12P021-06
ICS: C12N001-20; C12N018-00; C07H021-04
EXF 435/70.1; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/183; 435/212;
435/219; 536/23.1; 536/23.4; 536/23.7; 536/23.5; 536/24.3; 514/2;
424/94.63; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 252 OF 391 USPATFULL on STN
AN 2002:217052

TI Inhibitors of memapsin 2 and use thereof
IN Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Tang, Jordan J.N., Edmond, OK, UNITED STATES
Hong, Lin, Oklahoma City, OK, UNITED STATES
Ghosh, Arun K., River Forest, IL, UNITED STATES
PA Oklahoma Medical Research Foundation (U.S. corporation)
PI US 2002115600 A1 20020822
AI US 2001-845226 A1 20010430 (9)
RLI Division of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)

DT Utility
FS APPLICATION

LN.CNT 2377

INCL INCLM: 514/012.000
INCLS: 435/184.000; 530/326.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 530/326.000
IC [7]
ICM: A61K038-17
ICS: A61K038-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 253 OF 391 USPATFULL on STN
AN 2002:206604 USPATFULL
TI PREVENTION OF FETAL ALCOHOL SYNDROME AND NEURONAL CELL DEATH WITH ADNF
POLYPEPTIDES
IN BRENNEMAN, DOUGLAS E., DAMASCUS, MD, UNITED STATES
SPONG, CATHERINE Y., ARLINGTON, VA, UNITED STATES
GOZES, ILLANA, RAMAT HASHARON, ISRAEL
BASSAN, MERAV, RAMAT HASHARON, ISRAEL
ZAMOSTIANO, RACHEL, HOD HASHARON, ISRAEL
PI US 2002111301 A1 20020815
AI US 1999-267511 A1 19990312 (9)

DT Utility
FS APPLICATION

LN.CNT 1861
INCL INCLM: 514/012.000
INCLS: 514/002.000
NCL NCLM: 514/012.000
NCLS: 514/002.000
IC [7]
ICM: A61K038-00
ICS: A01N037-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 254 OF 391 USPATFULL on STN
AN 2002:202241 USPATFULL
TI Death domain containing receptor-4
IN Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Pan, James G., Belmont, CA, United States
Gentz, Reiner L., Rockville, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
The Regents of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)

PI US 6433147 B1 20020813
AI US 2000-565918 20000505 (9)
RLI Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998,
now patented, Pat. No. US 6342363

PRAI US 1999-132922P 19990506 (60)
US 1997-35722P 19970128 (60)
US 1997-37829P 19970205 (60)

DT Utility
FS GRANTED

LN.CNT 8675

INCL INCLM: 530/387.300
INCLS: 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500;
435/069.100; 435/325.000; 435/252.300; 435/254.110; 424/178.100

NCL NCLM: 530/387.300
NCLS: 434/178.100; 435/069.100; 435/252.300; 435/254.110; 435/225.000;

IC [7] 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500

EXF ICM: C07K014-705
530/300; 530/350; 530/402; 530/387.3; 536/23.1; 536/23.5; 536/23.4;
435/69.1; 435/375; 435/252.3; 435/254.11; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 391 USPATFULL on STN

AN 2002:201837 USPATFULL

TI Diagnostic applications of perlecan domain I splice variants

IN Maresh, Grace A., River Ridge, LA, United States

Snow, Alan D., Lynnwood, WA, United States

PA University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 6432636 B1 20020813

AI US 1997-918428 19970826 (8)

PRAI US 1996-25030P 19960826 (60)

DT Utility

FS GRANTED

LN.CNT 3479

INCL INCLM: 435/006.000

INCLS: 435/091.200; 536/023.500; 536/024.310; 536/024.330

NCL NCLM: 435/006.000

NCLS: 435/091.200; 536/023.500; 536/024.310; 536/024.330

IC [7]

ICM: C12Q001-68

ICS: C12Q019-34; C07H021-04; C07H021-02

EXF 435/6; 435/91.2; 536/23.5; 536/24.31; 536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 391 USPATFULL on STN

AN 2002:194691 USPATFULL

TI Protein fragment complementation assays for the detection of biological or drug interactions

IN Michnick, Stephen William Watson, Westmount, CANADA

Pelletier, Joelle Nina, Westmount, CANADA

Remy, Ingrid, Montreal, CANADA

PA Odyssey Pharmaceuticals, Inc., San Ramon, CA, United States (U.S. corporation)

PI US 6428951 B1 20020806

AI US 2000-499464 20000207 (9)

RLI Continuation of Ser. No. US 1998-17412, filed on 2 Feb 1998, now patented, Pat. No. US 6270964

PRAI CA 1997-2196496 19970131

DT Utility

FS GRANTED

LN.CNT 2595

INCL INCLM: 435/004.000

INCLS: 435/006.000; 530/350.000; 536/023.200; 536/023.400

NCL NCLM: 435/004.000

NCLS: 435/006.000; 530/350.000; 536/023.200; 536/023.400

IC [7]

ICM: C12Q001-25

ICS: C12Q001-68; C07K014-00; C12N015-11

EXF 435/4; 435/6; 530/350; 536/23.2; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 257 OF 391 USPATFULL on STN

AN 2002:193030 USPATFULL

TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease

IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES

Wands, Jack R., Waban, MA, UNITED STATES

PI US 2002104108 A1 20020801

AI US 2001-964666 A1 20010928 (9)

RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN

PRAI US 1997-38908P 19970226 (60)

DT Utility

FS APPLICATION

LN.CNT 2100

INCL INCLM: 800/012.000

INCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200

NCL NCLM: 800/012.000

NCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200

IC [7]

ICM: A01K007.027

ICS: C07H021-04; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 258 OF 391 USPATFULL on STN
AN 2002:192279 USPATFULL
TI Sequences characteristic of hypoxia-regulated gene transcription
IN Einat, Paz, Nes-Ziona, ISRAEL
Skaliter, Rami, Nes-Ziona, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PI US 2002103353 A1 20020801
AI US 2001-802472 A1 20010309 (9)
RLI Continuation-in-part of Ser. No. US 1999-384096, filed on 27 Aug 1999,
ABANDONED Continuation-in-part of Ser. No. US 1998-138109, filed on 21
Aug 1998, ABANDONED
PRAI US 1998-98158P 19980827 (60)
US 2001-132684P 20010905 (60)
US 1997-56453P 19970821 (60)
DT Utility
FS APPLICATION
LN.CNT 5096
INCL INCLM: 536/023.200
INCLS: 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 536/023.200
NCLS: 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C07H021-04
ICS: C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 259 OF 391 USPATFULL on STN
AN 2002:192113 USPATFULL
TI Cyclic malonamides as inhibitors of a beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Yang, Michael G., Wilmington, DE, UNITED STATES
PI US 2002103184 A1 20020801
AI US 2001-825211 A1 20010403 (9)
PRAI US 2000-194503P 20000403 (60)
DT Utility
FS APPLICATION
LN.CNT 6436
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; C07D223-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 260 OF 391 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length ***human*** cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 28061
INCL INCLM: 435/007.100
INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 261 OF 391 USPATFULL on STN
AN 2002:185265 USPATFULL
TI Modulators of amyloid aggregation
IN Findeis, Mark A., Cambridge, MA, UNITED STATES

Garnick, Marc B., Brookline, MA, UNITED STATES
Gefter, Malcolm L., Lincoln, MA, UNITED STATES
Hundal, Arvind, Brighton, MA, UNITED STATES
Kasman, Laura, Athens, GA, UNITED STATES
Musso, Gary, Hopkinton, MA, UNITED STATES
Signer, Ethan R., Cambridge, MA, UNITED STATES
Wakefield, James, Brookline, MA, UNITED STATES
Reed, Michael J., Marietta, GA, UNITED STATES
PA Praecis Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002098173 A1 20020725
AI US 2001-972475 A1 20011004 (9)
RLI Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, PATENTED
Continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995,
PATENTED Continuation-in-part of Ser. No. US 1995-404831, filed on 14
Mar 1995, PATENTED Continuation-in-part of Ser. No. US 1995-548998,
filed on 27 Oct 1995, ABANDONED

DT Utility
FS APPLICATION
LN.CNT 4009
INCL INCLM: 424/094.300
INCLS: 435/226.000
NCL NCLM: 424/094.300
NCLS: 435/226.000
IC [7]
ICM: A61K038-54
ICS: C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 262 OF 391 USPATFULL on STN
AN 2002:178549 USPATFULL
TI Vaccine for the prevention and treatment of alzheimer's and amyloid
related diseases
IN Chalifour, Robert, Ile Bizard, CANADA
Hebert, Lise, Brossard, CANADA
Kong, Xianqi, Dollard-des-Oremaux, CANADA
Gervais, Francine, Ile Bizard, CANADA
PI US 2002094335 A1 20020718
AI US 2001-867847 A1 20010529 (9)
RLI Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000,
PENDING

PRAI US 1999-168594P 19991129 (60)
DT Utility
FS APPLICATION
LN.CNT 1946
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 263 OF 391 USPATFULL on STN
AN 2002:175286 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses thereof
IN Gurney, Mark E., Grand Rapids, MI, United States
Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S.
corporation)
PI US 6420534 B1 20020716
AI US 2000-548372 20000412 (9)
RLI Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)

DT Utility
FS GRANTED
LN.CNT 5653
INCL INCLM: 530/827.000
INCLS: 530/350.000; 435/023.000; 435/024.000
NCL NCLM: 435/226.000
NCLS: 435/023.000; 435/024.000; 435/069.100; 530/350.000
IC [7]

ICS: C07K014-00; C07K017-00; C12Q001-37
EXF 530/300; 530/350; 530/827; 435/23; 435/24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 264 OF 391 USPATFULL on STN
AN 2002:174955 USPATFULL
TI Methods of screening for agents that inhibit aggregation of polypeptides
IN Housman, David E., Newton, MA, United States
Preisinger, Elizabeth A., Roslindale, MA, United States
Kazantsev, Aleksey G., Boston, MA, United States
PA Massachusetts Institute of Technology, Boston, MA, United States (U.S. corporation)
PI US 6420122 B1 20020716
AI US 1999-405048 19990927 (9)
DT Utility
FS GRANTED
LN.CNT 1135
INCL INCLM: 435/007.100
INCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000
NCL NCLM: 435/007.100
NCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000
IC [7]
ICM: G01N033-53
EXF 436/86; 436/501; 536/23.4; 530/300; 530/350; 435/7.1; 435/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 265 OF 391 USPATFULL on STN
AN 2002:172315 USPATFULL
TI Endothelin converting enzymes and the amyloid beta peptide
IN Eckman, Christopher B., Ponte Vedra Beach, FL, UNITED STATES
Eckman, Elizabeth A., Ponte Vedra Beach, FL, UNITED STATES
PI US 2002091072 A1 20020711
AI US 2001-824924 A1 20010403 (9)
PRAI US 2000-233012P 20000915 (60)
DT Utility
FS APPLICATION
LN.CNT 1315
INCL INCLM: 514/001.000
INCLS: 435/006.000; 435/007.210
NCL NCLM: 514/001.000
NCLS: 435/006.000; 435/007.210
IC [7]
ICM: A61K031-00
ICS: C12Q001-68; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 266 OF 391 USPATFULL on STN
AN 2002:164826 USPATFULL
TI PURIFIED 20 KDA PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF
SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
IN TANZI, RUDOLPH E., HULL, MA, UNITED STATES
KIM, TAE-WAN, WALTHAM, MA, UNITED STATES
PI US 2002086444 A1 20020704
AI US 1998-65902 A1 19980424 (9)
PRAI US 1997-44262P 19970424 (60)
DT Utility
FS APPLICATION
LN.CNT 2012
INCL INCLM: 436/536.000
INCLS: 530/388.100; 530/388.850; 436/548.000
NCL NCLM: 436/536.000
NCLS: 530/388.100; 530/388.850; 436/548.000
IC [7]
ICM: G01N033-53
ICS: C07K016-00; C12P021-08; G01N033-536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 267 OF 391 USPATFULL on STN
AN 2002:164825 USPATFULL
TI Magnetic in situ dilution
IN Bamdad, Cynthia C., Newton, MA, UNITED STATES
PI US 2002086443 A1 20020704
AI US 2001-971099 A1 20011003 (9)
PRAI US 2000-237427P 20001003 (60)
US 2001-272727P 20010301 (60)
DT Utility

FS APPLICATION
LN.CNT 1494
INCL INCLM: 436/526.000
NCL NCLM: 436/526.000
IC [7]
ICM: G01N033-553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 268 OF 391 USPATFULL on STN
AN 2002:157080 USPATFULL
TI NARC8 programmed cell-death-associated molecules and uses thereof
IN Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002081679 A1 20020627
AI US 2001-775009 A1 20010201 (9)
RLI Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000,
PENDING
PRAI US 1999-161188P 19991022 (60)
DT Utility
FS APPLICATION
LN.CNT 4095
INCL INCLM: 435/183.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
NCL NCLM: 435/183.000
NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
IC [7]
ICM: C12N009-00
ICS: C12N009-64; C07H021-04; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 269 OF 391 USPATFULL on STN
AN 2002:157035 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., Reykjavik, ICELAND
Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
PI US 2002081634 A1 20020627
AI US 2001-681442 A1 20010405 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999,
PENDING Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23
Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 5573
INCL INCLM: 435/007.210
INCLS: 435/006.000; 435/226.000
NCL NCLM: 435/007.210
NCLS: 435/006.000; 435/226.000
IC [7]
ICM: G01N033-567
ICS: C12Q001-68; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 270 OF 391 USPATFULL on STN
AN 2002:149132 USPATFULL
TI Synthetic immunogenic but non-amyloidogenic peptides homologous to
amyloid beta for induction of an immune response to amyloid beta and
amyloid deposits
IN Frangione, Blas, New York, NY, UNITED STATES
Wisniewski, Thomas, Staten Island, NY, UNITED STATES
Sigurdsson, Einar M., New York, NY, UNITED STATES
PA New York University, New York, NY (U.S. corporation)
PI US 2002077288 A1 20020620
AI US 2001-861847 A1 20010522 (9)
PRAI US 1996-16233P 19960426 (60)
DT Utility
FS APPLICATION
LN.CNT 1875
INCL INCLM: 514/012.000

NCL INCLS: 514/013.000; 514/014.000; 530/324.000; 530/326.000; 530/327.000
NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 530/324.000; 530/326.000; 530/327.000
[7]
ICM: A61K038-16
ICS: C07K014-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 271 OF 391 USPATFULL on STN
AN 2002:149131 USPATFULL
TI 28 ***human*** secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Li, Haodong, Gaithersburg, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
PI US 2002077287 A1 20020620
AI US 2001-852659 A1 20010511 (9)
RLI Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998,
UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 17779
INCL INCLM: 514/012.000
INCLS: 435/325.000; 435/320.100; 435/069.100; 435/183.000; 530/350.000;
536/023.200
NCL NCLM: 514/012.000
NCLS: 435/325.000; 435/320.100; 435/069.100; 435/183.000; 530/350.000;
536/023.200
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 272 OF 391 USPATFULL on STN
AN 2002:148656 USPATFULL
TI Compositions and methods for modulating TGF-beta signaling
IN Wang, Tongwen, Seattle, WA, UNITED STATES
PI US 2002076799 A1 20020620
AI US 2001-927738 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US3561, filed on 11 Feb 2000,
UNKNOWN
PRAI US 1999-119786P 19990211 (60)
DT Utility
FS APPLICATION
LN.CNT 5961
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260;
536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260;
536/023.200
IC [7]
ICM: C12N009-64
ICS: C12N009-00; C07H021-04; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 273 OF 391 USPATFULL on STN
AN 2002:148614 USPATFULL
TI 28 ***human*** secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES

Soppet, Daniel R., Centreville, VA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
PI US 2002076756 A1 20020620
AI US 2001-853161 A1 20010511 (9)
PRAI US 2001-265583P 20010202 (60)
DT Utility
FS APPLICATION
LN.CNT 17788
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07H021-04; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 274 OF 391 USPATFULL on STN
AN 2002:129982 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6399628 B1 20020604
AI US 1999-266908 19990312 (9)
RLI Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now patented, Pat. No. US 5965614
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS GRANTED
LN.CNT 2944
INCL INCLM: 514/311.000
INCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;
514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;
514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;
548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;
560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
NCL NCLM: 514/311.000
NCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;
514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;
514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;
548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;
560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
IC [7]
ICM: C07D215-38
ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02;
C07C229-28
EXF 514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471;
514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496;
548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161;
562/433; 562/457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 275 OF 391 USPATFULL on STN
AN 2002:129731 USPATFULL
TI Methods of detection of amyloidogenic proteins
IN Krishnamurthy, Girija, Chestnut Ridge, NY, United States
PA American Cyanamid Company, Madison, NY, United States (U.S. corporation)
PI US 6399314 B1 20020604
AI US 1999-474970 19991229 (9)
DT Utility

FS GRANTED
LN.CNT 1359
INCL INCLM: 435/007.100
INCLS: 514/001.000; 514/002.000; 530/387.100
NCL NCLM: 435/007.100
NCLS: 514/001.000; 514/002.000; 530/387.100
IC [7]
ICM: G01N033-53
ICS: A01N061-00; A61K031-00; C07K016-00
EXF 514/1; 514/2; 435/7.1; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 276 OF 391 USPATFULL on STN
AN 2002:126307 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., Grand Rapids, MI, UNITED STATES
Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
Pharmacia & Upjohn Company (U.S. corporation)
PA
PI US 2002064819 A1 20020530
AI US 2001-794925 A1 20010227 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 5465
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C07H021-04
ICS: C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 277 OF 391 USPATFULL on STN
AN 2002:122820 USPATFULL
TI Transgenic mice expressing ***human*** presenilin proteins
IN St. George-Hyslop, Peter H., Toronto, CANADA
Rommens, Johanna M., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA The Hospital for sick Children, Toronto, CANADA (non-U.S. corporation)
HSC Research and Development Limited Partnership, Toronto, CANADA
(non-U.S. corporation)
The Governing Council of the University of Toronto, Toronto, CANADA
(non-U.S. corporation)
PI US 6395960 B1 20020528
AI US 1998-124523 19980729 (9)
RLI Division of Ser. No. US 1997-967101, filed on 10 Nov 1997, now patented,
Pat. No. US 5840540 Division of Ser. No. US 1996-592541, filed on 26 Jan
1996, now patented, Pat. No. US 5986054 Continuation-in-part of Ser. No.
US 1995-509359, filed on 31 Jul 1995, now abandoned Continuation-in-part
of Ser. No. US 1995-496841, filed on 28 Jun 1995, now patented, Pat. No.
US 6210919 Continuation-in-part of Ser. No. US 1995-431048, filed on 28
Apr 1995
DT Utility
FS GRANTED
LN.CNT 4103
INCL INCLM: 800/018.000
INCLS: 800/012.000; 800/013.000; 800/014.000; 800/017.000
NCL NCLM: 800/018.000
NCLS: 800/012.000; 800/013.000; 800/014.000; 800/017.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; A01K067-033
EXF 800/8; 800/12; 800/13; 800/14; 800/17; 800/18

L4 ANSWER 278 OF 391 USPATFULL on STN
AN 2002:119886 USPATFULL
TI Substituted alkyl substituted 5-oxo-5,6-dihydro-4H-1,3-dioxin-2-ylmethyl

IN Yang, Michael G., Wilmington, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
PI US 2002061874 A1 20020523
AI US 2001-824945 A1 20010403 (9)
PRAI US 2000-194302P 20000403 (60)
DT Utility
FS APPLICATION
LN.CNT 4518
INCL INCLM: 514/212.040
INCLS: 514/212.070; 514/212.080; 514/221.000; 540/504.000; 540/522.000;
540/523.000; 540/524.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 514/212.080; 514/221.000; 540/504.000; 540/522.000;
540/523.000; 540/524.000
IC [7]
ICM: A61K031-5513
ICS: A61K031-55; C07D243-24; C07D223-16; C07D223-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 279 OF 391 USPATFULL on STN
AN 2002:112541 USPATFULL
TI Proteins related to schizophrenia and uses thereof
IN St. George-Hyslop, Peter H., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA The Governing Council of the University of Toronto (non-U.S.
corporation)
PI US 2002058276 A1 20020516
AI US 2001-945258 A1 20010831 (9)
PRAI US 2000-229889P 20000901 (60)
DT Utility
FS APPLICATION
LN.CNT 2909
INCL INCLM: 435/006.000
INCLS: 424/009.200; 800/003.000
NCL NCLM: 435/006.000
NCLS: 424/009.200; 800/003.000
IC [7]
ICM: C12Q001-68
ICS: A61K049-00; A01K067-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 280 OF 391 USPATFULL on STN
AN 2002:106320 USPATFULL
TI Method for treating alzheimer's disease
IN Bisgaier, Charles Larry, Ann Arbor, MI, UNITED STATES
Emmerling, Mark Richard, Chelsea, MI, UNITED STATES
Roher, Alex Eugene, Carefree, AZ, UNITED STATES
PI US 2002055529 A1 20020509
AI US 2001-888592 A1 20010626 (9)
RLI Division of Ser. No. US 2000-554994, filed on 23 May 2000, PENDING
PRAI WO 1998-US25495 19981202
DT Utility
FS APPLICATION
LN.CNT 819
INCL INCLM: 514/369.000
INCLS: 514/381.000; 514/356.000; 514/559.000; 514/560.000; 514/557.000
NCL NCLM: 514/369.000
NCLS: 514/381.000; 514/356.000; 514/559.000; 514/560.000; 514/557.000
IC [7]
ICM: A61K031-455
ICS: A61K031-426; A61K031-41; A61K031-202; A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 281 OF 391 USPATFULL on STN
AN 2002:106292 USPATFULL
TI Succinoylamino carbocycles and heterocycles as inhibitors of a-beta
protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Maduskuie, Thomas P., Wilmington, DE, UNITED STATES
Thompson, Lorin A., Wilmington, DE, UNITED STATES
Tebben, Andrew J., Wallingford, PA, UNITED STATES
Wang, Nenghui, Newark, DE, UNITED STATES
Deng, Wei, Wilmington, DE, UNITED STATES
Liu, Hong, Newark, DE, UNITED STATES
PI US 2002055501 A1 20020509
US 6525014 B2 20020225

AI US 2001-788227 A1 20010216 (9)
PRAI US 2000-183186P 20000217 (60)
DT Utility
FS APPLICATION
LN.CNT 7229
INCL INCLM: 514/212.050
INCLS: 514/221.000; 540/500.000; 540/523.000
NCL NCLM: 514/220.000
NCLS: 540/496.000
IC [7]
ICM: A61K031-551
ICS: A61K031-55; C07D498-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 282 OF 391 USPATFULL on STN
AN 2002:102272 USPATFULL
TI Alzheimer's related proteins and methods of use
IN St. George-Hyslop, Peter H., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
PA The Governing Council of the University of Toronto, Toronto, CANADA
(non-U.S. corporation)
PI US 6383758 B1 20020507
AI US 1999-227725 19990108 (9)
PRAI US 1998-70948P 19980109 (60)
DT Utility
FS GRANTED
LN.CNT 1420
INCL INCLM: 435/007.100
INCLS: 530/350.000
NCL NCLM: 435/007.100
NCLS: 530/350.000
IC [7]
ICM: G01M033-53
ICS: C07K014-00
EXF 435/7.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 283 OF 391 USPATFULL on STN
AN 2002:99459 USPATFULL
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of a
beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
Thompson III, Lorin A., Wilmington, DE, UNITED STATES
PI US 2002052360 A1 20020502
US 6503902 B2 20030107
AI US 2001-805645 A1 20010314 (9)
RLI Continuation-in-part of Ser. No. US 2000-661008, filed on 13 Sep 2000,
PENDING
PRAI US 1999-153511P 19990913 (60)
US 2000-224388P 20000809 (60)
DT Utility
FS APPLICATION
LN.CNT 6949
INCL INCLM: 514/212.040
INCLS: 514/218.000; 514/220.000; 540/522.000; 540/523.000; 540/504.000
NCL NCLM: 514/221.000
NCLS: 540/509.000
IC [7]
ICM: A61K031-55
ICS: A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 284 OF 391 USPATFULL on STN
AN 2002:99421 USPATFULL
TI Methods and compounds for inhibiting ***beta*** - ***amyloid***
peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nikolic, Zeljko S., Indianapolis, IN, UNITED STATES

Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
PI US 2002052322 A1 20020502
AI US 2001-789487 A1 20010220 (9)
RLI Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,
Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
US 1997-64859P 19970228 (60)
DT Utility
FS APPLICATION
LN.CNT 14911
INCL INCLM: 514/018.000
INCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
NCL NCLM: 514/018.000
NCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
IC [7]
ICM: A61K038-06
ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 285 OF 391 USPATFULL on STN
AN 2002:92777 USPATFULL
TI Catalytically active recombinant memapsin and methods of use thereof
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES
Lin, Xinli, Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Hong, Lin, Oklahoma City, OK, UNITED STATES
PI US 2002049303 A1 20020425
AI US 2001-796264 A1 20010228 (9)
RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200;
514/002.000; 530/387.900
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200;
514/002.000; 530/387.900
IC [7]
ICM: C12N015-09
ICS: C12N009-64; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 286 OF 391 USPATFULL on STN
AN 2002:91754 USPATFULL
TI Methods and composition for restoring conformational stability of a
protein of the p53 family
IN Rastinejad, Farzan, Old Saybrook, CT, UNITED STATES
Foster, Barbara A., Mystic, CT, UNITED STATES
Coffey, Heather A., Groton, CT, UNITED STATES
Connell, Richard D., East Lyme, CT, UNITED STATES
PI US 2002048271 A1 20020425
AI US 2001-863976 A1 20010523 (9)
RLI Continuation of Ser. No. US 1999-443542, filed on 19 Nov 1999, PENDING
PRAI US 1998-110542P 19981202 (60)
DT Utility
FS APPLICATION
LN.CNT 2082
INCL INCLM: 370/395.000
INCLS: 514/228.200; 514/232.800; 514/234.500; 514/252.170; 514/259.000;
514/253.020; 514/253.030; 514/284.000; 514/290.000
NCL NCLM: 370/395.000
NCLS: 514/228.200; 514/232.800; 514/234.500; 514/252.170; 514/259.000;
514/253.020; 514/253.030; 514/284.000; 514/290.000

IC [7]
ICM: A61K031-5415
ICS: A61K031-5377; A61K031-496; A61K031-517; A61K031-473; H04L012-28;
H04L012-56

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 287 OF 391 USPATFULL on STN
AN 2002:88227 USPATFULL
TI Screening methods for agents that modulate or inhibit tau association
with tau or map2
IN Wischik, Claude Michel, Cambridge, UNITED KINGDOM
Edwards, Patricia Carol, Cambridge, UNITED KINGDOM
Harrington, Charles Robert, Cambridge, UNITED KINGDOM
Roth, Martin, Cambridge, UNITED KINGDOM
Klug, Aaron, Cambridge, UNITED KINGDOM
PA University Court of the University of Aberdeen, Aberdeen, UNITED KINGDOM
(non-U.S. corporation)
PI US 6376205 B1 20020423
WO 9630766 19961003
AI US 1997-913915 19971212 (8)
WO 1996-EP1307 19960325
19971212 PCT 371 date
PRAI GB 1995-6197 19950327
DT Utility
FS GRANTED
LN.CNT 1856
INCL INCLM: 435/007.800
INCLS: 435/007.100; 435/007.920; 436/501.000; 436/503.000; 436/504.000
NCL NCLM: 435/007.800
NCLS: 435/007.100; 435/007.920; 436/501.000; 436/503.000; 436/504.000
IC [7]
ICM: G01N033-53
EXF 435/701; 435/7.8; 435/7.92; 436/501; 436/503; 436/504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 288 OF 391 USPATFULL on STN
AN 2002:85579 USPATFULL
TI Method and composition for modulating amyloidosis
IN Reiner, Peter B., Vancouver, CANADA
Connop, Bruce P., Vancouver, CANADA
PA The University of British Columbia (non-U.S. corporation)
PI US 2002045621 A1 20020418
US 6472145 B2 20021029
AI US 2001-874968 A1 20010605 (9)
RLI Continuation of Ser. No. US 2000-660599, filed on 13 Sep 2000, ABANDONED
Continuation of Ser. No. US 1999-383317, filed on 25 Aug 1999, PATENTED
Continuation of Ser. No. US 1998-80141, filed on 15 May 1998, PATENTED
DT Utility
FS APPLICATION
LN.CNT 1150
INCL INCLM: 514/237.800
INCLS: 514/247.000; 514/255.060; 514/255.010; 514/256.000; 514/317.000;
514/370.000; 514/377.000; 514/430.000; 514/415.000; 514/426.000;
514/459.000; 514/646.000
NCL NCLM: 435/004.000
NCLS: 435/029.000
IC [7]
ICM: A61K031-535
ICS: A61K031-50; A61K031-495; A61K031-135; A61K031-40; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 289 OF 391 USPATFULL on STN
AN 2002:78763 USPATFULL
TI ***Beta*** - ***amyloid*** inhibitors, processes for preparing
them, and their use in pharmaceutical compositions
IN Briem, Hans, Bremen, GERMANY, FEDERAL REPUBLIC OF
Mendla, Klaus, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Romig, Helmut Michael, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
Fechteler, Katja, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF
Fuchs, Klaus, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2002042420 A1 20020411
US 6514969 B2 20030204
AI US 2001-911825 A1 20010724 (9)
PRAI DE 2000-10040016 20000816
US 2000-227039P 20000823 (60)
DT Utility

FS APPLICATION
LN.CNT 1132
INCL INCLM: 514/253.040
INCLS: 514/300.000; 546/113.000; 514/233.200; 544/128.000; 544/362.000
NCL NCLM: 514/233.200
NCLS: 514/253.090; 514/322.000; 544/129.000; 544/364.000; 546/199.000
IC [7]
ICM: C07D471-02
ICS: A61K031-5377; A61K031-4745; A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 290 OF 391 USPATFULL on STN
AN 2002:67190 USPATFULL
TI METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS
IN REINER, PETER B., VANCOUVER, CANADA
LAM, FRED CHIU-LAI, VANCOUVER, CANADA
PI US 2002037843 A1 20020328
US 6514686 B2 20030204
AI US 1998-177413 A1 19981023 (9)
RLI Continuation-in-part of Ser. No. US 1998-67523, filed on 28 Apr 1998,
ABANDONED Continuation-in-part of Ser. No. US 1997-847616, filed on 28
Apr 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2452
INCL INCLM: 514/011.000
INCLS: 530/317.000; 435/004.000; 435/007.100; 436/086.000; 530/324.000;
435/183.000
NCL NCLM: 435/004.000
NCLS: 435/007.400; 436/086.000; 530/324.000
IC [7]
ICM: C12Q001-00
ICS: G01N033-53; A61K038-00; G01N033-00; C12N009-00; C07K005-00;
C07K007-00; C07K016-00; C07K017-00; A61K038-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 291 OF 391 USPATFULL on STN
AN 2002:66664 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., Grand Rapids, MI, UNITED STATES
Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
PA Pharmacia & Upjohn Company (U.S. corporation)
PI US 2002037315 A1 20020328
AI US 2001-794748 A1 20010227 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 5440
INCL INCLM: 424/450.000
INCLS: 424/093.210; 514/044.000
NCL NCLM: 424/450.000
NCLS: 424/093.210; 514/044.000
IC [7]
ICM: A61K048-00
ICS: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 292 OF 391 USPATFULL on STN
AN 2002:60975 USPATFULL
TI Avian and reptile derived polynucleotide encoding a polypeptide having
heparanase activity
IN Goldshmidt, Orit, Jerusalem, ISRAEL
Pecker, Iris, Rishon LeZion, ISRAEL
Vlodavsky, Israel, Mevaseret Zion, ISRAEL
Michal, Israel, Ashkelon, ISRAEL
Zcharia, Eyal, Jerusalem, ISRAEL
PA Insight Strategy And Marketing Ltd. (non-U.S. corporation)
PT US 2002034810 A1 20020321

AI US 2001-930218 A1 20010816 (9)
RLI Continuation-in-part of Ser. No. US 2000-666390, filed on 20 Sep 2000,
PENDING
DT Utility
FS APPLICATION
LN.CNT 2355
INCL INCLM: 435/200.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 424/094.610; 536/023.200
NCL NCLM: 435/200.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 424/094.610; 536/023.200
IC [7]
ICM: C12N009-24
ICS: C07H021-04; A61K038-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 293 OF 391 USPATFULL on STN
AN 2002:43588 USPATFULL
TI Substituted lactams as inhibitors of A beta protein production
IN Han, Qi, Hockessin, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
Olson, Richard E., Wilmington, DE, UNITED STATES
Yang, Michael G., Wilmington, DE, UNITED STATES
PI US 2002025955 A1 20020228
US 6632812 B2 20031014
AI US 2001-832455 A1 20010411 (9)
PRAI US 2000-196549P 20000411 (60)
DT Utility
FS APPLICATION
LN.CNT 5194
INCL INCLM: 514/212.040
INCLS: 514/212.070; 514/212.080; 514/221.000; 540/500.000; 540/522.000;
540/523.000; 540/524.000
NCL NCLM: 514/221.000
NCLS: 540/509.000
IC [7]
ICM: A61K031-55
ICS: A61K031-5513; C07D243-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 294 OF 391 USPATFULL on STN
AN 2002:32581 USPATFULL
TI Methods to treat alzheimer's disease
IN Hom, Roy, San Francisco, CA, UNITED STATES
Mamo, Shumeye S., Oakland, CA, UNITED STATES
Tung, Jay, Belmont, CA, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
PI US 2002019403 A1 20020214
AI US 2001-816876 A1 20010323 (9)
PRAI US 2000-191528P 20000323 (60)
DT Utility
FS APPLICATION
LN.CNT 8655
INCL INCLM: 514/256.000
INCLS: 514/519.000; 514/520.000; 514/534.000
NCL NCLM: 514/256.000
NCLS: 514/519.000; 514/520.000; 514/534.000
IC [7]
ICM: A61K031-505
ICS: A61K031-275; A61K031-277; A61K031-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 295 OF 391 USPATFULL on STN
AN 2002:28127 USPATFULL
TI TRANSGENIC ANIMAL EXPRESSING NON-NATIVE WILD-TYPE AND FAMILIAL
ALZHEIMER'S DISEASE MUTANT PRESENILIN 1 PROTEIN ON NATIVE PRESENILIN 1
NULL BACKGROUND
IN ZHENG, HUI, EDISON, NJ, UNITED STATES
JIANG, PING, PLAINSBORO, NJ, UNITED STATES
QIAN, SU, SAYREVILLE, NJ, UNITED STATES
VAN DER PLOEG, LEONARDUS H. T., SCOTCH PLAINS, NJ, UNITED STATES
WONG, PHILIP CHUN-YING, TIMONIUM, MD, UNITED STATES
SISODIA, SANGRAM S., CHICAGO, IL, UNITED STATES
PI US 2002016978 A1 20020207
US 6452065 B2 20020217

AI US 1998-78871 A1 19980514 (9)
PRAI US 1998-78465P 19980318 (60)
US 1997-46488P 19970514 (60)
DT Utility
FS APPLICATION
LN.CNT 1262
INCL INCLM: 800/009.000
INCLS: 800/012.000; 800/014.000; 800/018.000; 800/025.000; 800/003.000
NCL NCLM: 800/012.000
NCLS: 435/029.000; 435/354.000; 800/003.000; 800/018.000; 800/022.000;
800/025.000

IC [7]
ICM: A01K067-027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 296 OF 391 USPATFULL on STN
AN 2002:17292 USPATFULL
TI Lactams as inhibitors of A-beta protein production
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES
PI US 2002010172 A1 20020124
US 6495540 B2 20021217
AI US 2001-817957 A1 20010327 (9)
PRAI US 2000-192527P 20000328 (60)
DT Utility
FS APPLICATION
LN.CNT 1265
INCL INCLM: 514/212.030
INCLS: 540/527.000
NCL NCLM: 514/212.030
NCLS: 514/212.080; 540/524.000; 540/525.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: C07D223-10

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 297 OF 391 USPATFULL on STN
AN 2002:16894 USPATFULL
TI 18036, a novel calpain-like protease and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002009774 A1 20020124
US 6620592 B2 20030916
AI US 2001-794960 A1 20010226 (9)
PRAI US 2000-185333P 20000228 (60)
DT Utility
FS APPLICATION
LN.CNT 3989
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/183.000; 435/320.100; 536/023.100
NCL NCLM: 435/023.000
NCLS: 435/219.000; 435/069.100; 435/325.000; 435/320.100; 435/252.300;
536/023.200
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07H021-04; C12N005-00; C12N009-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 298 OF 391 USPATFULL on STN
AN 2002:16893 USPATFULL
TI DEATH DOMAIN CONTAINING RECEPTORS
IN YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
NI, JIAN, ROCKVILLE, MD, UNITED STATES
GENTZ, REINER L., SILVER SPRING, MD, UNITED STATES
DILLON, PATRICK J., GAITHERSBURG, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2002009773 A1 20020124
AI US 1999-333966 A1 19990616 (9)
RLI Division of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat.
No. US 6153402
PRAI US 1996-13285P 19960312 (60)
US 1996-28711P 19961017 (60)
US 1997-37341P 19970206 (60)
DT Utility
FS APPLICATION
LN.CNT 3011
INCL INCLM: 435/260.100

INCLS: 536/023.500; 435/320.100; 530/325.000; 435/325.000; 530/324.000;
530/387.900; 514/002.000
NCL NCLM: 435/069.100
NCLS: 536/023.500; 435/320.100; 530/325.000; 435/325.000; 530/324.000;
530/387.900; 514/002.000
IC [7]
ICM: A01N037-18
ICS: A61K038-00; C07H021-04; C12P021-06; C12N015-00; C12N015-09;
C12N015-63; C12N015-70; C12N015-74; C07K005-00; C07K007-00; C07K016-00;
C07K017-00; C12N005-00; C12N005-02; C07K001-00; C07K014-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 299 OF 391 USPATFULL on STN
AN 2002:16872 USPATFULL
TI Compounds that selectively bind to expanded polyglutamine repeat domains
and methods of use thereof
IN Burke, James R., Chapel Hill, NC, UNITED STATES
Strittmatter, Warren J., Durham, NC, UNITED STATES
Nagai, Yoshitaka, Osaka, JAPAN
PI US 2002009752 A1 20020124
US 6632616 B2 20031014
AI US 2001-780070 A1 20010209 (9)
PRAI US 2000-189781P 20000316 (60)
DT Utility
FS APPLICATION
LN.CNT 1749
INCL INCLM: 435/007.100
INCLS: 530/324.000; 435/325.000
NCL NCLM: 435/007.100
NCLS: 435/006.000; 435/004.000; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C12N005-06; C07K007-00; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 300 OF 391 USPATFULL on STN
AN 2002:1251 USPATFULL
TI Lactacystin analogs
IN Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)
PI US 6335358 B1 20020101
AI US 1995-421583 19950412 (8)
DT Utility
FS GRANTED
LN.CNT 2285
INCL INCLM: 514/412.000
INCLS: 514/210.000; 514/414.000; 514/422.000; 514/424.000; 514/428.000;
514/439.000; 514/441.000; 514/443.000; 514/444.000; 514/464.000;
514/465.000; 514/466.000
NCL NCLM: 514/412.000
NCLS: 514/192.000; 514/210.050; 514/210.060; 514/414.000; 514/422.000;
514/424.000; 514/428.000; 514/439.000; 514/441.000; 514/443.000;
514/444.000; 514/464.000; 514/465.000; 514/466.000
IC [7]
ICM: A61K031-36
ICS: A61K031-385; A61K031-38; A61K031-40
EXF 514/210; 514/412; 514/414; 514/422; 514/424; 514/428; 514/439; 514/441;
514/443; 514/444; 514/464; 514/465; 514/466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 301 OF 391 USPATFULL on STN
AN 2001:235274 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting . ***beta*** .-
amyloid peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States

PA Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
PI Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
US 6333351 B1 20011225
AI US 1999-303655 19990503 (9)
RLI Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS GRANTED
LN.CNT 3252
INCL INCLM: 514/538.000
INCLS: 560/037.000; 514/432.000; 514/452.000; 549/023.000; 549/362.000
NCL NCLM: 514/538.000
NCLS: 514/432.000; 514/452.000; 549/023.000; 549/362.000; 560/037.000
IC [7]
ICM: C07C229-06
ICS: A61K031-24; A61K031-38; A61K031-335
EXF 560/37; 514/538; 514/432; 514/452; 549/23; 549/362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 302 OF 391 USPATFULL on STN
AN 2001:231155 USPATFULL
TI Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production
IN Zaczek, Robert, 18 Roosevelt Way, Avondale, PA, United States 19311
Olson, Richard E., 7 Pelham Rd., Wilmington, DE, United States 19803
Seiffert, Dietmar A., 3719 Highland Dr., Boothwyn, PA, United States 19061
Thompson, Lorin Andrew, 600 Silverside Rd., Wilmington, DE, United States 19809
PI US 6331408 B1 20011218
AI US 1999-438901 19991112 (9)
PRAI US 1999-131284P 19990427 (60)
US 1998-108147P 19981112 (60)
DT Utility
FS GRANTED
LN.CNT 3570
INCL INCLM: 435/023.000
INCLS: 435/024.000; 435/004.000; 435/968.000
NCL NCLM: 435/023.000
NCLS: 435/004.000; 435/024.000; 435/968.000
IC [7]
ICM: C12Q001-37
ICS: C12Q001-00; G01N033-53
EXF 435/23; 435/24; 435/4; 435/968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 303 OF 391 USPATFULL on STN
AN 2001:229689 USPATFULL
TI Method for treating Alzheimer's disease
IN Ahn, Kyunghye, Ann Arbor, MI, United States
Emmerling, Mark Richard, Chelsea, MI, United States
Haske, Taraneh, Ann Arbor, MI, United States
Hupe, Donald J., Ann Arbor, MI, United States
Sebolt-Leopold, Judith, Ann Arbor, MI, United States
Levine, Harry, III, Ann Arbor, MI, United States
Scholten, Jeffrey David, Pinckney, MI, United States
PI US 2001051642 A1 20011213
AI US 2001-771529 A1 20010129 (9)
PRAI US 2000-197484P 20000417 (60)
DT Utility
FS APPLICATION
LN.CNT 729
INCL INCLM: 514/341.000
INCLS: 514/314.000; 514/400.000
NCL NCLM: 514/341.000
NCLS: 514/314.000; 514/400.000
IC [7]
ICM: A61K031-4164
ICS: A61K031-4439; A61K031-4709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 304 OF 391 USPATFULL on STN
AN 2001:211963 USPATFULL
TI Smilagenin and its use
IN Xia, Zongqin, Shanghai, China
Rubin, Ian, Leicester, Great Britain
Whittle, Brian, Hornsea, Great Britain
Gunning, Philip, Saffron Walden, Great Britain
Hu, Yaer, Shanghai, China
Brostoff, Jonathan, London, Great Britain
Wang, Weijun, Huntingdon, Great Britain
PI US 2001043955 A1 20011122
AI US 2001-866234 A1 20010525 (9)
RLI Division of Ser. No. US 1999-362328, filed on 28 Jul 1999, GRANTED, Pat.
No. US 6258386
PRAI GB 1999-5275 19990308
DT Utility
FS APPLICATION
LN.CNT 682
INCL INCLM: 424/725.000
INCLS: 424/769.000; 514/025.000
NCL NCLM: 424/725.000
NCLS: 424/769.000; 514/025.000
IC [7]
ICM: A61K035-78
ICS: A61K031-70

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 305 OF 391 USPATFULL on STN
AN 2001:208478 USPATFULL
TI Modulators of amyloid aggregation
IN Findeis, Mark A., Cambridge, MA, United States
Benjamin, Howard, Lexington, MA, United States
Garnick, Marc B., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
Hundal, Arvind, Brighton, MA, United States
Kasman, Laura, Athens, GA, United States
Musso, Gary, Hopkinton, MA, United States
Signer, Ethan R., Cambridge, MA, United States
Wakefield, James, Brookline, MA, United States
Reed, Michael J., Marietta, GA, United States
PA Praecis Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S.
corporation)
PI US 6319498 B1 20011120
AI US 1996-617267 19960314 (8)
RLI Continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct 1995,
now abandoned Continuation-in-part of Ser. No. US 1995-475579, filed on
7 Jun 1995, now patented, Pat. No. US 5854215 Continuation-in-part of
Ser. No. US 1995-404831, filed on 14 Mar 1995, now patented, Pat. No. US
5817626
DT Utility
FS GRANTED
LN.CNT 4293
INCL INCLM: 424/094.300
INCLS: 424/094.610; 435/188.000; 435/206.000; 514/007.000; 514/012.000;
514/021.000; 530/307.000; 530/324.000; 530/345.000; 530/350.000;
530/359.000; 530/382.000; 530/394.000; 530/402.000; 530/410.000
NCL NCLM: 424/094.300
NCLS: 424/094.610; 435/188.000; 435/206.000; 514/007.000; 514/012.000;
514/021.000; 530/307.000; 530/324.000; 530/345.000; 530/350.000;
530/359.000; 530/382.000; 530/394.000; 530/402.000; 530/410.000
IC [7]
ICM: A61K038-02
ICS: A61K038-17; C07K001-113; C07K014-47
EXF 514/7; 514/12; 514/21; 435/188; 435/206; 424/94.3; 424/94.61; 530/307;
530/324; 530/325; 530/326; 530/345; 530/350; 530/359; 530/382; 530/394;
530/402; 530/410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 306 OF 391 USPATFULL on STN
AN 2001:197049 USPATFULL
TI N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting . ***beta*** ..
amyloid peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, United States

Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6313152 B1 20011106
AI US 1999-390692 19990907 (9)
RLI Division of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS GRANTED
LN.CNT 3130
INCL INCLM: 514/357.000
INCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000;
514/469.000
NCL NCLM: 514/357.000
NCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000;
514/469.000
IC [7]
ICM: A61K031-44
ICS: A61K031-425
EXF 514/357; 514/375; 514/379; 514/438; 514/439; 514/461; 514/469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 307 OF 391 USPATFULL on STN
AN 2001:185101 USPATFULL
TI Controlling protein levels in eucaryotic organisms
IN Kenten, John H., Boyds, MD, United States
Roberts, Steven F., Bethesda, MD, United States
PA Proteinex, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 6306663 B1 20011023
AI US 1999-406781 19990928 (9)
PRAI US 1999-119851P 19990202 (60)
DT Utility
FS GRANTED
LN.CNT 2668
INCL INCLM: 436/501.000
INCLS: 424/094.100; 435/004.000; 435/007.720; 435/041.000; 435/106.000;
514/002.000; 530/300.000; 530/350.000; 930/020.000
NCL NCLM: 436/501.000
NCLS: 424/094.100; 435/004.000; 435/007.720; 435/041.000; 435/106.000;
514/002.000; 530/300.000; 530/350.000; 930/020.000
IC [7]
ICM: G01N033-566
EXF 435/41; 435/106; 435/4; 435/7.72; 436/501; 514/2; 530/300; 530/350;
930/20; 424/94.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 308 OF 391 USPATFULL on STN
AN 2001:173781 USPATFULL
TI Transgenic mouse expressing an APP-FAD DNA sequence
IN Hardy, John Anthony, Tampa, FL, United States
Chartier-Harlin, Marie-Christine, Villeneuve d'Ascq, France
Goate, Alison Mary, St. Louis, MO, United States
Owen, Michael John, South Glamorgan, United Kingdom
Mullan, Michael John, Tampa, FL, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6300540 B1 20011009
AI US 1995-464250 19950605 (8)
RLI Continuation of Ser. No. US 104165, now patented, Pat. No. US 5877015
PRAI GB 1991-1307 19910121
GB 1991-18445 19910828
DT Utility
FS GRANTED
LN.CNT 1358
INCL INCLM: 800/018.000
INCLS: 800/003.000; 800/012.000
800/013.000

IC NCLS: 800/003.000; 800/012.000
[7]
ICM: A01K067-027
ICS: A01K067-033; G01N033-00
EXF 800/2; 800/DIG.1; 800/3; 800/12; 800/18; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 309 OF 391 USPATFULL on STN
AN 2001:163000 USPATFULL
TI Protein fragment complementation assays for the detection of biological or drug interactions
IN Michnick, Stephen William Watson, Westmount, Canada
Remy, Ingrid, Montreal, Canada
PA Odyssey Pharmaceuticals Inc., San Ramon, CA, United States (U.S. corporation)
PI US 6294330 B1 20010925
AI US 1998-124850 19980730 (9)
RLI Continuation-in-part of Ser. No. US 1998-17412, filed on 2 Feb 1998
PRAI CA 1997-2196496 19970131
DT Utility
FS GRANTED
LN.CNT 3238
INCL INCLM: 435/006.000
INCLS: 435/069.700; 435/325.000; 435/252.300; 435/254.110; 435/440.000;
435/455.000; 435/468.000; 435/320.100; 536/023.400; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.700; 435/252.300; 435/254.110; 435/320.100; 435/325.000;
435/440.000; 435/455.000; 435/468.000; 536/023.400; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C12N005-10; C12N001-21; C12N015-11; C12N015-63
EXF 435/6; 435/69.7; 435/320.1; 435/325; 435/252.3; 435/254.11; 435/440;
435/455; 435/468; 536/23.4; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 310 OF 391 USPATFULL on STN
AN 2001:158079 USPATFULL
TI Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
IN Riopelle, Richard J., Kingston, Canada
Ross, Gregory M., Kingston, Canada
Dory, Magdalena I., Rhisnes, Belgium
Weaver, Donald F., Kingston, Canada
Shamovsky, Igor L., Kingston, Canada
PA Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)
PI US 6291247 B1 20010918
AI US 1997-853910 19970509 (8)
RLI Continuation-in-part of Ser. No. US 1994-241462, filed on 11 May 1994, now abandoned Continuation-in-part of Ser. No. US 1996-745608, filed on 8 Nov 1996, now abandoned
PRAI CA 1996-2190296 19961112
DT Utility
FS GRANTED
LN.CNT 2529
INCL INCLM: 436/002.000
INCLS: 435/007.200; 436/173.000; 436/164.000; 436/161.000; 436/183.000;
530/402.000; 530/412.000
NCL NCLM: 436/002.000
NCLS: 435/007.200; 436/161.000; 436/164.000; 436/173.000; 436/183.000;
530/402.000; 530/412.000
IC [7]
ICM: G01N030-00
ICS: G01N024-00; G01N033-00; G01N021-00
EXF 436/501; 436/164; 436/173; 436/183; 436/161; 436/2; 530/412; 530/402;
435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 311 OF 391 USPATFULL on STN
AN 2001:155460 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses therefor
IN Gurney, Mark E., Grand Rapids, MI, United States
Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
Parodi, Luis A., Stockholm, Sweden

PA Pharmacia & Upjohn Company (U.S. corporation)
PI US 2001021391 A1 20010913
AI US 2001-794743 A1 20010227 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 2962
INCL INCLM: 424/450.000
INCLS: 435/226.000
NCL NCLM: 424/450.000
NCLS: 435/226.000
IC [7]
ICM: C12N009-64
ICS: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 312 OF 391 USPATFULL on STN
AN 2001:150648 USPATFULL
TI N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS
COMPRISING SAME, AND METHODS FOR INHIBITING ***BETA*** -
AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH
COMPOUNDS
IN AUDIA, JAMES E., INDIANAPOLIS, IN, United States
FOLMER, BEVERLY K., NEWARK, DE, United States
JOHN, VARGHESE, SAN FRANCISCO, CA, United States
LATIMER, LEE H., OAKLAND, CA, United States
NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States
PORTER, WARREN J., INDIANAPOLIS, IN, United States
THORSETT, EUGENE D., MOSS BEACH, CA, United States
WU, JING, SAN MATEO, CA, United States
PI US 2001020097 A1 20010906
US 6495693 B2 20021217
AI US 1999-280966 A1 19990330 (9)
RLI Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED,
Pat. No. US 6096782
DT Utility
FS APPLICATION
LN.CNT 3729
INCL INCLM: 546/162.000
INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000;
514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000;
560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000;
548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000
NCL NCLM: 546/162.000
NCLS: 546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000;
560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000;
564/163.000; 564/168.000
IC [7]
ICM: C07D277-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 313 OF 391 USPATFULL on STN
AN 2001:145073 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., Grand Rapids, MI, United States
Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
Parodi, Luis A., Stockholm, Sweden
Yan, Riqiang, Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company (U.S. corporation)
PI US 2001018208 A1 20010830
AI US 2001-795847 A1 20010228 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 2995

NCL INCLS: 435/320.100; 536/023.200
NCLM: 435/325.000
NCLS: 435/320.100; 536/023.200
IC [7]
ICM: C07H021-04
ICS: C12N005-10

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 314 OF 391 USPATFULL on STN
AN 2001:139291 USPATFULL
TI Novel protein and monoclonal ***antibody*** specific thereto
IN Seiki, Motoharu, Shinagawa, Japan
Sato, Hiroshi, Kanazawa, Japan
Shinagawa, Akira, Takaoka, Japan
PI US 2001016333 A1 20010823
AI US 2000-734002 A1 20001212 (9)
RLI Division of Ser. No. US 1998-41, filed on 20 Feb 1998, GRANTED, Pat. No.
US 6191255 A 371 of International Ser. No. WO 1996-JP1956, filed on 12
Jul 1996, UNKNOWN
PRAI JP 1995-200319 19950714
JP 1995-200320 19950714
DT Utility
FS APPLICATION
LN.CNT 2744
INCL INCLM: 435/069.100
INCLS: 530/324.000; 435/070.100; 435/320.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 530/324.000; 435/070.100; 435/320.100; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12P021-08; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 315 OF 391 USPATFULL on STN
AN 2001:139289 USPATFULL
TI Serine protease specific monoclonal ***antibodies*** and their use
IN Kominami, Katsuya, Osaka, Japan
Okui, Akira, Yamatokoriyama-shi, Japan
Mitsui, Shinichi, Kyoto-shi, Japan
Yamaguchi, Nozomi, Kyoto-shi, Japan
PI US 2001016331 A1 20010823
AI US 2000-741171 A1 20001221 (9)
RLI Continuation-in-part of Ser. No. WO 1999-JP3578, filed on 2 Jul 1999,
UNKNOWN
PRAI JP 1998-187506 19980702
DT Utility
FS APPLICATION
LN.CNT 1613
INCL INCLM: 435/007.950
NCL NCLM: 435/007.950
IC [7]
ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 316 OF 391 USPATFULL on STN
AN 2001:139282 USPATFULL
TI Alzheimer's disease secretase, APP substrates therefor, and uses
therefor
IN Gurney, Mark E., Grand Rapids, MI, United States
Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
Parodi, Luis A., Stockholm, Sweden
Yan, Riqiang, Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company (U.S. corporation)
PI US 2001016324 A1 20010823
AI US 2001-794927 A1 20010227 (9)
RLI Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
PRAI US 1999-155493P 19990923 (60)
US 1998-101594P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 5574
INCL INCLM: 435/007.100

NCL NCLM: 435/007.100
NCLS: 435/006.000

IC [7]

ICM: C12Q001-68

ICS: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 317 OF 391 USPATFULL on STN

AN 2001:134006 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, United States

Safar, Jiri G., Concord, CA, United States

PI US 2001014455 A1 20010816

US 6406864 B2 20020618

AI US 2001-754443 A1 20010103 (9)

RLI Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
Pat. No. US 6214565

DT Utility

FS APPLICATION

LN.CNT 1618

INCL INCLM: 435/007.100

INCLS: 435/068.100

NCL NCLM: 435/007.100

NCLS: 424/009.100; 424/130.100; 424/147.100; 435/070.100; 435/071.100;
436/503.000; 436/518.000; 436/547.000; 530/387.100

IC [7]

ICM: G01N033-573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 318 OF 391 USPATFULL on STN

AN 2001:128901 USPATFULL

TI 36 ***human*** secreted proteins

IN LaFleur, David W., Washington, DC, United States

Soppet, Daniel R., Centreville, VA, United States

Olsen, Henrik, Gaithersburg, MD, United States

Ruben, Steven M., Olney, MD, United States

Ni, Jian, Rockville, MD, United States

Rosen, Craig A., Laytonsville, MD, United States

Brewer, Laurie A., St. Paul, MN, United States

Duan, Roxanne, Bethesda, MD, United States

Ebner, Reinhart, Gaithersburg, MD, United States

PI US 2001012889 A1 20010809

AI US 2000-739907 A1 20001220 (9)

RLI Continuation of Ser. No. US 1999-348457, filed on 7 Jul 1999, ABANDONED

Continuation-in-part of Ser. No. WO 1999-US108, filed on 6 Jan 1999,

UNKNOWN

PRAI US 1998-70704P 19980107 (60)

US 1998-70658P 19980107 (60)

US 1998-70692P 19980107 (60)

US 1998-70657P 19980107 (60)

DT Utility

FS APPLICATION

LN.CNT 10341

INCL INCLM: 536/023.100

INCLS: 530/300.000; 530/387.100; 435/006.000; 435/007.100; 435/325.000;
435/069.100

NCL NCLM: 536/023.100

NCLS: 530/300.000; 530/387.100; 435/006.000; 435/007.100; 435/325.000;
435/069.100

IC [7]

ICM: C07H021-00

ICS: A61K038-00; C07K016-00; C12Q001-68; G01N033-53; C12P021-06;

C12N005-00; C12N005-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 319 OF 391 USPATFULL on STN

AN 2001:125737 USPATFULL

TI Protein fragment complementation assays for the detection of biological
or drug interactions

IN Michnick, Stephen William Watson, Westmount, Canada

Pelletier, Joelle Nina, Westmount, Canada

Remy, Ingrid, Montreal, Canada

PA Odyssey Pharmaceuticals Inc., San Ramon, CA, United States (U.S.
corporation)

PI US 6270964 B1 20010807

PRAI CA 1997-2196496 19970131
DT Utility
FS GRANTED
LN.CNT 2701
INCL INCLM: 435/006.000
INCLS: 435/069.700; 435/410.000; 435/243.000; 435/325.000; 530/350.000;
536/023.100; 536/023.400
NCL NCLM: 435/006.000
NCLS: 435/069.700; 435/243.000; 435/325.000; 435/410.000; 530/350.000;
536/023.100; 536/023.400
IC [7]
ICM: C12Q001-68
ICS: C12P021-02; C12N015-52
EXF 435/6; 435/4; 435/69.7; 435/410; 435/243; 435/325; 530/350; 536/23.4;
536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 320 OF 391 USPATFULL on STN
AN 2001:117037 USPATFULL
TI Flourine-substituted biphenyl butyric acids and their derivatives as
inhibitors of matrix metalloproteinases
IN Purchase, Jr., Claude Forsey, Ann Arbor, MI, United States
Roth, Bruce David, Plymouth, MI, United States
Schielke, Gerald Paul, Ann Arbor, MI, United States
Walker, Lary Craswell, Ann Arbor, MI, United States
White, Andrew David, Pinckney, MI, United States
PA Warner-Lambert, Morris Plains, NJ, United States (U.S. corporation)
PI US 6265432 B1 20010724
AI US 2000-503235 20000211 (9)
RLI Division of Ser. No. US 1999-256714, filed on 24 Feb 1999, now patented,
Pat. No. US 6169103
PRAI US 1998-76633P 19980303 (60)
DT Utility
FS GRANTED
LN.CNT 2226
INCL INCLM: 514/417.000
INCLS: 514/532.000; 514/522.000; 514/553.000; 514/561.000; 548/477.000;
560/027.000; 560/035.000; 562/026.000; 562/426.000; 562/440.000
NCL NCLM: 514/417.000
NCLS: 514/522.000; 514/532.000; 514/553.000; 514/561.000; 548/477.000;
560/027.000; 560/035.000; 562/026.000; 562/426.000; 562/440.000
IC [7]
ICM: A61K031-40
ICS: A61K031-275; C07D209-48; C07C229-08; C07C249-10
EXF 548/477; 514/389; 514/522; 514/561; 514/553; 514/532; 514/417; 562/435;
558/414
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 321 OF 391 USPATFULL on STN
AN 2001:112566 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical
compositions comprising same, and methods for inhibiting . ***beta***
.- ***amyloid*** peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S.
corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6262302 B1 20010717
AI US 1999-398211 19990917 (9)
RLI Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now
patented, Pat. No. US 6153652
PRAI US 1996-98551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS GRANTED
LN.CNT 4050
INCL INCLM: 564/152.000
INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000;

NCL NCLM: 548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000;
514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000
NCL NCLS: 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000;
560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000;
564/158.000; 564/168.000

IC [7]
ICM: C07C229-38
ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00
EXF 560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352;
514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168;
564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 322 OF 391 USPATFULL on STN
AN 2001:107472 USPATFULL
TI Smilagenin and its use
IN Xia, Zongqin, Shanghai, China
Rubin, Ian, Castle Donington, United Kingdom
Whittle, Brian, Hornsea, United Kingdom
Gunning, Philip, Saffron Walden, United Kingdom
Hu, Yaer, Shanghai, China
Brostoff, Jonathan, London, United Kingdom
Wang, weijun, Huntingdon, United Kingdom
PA Phytopharm PLC, Cambridgeshire, United Kingdom (non-U.S. corporation)
PI US 6258386 B1 20010710
AI US 1999-362328 19990728 (9)
PRAI GB 1999-5275 19990308

DT Utility
FS GRANTED
LN.CNT 550
INCL INCLM: 424/725.000
NCL NCLM: 424/725.000
IC [7]
ICM: A61K035-78
EXF 424/195.1; 424/725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 323 OF 391 USPATFULL on STN
AN 2001:86665 USPATFULL
TI Transgenic rodent comprising APP-Swedish
IN McLonlogue, Lisa C., San Francisco, CA, United States
Zhao, Jun, La Jolla, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6245964 B1 20010612
AI US 1998-209647 19981210 (9)
RLI Continuation of Ser. No. US 1997-785943, filed on 22 Jan 1997, now
patented, Pat. No. US 5850003 Continuation of Ser. No. US 1993-148211,
filed on 1 Nov 1993, now patented, Pat. No. US 5612486
Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993,
now patented, Pat. No. US 5604102
DT Utility
FS GRANTED
LN.CNT 2117
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; G01N033-00; C12N015-00
EXF 800/3; 800/12; 800/14; 800/18; 800/22; 424/9.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 324 OF 391 USPATFULL on STN
AN 2001:71330 USPATFULL
TI Recombinant helix modification recognition proteins and uses thereof
IN Kmiec, Eric B., Malvern, PA, United States
Holloman, William K., Yorktown Heights, NY, United States
Gerhold, David, Lansdale, PA, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.
corporation)
PI US 6232095 B1 20010515

DT Utility
FS Granted
LN.CNT 1621
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/069.700; 435/252.300; 536/023.400;
536/023.740; 530/350.000; 530/371.000
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/252.300; 435/320.100; 435/325.000; 530/350.000;
530/371.000; 536/023.400; 536/023.740
IC [7]
ICM: C12N015-00
ICS: C12N015-63; C12N001-20; C12N015-85; C07H021-04; C07K014-00
EXF 435/6; 435/252.3; 435/69.1; 435/69.7; 435/325; 435/320.1; 530/350;
530/371; 530/387.1; 536/23.1; 536/23.4; 536/23.74; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 325 OF 391 USPATFULL on STN
AN 2001:59689 USPATFULL
TI Method and composition for modulating amyloidosis
IN Reiner, Peter B., Vancouver, Canada
Connop, Bruce P., Vancouver, Canada
PA The University of British Columbia, Vancouver, British Columbia, United
States (non-U.S. corporation)
PI US 6221667 B1 20010424
AI US 1999-383317 19990825 (9)
RLI Continuation of Ser. No. US 1998-80141, filed on 15 May 1998, now
patented, Pat. No. US 5981168
DT Utility
FS Granted
LN.CNT 982
INCL INCLM: 435/975.000
INCLS: 435/004.000; 514/741.000
NCL NCLM: 514/248.000
NCLS: 435/004.000; 514/231.500; 514/255.010; 514/255.060; 514/313.000;
514/352.000; 514/370.000; 514/383.000; 514/415.000; 514/447.000;
514/741.000
IC [7]
ICM: G01N033-53
ICS: C12Q001-00
EXF 435/975; 435/4; 514/741
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 326 OF 391 USPATFULL on STN
AN 2001:56082 USPATFULL
TI Amyloid .beta. protein (globular assembly and uses thereof)
IN Krafft, Grant A., Glenview, IL, United States
Klein, William L., Winnetka, IL, United States
Chromy, Brett A., Evanston, IL, United States
Lambert, Mary P., Glenview, IL, United States
Finch, Caleb E., Altadena, CA, United States
Morgan, Todd, Manhattan Beach, CA, United States
Wals, Pat, Los Angeles, CA, United States
Rozovsky, Irina, Pasadena, CA, United States
Barlow, Ann, Evanston, IL, United States
PA Northwestern University, Evanston, IL, United States (U.S. corporation)
University of Southern California, Los Angeles, CA, United States (U.S.
corporation)
PI US 6218506 B1 20010417
AI US 1997-796089 19970205 (8)
DT Utility
FS Granted
LN.CNT 941
INCL INCLM: 530/324.000
INCLS: 530/350.000; 514/012.000; 436/086.000
NCL NCLM: 530/324.000
NCLS: 436/086.000; 530/350.000
IC [7]
ICM: A61K038-16
ICS: C07K014-435
EXF 530/324; 530/350; 514/12; 436/86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 327 OF 391 USPATFULL on STN
AN 2001:52086 USPATFULL
TI Lactacystin analogs

PA Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)

PI US 6214862 B1 20010410
AI US 1997-937228 19970911 (8)
RLI Continuation of Ser. No. US 1995-421583, filed on 12 Apr 1995
DT Utility
FS Granted
LN.CNT 2249
INCL INCLM: 514/423.000
INCLS: 514/369.000; 514/370.000; 514/371.000; 514/376.000; 514/377.000;
514/365.000; 514/445.000; 514/446.000; 514/448.000; 514/439.000;
514/441.000; 514/440.000; 514/473.000; 514/452.000

NCL NCLM: 514/423.000
NCLS: 514/365.000; 514/369.000; 514/370.000; 514/371.000; 514/376.000;
514/377.000; 514/439.000; 514/440.000; 514/441.000; 514/445.000;
514/446.000; 514/448.000; 514/452.000; 514/473.000

IC [7]
ICM: A01N043-36
ICS: A01N043-78; A01N043-76; A01N043-06
EXF 514/423; 514/369; 514/370; 514/371; 514/376; 514/377; 514/365; 514/445;
514/446; 514/448; 514/439; 514/441; 514/440; 514/473; 514/452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 328 OF 391 USPATFULL on STN
AN 2001:51789 USPATFULL
TI Assay for disease related conformation of a protein and isolating same
IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri G., Concord, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6214565 B1 20010410
AI US 1998-169574 19981009 (9)
DT Utility
FS Granted
LN.CNT 1675
INCL INCLM: 435/007.100
INCLS: 435/070.100; 435/071.100; 424/009.100; 424/130.100; 424/147.100;
436/503.000; 436/518.000; 436/547.000; 530/387.100

NCL NCLM: 435/007.100
NCLS: 424/009.100; 424/130.100; 424/147.100; 435/070.100; 435/071.100;
436/503.000; 436/518.000; 436/547.000; 530/387.100

IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12P021-04; A61K049-00; C07K016-00
EXF 424/9.1; 424/130.1; 424/147.1; 435/7.1; 435/70.1; 435/71.1; 530/387.1;
436/518; 436/503; 436/547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 329 OF 391 USPATFULL on STN
AN 2001:48108 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide
release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)
PI US 6211235 B1 20010403
AI US 1998-164448 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)

DT US 1997-98558P 19970228 (60)
FS Utility
Granted
LN.CNT 14056
INCL INCLM: 514/534.000
INCLS: 574/619.000; 560/041.000; 560/040.000; 564/163.000
NCL NCLM: 514/534.000
NCLS: 514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000;
548/479.000; 548/496.000; 560/040.000; 560/041.000; 564/163.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/534; 514/619; 564/163; 560/40; 560/41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 330 OF 391 USPATFULL on STN
AN 2001:47793 USPATFULL
TI Genetic sequences and proteins related to alzheimer's disease
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA HSC Research and Development Limited Partnership, Toronto, Canada
(non-U.S. corporation)
PI US 6210919 B1 20010403
AI US 1995-496841 19950628 (8)
RLI Continuation-in-part of Ser. No. US 1995-431048, filed on 28 Apr 1995
DT Utility
FS Granted
LN.CNT 2533
INCL INCLM: 435/069.100
INCLS: 536/023.500; 536/023.100; 435/320.100; 435/325.000; 435/455.000;
530/350.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/455.000; 530/350.000; 536/023.100;
536/023.500
IC [7]
ICM: C12N015-63
ICS: C07H021-04; C07K014-47
EXF 536/23.5; 435/6; 435/69.1; 435/172.1; 435/172.3; 435/325; 435/375;
435/320.1; 435/455; 800/2; 800/DIG.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 331 OF 391 USPATFULL on STN
AN 2001:44268 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide
release and/or its synthesis
IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6207710 B1 20010327
AI US 1998-164385 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS Granted
LN.CNT 12026
INCL INCLM: 514/551.000
INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000;

NCL NCLM: 514/551.000
NCLS: 514/534.000; 514/563.000; 530/331.000; 560/037.000; 560/038.000;
560/040.000; 560/041.000; 564/123.000; 564/155.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123;
564/155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 332 OF 391 USPATFULL on STN
AN 2001:29306 USPATFULL
TI Methods for determining risk of developing alzheimer's disease by
detecting mutations in the presenilin 1 (PS-1) gene
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA The Hospital for Sick Children, HSC Research and Development Limited
Partnership, Canada (non-U.S. corporation)
The Governing Council of the University of Toronto, Canada (non-U.S.
corporation)
PI US 6194153 B1 20010227
AI US 1998-127480 19980731 (9)

RLI Division of Ser. No. US 1996-592541, filed on 26 Jan 1996, now patented,
Pat. No. US 5986054 Continuation-in-part of Ser. No. US 1995-509359,
filed on 31 Jul 1995 Continuation-in-part of Ser. No. US 1995-496841,
filed on 28 Jun 1995 Continuation-in-part of Ser. No. US 1995-431048,
filed on 28 Apr 1995

DT Utility
FS Granted

LN.CNT 4255
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/091.200; 536/023.500; 536/024.310; 536/024.330

NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/091.200; 536/023.500; 536/024.310; 536/024.330

IC [7]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-04
EXF 435/6; 435/91.2; 435/7.1; 536/21.31; 536/24.33; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 333 OF 391 USPATFULL on STN
AN 2001:26018 USPATFULL
TI Protein and monoclonal ***antibody*** specific thereto
IN Seiki, Motoharu, Shinagawa, Japan
Sato, Hiroshi, Kanazawa, Japan
Shinagawa, Akira, Takaoka, Japan
PA Fuji Yakuin Kogyo Kabushiki Kaisha, Toyama, Japan (non-U.S.
corporation)
PI US 6191255 B1 20010220
WO 9704080 19970206

AI US 1998-41 19980220 (9)
WO 1996-JP1956 19960712
19980220 PCT 371 date
19980220 PCT 102(e) date
PRAI JP 1995-200319 19950714
JP 1995-200320 19950714

DT Utility
FS Granted
LN.CNT 2653
INCL INCLM: 530/324.000
INCLS: 530/400.000; 536/023.200; 536/023.500; 536/024.310; 435/069.100;
435/320.100; 435/325.000
NCL NCLM: 530/324.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/400.000; 536/023.200;
536/023.500; 536/024.310
IC [7]
ICM: A61K038-43
ICS: C07K001-00; C07H021-04
EXF 530/324; 530/400; 536/23.5; 536/23.2; 536/24.31; 435/69.1; 435/320.1;
435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 334 OF 391 USPATFULL on STN
AN 2001:25931 USPATFULL

IN peptide release and/or its synthesis
Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
Varghese, John, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
Eid, Clark Norman, Cheshire, CT, United States
Scott, William Leonard, Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
AI US 6191166 B1 20010220
PRAI AI US 1997-976289 19971121 (8)
US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-698556P 19970228 (60)
DT Utility
FS Granted
LN.CNT 12827
INCL INCLM: 514/534.000
INCLS: 514/535.000; 514/616.000; 514/619.000
NCL NCLM: 514/534.000
NCLS: 514/535.000; 514/616.000; 514/619.000
IC [7]
ICM: A01N037-12
EXF 574/534; 574/535; 574/616; 574/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 335 OF 391 USPATFULL on STN
AN 2001:14622 USPATFULL
TI Peptide nucleic acid conjugates
IN Wickstrom, Eric, Philadelphia, PA, United States
Basu, Soumitra, New Haven, CT, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
PI US 6180767 B1 20010130
AI US 1997-779072 19970107 (8)
PRAI US 1996-9747P 19960111 (60)
DT Utility
FS Granted
LN.CNT 1510
INCL INCLM: 536/022.100
INCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
536/025.330; 536/025.340
NCL NCLM: 536/022.100
NCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
536/025.330; 536/025.340
IC [7]
ICM: C07H019-00
ICS: C07H021-02; C07H021-00; C07H021-04
EXF 536/22.1; 536/23.1; 536/25.3; 536/25.31; 536/25.32; 536/25.33;
536/25.34; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 336 OF 391 USPATFULL on STN
AN 2001:14261 USPATFULL
TI Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
IN Flournoy, Shin Cheng, San Diego, CA, United States
Bennett, C. Frank, Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6180403 B1 20010130
AI US 1999-429093 19991028 (9)
DT Utility

LN.CNT 1609
INCL INCLM: 435/375.000
INCLS: 435/366.000; 435/006.000; 435/091.100; 435/325.000; 536/023.100;
536/024.310; 536/024.330; 536/024.500
NCL NCLM: 435/375.000
NCLS: 435/006.000; 435/091.100; 435/325.000; 435/366.000; 536/023.100;
536/024.310; 536/024.330; 536/024.500
IC [7]
ICM: C07H021-04
ICS: C12N015-00; C12Q001-68
EXF 435/6; 435/91.1; 435/91.3; 435/375; 435/325; 536/23.1; 536/23.2;
536/24.5; 536/24.3; 536/24.33; 536/24.31; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 337 OF 391 USPATFULL on STN
AN 2001:8029 USPATFULL
TI Neurotrophic peptides of activity dependent neurotrophic factor
IN Brenneman, Douglas E., Damascus, MD, United States
PA Ramot University Authority for Applied Research and Industrial
Development, Ltd., Tel Aviv, Israel (non-U.S. corporation)
The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 6174862 B1 20010116
AI US 1994-324297 19941017 (8)
RLI Continuation-in-part of Ser. No. US 1992-871973, filed on 22 Apr 1992,
now patented, Pat. No. US 5767240 Continuation-in-part of Ser. No. US
1991-688087, filed on 22 Apr 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1591
INCL INCLM: 514/015.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 530/326.000; 530/327.000;
530/328.000; 530/324.000
NCL NCLM: 514/015.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 530/324.000; 530/326.000;
530/327.000; 530/328.000
IC [7]
ICM: A61K038-08
ICS: A61K038-10; A61K038-17
EXF 514/12-15; 530/324; 530/326-328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 338 OF 391 USPATFULL on STN
AN 2001:4717 USPATFULL
TI Treatments for neurotoxicity in Alzheimer's disease caused by .
beta . ***amyloid*** peptides
IN Ingram, Vernon M., Cambridge, MA, United States
Blanchard, Barbara J., Cambridge, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States
(U.S. corporation)
PI US 6172043 B1 20010109
AI US 1998-5215 19980109 (9)
RLI Continuation-in-part of Ser. No. US 1997-960188, filed on 29 Oct 1997,
now abandoned
PRAI US 1997-35847P 19970110 (60)
DT Patent
FS Granted
LN.CNT 1822
INCL INCLM: 514/017.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
NCL NCLM: 514/017.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
IC [7]
ICM: A61K038-04
ICS: C07K007-00
EXF 530/325-330; 514/13-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 339 OF 391 USPATFULL on STN
AN 2001:1790 USPATFULL
TI Fluorine-substituted biphenyl butyric acids and their derivatives as
inhibitors of matrix metalloproteinases
IN Purchase, Jr., Claude Forsey, Ann Arbor, MI, United States

Schielke, Gerald Paul, Ann Arbor, MI, United States
Walker, Lary Craswell, Ann Arbor, MI, United States
White, Andrew David, Pinckney, MI, United States
PA Warner-Lambert, Morris Plains, NJ, United States (U.S. corporation)
PI US 6169103 B1 20010102
AI US 1999-256714 19990224 (9)
PRAI US 1998-76633P 19980303 (60)
DT Utility
FS Granted
LN.CNT 2031
INCL INCLM: 514/389.000
INCLS: 514/389.000; 514/522.000; 514/419.000; 514/567.000; 558/414.000;
548/494.000; 548/319.500; 548/477.000; 560/035.000; 562/492.000
NCL NCLM: 514/389.000
NCLS: 514/419.000; 514/522.000; 514/567.000; 548/319.500; 548/477.000;
548/494.000; 558/414.000; 560/035.000; 562/492.000
IC [7]
ICM: A61K031-40
ICS: A61K031-275; C07D209-48
EXF 558/414; 548/319.5; 548/494; 548/477; 548/479; 562/440; 560/35; 514/425;
514/522; 514/555; 514/389; 514/419; 514/417; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 340 OF 391 USPATFULL on STN
AN 2000:161048 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical
compositions comprising same, and methods for inhibiting . ***beta***
.- ***amyloid*** peptide release and/or its synthesis by use of such
compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6153652 20001128
AI US 1997-976295 19971121 (8)
PRAI US 1996-1551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS Granted
LN.CNT 3652
INCL INCLM: 514/619.000
INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;
514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;
549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;
560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
NCL NCLM: 514/619.000
NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;
514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;
549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;
560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
IC [7]
ICM: A01N037-18
ICS: A01N037-12; A01N037-44; A61K031-165
EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303;
549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357;
514/417; 514/470; 514/535; 514/539; 514/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 341 OF 391 USPATFULL on STN
AN 2000:160799 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Darnestown, MD, United States
Ni, Jian, Rockville, MD, United States
Gentz, Reiner L., Silver Spring, MD, United States
Dillon, Patrick J., Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6153402 20001128
AI US 1997-815469 19970311 (8)

US 1996-28711P 19961017 (60)
US 1997-37341P 19970206 (60)
DT Utility
FS Granted
LN.CNT 3364
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/320.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 536/023.500
IC [7]
ICM: C12N015-12
EXF 435/69.1; 435/325; 435/252.3; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 342 OF 391 USPATFULL on STN
AN 2000:153855 USPATFULL
TI Lactacystin analogs
IN Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)
PI US 6147223 20001114
AI US 1995-468408 19950606 (8)
RLI Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
DT Utility
FS Granted
LN.CNT 2354
INCL INCLM: 548/453.000
NCL NCLM: 548/453.000
IC [7]
ICM: C07D491-044
EXF 548/453; 540/203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 343 OF 391 USPATFULL on STN
AN 2000:121621 USPATFULL
TI Presenilin-2 and mutations thereof
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA The Governing Council of the University of Toronto, Toronto, Canada
(non-U.S. corporation)
HSC Research and Development Limited Partnership, Toronto, Canada
(non-U.S. corporation)
PI US 6117978 20000912
AI US 1998-124698 19980729 (9)
RLI Division of Ser. No. US 1997-967101, filed on 10 Nov 1997, now patented,
Pat. No. US 5840540 which is a division of Ser. No. US 1996-592541,
filed on 26 Jan 1996, now patented, Pat. No. US 5986054 which is a
continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28
Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
filed on 28 Apr 1995
DT Utility
FS Granted
LN.CNT 7847
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-00
EXF 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 344 OF 391 USPATFULL on STN
AN 2000:121544 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for use
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States

PA Audia, James E., Indianapolis, IN, United States
Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
PI Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
US 6117901 20000912
AI US 1997-976179 19971121 (8)
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS Granted
LN.CNT 3321
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-16
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 345 OF 391 USPATFULL on STN
AN 2000:98466 USPATFULL
TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6096782 20000801
AI US 1997-976191 19971121 (8)
PRAI US 1996-77175P 19961122 (60)
DT Utility
FS Granted
LN.CNT 3343
INCL INCLM: 514/506.000
INCLS: 514/399.000; 548/335.500; 560/041.000
NCL NCLM: 514/506.000
NCLS: 514/399.000; 548/335.500; 560/041.000
IC [7]
ICM: A01N037-20
ICS: A01N043-50; C07C229-24; C07D233-61
EXF 560/41; 514/506; 514/399; 548/335.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 346 OF 391 USPATFULL on STN
AN 2000:94696 USPATFULL
TI Amyloid precursor protein protease
IN Dixon, Eric P, Apex, NC, United States
Johnstone, Edward M., Indianapolis, IN, United States
Little, Sheila P., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6093397 20000725
WO 9631122 19961010
AI US 1997-930188 19971002 (8)
WO 1996-US4294 19960402
19971002 PCT 371 date
19971002 PCT 102(e) date
RLI Continuation of Ser. No. US 1995-416257, filed on 4 Apr 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1530
INCL INCLM: 424/094.640
INCLS: 424/078.020; 424/094.620; 435/069.100; 435/212.000; 435/213.000;
435/219.000; 435/226.000; 435/252.300; 435/320.100
NCL NCLM: 424/094.640
NCLS: 424/078.020; 424/094.620; 435/069.100; 435/212.000; 435/213.000;

IC [7]
ICM: A61K038-48
ICS: C12N009-48; C12N001-20; C07H021-04
EXF 435/212; 435/213; 435/226; 435/219; 435/69.1; 435/252.3; 435/320.1;
435/252.33; 536/23.2; 536/23.5; 424/78.02; 424/94.62; 424/94.64; 935/14;
935/29; 935/32; 935/70; 935/73
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 347 OF 391 USPATFULL on STN
AN 2000:91941 USPATFULL
TI Serine proteases, their activity and their synthetic inhibitors
IN Augustyns, Koen Jan Ludovicus, Minderhout, Belgium
Vanhoof, Greta Constantia, Mortsel, Belgium
Borloo, Marianne Jean Frieda, Deurne, Belgium
De Meester, Ingrid Anna Jozef, Wilrijk, Belgium
Goossens, Filip Jozef Anny, Lokeren, Belgium
Haemers, Achiel Jean-Marie, Gent, Belgium
Hendriks, Dirk Frans, Aartselaar, Belgium
Lambeir, Anne-Marie Virginie Renee, Heverlee, Belgium
Scharpe, Simon Lodewijk, Wieze, Belgium
PA FondaTech Benelux N.V., Belgium (non-U.S. corporation)
PI US 6090786 20000718
WO 9534538 19951221
AI US 1997-750484 19970219 (8)
WO 1995-EP2255 19950609
19970219 PCT 371 date
19970219 PCT 102(e) date
PRAI EP 1994-201668 19940610
EP 1994-203707 19941220
DT Utility
FS Granted
LN.CNT 1511
INCL INCLM: 514/019.000
INCLS: 514/020.000; 514/002.000; 530/330.000; 540/130.000
NCL NCLM: 514/019.000
NCLS: 514/002.000; 514/020.000; 530/330.000; 540/130.000
IC [7]
ICM: A61K038-05
ICS: C07K005-078
EXF 514/19; 514/20; 514/2; 530/330; 540/130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 348 OF 391 USPATFULL on STN
AN 2000:84054 USPATFULL
TI Cloning and expression of .beta.APP-C100 receptor (C100-R)
IN Manly, Susan P., Wallingford, CT, United States
Kozlowski, Michael R., Palo Alto, CA, United States
Neve, Rachael L., Belmont, MA, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S.
corporation)
McLean Hospital Corporation, Belmont, MA, United States (U.S.
corporation)
PI US 6083713 20000704
AI US 1995-559397 19951115 (8)
RLI Continuation-in-part of Ser. No. US 1993-114555, filed on 30 Aug 1993,
now patented, Pat. No. US 5854392 And a continuation-in-part of Ser. No.
US 1992-938184, filed on 31 Aug 1992, now abandoned
DT Utility
FS Granted
LN.CNT 3220
INCL INCLM: 435/069.100
INCLS: 435/069.700; 435/325.000; 435/252.300; 435/320.100; 536/023.100;
536/023.400; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/252.300; 435/320.100; 435/325.000; 536/023.100;
536/023.400; 536/023.500
IC [7]
ICM: C12N015-12
ICS: C12N015-70; C12N015-85
EXF 536/23.1; 536/23.4; 536/23.5; 435/69.1; 435/320.1; 435/325; 435/252.3;
435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 349 OF 391 USPATFULL on STN
AN 2000:77202 USPATFULL

IN Der, Channing, Chapel Hill, NC, United States
O'Bryan, John, Chapel Hill, NC, United States
Pawson, Anthony, Toronto, Canada
PA Mount Sinai Hospital Corporation, Toronto, Canada (non-U.S. corporation)
University of North Carolina at Chapel Hill, NC, United States (U.S. corporation)
PI US 6077686 20000620
AI US 1997-807342 19970228 (8)
DT Utility
FS Granted
LN.CNT 2849
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 435/252.100
NCL NCLM: 435/069.100
NCLS: 435/252.100; 435/320.100; 435/325.000
IC [7]
ICM: C12P021-06
ICS: C12N001-12; C12N015-00; C12N005-00
EXF 435/69.1; 435/252.3; 435/320.1; 435/325; 435/252.1; 530/350; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 350 OF 391 USPATFULL on STN
AN 2000:37839 USPATFULL
TI Tyramine compounds and their neuronal effects
IN Julian, Dana J., Houston, TX, United States
PA Baylor College of Medicine, Houston, TX, United States (U.S. corporation)
PI US 6043283 20000328
AI US 1997-870967 19970606 (8)
RLI Continuation-in-part of Ser. No. US 1996-717551, filed on 20 Sep 1996
DT Utility
FS Granted
LN.CNT 3153
INCL INCLM: 514/617.000
NCL NCLM: 514/617.000
IC [7]
ICM: A61K031-165
EXF 514/152; 514/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 351 OF 391 USPATFULL on STN
AN 2000:31594 USPATFULL
TI Transgenic mouse expressing an . ***beta*** .- ***Amyloid*** transgene
IN Sato, Masahiro, Kawagoe, Japan
Kobayashi, Takashi, Fukuoka, Japan
Tada, Norihiro, Kawagoe, Japan
Shoji, Mikio, Gunma-gun, Japan
Kawarabayashi, Takeshi, Maebashi, Japan
PA Hoechst Japan Limited, Tokyo, Japan (non-U.S. corporation)
PI US 6037521 20000314
AI US 1994-339708 19941114 (8)
PRAI JP 1993-306026 19931112
DT Utility
FS Granted
LN.CNT 1316
INCL INCLM: 800/018.000
INCLS: 800/009.000; 800/012.000; 800/003.000; 424/009.100; 424/009.200
NCL NCLM: 800/018.000
NCLS: 424/009.100; 424/009.200; 800/003.000; 800/009.000; 800/012.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027
EXF 800/2; 435/172.3; 424/9; 424/9.1; 424/9.2

L4 ANSWER 352 OF 391 USPATFULL on STN
AN 2000:28107 USPATFULL
TI .beta.-sheet nucleating peptidomimetics
IN Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United States 77840
PI US 6034211 20000307
AI US 1996-664379 19960614 (8)
PRAI US 1996-18925P 19960603 (60)
DT Utility
FS Granted
LN.CNT 1625

INCL INCLM: 530/317.000
INCLS: 546/101.000
NCL NCLM: 530/317.000
NCLS: 546/101.000
IC [7]
ICM: C07K005-00
EXF 548/427; 546/101; 514/323-328; 530/317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 353 OF 391 USPATFULL on STN
AN 2000:12606 USPATFULL
TI Method for identifying substances that affect the interaction of a presenilin-1-interacting protein with a mammalian presenilin-1 protein
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA Research and Development Limited Partnership, Toronto, Canada (non-U.S. corporation)
PI US 6020143 20000201
AI US 1997-888077 19970703 (8)
RLI Continuation-in-part of Ser. No. US 1996-592541, filed on 26 Jan 1996
PRAI US 1996-21673P 19960705 (60)
US 1996-21700P 19960712 (60)
US 1996-29895P 19961108 (60)
US 1997-34590P 19970102 (60)

DT Utility
FS Granted
LN.CNT 7847
INCL INCLM: 435/007.100
INCLS: 530/350.000
NCL NCLM: 435/007.100
NCLS: 530/350.000
IC [6]
ICM: C12Q001-00
ICS: C07K014-00
EXF 435/7.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 354 OF 391 USPATFULL on STN
AN 2000:12437 USPATFULL
TI SPE-4 peptides
IN L'Hernault, Steven W., Atlanta, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 6019974 20000201
AI US 1997-788231 19970124 (8)
PRAI US 1996-10672P 19960126 (60)
DT Utility
FS Granted
LN.CNT 1297
INCL INCLM: 424/191.100
INCLS: 424/185.100; 424/184.100; 424/192.100; 424/193.100; 424/194.100;
530/300.000; 530/350.000; 530/326.000; 530/327.000; 530/387.100
NCL NCLM: 424/191.100
NCLS: 424/184.100; 424/185.100; 424/192.100; 424/193.100; 424/194.100;
530/300.000; 530/326.000; 530/327.000; 530/350.000; 530/387.100
IC [6]
ICM: C07K007-00
ICS: A61K039-00
EXF 530/300; 530/350; 530/326; 530/327; 530/387.1; 424/184.1; 424/185.1;
424/192.1; 424/193.1; 424/194.1; 424/191.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 355 OF 391 USPATFULL on STN
AN 1999:146753 USPATFULL
TI Genetic sequences and proteins related to alzheimer's disease
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA The Hospital for Sick Children, HSC Research and Development Limited Partnership, Canada (non-U.S. corporation)
The Governing Council of the University of Toronto, Canada (non-U.S. corporation)
PI US 5986054 19991116
AI US 1996-592541 19960126 (8)
RLI Continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995

Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048, filed on 28 Apr 1995

DT Utility
FS Granted
LN.CNT 7292
INCL INCLM: 530/350.000
INCLS: 435/069.100
NCL NCLM: 530/350.000
NCLS: 435/069.100
IC [6]
ICM: C07K014-00
ICS: C12P021-06
EXF 530/350; 435/69.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 356 OF 391 USPATFULL on STN
AN 1999:141615 USPATFULL
TI Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein
IN Tamburini, Paul P., Kensington, CT, United States
Dreyer, Robert N., Wallingford, CT, United States
Bausch, Kathryn M., West Haven, CT, United States
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PI US 5981208 19991109
AI US 1994-319339 19941006 (8)
RLI Continuation of Ser. No. US 1993-156516, filed on 23 Nov 1993, now abandoned which is a continuation of Ser. No. US 1992-865167, filed on 9 Apr 1992, now abandoned
DT Utility
FS Granted
LN.CNT 901
INCL INCLM: 435/023.000
INCLS: 435/007.100; 436/518.000; 436/811.000
NCL NCLM: 435/023.000
NCLS: 435/007.100; 436/518.000; 436/811.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.9; 435/7.92; 435/7.93; 435/7.94; 435/7.95; 435/23;
435/24; 435/975; 435/4; 436/501; 436/518; 436/528; 436/531; 436/811;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 357 OF 391 USPATFULL on STN
AN 1999:141575 USPATFULL
TI Method and composition for modulating amyloidosis
IN Reiner, Peter B., Vancouver, Canada
Connop, Bruce P., Vancouver, Canada
PA The University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5981168 19991109
AI US 1998-80141 19980515 (9)
DT Utility
FS Granted
LN.CNT 1184
INCL INCLM: 435/004.000
INCLS: 435/029.000; 514/639.000; 514/638.000; 514/600.000; 514/601.000;
514/395.000; 514/310.000; 514/255.000
NCL NCLM: 435/004.000
NCLS: 435/029.000; 514/255.060; 514/310.000; 514/395.000; 514/600.000;
514/601.000; 514/638.000; 514/639.000
IC [6]
ICM: C12Q001-00
EXF 435/4; 435/29; 514/639; 514/638; 514/600; 514/601; 514/395; 514/310;
514/255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 358 OF 391 USPATFULL on STN
AN 1999:132768 USPATFULL
TI Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
IN Gozes, Illana, Ramat Hasharon, Israel
Fridkin, Matityahu, Rehovot, Israel
PA Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)
Ramot University Authority for Applied Research and Industrial

PI US 5972883 19991026
AI US 1995-413708 19950330 (8)
RLI Continuation-in-part of Ser. No. US 1994-207671, filed on 9 Mar 1994,
now abandoned
PRAI IL 1993-105061 19930316
DT Utility
FS Granted
LN.CNT 1190
INCL INCLM: 514/012.000
INCLS: 530/324.000
NCL NCLM: 514/012.000
NCLS: 530/324.000
IC [6]
ICM: A61K038-00
EXF 514/12; 514/879; 530/324; 530/327; 530/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 359 OF 391 USPATFULL on STN
AN 1999:132524 USPATFULL
TI Diagnostic assay for Alzheimer's disease: assessment of A.beta.
abnormalities
IN Tanzi, Rudolph E., Canton, MA, United States
Bush, Ashley I., Somerville, MA, United States
Moir, Robert D., Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5972634 19991026
WO 9612544 19960502
AI US 1997-817423 19970804 (8)
WO 1994-US11895 19941019
19970804 PCT 371 date
19970804 PCT 102(e) date

DT Utility
FS Granted
LN.CNT 2476
INCL INCLM: 435/007.940
INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000;
436/525.000; 436/164.000; 436/172.000
NCL NCLM: 435/007.940
NCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000;
436/164.000; 436/172.000; 436/525.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.92; 435/7.94; 435/7.95; 435/975; 435/7.9; 436/525;
436/164; 436/172; 436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 360 OF 391 USPATFULL on STN
AN 1999:124950 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting . ***beta*** .-
amyloid peptide release and/or its synthesis by use of such
compounds

IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., United States (U.S. corporation)
PI US 5965614 19991012
AI US 1997-975977 19971121 (8)
PRAI US 1996-104593P 19961122 (60)

DT Utility
FS Granted
LN.CNT 2939
INCL INCLM: 514/538.000
INCLS: 514/508.000; 560/043.000; 560/035.000
NCL NCLM: 514/538.000
NCLS: 514/508.000; 560/035.000; 560/043.000
IC [6]
ICM: A01N037-12
ICS: A01N037-52; C07C229-28
EXF 514/528; 514/532; 560/11

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 361 OF 391 USPATFULL on STN
AN 1999:113631 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Holmes, Todd, Somerville, MA, United States
Zhang, Shuguang, Cambridge, MA, United States
Rich, Alexander, Cambridge, MA, United States
DiPersio, C. Michael, Norton, MA, United States
Lockshin, Curtis, Lexington, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States
(U.S. corporation)
PI US 5955343 19990921
AI US 1994-293284 19940822 (8)
RLI Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2516
INCL INCLM: 435/240.100
INCLS: 435/240.200; 435/240.230; 435/240.241
NCL NCLM: 435/325.000
NCLS: 435/378.000; 435/395.000; 435/401.000
IC [6]
ICM: C12N005-02
EXF 435/240.1; 435/240.2; 435/240.23; 435/240.241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 362 OF 391 USPATFULL on STN
AN 1999:106439 USPATFULL
TI Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
IN Soto-Jara, Claudio, New York, NY, United States
Baumann, Marc H., Helsinki, Finland
Frangione, Blas, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5948763 19990907
AI US 1996-630645 19960410 (8)
RLI Continuation-in-part of Ser. No. US 1995-478326, filed on 6 Jun 1995
DT Utility
FS Granted
LN.CNT 1306
INCL INCLM: 514/014.000
INCLS: 514/015.000; 514/016.000; 514/017.000; 514/018.000
NCL NCLM: 514/014.000
NCLS: 514/015.000; 514/016.000; 514/017.000; 514/018.000
IC [6]
ICM: A61K038-00
EXF 514/2; 514/14; 514/15; 514/16; 514/17; 514/18; 530/300; 530/326; 530/327; 530/328; 530/329; 530/330; 530/331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 363 OF 391 USPATFULL on STN
AN 1999:85236 USPATFULL
TI Kit for detecting Alzheimer's disease
IN Nixon, Ralph A., Arlington, MA, United States
Saito, Ken-Ichi, Yokahama, Japan
PA The McLean Hospital Corporation, Belmont, MA, United States (U.S. corporation)
PI US 5928885 19990727
AI US 1996-681375 19960723 (8)
RLI Continuation of Ser. No. US 1994-184603, filed on 24 Jan 1994, now patented, Pat. No. US 5624807 which is a continuation of Ser. No. US 1993-95319, filed on 22 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-925594, filed on 22 Jul 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1112
INCL INCLM: 435/007.400
INCLS: 435/967.000; 435/975.000; 436/518.000; 530/387.100; 530/388.100; 530/388.260
NCL NCLM: 435/007.400
NCLS: 435/967.000; 435/975.000; 436/518.000; 530/387.100; 530/388.100; 530/388.260

530/388.260

IC [6]
ICM: G01N033-573
ICS: C07K016-00; C12P021-08
EXF 435/975; 435/7.1; 435/7.4; 435/7.92; 435/7.93; 435/7.94; 435/7.95;
435/967; 436/518; 436/524; 436/528; 436/530; 436/531; 530/357.1;
530/388.1; 530/388.26

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 364 OF 391 USPATFULL on STN
AN 1999:67429 USPATFULL
TI Transgenic non- ***human*** mice displaying the amyloid-forming
pathology of alzheimer's disease
IN Cordell, Barbara, Palo Alto, CA, United States
PA Scios Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5912410 19990615
AI US 1995-422333 19950413 (8)
RLI Continuation of Ser. No. US 1994-327381, filed on 21 Oct 1994, now
abandoned which is a continuation-in-part of Ser. No. US 1991-716725,
filed on 17 Jun 1991, now patented, Pat. No. US 5387742 which is a
continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,
now abandoned
DT Utility
FS Granted
LN.CNT 2702
INCL INCLM: 800/002.000
INCLS: 800/DIG.001; 424/009.200; 935/062.000
NCL NCLM: 800/012.000
NCLS: 424/009.200
IC [6]
ICM: C12N015-00
ICS: C12N005-00; A61K049-00
EXF 800/2; 800/DIG.1; 935/62; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 365 OF 391 USPATFULL on STN
AN 1999:27476 USPATFULL
TI APP770 mutant in alzheimer's disease
IN Hardy, John Anthony, Tampa, FL, United States
Chartier-Harlin, Marie-Christine, Villeneuve d'Ascq, France
Goate, Alison Mary, Michael, MO, United States
Owen, Michael John, South Glamorgan, Scotland
Mullan, Michael John, Tampa, FL, United States
PA Imperial College of Science, Technology of Medicine, London, England
(non-U.S. corporation)
PI US 5877015 19990302
WO 9213069 19920806
AI US 1992-104165 19920121 (8)
WO 1992-GB123 19920121
19940121 PCT 371 date
19940121 PCT 102(e) date
PRAI GB 1991-1307 19910121
GB 1991-18445 19910828
DT Utility
FS Granted
LN.CNT 1734
INCL INCLM: 435/325.000
INCLS: 435/252.300; 536/023.500
NCL NCLM: 435/325.000
NCLS: 435/252.300; 536/023.500
IC [6]
ICM: C12N005-10
ICS: C12N001-21; C07H021-04
EXF 435/29; 435/240.1; 435/252.3; 435/6; 435/325; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 366 OF 391 USPATFULL on STN
AN 1998:162469 USPATFULL
TI A. beta. peptides that modulate . ***beta*** .- ***amyloid***
aggregation
IN Findeis, Mark A., Cambridge, MA, United States
Benjamin, Howard, Lexington, MA, United States
Garnick, Marc B., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
Hundal, Arvind, Brighton, MA, United States

Musso, Gary, Hopkinton, MA, United States
Signer, Ethan R., Cambridge, MA, United States
Wakefield, James, Brookline, MA, United States
Reed, Michael, Marietta, GA, United States
Molineaux, Susan, Brookline, MA, United States
Kubasek, William, Belmont, MA, United States
Chin, Joseph, Salem, MA, United States
Lee, Jung-Ja, Wayland, MA, United States
Kelley, Michael, Arlington, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5854204 19981229
AI US 1996-612785 19960314 (8)
RLI Continuation-in-part of Ser. No. US 1995-404831, filed on 14 Mar 1995
And a continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun
1995 And a continuation-in-part of Ser. No. US 1995-548998, filed on 27
Oct 1995
DT Utility
FS Granted
LN.CNT 4304
INCL INCLM: 514/002.000
INCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000
NCL NCLM: 514/002.000
NCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000
IC [6]
ICM: C07K014-435
ICS: C07K007-08
EXF 514/14; 514/12; 514/2; 530/300; 530/324; 530/326; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 367 OF 391 USPATFULL on STN
AN 1998:157207 USPATFULL
TI Diagnostic assays for Alzheimer's disease
IN Nixon, Ralph, Arlington, MA, United States
Honda, Toshiyuki, Yokohama, Japan
PA The McLean Hospital Corporation, Belmont, MA, United States (U.S.
corporation)
PI US 5849600 19981215
AI US 1993-149975 19931110 (8)
DT Utility
FS Granted
LN.CNT 960
INCL INCLM: 436/518.000
INCLS: 436/528.000; 436/529.000; 436/530.000; 436/161.000; 436/811.000
NCL NCLM: 436/518.000
NCLS: 436/161.000; 436/528.000; 436/529.000; 436/530.000; 436/811.000
IC [6]
ICM: G01N033-544
EXF 435/7.1; 435/975; 436/518; 436/530; 436/547; 436/524; 436/528; 436/529;
436/811; 436/161; 530/350; 530/387.1; 530/387.9; 530/389.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 368 OF 391 USPATFULL on STN
AN 1998:147262 USPATFULL
TI Nucleic acids encoding presenilin II
IN St. George-Hyslop, Peter H., Toronto, Canada
Rommens, Johanna M., Toronto, Canada
Fraser, Paul E., Toronto, Canada
PA The Hospital for Sick Children, Canada (non-U.S. corporation)
HSC Research and Development Limited Partnership, Canada (non-U.S.
corporation)
PI US 5840540 19981124
AI US 1997-967101 19971110 (8)
RLI Division of Ser. No. US 1996-592541, filed on 26 Jan 1996 which is a
continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28
Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
filed on 28 Apr 1995
DT Utility
FS Granted
LN.CNT 6709
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/252.300; 435/325.000; 536/023.100; 536/024.300;
530/350.000
NCL NCLM: 435/069.100

IC [6]
 ICM: C12P021-06
 ICS: C07H017-00; C07K014-00
 EXF 435/69.1; 435/320.1; 435/252.3; 435/325; 536/23.1; 536/24.3; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 369 OF 391 USPATFULL on STN
 AN 1998:143904 USPATFULL
 TI Directed evolution of novel binding proteins
 IN Ladner, Robert Charles, Ijamsville, MD, United States
 Gutterman, Sonia Kosow, Belmont, MA, United States
 Roberts, Bruce Lindsay, Milford, MA, United States
 Markland, William, Milford, MA, United States
 Ley, Arthur Charles, Newton, MA, United States
 Kent, Rachel Baribault, Boxborough, MA, United States
 PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)
 PI US 5837500 19981117
 AI US 1995-415922 19950403 (8)
 RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now
 patented, Pat. No. US 5403484 which is a division of Ser. No. US
 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409
 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2
 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US
 1988-240160, filed on 2 Sep 1988, now abandoned

DT Utility
 FS Granted
 LN.CNT 15973
 INCL INCLM: 435/069.700
 INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400
 NCL NCLM: 435/069.700
 NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;
 536/023.400

IC [6]
 ICM: C12N015-62
 ICS: C07K019-00
 EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 370 OF 391 USPATFULL on STN
 AN 1998:139024 USPATFULL
 TI Soluble form of PrP.sup.SC which is insoluble in native form
 IN Prusiner, Stanley B., San Francisco, CA, United States
 Cohen, Fred E., San Francisco, CA, United States
 Muramoto, Tamaki, San Francisco, CA, United States
 PA The Regents of the University of California, Oakland, CA, United States
 (U.S. corporation)
 PI US 5834593 19981110
 AI US 1996-740947 19961105 (8)
 DT Utility
 FS Granted
 LN.CNT 1331
 INCL INCLM: 530/350.000
 INCLS: 530/356.000; 435/006.000; 435/007.100; 435/002.300; 435/072.300;
 435/236.000
 NCL NCLM: 530/350.000
 NCLS: 435/006.000; 435/007.100; 435/023.000; 435/236.000; 530/356.000
 IC [6]
 ICM: C07K001-00
 ICS: C07K014-00; C07K016-00; C07K017-00
 EXF 530/350; 530/356; 435/236; 435/23; 435/6; 435/7.1; 435/172.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 371 OF 391 USPATFULL on STN
 AN 1998:98980 USPATFULL
 TI Amyloid precursor protein in alzheimer's disease
 IN Mullan, Michael John, Tampa, FL, United States
 PA Alzheimer's Institute of America, Prairie Village, KS, United States
 (U.S. corporation)
 PI US 5795963 19980818
 AI US 1997-815637 19970313 (8)
 RLI Continuation of Ser. No. US 1995-487118, filed on 7 Jun 1995, now
 abandoned which is a division of Ser. No. US 1993-94547, filed on 19 Feb
 1993, now abandoned which is a continuation of Ser. No. US 1992-894211,
 filed on 4 Jun 1992, now patented, Pat. No. US 5455169, issued on 3 Oct
 1995

DT Utility
FS Granted
LN.CNT 1053
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [6]
EXF ICM: C07K001-00
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 372 OF 391 USPATFULL on STN
AN 1998:88671 USPATFULL
TI Monoclonal ***antibody*** 369.2B specific for .beta. A4 peptide
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)
PI US 5786180 19980728
AI US 1995-388463 19950214 (8)
DT Utility
FS Granted
LN.CNT 926
INCL INCLM: 435/070.210
INCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900;
530/388.100; 530/389.100
NCL NCLM: 435/070.210
NCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900;
530/388.100; 530/389.100
IC [6]
EXF ICM: A61K039-395
435/70.21; 435/240.27; 435/70.2; 435/326; 435/331; 530/388.1; 530/388.2;
530/327; 530/387.9; 530/389.1; 436/548; 436/547; 424/184.1; 424/185.1;
424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 373 OF 391 USPATFULL on STN
AN 1998:58182 USPATFULL
TI Lactacystin analogs
IN Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)
PI US 5756764 19980526
AI US 1995-466468 19950606 (8)
RLI Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
DT Utility
FS Granted
LN.CNT 2392
INCL INCLM: 548/541.000
INCLS: 548/512.000; 548/543.000; 548/557.000
NCL NCLM: 548/541.000
NCLS: 548/512.000; 548/543.000; 548/557.000
IC [6]
EXF ICM: C07D207-12
ICS: C07D207-10; C07D207-08
EXF 548/543; 548/512; 548/557; 548/541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 374 OF 391 USPATFULL on STN
AN 1998:30992 USPATFULL
TI Method for treating Alzheimer's disease using glial line-derived
neurotrophic factor (GDNF) protein product
IN Williams, Lawrence R., Thousand Oaks, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 5731284 19980324
AI US 1995-535682 19950928 (8)
DT Utility
FS Granted
LN.CNT 1677
INCL INCLM: 514/008.000
INCLS: 514/021.000
NCL NCLM: 514/008.000
NCLS: 514/021.000
IC [6]

ICS: A61K047-00; A61K031-685; A61K038-00
EXF 514/8; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 375 OF 391 USPATFULL on STN
AN 1998:28190 USPATFULL
TI ***Antibodies*** directed against elk ligand
IN Lyman, Stewart, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5728813 19980317
AI US 1996-747240 19961112 (8)
RLI Division of Ser. No. US 1995-460741, filed on 2 Jun 1995, now patented,
Pat. No. US 5670625 which is a division of Ser. No. US 1994-213403,
filed on 15 Mar 1994, now patented, Pat. No. US 5512457 which is a
continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1717
INCL INCLM: 530/387.900
INCLS: 530/388.230; 424/139.100
NCL NCLM: 530/387.900
NCLS: 424/139.100; 530/388.230
IC [6]
ICM: C07K016-24
EXF 530/387.9; 530/388.23; 530/350; 435/69.1; 435/325; 435/331; 435/335;
424/139.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 376 OF 391 USPATFULL on STN
AN 1998:19582 USPATFULL
TI In Vitro method for screening . ***beta*** .- ***amyloid*** .
deposition
IN Maggio, John E., Brookline, MA, United States
Mantyh, Patrick W., Edina, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States
(U.S. corporation)
President and Fellows of Harvard College, Boston, MA, United States
(U.S. corporation)
PI US 5721106 19980224
AI US 1994-304585 19940912 (8)
RLI Continuation-in-part of Ser. No. US 1991-744767, filed on 13 Aug 1991,
now patented, Pat. No. US 5434050
DT Utility
FS Granted
LN.CNT 1977
INCL INCLM: 435/007.800
INCLS: 435/007.100; 435/007.900; 436/501.000; 436/504.000
NCL NCLM: 435/007.800
NCLS: 435/007.100; 435/007.900; 436/501.000; 436/504.000
IC [6]
ICM: G01N033-53
EXF 435/4; 435/7.1; 435/7.21; 435/7.8; 435/7.9; 436/501; 436/86; 436/504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 377 OF 391 USPATFULL on STN
AN 97:123343 USPATFULL
TI Amyloid precursor proteins and method of using same to assess agents
which down-regulate formation of . ***beta*** .- ***amyloid***
peptide
IN Vitek, Michael Peter, East Norwich, NY, United States
Jacobsen, Jack Steven, Ramsey, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5703209 19971230
AI US 1995-464248 19950605 (8)
RLI Division of Ser. No. US 1993-123659, filed on 20 Sep 1993 which is a
continuation-in-part of Ser. No. US 1992-877675, filed on 1 May 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1937
INCL INCLM: 530/350.000
INCLS: 530/539.000; 514/012.000; 435/069.100; 435/172.300

IC NCLS: 435/069.100; 530/839.000
[6]
EXF ICM: C07K014-435
ICS: C07K014-47; C12N015-12
435/69.1; 435/172.3; 514/2; 514/12; 530/350; 530/839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 378 OF 391 USPATFULL on STN
AN 97:112579 USPATFULL
TI Method of isolating .beta.A4 peptide species ending at carboxy-terminals
residue 42 using monoclonal ***antibody*** 369.2B
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PI US 5693753 19971202
AI US 1995-472627 19950607 (8)
RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
DT Utility
FS Granted
LN.CNT 924
INCL INCLM: 530/344.000
INCLS: 530/412.000; 530/413.000
NCL NCLM: 530/344.000
NCLS: 530/412.000; 530/413.000
IC [6]
EXF ICM: C07K001-22
530/387.9; 530/388.1; 530/389.1; 530/391.1; 530/391.3; 530/391.5;
530/391.9; 530/344; 530/412; 530/413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 379 OF 391 USPATFULL on STN
AN 97:96730 USPATFULL
TI Methods of detecting .beta.A4 peptide species ending at carboxy-terminus
residue 42 using monoclonal ***antibody*** 369.2B
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PI US 5679531 19971021
AI US 1995-484969 19950607 (8)
RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
DT Utility
FS Granted
LN.CNT 932
INCL INCLM: 435/007.100
INCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900;
530/388.100
NCL NCLM: 435/007.100
NCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900;
530/388.100
IC [6]
EXF ICM: G01N033-53
ICS: C07K016-18
435/70.21; 435/240.27; 435/387.9; 435/7.1; 435/7.21; 435/7.9; 435/40.52;
435/40.5; 435/7.92; 435/7.95; 530/388.1; 530/358.2; 530/327; 436/548;
424/184.1; 424/185.1; 424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 380 OF 391 USPATFULL on STN
AN 97:86731 USPATFULL
TI Elk ligand fusion proteins
IN Lyman, Stewart, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5670625 19970923
AI US 1995-460741 19950602 (8)
RLI Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
Pat. No. US 5512457, issued on 30 Apr 1996 which is a
continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1742
INCL INCLM: 530/387.300
INCLS: 435/069.700; 435/172.300; 424/085.100; 424/192.100; 536/023.400;

NCL NCLM: 530/387.300
NCLS: 424/085.100; 424/192.100; 435/069.700; 530/351.000; 536/023.400;
930/140.000
IC [6]
ICM: C07K014-52
ICS: C07K019-00
EXF 530/387.3; 530/351; 435/69.7; 435/172.3; 435/69.1; 435/320.1; 424/85.1;
424/192.1; 536/23.4; 536/23.5; 935/10; 930/140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 381 OF 391 USPATFULL on STN
AN 97:86591 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic
peptides and uses therefor
IN Zhang, Shuguang, Cambridge, MA, United States
Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States
Holmes, Todd, Cambridge, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States
(U.S. corporation)
PI US 5670483 19970923
AI US 1994-346849 19941130 (8)
RLI Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now
abandoned
DT Utility
FS Granted
LN.CNT 2210
INCL INCLM: 514/014.000
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/350.000
NCL NCLM: 514/014.000
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/350.000
IC [6]
ICM: A61K007-08
ICS: A61K014-00; C07K038-10; C07K038-16
EXF 530/300; 530/350; 514/12; 514/13; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 382 OF 391 USPATFULL on STN
AN 97:70918 USPATFULL
TI Amyloid precursor proteins and method of using same to assess agents
which down-regulate formation of . ***beta*** .- ***amyloid***
peptide
IN Vitek, Michael Peter, East Norwich, NY, United States
Jacobsen, Jack Steven, Ramsey, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5656477 19970812
AI US 1993-123659 19930920 (8)
RLI Continuation-in-part of Ser. No. US 1992-877675, filed on 1 May 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 2040
INCL INCLM: 435/325.000
INCLS: 435/252.300; 435/254.110; 435/348.000; 435/358.000; 435/365.000;
435/365.100; 435/366.000; 536/023.500; 530/839.000
NCL NCLM: 435/325.000
NCLS: 435/252.300; 435/254.110; 435/348.000; 435/358.000; 435/365.000;
435/365.100; 435/366.000; 530/839.000; 536/023.500
IC [6]
ICM: C12N001-15
ICS: C12N001-21; C12N005-10; C12N015-12
EXF 435/172.3; 435/240.2; 435/252.3; 435/254.11; 435/320.1; 536/23.5;
935/79; 530/350; 530/839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 383 OF 391 USPATFULL on STN
AN 97:49530 USPATFULL
TI Method of modulating DNA binding activity of recombinant .alpha.-1
antichymotrypsin and other serine protease inhibitors
IN Rubin, Harvey, Philadelphia, PA, United States
Cooperman, Barry, Penn Valley, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)
5670483

AI US 1995-435480 19950505 (8)
RLI Continuation-in-part of Ser. No. US 1994-276936, filed on 19 Jul 1994,
now patented, Pat. No. US 5612194 which is a continuation-in-part of
Ser. No. US 1994-229286, filed on 18 Apr 1994, now abandoned which is a
continuation-in-part of Ser. No. US 1994-221078, filed on 31 Mar 1994
Ser. No. Ser. No. US 1994-221171, filed on 31 Mar 1994 And Ser. No. US
1993-5908, filed on 15 Jan 1993, now patented, Pat. No. US 5367064 which
is a division of Ser. No. US 1991-735335, filed on 24 Jul 1991, now
patented, Pat. No. US 5252725 which is a division of Ser. No. US
1989-370704, filed on 23 Jun 1989, now patented, Pat. No. US 5079336 ,
said Ser. No. US -221078 which is a continuation-in-part of Ser. No.
US -5908

DT Utility

FS Granted

LN.CNT 702

INCL INCLM: 435/069.200

INCLS: 435/172.300; 530/350.000; 530/395.000; 536/023.500

NCL NCLM: 435/069.200

NCLS: 530/350.000; 530/395.000; 536/023.500

IC [6]

ICM: C07K014-435

ICS: C07K014-81; C12N015-15

EXF 435/69.2; 435/172.3; 530/350; 530/395; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 384 OF 391 USPATFULL on STN

AN 97:38610 USPATFULL

TI Cytokine designated elk ligand

IN Lyman, Stewart, Seattle, WA, United States

Beckmann, M. Patricia, Poulsbo, WA, United States

Baum, Peter R., Seattle, WA, United States

PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)

PI US 5627267 19970506

AI US 1995-458077 19950601 (8)

RLI Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
Pat. No. US 5512457 which is a continuation-in-part of Ser. No. US
1992-977693, filed on 13 Nov 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1743

INCL INCLM: 530/351.000

INCLS: 424/085.100; 435/069.500; 536/023.500; 935/009.000; 930/140.000

NCL NCLM: 530/351.000

NCLS: 424/085.100; 435/069.500; 536/023.500; 930/140.000

IC [6]

ICM: C07K014-52

EXF 530/351; 424/85.1; 514/12; 435/69.5; 536/23.5; 935/9; 930/140

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 385 OF 391 USPATFULL on STN

AN 97:36068 USPATFULL

TI Methods for detecting Alzheimer's disease by measuring ratios of
calcium-activated neutral protease isoforms

IN Nixon, Ralph A., Arlington, MA, United States

Saito, Ken-Ichi, Yokohama, Japan

PA The McLean Hospital Corporation, Belmont, MA, United States (U.S.
corporation)

PI US 5624807 19970429

AI US 1994-184603 19940124 (8)

RLI Continuation of Ser. No. US 1993-95319, filed on 22 Jul 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1992-925594,
filed on 22 Jul 1992, now abandoned

DT Utility

FS Granted

LN.CNT 1268

INCL INCLM: 435/007.400

INCLS: 435/007.900; 435/007.920; 436/063.000; 436/518.000; 436/547.000;
436/548.000; 436/811.000

NCL NCLM: 435/007.400

NCLS: 435/007.900; 435/007.920; 436/063.000; 436/518.000; 436/547.000;
436/548.000; 436/811.000

IC [6]

ICM: G01N033-573

ICS: G01N033-53; G01N033-48

EXF 435/7.4; 435/7.9; 435/7.92; 435/7.95; 435/975; 435/973; 435/967;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 386 OF 391 USPATFULL on STN
AN 96:101466 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)
PI US 5571698 19961105
AI US 1993-57667 19930618 (8)
RLI Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15323
INCL INCLM: 435/069.700
INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100
NCL NCLM: 435/069.700
NCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000
IC [6]
ICM: C12N025-62
EXF 435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 387 OF 391 USPATFULL on STN
AN 96:36458 USPATFULL
TI Cytokine designated elk ligand
IN Lyman, Stewart, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
Carpenter, Melissa K., Issaquah, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5512457 19960430
AI US 1994-213403 19940315 (8)
RLI Continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1746
INCL INCLM: 435/069.500
INCLS: 435/172.100; 435/320.100; 424/085.100; 536/023.500; 536/024.310;
935/009.000; 530/351.000; 930/140.000
NCL NCLM: 435/069.500
NCLS: 424/085.100; 435/320.100; 530/351.000; 536/023.500; 536/024.310;
930/140.000
IC [6]
ICM: C07H021-04
ICS: C12P021-02; C12N015-19; C07K014-52
EXF 536/23.5; 536/24.5; 536/24.31; 530/350; 530/351; 435/69.1; 435/320.1;
435/172.1; 935/9; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 388 OF 391 USPATFULL on STN
AN 95:88386 USPATFULL
TI Nucleic acids for diagnosing and modeling Alzheimer's disease
IN Mullan, Michael J., Tampa, FL, United States
PA Alzheimer's Institute of America, Inc., Prairie Village, KS, United States (U.S. corporation)
PI US 5455169 19951003
AI US 1992-894211 19920604 (7)
DT Utility
FS Granted
LN.CNT 1040
INCL INCLM: 435/240.200
INCLS: 435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330
NCL NCLM: 435/325.000
NCLS: 435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330

ICM: C12N005-10
EXF ICS: C12N015-12; C12N015-85
435/240.2; 435/320.1; 435/172.3; 435/6; 536/23.1; 536/23.5; 536/24.31;
536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 389 OF 391 USPATFULL on STN
AN 95:11757 USPATFULL
TI Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
IN Cordell, Barbara, Palo Alto, CA, United States
PA Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5387742 19950207
AI US 1991-716725 19910617 (7)
RLI Continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,
now abandoned
DT Utility
FS Granted
LN.CNT 2014
INCL INCLM: 800/002.000
INCLS: 424/009.000; 435/142.300; 536/023.500
NCL NCLM: 800/012.000
NCLS: 536/023.500; 800/018.000
IC [6]
ICM: A61K049-00
ICS: C12N015-00; C07H015-12
EXF 800/2; 435/6; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 390 OF 391 USPATFULL on STN
AN 93:52487 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Buxborough, MA, United States
PA Protein Engineering Corp., Cambridge, MA, United States (U.S.
corporation)
PI US 5223409 19930629
AI US 1991-664989 19910301 (7)
RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
now abandoned And a continuation-in-part of Ser. No. US 1988-240160,
filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15410
INCL INCLM: 435/069.700
INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300;
530/387.500
NCL NCLM: 435/069.700
NCLS: 435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000;
530/387.300; 530/387.500
IC [5]
ICM: C12N015-09
ICS: C12N015-62; C12N015-63
EXF 435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 391 OF 391 USPATFULL on STN
AN 92:61895 USPATFULL
TI Nerve growth factor peptides
IN Mobley, William C., Moraga, CA, United States
Longo, Frank M., San Francisco, CA, United States
Kauer, James C., Kennett Square, PA, United States
PA Regents of the University of California, Berkeley, CA, United States
(U.S. corporation)
PI US 5134121 19920728
AI US 1991-640577 19910114 (7)
RLI Continuation of Ser. No. US 1989-299698, filed on 23 Jan 1989, now
abandoned which is a continuation-in-part of Ser. No. US 1988-173975,
filed on 28 Mar 1988, now abandoned
DT Utility
FS Granted